WO2024050389A1 - Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda - Google Patents
Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda Download PDFInfo
- Publication number
- WO2024050389A1 WO2024050389A1 PCT/US2023/073125 US2023073125W WO2024050389A1 WO 2024050389 A1 WO2024050389 A1 WO 2024050389A1 US 2023073125 W US2023073125 W US 2023073125W WO 2024050389 A1 WO2024050389 A1 WO 2024050389A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alk
- cycloalk
- phenyl
- methyl
- amino
- Prior art date
Links
- 108091006146 Channels Proteins 0.000 title claims abstract description 126
- 239000012190 activator Substances 0.000 title claims abstract description 121
- 229910052751 metal Inorganic materials 0.000 title claims abstract description 26
- 239000002184 metal Substances 0.000 title claims abstract description 26
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title description 11
- 238000002648 combination therapy Methods 0.000 title description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 28
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims abstract description 19
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 16
- 208000012902 Nervous system disease Diseases 0.000 claims abstract description 14
- 230000000926 neurological effect Effects 0.000 claims abstract description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 208000020401 Depressive disease Diseases 0.000 claims abstract description 8
- 208000027520 Somatoform disease Diseases 0.000 claims abstract description 7
- 208000027753 pain disease Diseases 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 143
- 150000003839 salts Chemical class 0.000 claims description 78
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- FWUQWDCOOWEXRY-ZDUSSCGKSA-N lanicemine Chemical compound C([C@H](N)C=1C=CC=CC=1)C1=CC=CC=N1 FWUQWDCOOWEXRY-ZDUSSCGKSA-N 0.000 claims description 6
- 229950003165 lanicemine Drugs 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 5
- 206010001497 Agitation Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 4
- 206010008025 Cerebellar ataxia Diseases 0.000 claims description 3
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical group C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 208000029560 autism spectrum disease Diseases 0.000 claims description 3
- 229960003299 ketamine Drugs 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000002339 Frontotemporal Lobar Degeneration Diseases 0.000 claims description 2
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000019695 Migraine disease Diseases 0.000 claims description 2
- 208000019022 Mood disease Diseases 0.000 claims description 2
- 102100034354 Potassium voltage-gated channel subfamily KQT member 2 Human genes 0.000 claims description 2
- 208000006289 Rett Syndrome Diseases 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 230000008482 dysregulation Effects 0.000 claims description 2
- 201000003723 learning disability Diseases 0.000 claims description 2
- 206010027599 migraine Diseases 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036407 pain Effects 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 2
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 2
- 238000013019 agitation Methods 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 229960001985 dextromethorphan Drugs 0.000 claims 2
- LPKTWLVEGBNOOX-UHFFFAOYSA-N methoxetamine Chemical compound C=1C=CC(OC)=CC=1C1(NCC)CCCCC1=O LPKTWLVEGBNOOX-UHFFFAOYSA-N 0.000 claims 2
- 208000027061 mild cognitive impairment Diseases 0.000 claims 2
- 230000002085 persistent effect Effects 0.000 claims 2
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 claims 2
- 239000004036 potassium channel stimulating agent Substances 0.000 claims 2
- 208000012672 seasonal affective disease Diseases 0.000 claims 2
- 206010001297 Adjustment disorder with depressed mood Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002942 Apathy Diseases 0.000 claims 1
- 206010058019 Cancer Pain Diseases 0.000 claims 1
- 208000027691 Conduct disease Diseases 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 206010013142 Disinhibition Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001914 Fragile X syndrome Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 206010028570 Myelopathy Diseases 0.000 claims 1
- 208000001294 Nociceptive Pain Diseases 0.000 claims 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 claims 1
- 208000004550 Postoperative Pain Diseases 0.000 claims 1
- 201000009916 Postpartum depression Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 206010059604 Radicular pain Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 208000009205 Tinnitus Diseases 0.000 claims 1
- 208000005298 acute pain Diseases 0.000 claims 1
- 208000025748 atypical depressive disease Diseases 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 208000037119 hereditary cerebellar ataxia Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 230000036651 mood Effects 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000022821 personality disease Diseases 0.000 claims 1
- 229950010883 phencyclidine Drugs 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 230000002035 prolonged effect Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 238000001228 spectrum Methods 0.000 claims 1
- 231100000886 tinnitus Toxicity 0.000 claims 1
- 239000000460 chlorine Substances 0.000 description 472
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 465
- 229910052731 fluorine Inorganic materials 0.000 description 458
- 229910052801 chlorine Inorganic materials 0.000 description 435
- 125000001424 substituent group Chemical group 0.000 description 404
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 344
- 229910052794 bromium Inorganic materials 0.000 description 338
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 311
- 229910052740 iodine Inorganic materials 0.000 description 299
- 125000001931 aliphatic group Chemical group 0.000 description 287
- 229910052739 hydrogen Inorganic materials 0.000 description 232
- 229910052760 oxygen Inorganic materials 0.000 description 191
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 157
- 229910003204 NH2 Inorganic materials 0.000 description 153
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 126
- -1 small molecule compounds Chemical class 0.000 description 117
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 112
- 239000001257 hydrogen Substances 0.000 description 110
- 125000003118 aryl group Chemical group 0.000 description 104
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 95
- 229910052757 nitrogen Inorganic materials 0.000 description 89
- 229910052717 sulfur Inorganic materials 0.000 description 82
- 125000004076 pyridyl group Chemical group 0.000 description 75
- 125000001072 heteroaryl group Chemical group 0.000 description 74
- 229910052736 halogen Inorganic materials 0.000 description 72
- 229910052799 carbon Inorganic materials 0.000 description 70
- 229920006395 saturated elastomer Polymers 0.000 description 56
- 150000002367 halogens Chemical class 0.000 description 55
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 53
- 125000001544 thienyl group Chemical group 0.000 description 51
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 50
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 49
- 125000004433 nitrogen atom Chemical group N* 0.000 description 49
- 125000005842 heteroatom Chemical group 0.000 description 48
- 125000000753 cycloalkyl group Chemical group 0.000 description 47
- 125000002252 acyl group Chemical group 0.000 description 45
- 125000004093 cyano group Chemical group *C#N 0.000 description 42
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 41
- 150000001721 carbon Chemical group 0.000 description 37
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 33
- 125000000217 alkyl group Chemical group 0.000 description 32
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 30
- 229910052729 chemical element Inorganic materials 0.000 description 26
- 125000000392 cycloalkenyl group Chemical group 0.000 description 26
- 125000002541 furyl group Chemical group 0.000 description 26
- 125000002971 oxazolyl group Chemical group 0.000 description 26
- 125000000335 thiazolyl group Chemical group 0.000 description 26
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 24
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 23
- 125000005843 halogen group Chemical group 0.000 description 22
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 22
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 19
- 108090000623 proteins and genes Proteins 0.000 description 19
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 18
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 description 17
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 15
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 14
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 14
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 14
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 13
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 12
- 125000000623 heterocyclic group Chemical group 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 12
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 description 10
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 9
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 7
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 7
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 7
- 239000012458 free base Substances 0.000 description 7
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 6
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 6
- 208000001089 Multiple system atrophy Diseases 0.000 description 6
- 102000014649 NMDA glutamate receptor activity proteins Human genes 0.000 description 6
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 6
- 125000004103 aminoalkyl group Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000000842 isoxazolyl group Chemical group 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 6
- 125000003386 piperidinyl group Chemical group 0.000 description 6
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- 239000012453 solvate Substances 0.000 description 6
- 208000025966 Neurological disease Diseases 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- PCOBBVZJEWWZFR-UHFFFAOYSA-N ezogabine Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1 PCOBBVZJEWWZFR-UHFFFAOYSA-N 0.000 description 5
- 229960003312 retigabine Drugs 0.000 description 5
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 4
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 description 4
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 4
- CGXLVFZJJOXEDF-UHFFFAOYSA-N 1,8-naphthyridine-3-carboxylic acid Chemical compound N1=CC=CC2=CC(C(=O)O)=CN=C21 CGXLVFZJJOXEDF-UHFFFAOYSA-N 0.000 description 4
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 4
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 4
- 150000003973 alkyl amines Chemical class 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 125000001153 fluoro group Chemical group F* 0.000 description 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 4
- 238000005304 joining Methods 0.000 description 4
- AQIYYEYDCKZSCQ-UHFFFAOYSA-N n-[4-[[(2,4-diaminoquinazolin-6-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N=C(N)N=C2N)C2=C1 AQIYYEYDCKZSCQ-UHFFFAOYSA-N 0.000 description 4
- 125000000963 oxybis(methylene) group Chemical group [H]C([H])(*)OC([H])([H])* 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 125000000304 alkynyl group Chemical group 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 125000004366 heterocycloalkenyl group Chemical group 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- GLBDFDMKCASXQQ-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-cyclopentylacetamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)CC1CCCC1 GLBDFDMKCASXQQ-UHFFFAOYSA-N 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 125000003107 substituted aryl group Chemical group 0.000 description 3
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 3
- GMOJAGQEZFLHJR-SMDDNHRTSA-N (3R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)C(C)(C)C GMOJAGQEZFLHJR-SMDDNHRTSA-N 0.000 description 2
- UYQMYWWYVZCQIW-STQMWFEESA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@H](C(C)(C)C)O)=O)F UYQMYWWYVZCQIW-STQMWFEESA-N 0.000 description 2
- XSYJSFMLFDIWJF-GWCFXTLKSA-N (3S)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](C)NC(C[C@@H](C(C)(C)C)O)=O)F XSYJSFMLFDIWJF-GWCFXTLKSA-N 0.000 description 2
- 125000004645 (C1-C12) acylamino group Chemical group 0.000 description 2
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 description 2
- 125000006706 (C3-C6) carbocyclyl group Chemical group 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 description 2
- UXYVHBXLPAZMCZ-UHFFFAOYSA-N 1-(1-benzylindol-5-yl)-3-quinolin-4-ylurea Chemical compound C=1C=NC2=CC=CC=C2C=1NC(=O)NC(C=C1C=C2)=CC=C1N2CC1=CC=CC=C1 UXYVHBXLPAZMCZ-UHFFFAOYSA-N 0.000 description 2
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 2
- LOBHSNZQHCWYLU-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 LOBHSNZQHCWYLU-UHFFFAOYSA-N 0.000 description 2
- UYMDMWMYTNGODR-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-methyl-4-[[6-(4-methylphenoxy)pyridin-3-yl]methylamino]phenyl]acetamide Chemical compound C1=CC(C)=CC=C1OC(N=C1)=CC=C1CNC(C=C1C)=CC=C1NC(=O)CC1=CC=C(F)C=C1 UYMDMWMYTNGODR-UHFFFAOYSA-N 0.000 description 2
- VAUTZIXBXVUZQA-UHFFFAOYSA-N 2-[(4-acetamidophenyl)methylamino]-5-chloro-n-(5-chloropyridin-2-yl)benzamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(Cl)C=C1C(=O)NC1=CC=C(Cl)C=N1 VAUTZIXBXVUZQA-UHFFFAOYSA-N 0.000 description 2
- HBAVDOFSYDZLMI-UHFFFAOYSA-N 2-amino-4-methyl-n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]pentanamide Chemical compound C1=C(C)C(NC(=O)C(N)CC(C)C)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 HBAVDOFSYDZLMI-UHFFFAOYSA-N 0.000 description 2
- UJNJKBYTNPBNBN-UHFFFAOYSA-N 2-chloro-4-N-[(5-chlorothiophen-2-yl)methyl]benzene-1,4-diamine Chemical compound C1=C(Cl)C(N)=CC=C1NCC1=CC=C(Cl)S1 UJNJKBYTNPBNBN-UHFFFAOYSA-N 0.000 description 2
- IAAITAGXZWCRTQ-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 IAAITAGXZWCRTQ-UHFFFAOYSA-N 0.000 description 2
- JNWPEEJRMRBMPA-UHFFFAOYSA-N 2-cyclopentyl-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCC1 JNWPEEJRMRBMPA-UHFFFAOYSA-N 0.000 description 2
- IMOFGKWQMCCNKF-UHFFFAOYSA-N 2-cyclopentyl-n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCC1 IMOFGKWQMCCNKF-UHFFFAOYSA-N 0.000 description 2
- NJUKIJYUAQHUKN-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-4-[[6-(4-methylphenoxy)pyridin-3-yl]methylamino]phenyl]butanamide Chemical compound C1=CC(C)=CC=C1OC(N=C1)=CC=C1CNC1=CC=C(NC(=O)CC(C)(C)C)C(C)=C1 NJUKIJYUAQHUKN-UHFFFAOYSA-N 0.000 description 2
- FJHHRZVGLKCHRZ-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-4-[[6-(trifluoromethyl)pyridin-3-yl]methylamino]phenyl]butanamide Chemical compound C1=C(NC(=O)CC(C)(C)C)C(C)=CC(NCC=2C=NC(=CC=2)C(F)(F)F)=C1 FJHHRZVGLKCHRZ-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000016560 COFS syndrome Diseases 0.000 description 2
- 206010008748 Chorea Diseases 0.000 description 2
- 208000030939 Chronic inflammatory demyelinating polyneuropathy Diseases 0.000 description 2
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 2
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 2
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 2
- 208000004986 Diffuse Cerebral Sclerosis of Schilder Diseases 0.000 description 2
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 description 2
- 101710121995 Glutamate receptor ionotropic, NMDA 1 Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000000588 Klippel-Trenaunay-Weber Syndrome Diseases 0.000 description 2
- 208000034642 Klippel-Trénaunay syndrome Diseases 0.000 description 2
- 201000002832 Lewy body dementia Diseases 0.000 description 2
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 2
- 208000021642 Muscular disease Diseases 0.000 description 2
- 201000009623 Myopathy Diseases 0.000 description 2
- 208000010316 Myotonia congenita Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 102000004257 Potassium Channel Human genes 0.000 description 2
- 208000024777 Prion disease Diseases 0.000 description 2
- 125000000066 S-methyl group Chemical group [H]C([H])([H])S* 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 206010042928 Syringomyelia Diseases 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000004442 acylamino group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 208000012948 angioosteohypertrophic syndrome Diseases 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 125000003725 azepanyl group Chemical group 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 208000025434 cerebellar degeneration Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 201000005795 chronic inflammatory demyelinating polyneuritis Diseases 0.000 description 2
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 description 2
- 125000004611 dihydroisoindolyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 2
- 206010014599 encephalitis Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- YCMRKXZMNUMKST-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 YCMRKXZMNUMKST-UHFFFAOYSA-N 0.000 description 2
- JRMWXXMVCOHXCB-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 JRMWXXMVCOHXCB-UHFFFAOYSA-N 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 2
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 208000005264 motor neuron disease Diseases 0.000 description 2
- BKFDFCVASNKPOA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=N1 BKFDFCVASNKPOA-UHFFFAOYSA-N 0.000 description 2
- BPFWCATXXHFMHU-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(F)C(NC(=O)CCCCC)=C(F)C=C1N1CCOCC1 BPFWCATXXHFMHU-UHFFFAOYSA-N 0.000 description 2
- OVEJXWFUXCATFY-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 OVEJXWFUXCATFY-UHFFFAOYSA-N 0.000 description 2
- DKKUESYXEUWVTR-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C=C1 DKKUESYXEUWVTR-UHFFFAOYSA-N 0.000 description 2
- UMFJAHHVKNCGLG-UHFFFAOYSA-N n-Nitrosodimethylamine Chemical compound CN(C)N=O UMFJAHHVKNCGLG-UHFFFAOYSA-N 0.000 description 2
- OUNTYCMSLMESTI-UHFFFAOYSA-N n-[2,6-dimethyl-4-[7-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC(=CC=C3CC2)C(F)(F)F)=C1 OUNTYCMSLMESTI-UHFFFAOYSA-N 0.000 description 2
- WOVDEFIGDUUBDM-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]propanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC)=C(Br)C=C1N1CCOCC1 WOVDEFIGDUUBDM-UHFFFAOYSA-N 0.000 description 2
- PCHKLVYYPQCHED-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-(4-chlorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(Cl)=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 PCHKLVYYPQCHED-UHFFFAOYSA-N 0.000 description 2
- ROGXWDNMPNMNEI-UHFFFAOYSA-N n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]hexanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 ROGXWDNMPNMNEI-UHFFFAOYSA-N 0.000 description 2
- JTNKTTCJVFXBEH-UHFFFAOYSA-N n-[4-[(3,4,5-trimethoxyanilino)methyl]phenyl]acetamide Chemical compound COC1=C(OC)C(OC)=CC(NCC=2C=CC(NC(C)=O)=CC=2)=C1 JTNKTTCJVFXBEH-UHFFFAOYSA-N 0.000 description 2
- ZNDKCOPIFNSNSB-UHFFFAOYSA-N n-[4-[(6-chloropyridin-3-yl)methylamino]-2-methylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=CC=1NCC1=CC=C(Cl)N=C1 ZNDKCOPIFNSNSB-UHFFFAOYSA-N 0.000 description 2
- PFUWYMNNTQXYIU-UHFFFAOYSA-N n-[4-[[2-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=CC=C1CN1C=NC=C1 PFUWYMNNTQXYIU-UHFFFAOYSA-N 0.000 description 2
- XETNUEHTWCZNAQ-UHFFFAOYSA-N n-[4-[[6-(4-cyanophenoxy)pyridin-3-yl]methylamino]-2-methylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=CC=1NCC(C=N1)=CC=C1OC1=CC=C(C#N)C=C1 XETNUEHTWCZNAQ-UHFFFAOYSA-N 0.000 description 2
- CXLNABRKNCFEPE-UHFFFAOYSA-N n-[4-amino-6-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-5-yl]-2-(3-chlorophenyl)acetamide Chemical compound N=1C(N)=C(NC(=O)CC=2C=C(Cl)C=CC=2)C(C)=NC=1NCC1=CC=C(C(F)(F)F)C=C1 CXLNABRKNCFEPE-UHFFFAOYSA-N 0.000 description 2
- XVSOQDVGOHMGII-UHFFFAOYSA-N n-[4-amino-6-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound N=1C(N)=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=NC=1NCC1=CC=C(C(F)(F)F)C=C1 XVSOQDVGOHMGII-UHFFFAOYSA-N 0.000 description 2
- MADIUWVCWDQSFO-UHFFFAOYSA-N n-[4-amino-6-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-5-yl]-2-cyclopentylacetamide Chemical compound N=1C(N)=C(NC(=O)CC2CCCC2)C(C)=NC=1NCC1=CC=C(C(F)(F)F)C=C1 MADIUWVCWDQSFO-UHFFFAOYSA-N 0.000 description 2
- ORCPEBUYIDIIBI-UHFFFAOYSA-N n-[4-amino-6-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-5-yl]-3,3-dimethylbutanamide Chemical compound NC1=C(NC(=O)CC(C)(C)C)C(C)=NC(NCC=2C=CC(=CC=2)C(F)(F)F)=N1 ORCPEBUYIDIIBI-UHFFFAOYSA-N 0.000 description 2
- OSWHOUIOMBVTRL-UHFFFAOYSA-N n-[4-amino-6-methyl-2-[[4-(trifluoromethyl)phenyl]methylamino]pyrimidin-5-yl]hexanamide Chemical compound N1=C(N)C(NC(=O)CCCCC)=C(C)N=C1NCC1=CC=C(C(F)(F)F)C=C1 OSWHOUIOMBVTRL-UHFFFAOYSA-N 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 201000010193 neural tube defect Diseases 0.000 description 2
- 208000002040 neurosyphilis Diseases 0.000 description 2
- 125000005961 oxazepanyl group Chemical group 0.000 description 2
- IPWFJLQDVFKJDU-UHFFFAOYSA-N pentanamide Chemical compound CCCCC(N)=O IPWFJLQDVFKJDU-UHFFFAOYSA-N 0.000 description 2
- 108020001213 potassium channel Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 208000006542 von Hippel-Lindau disease Diseases 0.000 description 2
- FHZUOZWUOXJEHV-UHFFFAOYSA-N (2-chlorophenyl)methyl n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)carbamate Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)OCC1=CC=CC=C1Cl FHZUOZWUOXJEHV-UHFFFAOYSA-N 0.000 description 1
- FDONRMIZVSGMJB-UHFFFAOYSA-N (2-chlorophenyl)methyl n-(2,6-dimethyl-4-morpholin-4-ylphenyl)carbamate Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)OCC1=CC=CC=C1Cl FDONRMIZVSGMJB-UHFFFAOYSA-N 0.000 description 1
- RIWKCXYUIMTQHW-UHFFFAOYSA-N (2-chlorophenyl)methyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCC=2C(=CC=CC=2)Cl)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 RIWKCXYUIMTQHW-UHFFFAOYSA-N 0.000 description 1
- OOMFPKMRUNSGGI-LJQANCHMSA-N (2r)-2-amino-n-[2,6-dimethyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-4-methylpentanamide Chemical compound C1=C(C)C(NC(=O)[C@H](N)CC(C)C)=C(C)C=C1NCC1=CC=C(C(F)(F)F)C=C1 OOMFPKMRUNSGGI-LJQANCHMSA-N 0.000 description 1
- SGBNXBBEMOZSSZ-IBGZPJMESA-N (2s)-2-amino-n-[2,6-dimethyl-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]-3-methylbutanamide Chemical compound C1=C(C)C(NC(=O)[C@@H](N)C(C)C)=C(C)C=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 SGBNXBBEMOZSSZ-IBGZPJMESA-N 0.000 description 1
- KPPMLIQTECGRGP-FQEVSTJZSA-N (2s)-2-amino-n-[2,6-dimethyl-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]-4-methylpentanamide Chemical compound C1=C(C)C(NC(=O)[C@@H](N)CC(C)C)=C(C)C=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 KPPMLIQTECGRGP-FQEVSTJZSA-N 0.000 description 1
- BVCFMTPSASIOGN-DZGCQCFKSA-N (3R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]butanamide Chemical compound FC1(CC1)[C@](CC(=O)N[C@@H](COC)C1=CC(=CC=C1)OC(F)(F)F)(C)O BVCFMTPSASIOGN-DZGCQCFKSA-N 0.000 description 1
- QYDAXJTYTUGMDA-IINYFYTJSA-N (3R)-3-(1-fluorocyclopropyl)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]butanamide Chemical compound FC1(CC1)[C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O QYDAXJTYTUGMDA-IINYFYTJSA-N 0.000 description 1
- AJIQRRTWTYNXCD-TVQRCGJNSA-N (3R)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propanamide Chemical compound FC1(CC(C1)[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)O)F AJIQRRTWTYNXCD-TVQRCGJNSA-N 0.000 description 1
- JXROOIQJGMWIPA-QWHCGFSZSA-N (3R)-3-(3,3-difluorocyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)F)O)F JXROOIQJGMWIPA-QWHCGFSZSA-N 0.000 description 1
- NXCGVJRTEVJPJV-QWHCGFSZSA-N (3R)-3-(3,3-difluorocyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)(F)F)O)F NXCGVJRTEVJPJV-QWHCGFSZSA-N 0.000 description 1
- PWNSUVWRMNJZBR-LSDHHAIUSA-N (3R)-3-(3,3-difluorocyclobutyl)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]butyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@@H](CC(=O)N[C@@H](CCC)C1=CC(=CC=C1)OC(F)F)O)F PWNSUVWRMNJZBR-LSDHHAIUSA-N 0.000 description 1
- AVQBWHCPNABSSH-JOYOIKCWSA-N (3R)-3-[1-(difluoromethyl)cyclopropyl]-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propanamide Chemical compound FC(C1(CC1)[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)O)F AVQBWHCPNABSSH-JOYOIKCWSA-N 0.000 description 1
- SJXBACWMIQQWOB-LSDHHAIUSA-N (3R)-3-cyclopentyl-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound C1(CCCC1)[C@@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)F)O SJXBACWMIQQWOB-LSDHHAIUSA-N 0.000 description 1
- KFQZZCZVPUZGAY-MEDUHNTESA-N (3R)-3-cyclopropyl-3-hydroxy-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]butanamide Chemical compound C1(CC1)[C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C)O KFQZZCZVPUZGAY-MEDUHNTESA-N 0.000 description 1
- CNUMXNCWPQLNDB-XJKSGUPXSA-N (3R)-3-cyclopropyl-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxybutanamide Chemical compound C1(CC1)[C@](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)(F)F)(C)O CNUMXNCWPQLNDB-XJKSGUPXSA-N 0.000 description 1
- KSJFVZDSVVTWQT-GXFFZTMASA-N (3R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C KSJFVZDSVVTWQT-GXFFZTMASA-N 0.000 description 1
- DIFZQEHWYNTPQD-UONOGXRCSA-N (3R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]propyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](CC)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C DIFZQEHWYNTPQD-UONOGXRCSA-N 0.000 description 1
- LMIINRXMQUNREC-GXFFZTMASA-N (3R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethyl)phenyl]ethyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)C(F)(F)F)C(C)(C)C LMIINRXMQUNREC-GXFFZTMASA-N 0.000 description 1
- ZJSNQDOKKXXIEB-XHDPSFHLSA-N (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide Chemical compound O[C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C(C)C)C(F)(F)F ZJSNQDOKKXXIEB-XHDPSFHLSA-N 0.000 description 1
- ZUOHVGUPYOIKHV-SMDDNHRTSA-N (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)C(C)C ZUOHVGUPYOIKHV-SMDDNHRTSA-N 0.000 description 1
- UIBDMSSEIRBQDC-GXFFZTMASA-N (3R)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C(C)C UIBDMSSEIRBQDC-GXFFZTMASA-N 0.000 description 1
- RYKRGJLBQWKBGT-UONOGXRCSA-N (3R)-3-hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethylpentanamide Chemical compound O[C@H](CC(=O)N[C@@H](COC)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C RYKRGJLBQWKBGT-UONOGXRCSA-N 0.000 description 1
- YHHZDTBVECMKOL-JOYOIKCWSA-N (3R)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-[1-(trifluoromethyl)cyclopropyl]propanamide Chemical compound O[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C1(CC1)C(F)(F)F YHHZDTBVECMKOL-JOYOIKCWSA-N 0.000 description 1
- QJDBREPSHXKAHJ-TVQRCGJNSA-N (3R)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]butanamide Chemical compound FC([C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C)O)(F)F QJDBREPSHXKAHJ-TVQRCGJNSA-N 0.000 description 1
- UCQCOAQSODWNFL-ISVAXAHUSA-N (3R)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound FC([C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O)(C(F)F)F UCQCOAQSODWNFL-ISVAXAHUSA-N 0.000 description 1
- MZFKOKNHODEJBS-TVQRCGJNSA-N (3R)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound FC(C[C@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O)(F)F MZFKOKNHODEJBS-TVQRCGJNSA-N 0.000 description 1
- YFEXROIPFBZMJX-UONOGXRCSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(1-ethylcyclopropyl)-3-hydroxypropanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@H](O)C1(CC1)CC)=O)F YFEXROIPFBZMJX-UONOGXRCSA-N 0.000 description 1
- JKKHWVGGTHKOOY-BLLLJJGKSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(1-fluorocyclopropyl)-3-hydroxybutanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@](C)(O)C1(CC1)F)=O)F JKKHWVGGTHKOOY-BLLLJJGKSA-N 0.000 description 1
- RITNVXLACQQIDC-LSDHHAIUSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(3,3-dimethylcyclobutyl)-3-hydroxypropanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@H](O)C1CC(C1)(C)C)=O)F RITNVXLACQQIDC-LSDHHAIUSA-N 0.000 description 1
- NCOLOMCPTZJRSC-SUMWQHHRSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3,4-dimethylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@](C(C)C)(C)O)=O)F NCOLOMCPTZJRSC-SUMWQHHRSA-N 0.000 description 1
- HASQLFGGRHZQOE-KBXCAEBGSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3,5-dimethylhexanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@](CC(C)C)(C)O)=O)F HASQLFGGRHZQOE-KBXCAEBGSA-N 0.000 description 1
- VSBSHZWNFVHXRL-NWDGAFQWSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3-[1-(trifluoromethyl)cyclopropyl]propanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@H](C1(CC1)C(F)(F)F)O)=O)F VSBSHZWNFVHXRL-NWDGAFQWSA-N 0.000 description 1
- UYQMYWWYVZCQIW-QWHCGFSZSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical group FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@H](C(C)(C)C)O)=O)F UYQMYWWYVZCQIW-QWHCGFSZSA-N 0.000 description 1
- RQEXYYDMJVKYGK-XHDPSFHLSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-5,5,5-trifluoro-3-hydroxy-3-methylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@](CC(F)(F)F)(C)O)=O)F RQEXYYDMJVKYGK-XHDPSFHLSA-N 0.000 description 1
- FQPRANNXIAWLCE-SWLSCSKDSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(1-fluorocyclopropyl)-3-hydroxybutanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@@](C)(O)C1(CC1)F)=O)F FQPRANNXIAWLCE-SWLSCSKDSA-N 0.000 description 1
- JSFJBYFZDTYEHX-NWDGAFQWSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxy-3-[1-(trifluoromethyl)cyclopropyl]propanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@H](C1(CC1)C(F)(F)F)O)=O)F JSFJBYFZDTYEHX-NWDGAFQWSA-N 0.000 description 1
- RLKLPBLSMYCIMR-QWHCGFSZSA-N (3R)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@H](C(C)(C)C)O)=O)F RLKLPBLSMYCIMR-QWHCGFSZSA-N 0.000 description 1
- XSYJSFMLFDIWJF-GXFFZTMASA-N (3R)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](C)NC(C[C@H](C(C)(C)C)O)=O)F XSYJSFMLFDIWJF-GXFFZTMASA-N 0.000 description 1
- BVCFMTPSASIOGN-ZFWWWQNUSA-N (3S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]butanamide Chemical compound FC1(CC1)[C@@](CC(=O)N[C@@H](COC)C1=CC(=CC=C1)OC(F)(F)F)(C)O BVCFMTPSASIOGN-ZFWWWQNUSA-N 0.000 description 1
- QYDAXJTYTUGMDA-HZMBPMFUSA-N (3S)-3-(1-fluorocyclopropyl)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]butanamide Chemical compound FC1(CC1)[C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O QYDAXJTYTUGMDA-HZMBPMFUSA-N 0.000 description 1
- AJIQRRTWTYNXCD-ZANVPECISA-N (3S)-3-(3,3-difluorocyclobutyl)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propanamide Chemical compound FC1(CC(C1)[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)O)F AJIQRRTWTYNXCD-ZANVPECISA-N 0.000 description 1
- JXROOIQJGMWIPA-STQMWFEESA-N (3S)-3-(3,3-difluorocyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)F)O)F JXROOIQJGMWIPA-STQMWFEESA-N 0.000 description 1
- NXCGVJRTEVJPJV-STQMWFEESA-N (3S)-3-(3,3-difluorocyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)(F)F)O)F NXCGVJRTEVJPJV-STQMWFEESA-N 0.000 description 1
- PWNSUVWRMNJZBR-GJZGRUSLSA-N (3S)-3-(3,3-difluorocyclobutyl)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]butyl]-3-hydroxypropanamide Chemical compound FC1(CC(C1)[C@H](CC(=O)N[C@@H](CCC)C1=CC(=CC=C1)OC(F)F)O)F PWNSUVWRMNJZBR-GJZGRUSLSA-N 0.000 description 1
- AVQBWHCPNABSSH-CABZTGNLSA-N (3S)-3-[1-(difluoromethyl)cyclopropyl]-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]propanamide Chemical compound FC(C1(CC1)[C@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)O)F AVQBWHCPNABSSH-CABZTGNLSA-N 0.000 description 1
- SJXBACWMIQQWOB-GJZGRUSLSA-N (3S)-3-cyclopentyl-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxypropanamide Chemical compound C1(CCCC1)[C@H](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)F)O SJXBACWMIQQWOB-GJZGRUSLSA-N 0.000 description 1
- KFQZZCZVPUZGAY-ZBEGNZNMSA-N (3S)-3-cyclopropyl-3-hydroxy-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]butanamide Chemical compound C1(CC1)[C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C)O KFQZZCZVPUZGAY-ZBEGNZNMSA-N 0.000 description 1
- CNUMXNCWPQLNDB-BBRMVZONSA-N (3S)-3-cyclopropyl-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxybutanamide Chemical compound C1(CC1)[C@@](CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)(F)F)(C)O CNUMXNCWPQLNDB-BBRMVZONSA-N 0.000 description 1
- GUBAUVBQJNTWJV-STQMWFEESA-N (3S)-3-hydroxy-4,4-dimethyl-N-[(1R)-2-(trifluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](COC(F)(F)F)NC(C[C@@H](C(C)(C)C)O)=O)(F)F GUBAUVBQJNTWJV-STQMWFEESA-N 0.000 description 1
- GMOJAGQEZFLHJR-FZMZJTMJSA-N (3S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)C(C)(C)C GMOJAGQEZFLHJR-FZMZJTMJSA-N 0.000 description 1
- KSJFVZDSVVTWQT-GWCFXTLKSA-N (3S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C KSJFVZDSVVTWQT-GWCFXTLKSA-N 0.000 description 1
- DIFZQEHWYNTPQD-KBPBESRZSA-N (3S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]propyl]pentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](CC)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C DIFZQEHWYNTPQD-KBPBESRZSA-N 0.000 description 1
- ZJSNQDOKKXXIEB-NHYWBVRUSA-N (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]-3-(trifluoromethyl)pentanamide Chemical compound O[C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C(C)C)C(F)(F)F ZJSNQDOKKXXIEB-NHYWBVRUSA-N 0.000 description 1
- ZUOHVGUPYOIKHV-FZMZJTMJSA-N (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)C(C)C ZUOHVGUPYOIKHV-FZMZJTMJSA-N 0.000 description 1
- UIBDMSSEIRBQDC-GWCFXTLKSA-N (3S)-3-hydroxy-4-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C(C)C UIBDMSSEIRBQDC-GWCFXTLKSA-N 0.000 description 1
- RYKRGJLBQWKBGT-KBPBESRZSA-N (3S)-3-hydroxy-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-4,4-dimethylpentanamide Chemical compound O[C@@H](CC(=O)N[C@@H](COC)C1=CC(=CC=C1)OC(F)(F)F)C(C)(C)C RYKRGJLBQWKBGT-KBPBESRZSA-N 0.000 description 1
- YHHZDTBVECMKOL-CABZTGNLSA-N (3S)-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-[1-(trifluoromethyl)cyclopropyl]propanamide Chemical compound O[C@@H](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)C1(CC1)C(F)(F)F YHHZDTBVECMKOL-CABZTGNLSA-N 0.000 description 1
- QJDBREPSHXKAHJ-ZANVPECISA-N (3S)-4,4,4-trifluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]butanamide Chemical compound FC([C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F)(C)O)(F)F QJDBREPSHXKAHJ-ZANVPECISA-N 0.000 description 1
- UCQCOAQSODWNFL-SDBXPKJASA-N (3S)-4,4,5,5-tetrafluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound FC([C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O)(C(F)F)F UCQCOAQSODWNFL-SDBXPKJASA-N 0.000 description 1
- MZFKOKNHODEJBS-ZANVPECISA-N (3S)-5,5,5-trifluoro-3-hydroxy-3-methyl-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]pentanamide Chemical compound FC(C[C@@](CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C)O)(F)F MZFKOKNHODEJBS-ZANVPECISA-N 0.000 description 1
- DZHRVMQRFKIUTR-STQMWFEESA-N (3S)-N-[(1R)-1-[3-(difluoromethoxy)phenyl]-2-(trifluoromethoxy)ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](COC(F)(F)F)NC(C[C@@H](C(C)(C)C)O)=O)F DZHRVMQRFKIUTR-STQMWFEESA-N 0.000 description 1
- YFEXROIPFBZMJX-KBPBESRZSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(1-ethylcyclopropyl)-3-hydroxypropanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@H](O)C1(CC1)CC)=O)F YFEXROIPFBZMJX-KBPBESRZSA-N 0.000 description 1
- JKKHWVGGTHKOOY-LRDDRELGSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(1-fluorocyclopropyl)-3-hydroxybutanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@](C)(O)C1(CC1)F)=O)F JKKHWVGGTHKOOY-LRDDRELGSA-N 0.000 description 1
- RITNVXLACQQIDC-GJZGRUSLSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-(3,3-dimethylcyclobutyl)-3-hydroxypropanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@H](O)C1CC(C1)(C)C)=O)F RITNVXLACQQIDC-GJZGRUSLSA-N 0.000 description 1
- NCOLOMCPTZJRSC-GUYCJALGSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3,4-dimethylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@](C(C)C)(C)O)=O)F NCOLOMCPTZJRSC-GUYCJALGSA-N 0.000 description 1
- HASQLFGGRHZQOE-KSSFIOAISA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3,5-dimethylhexanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@](CC(C)C)(C)O)=O)F HASQLFGGRHZQOE-KSSFIOAISA-N 0.000 description 1
- VSBSHZWNFVHXRL-RYUDHWBXSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-3-[1-(trifluoromethyl)cyclopropyl]propanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@H](C1(CC1)C(F)(F)F)O)=O)F VSBSHZWNFVHXRL-RYUDHWBXSA-N 0.000 description 1
- RQEXYYDMJVKYGK-NHYWBVRUSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]-5,5,5-trifluoro-3-hydroxy-3-methylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@](CC(F)(F)F)(C)O)=O)F RQEXYYDMJVKYGK-NHYWBVRUSA-N 0.000 description 1
- FQPRANNXIAWLCE-WFASDCNBSA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(1-fluorocyclopropyl)-3-hydroxybutanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@](C)(O)C1(CC1)F)=O)F FQPRANNXIAWLCE-WFASDCNBSA-N 0.000 description 1
- RLKLPBLSMYCIMR-STQMWFEESA-N (3S)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@@H](C(C)(C)C)O)=O)F RLKLPBLSMYCIMR-STQMWFEESA-N 0.000 description 1
- FKYDTEWCMGFQME-HOTGVXAUSA-N (3S)-N-[(1R)-2-cyclopropyloxy-1-[3-(difluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound C1(CC1)OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(C[C@@H](C(C)(C)C)O)=O FKYDTEWCMGFQME-HOTGVXAUSA-N 0.000 description 1
- RCTWVMOPWPEPRZ-STQMWFEESA-N (3S)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]-3,3-difluoropropyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](CC(F)F)NC(C[C@@H](C(C)(C)C)O)=O)F RCTWVMOPWPEPRZ-STQMWFEESA-N 0.000 description 1
- XRSYTQBBNZBUGO-KBPBESRZSA-N (3S)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]-4,4-difluorobutyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](CCC(F)F)NC(C[C@@H](C(C)(C)C)O)=O)F XRSYTQBBNZBUGO-KBPBESRZSA-N 0.000 description 1
- PAEIGVRFOXLAPN-GJZGRUSLSA-N (3S)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]butyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound FC(OC=1C=C(C=CC=1)[C@H](CCC)NC(C[C@@H](C(C)(C)C)O)=O)F PAEIGVRFOXLAPN-GJZGRUSLSA-N 0.000 description 1
- NZULTRWXRLHUJE-KBPBESRZSA-N (3S)-N-[(1S)-2-cyano-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound C(#N)C[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@@H](C(C)(C)C)O)=O NZULTRWXRLHUJE-KBPBESRZSA-N 0.000 description 1
- MCPFPIFHVGHVKC-GJZGRUSLSA-N (3S)-N-[(1S)-3-cyano-1-[3-(trifluoromethoxy)phenyl]propyl]-3-hydroxy-4,4-dimethylpentanamide Chemical compound C(#N)CC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(C[C@@H](C(C)(C)C)O)=O MCPFPIFHVGHVKC-GJZGRUSLSA-N 0.000 description 1
- PIQCXJAFLBNPHH-UHFFFAOYSA-N (4-nitrophenyl)methyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCC=2C=CC(=CC=2)[N+]([O-])=O)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 PIQCXJAFLBNPHH-UHFFFAOYSA-N 0.000 description 1
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 description 1
- UEERNRSKJQAXQM-UHFFFAOYSA-N 1-(1-benzyl-2,3-dihydroindol-5-yl)-3-phenylurea Chemical compound C=1C=C2N(CC=3C=CC=CC=3)CCC2=CC=1NC(=O)NC1=CC=CC=C1 UEERNRSKJQAXQM-UHFFFAOYSA-N 0.000 description 1
- JBARPWSDHRKCOV-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-(2-phenylethyl)urea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NCCC=3C=CC=CC=3)C=C2CC1 JBARPWSDHRKCOV-UHFFFAOYSA-N 0.000 description 1
- ZAYJLLOZEKWCBU-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-ethylurea Chemical compound C1CC2=CC(NC(=O)NCC)=CC=C2N1CC1=CC=C(Cl)S1 ZAYJLLOZEKWCBU-UHFFFAOYSA-N 0.000 description 1
- GCGSQXNLMVWOOM-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-thiophen-2-ylurea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NC=3SC=CC=3)C=C2CC1 GCGSQXNLMVWOOM-UHFFFAOYSA-N 0.000 description 1
- YOJFQPSCGOKXON-UHFFFAOYSA-N 1-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3-thiophen-3-ylurea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NC3=CSC=C3)C=C2CC1 YOJFQPSCGOKXON-UHFFFAOYSA-N 0.000 description 1
- FFSFFZPIMVSEAI-UHFFFAOYSA-N 1-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-3-(2-fluorophenyl)urea Chemical compound C=1C=C(NC(=O)NC=2C(=CC=CC=2)F)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 FFSFFZPIMVSEAI-UHFFFAOYSA-N 0.000 description 1
- XXORMBACYMRYFK-UHFFFAOYSA-N 1-[2-cyclopentyloxy-4-[(4-fluorophenyl)methyl-methylamino]phenyl]-3-ethylurea Chemical compound CCNC(=O)NC1=CC=C(N(C)CC=2C=CC(F)=CC=2)C=C1OC1CCCC1 XXORMBACYMRYFK-UHFFFAOYSA-N 0.000 description 1
- YNNPZLJSEXYKHU-UHFFFAOYSA-N 1-amino-n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]cyclopropane-1-carboxamide Chemical compound C=1C=C(NC(=O)C2(N)CC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 YNNPZLJSEXYKHU-UHFFFAOYSA-N 0.000 description 1
- LLIJZRLDYOMJMP-UHFFFAOYSA-N 1-benzyl-3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]urea Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)NCC=3C=CC=CC=3)C=C2CC1 LLIJZRLDYOMJMP-UHFFFAOYSA-N 0.000 description 1
- RIGHAWDGCPENFC-UHFFFAOYSA-N 1-tert-butyl-3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]urea Chemical compound C1CC2=CC(NC(=O)NC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 RIGHAWDGCPENFC-UHFFFAOYSA-N 0.000 description 1
- NHUKLKFWYRPWKW-UHFFFAOYSA-N 2,2,2-trichloro-n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]acetamide Chemical compound C=1C=C(NC(=O)C(Cl)(Cl)Cl)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 NHUKLKFWYRPWKW-UHFFFAOYSA-N 0.000 description 1
- GRPYQETWCYYASI-UHFFFAOYSA-N 2,2-dimethyl-n-[2-methyl-4-[(3-methyl-5-phenyl-1,2-oxazol-4-yl)methylamino]phenyl]propanamide Chemical compound CC1=NOC(C=2C=CC=CC=2)=C1CNC1=CC=C(NC(=O)C(C)(C)C)C(C)=C1 GRPYQETWCYYASI-UHFFFAOYSA-N 0.000 description 1
- GLHVEYVVFXLYTL-UHFFFAOYSA-N 2,2-dimethyl-n-[2-methyl-4-[(6-phenoxypyridin-3-yl)methylamino]phenyl]propanamide Chemical compound C1=C(NC(=O)C(C)(C)C)C(C)=CC(NCC=2C=NC(OC=3C=CC=CC=3)=CC=2)=C1 GLHVEYVVFXLYTL-UHFFFAOYSA-N 0.000 description 1
- DEVMYXUBWJWPOI-UHFFFAOYSA-N 2,2-dimethyl-n-[6-nitro-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]propanamide Chemical compound C1=2C=C([N+]([O-])=O)C(NC(=O)C(C)(C)C)=CC=2CCN1CC1=CC=C(C(F)(F)F)C=C1 DEVMYXUBWJWPOI-UHFFFAOYSA-N 0.000 description 1
- MYGXIGJESMGAQN-UHFFFAOYSA-N 2,2-dimethylpropyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCC(C)(C)C)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 MYGXIGJESMGAQN-UHFFFAOYSA-N 0.000 description 1
- YLPMMKAFBIWKMT-NSHDSACASA-N 2-(1-hydroxycyclobutyl)-N-[(1S)-1-[3-(2,2,2-trifluoroethoxy)phenyl]ethyl]acetamide Chemical compound OC1(CCC1)CC(=O)N[C@@H](C)C1=CC(=CC=C1)OCC(F)(F)F YLPMMKAFBIWKMT-NSHDSACASA-N 0.000 description 1
- UJCHGIKQETVOMC-AWEZNQCLSA-N 2-(1-hydroxycyclopentyl)-N-[(1R)-2-methoxy-1-[3-(trifluoromethoxy)phenyl]ethyl]acetamide Chemical compound OC1(CCCC1)CC(=O)N[C@@H](COC)C1=CC(=CC=C1)OC(F)(F)F UJCHGIKQETVOMC-AWEZNQCLSA-N 0.000 description 1
- SKNMSASRJJFRGX-UHFFFAOYSA-N 2-(2,2-difluoroethoxy)-n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(OCC(F)F)=C1C(=O)NCC1=CC=C(F)C=C1 SKNMSASRJJFRGX-UHFFFAOYSA-N 0.000 description 1
- MBGBDCSGKYOPEA-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC=C1Cl MBGBDCSGKYOPEA-UHFFFAOYSA-N 0.000 description 1
- OSYNGASVTMRBTH-NSHDSACASA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1R)-1-[3-(difluoromethoxy)phenyl]-2-(trifluoromethoxy)ethyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](COC(F)(F)F)C1=CC(=CC=C1)OC(F)F)F OSYNGASVTMRBTH-NSHDSACASA-N 0.000 description 1
- XKXZUZYXIMBRHM-NSHDSACASA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(difluoromethoxy)phenyl]ethyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)F)F XKXZUZYXIMBRHM-NSHDSACASA-N 0.000 description 1
- LGBTWNLXSWDIKU-NSHDSACASA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1R)-2-(difluoromethoxy)-1-[3-(trifluoromethoxy)phenyl]ethyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](COC(F)F)C1=CC(=CC=C1)OC(F)(F)F)F LGBTWNLXSWDIKU-NSHDSACASA-N 0.000 description 1
- WRRRGEGPSKEFOF-LBPRGKRZSA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]-4,4-difluorobutyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](CCC(F)F)C1=CC(=CC=C1)OC(F)F)F WRRRGEGPSKEFOF-LBPRGKRZSA-N 0.000 description 1
- JKUCYYBPLCNZNR-ZDUSSCGKSA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1S)-1-[3-(difluoromethoxy)phenyl]butyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](CCC)C1=CC(=CC=C1)OC(F)F)F JKUCYYBPLCNZNR-ZDUSSCGKSA-N 0.000 description 1
- HPBORWCPJFILIF-VIFPVBQESA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)F HPBORWCPJFILIF-VIFPVBQESA-N 0.000 description 1
- ZDOFNGNHYFRWHV-LBPRGKRZSA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]propyl]acetamide Chemical compound FC1(CC(C1)(O)CC(=O)N[C@@H](CC)C1=CC(=CC=C1)OC(F)(F)F)F ZDOFNGNHYFRWHV-LBPRGKRZSA-N 0.000 description 1
- OIAURZOOVQHDDC-NSHDSACASA-N 2-(3,3-difluoro-1-hydroxycyclobutyl)-N-[(1S)-3,3-difluoro-1-[3-(trifluoromethoxy)phenyl]propyl]acetamide Chemical compound FC(C[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(CC1(CC(C1)(F)F)O)=O)F OIAURZOOVQHDDC-NSHDSACASA-N 0.000 description 1
- CKYXLLATWNDTOC-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 CKYXLLATWNDTOC-UHFFFAOYSA-N 0.000 description 1
- HQFQNYRKJOYWEY-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(Cl)C(Cl)=C1 HQFQNYRKJOYWEY-UHFFFAOYSA-N 0.000 description 1
- XBRHVWUAWYACKQ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 XBRHVWUAWYACKQ-UHFFFAOYSA-N 0.000 description 1
- IRYKZAAWGNDZJR-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 IRYKZAAWGNDZJR-UHFFFAOYSA-N 0.000 description 1
- LJUSTXRGYUENLJ-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(F)C(F)=C1 LJUSTXRGYUENLJ-UHFFFAOYSA-N 0.000 description 1
- YYIRIYBLIVBHTF-UHFFFAOYSA-N 2-(3,4-difluorophenyl)-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1=CC=C(F)C(F)=C1 YYIRIYBLIVBHTF-UHFFFAOYSA-N 0.000 description 1
- ILHJZFCXQIZPDX-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)-n-(2,6-difluoro-4-morpholin-4-ylphenyl)acetamide Chemical compound C=1C(F)=C(NC(=O)CC2C3CCC(C3)C2)C(F)=CC=1N1CCOCC1 ILHJZFCXQIZPDX-UHFFFAOYSA-N 0.000 description 1
- GTZXKLYUHHQHSC-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound C=1C(C)=C(NC(=O)CC2C3CCC(C3)C2)C(C)=CC=1N1CCOCC1 GTZXKLYUHHQHSC-UHFFFAOYSA-N 0.000 description 1
- QYSLJXPOHRZRIG-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound C=1C(C)=C(NC(=O)CC2C3CCC(C3)C2)C(OC)=CC=1N1CCOCC1 QYSLJXPOHRZRIG-UHFFFAOYSA-N 0.000 description 1
- NUSLMFYDIBZGMM-UHFFFAOYSA-N 2-(3-bicyclo[2.2.1]heptanyl)-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C=1C(C(F)(F)F)=C(NC(=O)CC2C3CCC(C3)C2)C(C)=CC=1N1CCOCC1 NUSLMFYDIBZGMM-UHFFFAOYSA-N 0.000 description 1
- LTYGQAJETYOFCA-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(Br)=C1 LTYGQAJETYOFCA-UHFFFAOYSA-N 0.000 description 1
- HJIGCVIPHPXEAG-UHFFFAOYSA-N 2-(3-bromophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(Br)=C1 HJIGCVIPHPXEAG-UHFFFAOYSA-N 0.000 description 1
- IWPAOTPPULTUIR-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(Cl)=C1 IWPAOTPPULTUIR-UHFFFAOYSA-N 0.000 description 1
- NBHOSDYTOKFPRM-UHFFFAOYSA-N 2-(3-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(Cl)=C1 NBHOSDYTOKFPRM-UHFFFAOYSA-N 0.000 description 1
- SUSVXXUDGGTLSU-UHFFFAOYSA-N 2-(3-fluorophenyl)-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(F)=C1 SUSVXXUDGGTLSU-UHFFFAOYSA-N 0.000 description 1
- BTBAXIZZRMPJQV-UHFFFAOYSA-N 2-(4-chlorophenyl)-2-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1C(C(N)=O)C1=CC=C(Cl)C=C1 BTBAXIZZRMPJQV-UHFFFAOYSA-N 0.000 description 1
- NWZHLVIUDQICHI-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(Cl)C=C1 NWZHLVIUDQICHI-UHFFFAOYSA-N 0.000 description 1
- AFRIITXJFGWUIR-UHFFFAOYSA-N 2-(4-chlorophenyl)-n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(Cl)=CC=2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 AFRIITXJFGWUIR-UHFFFAOYSA-N 0.000 description 1
- ZPFYRNYAFHWGCP-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(3-methyl-1-benzothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound S1C2=CC=CC=C2C(C)=C1CN(C1=CC=2)CCC1=CC=2NC(=O)CC1=CC=C(F)C=C1 ZPFYRNYAFHWGCP-UHFFFAOYSA-N 0.000 description 1
- LPDVJOCWBDEEEW-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CN1C2=CC=C(NC(=O)CC=3C=CC(F)=CC=3)C=C2CC1 LPDVJOCWBDEEEW-UHFFFAOYSA-N 0.000 description 1
- FUQCSQOPQGGTMJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(4-propan-2-ylphenyl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(C(C)C)=CC=C1CN1C2=CC=C(NC(=O)CC=3C=CC(F)=CC=3)C=C2CC1 FUQCSQOPQGGTMJ-UHFFFAOYSA-N 0.000 description 1
- XWWIWAYHYBUEOM-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(4-pyrrol-1-ylphenyl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=CC(=CC=2)N2C=CC=C2)CC2)C2=C1 XWWIWAYHYBUEOM-UHFFFAOYSA-N 0.000 description 1
- QQUSMFXPMZFVKA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(5-methylthiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound S1C(C)=CC=C1CN1C2=CC=C(NC(=O)CC=3C=CC(F)=CC=3)C=C2CC1 QQUSMFXPMZFVKA-UHFFFAOYSA-N 0.000 description 1
- QNRZUZICHNHCIG-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[(6-phenoxypyridin-3-yl)methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=NC(OC=3C=CC=CC=3)=CC=2)CC2)C2=C1 QNRZUZICHNHCIG-UHFFFAOYSA-N 0.000 description 1
- RMHGQWOFMGLFEZ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[[1-(4-fluorophenyl)-5-methylpyrazol-4-yl]methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=NN(C=2C=CC(F)=CC=2)C(C)=C1CN(C1=CC=2)CCC1=CC=2NC(=O)CC1=CC=C(F)C=C1 RMHGQWOFMGLFEZ-UHFFFAOYSA-N 0.000 description 1
- LJCVHMNQOJFZMH-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=C(F)C(=CC=2)C(F)(F)F)CC2)C2=C1 LJCVHMNQOJFZMH-UHFFFAOYSA-N 0.000 description 1
- AFQXQYAUOYAODD-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=CC(=CC=2)C(F)(F)F)CC2)C2=C1 AFQXQYAUOYAODD-UHFFFAOYSA-N 0.000 description 1
- BVVODLBVDQPGLE-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-(2-methoxyphenyl)-4,6-dimethylphenyl]acetamide Chemical compound COC1=CC=CC=C1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 BVVODLBVDQPGLE-UHFFFAOYSA-N 0.000 description 1
- NZPNIYSWXIODAQ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-(3-hydroxyphenyl)-4,6-dimethylphenyl]acetamide Chemical compound C=1C=CC(O)=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 NZPNIYSWXIODAQ-UHFFFAOYSA-N 0.000 description 1
- PJDXAWQBHMKTGT-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-(4-fluorophenyl)-4,6-dimethylphenyl]acetamide Chemical compound C=1C=C(F)C=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 PJDXAWQBHMKTGT-UHFFFAOYSA-N 0.000 description 1
- SWBMVGKDTGXPPJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-(4-hydroxy-3-methoxyphenyl)-4,6-dimethylphenyl]acetamide Chemical compound C1=C(O)C(OC)=CC(C=2C(=C(C)C=C(C)C=2)NC(=O)CC=2C=CC(F)=CC=2)=C1 SWBMVGKDTGXPPJ-UHFFFAOYSA-N 0.000 description 1
- GYRGAOXFXFTXRY-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-[2-(methanesulfonamido)phenyl]-4,6-dimethylphenyl]acetamide Chemical compound C=1C=CC=C(NS(C)(=O)=O)C=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 GYRGAOXFXFTXRY-UHFFFAOYSA-N 0.000 description 1
- PRGUIBZYEJEARJ-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-methyl-4-[(4-methyl-2-phenylpyrimidin-5-yl)methylamino]phenyl]acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=CC=1NCC(C(=N1)C)=CN=C1C1=CC=CC=C1 PRGUIBZYEJEARJ-UHFFFAOYSA-N 0.000 description 1
- DNHDTULZZSOSBN-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[2-methyl-4-[[6-(trifluoromethyl)pyridin-3-yl]methylamino]phenyl]acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)N=C1 DNHDTULZZSOSBN-UHFFFAOYSA-N 0.000 description 1
- PSPKOXMCPHZZFA-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[4-morpholin-4-yl-2-pyridin-3-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=C(C=2C=NC=CC=2)C=C(N2CCOCC2)C=C1C(F)(F)F PSPKOXMCPHZZFA-UHFFFAOYSA-N 0.000 description 1
- CSEQTDRDZQLHLC-UHFFFAOYSA-N 2-(4-fluorophenyl)-n-[6-nitro-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]acetamide Chemical compound C1CC=2C=C(NC(=O)CC=3C=CC(F)=CC=3)C([N+](=O)[O-])=CC=2N1CC1=CC=C(C(F)(F)F)C=C1 CSEQTDRDZQLHLC-UHFFFAOYSA-N 0.000 description 1
- MEPMQOPXUQHOJD-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CCCCC1 MEPMQOPXUQHOJD-UHFFFAOYSA-N 0.000 description 1
- RDNDOPVAJJVCBT-UHFFFAOYSA-N 2-(cyclopropylmethoxy)-n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1OCC1CC1 RDNDOPVAJJVCBT-UHFFFAOYSA-N 0.000 description 1
- OUSZPGODKNTAAX-UHFFFAOYSA-N 2-[2,6-dichloro-4-[(4-fluoroanilino)methyl]phenyl]acetamide Chemical compound ClC1=C(C(=CC(=C1)CNC1=CC=C(C=C1)F)Cl)CC(=O)N OUSZPGODKNTAAX-UHFFFAOYSA-N 0.000 description 1
- PGLSVMVUFODKTC-UHFFFAOYSA-N 2-[methyl(oxan-4-yl)amino]-4-propan-2-yl-n-[1-[3-(trifluoromethoxy)phenyl]ethyl]-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N(C)C2CCOCC2)SC=1C(=O)NC(C)C1=CC=CC(OC(F)(F)F)=C1 PGLSVMVUFODKTC-UHFFFAOYSA-N 0.000 description 1
- CKPWEXYYJQYKLW-UHFFFAOYSA-N 2-[methyl(oxan-4-yl)amino]-n-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC(OC(F)(F)F)=CC=1C(C)NC(=O)C(=C(N=1)C(F)(F)F)SC=1N(C)C1CCOCC1 CKPWEXYYJQYKLW-UHFFFAOYSA-N 0.000 description 1
- CTLDXAQOOXXBHX-UHFFFAOYSA-N 2-[methyl(oxan-4-yl)amino]-n-[[3-(trifluoromethoxy)phenyl]methyl]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound N=1C(C(F)(F)F)=C(C(=O)NCC=2C=C(OC(F)(F)F)C=CC=2)SC=1N(C)C1CCOCC1 CTLDXAQOOXXBHX-UHFFFAOYSA-N 0.000 description 1
- GEJNAMJGDWMGLL-UHFFFAOYSA-N 2-[methyl(oxan-4-ylmethyl)amino]-4-propan-2-yl-n-[1-[3-(trifluoromethoxy)phenyl]ethyl]-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N(C)CC2CCOCC2)SC=1C(=O)NC(C)C1=CC=CC(OC(F)(F)F)=C1 GEJNAMJGDWMGLL-UHFFFAOYSA-N 0.000 description 1
- ZIIPIPZHXCNHRT-UHUGOGIASA-N 2-butan-2-yl-n-(4,4-dimethylpentyl)-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(C(C)CC)=NC(N2[C@@H](COCC2)C)=C1 ZIIPIPZHXCNHRT-UHUGOGIASA-N 0.000 description 1
- VYCXZZDSDUCFJZ-UHFFFAOYSA-N 2-butan-2-yl-n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(C(C)CC)=NC(N2CCOCC2)=C1 VYCXZZDSDUCFJZ-UHFFFAOYSA-N 0.000 description 1
- ALAZDLNJMPJATH-UHFFFAOYSA-N 2-butan-2-yl-n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 ALAZDLNJMPJATH-UHFFFAOYSA-N 0.000 description 1
- DAWBWEJLCDJYLO-UHFFFAOYSA-N 2-butan-2-yl-n-[(4-chlorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 DAWBWEJLCDJYLO-UHFFFAOYSA-N 0.000 description 1
- YUAAPTMCQMLUIS-OMOCHNIRSA-N 2-butan-2-yl-n-[(4-fluorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CCC(C)C1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 YUAAPTMCQMLUIS-OMOCHNIRSA-N 0.000 description 1
- UPCJNRTTXBYUJZ-UHFFFAOYSA-N 2-butoxy-n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCCCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 UPCJNRTTXBYUJZ-UHFFFAOYSA-N 0.000 description 1
- SNEXUGCLLJJMOX-UHFFFAOYSA-N 2-chloro-4-n-[(5-chlorothiophen-2-yl)methyl]-4-n-methylbenzene-1,4-diamine Chemical compound C=1C=C(N)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 SNEXUGCLLJJMOX-UHFFFAOYSA-N 0.000 description 1
- VUAMDENGEUCDEU-UHFFFAOYSA-N 2-cycloheptyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCCCC1 VUAMDENGEUCDEU-UHFFFAOYSA-N 0.000 description 1
- RBNYGVBKVZOQMQ-UHFFFAOYSA-N 2-cyclohexyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCCC1 RBNYGVBKVZOQMQ-UHFFFAOYSA-N 0.000 description 1
- TZAZWGAJSJSJCU-UHFFFAOYSA-N 2-cyclohexyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCCCC1 TZAZWGAJSJSJCU-UHFFFAOYSA-N 0.000 description 1
- SZAJYDMCXYMAMV-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCC=C1 SZAJYDMCXYMAMV-UHFFFAOYSA-N 0.000 description 1
- SHIXPWQRHRYAPF-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-(2,6-difluoro-4-morpholin-4-ylphenyl)acetamide Chemical compound FC1=CC(N2CCOCC2)=CC(F)=C1NC(=O)CC1CCC=C1 SHIXPWQRHRYAPF-UHFFFAOYSA-N 0.000 description 1
- NSJRMPWZUISROM-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCC=C1 NSJRMPWZUISROM-UHFFFAOYSA-N 0.000 description 1
- ZIRYOJPIWUDDFZ-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)acetamide Chemical compound COC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1CCC=C1 ZIRYOJPIWUDDFZ-UHFFFAOYSA-N 0.000 description 1
- LTINJHGWWBUWHC-UHFFFAOYSA-N 2-cyclopent-2-en-1-yl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1CCC=C1 LTINJHGWWBUWHC-UHFFFAOYSA-N 0.000 description 1
- ZWODLPCPFZMMPF-UHFFFAOYSA-N 2-cyclopentyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1CCCC1 ZWODLPCPFZMMPF-UHFFFAOYSA-N 0.000 description 1
- ULKJRSJOIDFZPK-UHFFFAOYSA-N 2-cyclopentyl-n-(2,4-dimethyl-6-phenylphenyl)acetamide Chemical compound C=1C=CC=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1CCCC1 ULKJRSJOIDFZPK-UHFFFAOYSA-N 0.000 description 1
- RUAANJRZGQTEQK-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-diethyl-4-morpholin-4-ylphenyl)acetamide Chemical compound CCC1=CC(N2CCOCC2)=CC(CC)=C1NC(=O)CC1CCCC1 RUAANJRZGQTEQK-UHFFFAOYSA-N 0.000 description 1
- XBHFMQFTDNMLBJ-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-difluoro-4-morpholin-4-ylphenyl)acetamide Chemical compound FC1=CC(N2CCOCC2)=CC(F)=C1NC(=O)CC1CCCC1 XBHFMQFTDNMLBJ-UHFFFAOYSA-N 0.000 description 1
- DUSXFTDHIFENLP-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-dimethyl-4-pyrrol-1-ylphenyl)acetamide Chemical compound CC1=CC(N2C=CC=C2)=CC(C)=C1NC(=O)CC1CCCC1 DUSXFTDHIFENLP-UHFFFAOYSA-N 0.000 description 1
- IKPVUBMYZIWNRW-UHFFFAOYSA-N 2-cyclopentyl-n-(2,6-dimethyl-4-thiomorpholin-4-ylphenyl)acetamide Chemical compound CC1=CC(N2CCSCC2)=CC(C)=C1NC(=O)CC1CCCC1 IKPVUBMYZIWNRW-UHFFFAOYSA-N 0.000 description 1
- AXEGVKSLGNHUDL-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dichloro-4-[[[5-(trifluoromethyl)pyridin-2-yl]amino]methyl]phenyl]acetamide Chemical compound N1=CC(C(F)(F)F)=CC=C1NCC(C=C1Cl)=CC(Cl)=C1NC(=O)CC1CCCC1 AXEGVKSLGNHUDL-UHFFFAOYSA-N 0.000 description 1
- KDEDDVIUECCASI-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-(2-phenylmorpholin-4-yl)phenyl]acetamide Chemical compound CC1=CC(N2CC(OCC2)C=2C=CC=CC=2)=CC(C)=C1NC(=O)CC1CCCC1 KDEDDVIUECCASI-UHFFFAOYSA-N 0.000 description 1
- WAVXDFUOPQGUBX-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-(2-phenylthiomorpholin-4-yl)phenyl]acetamide Chemical compound CC1=CC(N2CC(SCC2)C=2C=CC=CC=2)=CC(C)=C1NC(=O)CC1CCCC1 WAVXDFUOPQGUBX-UHFFFAOYSA-N 0.000 description 1
- WNTSBBJWRJVJGJ-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-(3-pyridin-3-ylthiomorpholin-4-yl)phenyl]acetamide Chemical compound CC1=CC(N2C(CSCC2)C=2C=NC=CC=2)=CC(C)=C1NC(=O)CC1CCCC1 WNTSBBJWRJVJGJ-UHFFFAOYSA-N 0.000 description 1
- WRDIBHFRJFDWAW-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[(4-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(C)=CC=C1NCC(C=C1C)=CC(C)=C1NC(=O)CC1CCCC1 WRDIBHFRJFDWAW-UHFFFAOYSA-N 0.000 description 1
- OYVKDFWBJVLPQJ-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[2-[4-(trifluoromethyl)phenyl]morpholin-4-yl]phenyl]acetamide Chemical compound CC1=CC(N2CC(OCC2)C=2C=CC(=CC=2)C(F)(F)F)=CC(C)=C1NC(=O)CC1CCCC1 OYVKDFWBJVLPQJ-UHFFFAOYSA-N 0.000 description 1
- PMAATXNYIJEXNJ-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[2-[4-(trifluoromethyl)phenyl]pyrrolidin-1-yl]phenyl]acetamide Chemical compound CC1=CC(N2C(CCC2)C=2C=CC(=CC=2)C(F)(F)F)=CC(C)=C1NC(=O)CC1CCCC1 PMAATXNYIJEXNJ-UHFFFAOYSA-N 0.000 description 1
- FKTVZYJYGPVDFU-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[2-[4-(trifluoromethyl)phenyl]thiomorpholin-4-yl]phenyl]acetamide Chemical compound CC1=CC(N2CC(SCC2)C=2C=CC(=CC=2)C(F)(F)F)=CC(C)=C1NC(=O)CC1CCCC1 FKTVZYJYGPVDFU-UHFFFAOYSA-N 0.000 description 1
- BHVKYMSGYOOSCM-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[[3-(trifluoromethyl)anilino]methyl]phenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=CC(C(F)(F)F)=C1 BHVKYMSGYOOSCM-UHFFFAOYSA-N 0.000 description 1
- CUDFPNFQWMAENQ-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=C(C(F)(F)F)C=C1 CUDFPNFQWMAENQ-UHFFFAOYSA-N 0.000 description 1
- DLDVNHYJIZFLMR-UHFFFAOYSA-N 2-cyclopentyl-n-[2,6-dimethyl-4-[[6-(trifluoromethyl)pyridin-3-yl]methylamino]phenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)N=C1 DLDVNHYJIZFLMR-UHFFFAOYSA-N 0.000 description 1
- ODKCVNGBBSVGMV-UHFFFAOYSA-N 2-cyclopentyl-n-[2-(3,4-difluorophenyl)-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1=C(F)C(F)=CC=C1C1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1CCCC1 ODKCVNGBBSVGMV-UHFFFAOYSA-N 0.000 description 1
- ODMKRGYVCINZSZ-UHFFFAOYSA-N 2-cyclopentyl-n-[2-(3-methylphenyl)-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC=CC(C=2C(=C(C=C(C=2)N2CCOCC2)C(F)(F)F)NC(=O)CC2CCCC2)=C1 ODMKRGYVCINZSZ-UHFFFAOYSA-N 0.000 description 1
- ZEIHZBPMFYBKDA-UHFFFAOYSA-N 2-cyclopentyl-n-[2-(4-fluorophenyl)-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(F)=CC=C1C1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1CCCC1 ZEIHZBPMFYBKDA-UHFFFAOYSA-N 0.000 description 1
- IBCAZLGTVOBBRF-UHFFFAOYSA-N 2-cyclopentyl-n-[2-(4-methylphenyl)-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1=CC(C)=CC=C1C1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1CCCC1 IBCAZLGTVOBBRF-UHFFFAOYSA-N 0.000 description 1
- OGNZSCJYYOGBKZ-UHFFFAOYSA-N 2-cyclopentyl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C(F)(F)F)=C1NC(=O)CC1CCCC1 OGNZSCJYYOGBKZ-UHFFFAOYSA-N 0.000 description 1
- LCYQPINKRYIIOS-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[(3,4-difluoroanilino)methyl]-2,6-dimethylphenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=C(F)C(F)=C1 LCYQPINKRYIIOS-UHFFFAOYSA-N 0.000 description 1
- AMWMRPRVCNJRRI-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[(3,5-difluoroanilino)methyl]-2,6-dimethylphenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC(F)=CC(F)=C1 AMWMRPRVCNJRRI-UHFFFAOYSA-N 0.000 description 1
- QZCCCEGFZZERCR-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[(3-fluoroanilino)methyl]-2,6-dimethylphenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=CC(F)=C1 QZCCCEGFZZERCR-UHFFFAOYSA-N 0.000 description 1
- BPVGYTFULZLUOK-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[(3-methoxyanilino)methyl]-2,6-dimethylphenyl]acetamide Chemical compound COC1=CC=CC(NCC=2C=C(C)C(NC(=O)CC3CCCC3)=C(C)C=2)=C1 BPVGYTFULZLUOK-UHFFFAOYSA-N 0.000 description 1
- QMYLQTWZCYUOFN-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[2-(4-fluorophenyl)morpholin-4-yl]-2,6-dimethylphenyl]acetamide Chemical compound CC1=CC(N2CC(OCC2)C=2C=CC(F)=CC=2)=CC(C)=C1NC(=O)CC1CCCC1 QMYLQTWZCYUOFN-UHFFFAOYSA-N 0.000 description 1
- AQEXWXASGXBTCS-UHFFFAOYSA-N 2-cyclopentyl-n-[4-[[(2,6-dichloropyridin-4-yl)amino]methyl]-2,6-dimethylphenyl]acetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC(Cl)=NC(Cl)=C1 AQEXWXASGXBTCS-UHFFFAOYSA-N 0.000 description 1
- SEMYLXWJGQSZRH-UHFFFAOYSA-N 2-cyclopentyl-n-[4-morpholin-4-yl-2,6-di(propan-2-yl)phenyl]acetamide Chemical compound CC(C)C1=CC(N2CCOCC2)=CC(C(C)C)=C1NC(=O)CC1CCCC1 SEMYLXWJGQSZRH-UHFFFAOYSA-N 0.000 description 1
- PRRCZFLHDUNRPA-UHFFFAOYSA-N 2-cyclopentyl-n-[4-morpholin-4-yl-2-phenyl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1CCCC1CC(=O)NC=1C(C(F)(F)F)=CC(N2CCOCC2)=CC=1C1=CC=CC=C1 PRRCZFLHDUNRPA-UHFFFAOYSA-N 0.000 description 1
- ZLWDSPAALMHRPZ-UHFFFAOYSA-N 2-cyclopentyl-n-[4-morpholin-4-yl-2-pyridin-3-yl-6-(trifluoromethyl)phenyl]acetamide Chemical compound C1CCCC1CC(=O)NC=1C(C(F)(F)F)=CC(N2CCOCC2)=CC=1C1=CC=CN=C1 ZLWDSPAALMHRPZ-UHFFFAOYSA-N 0.000 description 1
- HBBWROKDDZEFRV-UHFFFAOYSA-N 2-cyclopropyl-4-methyl-6-morpholin-4-yl-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound FC(F)(F)CCCNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 HBBWROKDDZEFRV-UHFFFAOYSA-N 0.000 description 1
- TZHSELNBKFGDQG-UHFFFAOYSA-N 2-cyclopropyl-4-methyl-6-morpholin-4-yl-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 TZHSELNBKFGDQG-UHFFFAOYSA-N 0.000 description 1
- UILLPWDZKNMHDA-MRXNPFEDSA-N 2-cyclopropyl-n-(4,4-dimethylpentyl)-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound C[C@@H]1COCCN1C1=CC(C)=C(C(=O)NCCCC(C)(C)C)C(C2CC2)=N1 UILLPWDZKNMHDA-MRXNPFEDSA-N 0.000 description 1
- RBMAGQBDCSZGQC-UHFFFAOYSA-N 2-cyclopropyl-n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC(C)(C)CCCNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 RBMAGQBDCSZGQC-UHFFFAOYSA-N 0.000 description 1
- CASVXKAIMIIKOF-UHFFFAOYSA-N 2-cyclopropyl-n-[(3,4-difluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(F)C(F)=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 CASVXKAIMIIKOF-UHFFFAOYSA-N 0.000 description 1
- VUVZCZFQDXONSY-UHFFFAOYSA-N 2-cyclopropyl-n-[(3,5-difluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C(F)=CC(F)=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 VUVZCZFQDXONSY-UHFFFAOYSA-N 0.000 description 1
- LSNNVAQGIIAPRS-UHFFFAOYSA-N 2-cyclopropyl-n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=CC(F)=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 LSNNVAQGIIAPRS-UHFFFAOYSA-N 0.000 description 1
- HMNYDOODTQTHBJ-OAHLLOKOSA-N 2-cyclopropyl-n-[(4-fluorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound C[C@@H]1COCCN1C(N=C1C2CC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 HMNYDOODTQTHBJ-OAHLLOKOSA-N 0.000 description 1
- LOYTXOODDVLDNC-UHFFFAOYSA-N 2-cyclopropyl-n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(F)C=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 LOYTXOODDVLDNC-UHFFFAOYSA-N 0.000 description 1
- CSSOFWTXKFELHV-UHFFFAOYSA-N 2-cyclopropyl-n-[[3-fluoro-4-(methoxymethyl)phenyl]methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C1=C(F)C(COC)=CC=C1CNC(=O)C1=C(C)C=C(N2CCOCC2)N=C1C1CC1 CSSOFWTXKFELHV-UHFFFAOYSA-N 0.000 description 1
- VWDOJNYXPFNGOI-UHFFFAOYSA-N 2-cyclopropyl-n-[[4-fluoro-3-(methoxymethyl)phenyl]methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C1=C(F)C(COC)=CC(CNC(=O)C=2C(=NC(=CC=2C)N2CCOCC2)C2CC2)=C1 VWDOJNYXPFNGOI-UHFFFAOYSA-N 0.000 description 1
- KKLIKEWSMXZEDD-UHFFFAOYSA-N 2-ethoxy-4-methyl-6-morpholin-4-yl-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(F)(F)F)C(OCC)=NC(N2CCOCC2)=C1 KKLIKEWSMXZEDD-UHFFFAOYSA-N 0.000 description 1
- ISWAUUWDOSDKNG-UHFFFAOYSA-N 2-ethoxy-4-methyl-6-morpholin-4-yl-n-[(2-phenylphenyl)methyl]pyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC=C1C1=CC=CC=C1 ISWAUUWDOSDKNG-UHFFFAOYSA-N 0.000 description 1
- MSILEJYBESKGRU-UHFFFAOYSA-N 2-ethoxy-4-methyl-6-morpholin-4-yl-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 MSILEJYBESKGRU-UHFFFAOYSA-N 0.000 description 1
- XNDKLMODEYHANF-OAHLLOKOSA-N 2-ethoxy-n-[(4-fluorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CCOC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 XNDKLMODEYHANF-OAHLLOKOSA-N 0.000 description 1
- NLXHEAQTKWGWDS-UHFFFAOYSA-N 2-ethoxy-n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 NLXHEAQTKWGWDS-UHFFFAOYSA-N 0.000 description 1
- KCXAFJUCUBASPC-UHFFFAOYSA-N 2-ethyl-n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 KCXAFJUCUBASPC-UHFFFAOYSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- MGKRAIFZDKOISW-GFCCVEGCSA-N 2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(F)(F)F)C(OC)=NC(N2[C@@H](COCC2)C)=C1 MGKRAIFZDKOISW-GFCCVEGCSA-N 0.000 description 1
- RDGODMZVSLEMAG-CQSZACIVSA-N 2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 RDGODMZVSLEMAG-CQSZACIVSA-N 0.000 description 1
- TZWAJKRRQSYSJV-UHFFFAOYSA-N 2-methoxy-4-methyl-6-morpholin-4-yl-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(F)(F)F)C(OC)=NC(N2CCOCC2)=C1 TZWAJKRRQSYSJV-UHFFFAOYSA-N 0.000 description 1
- NHQCCNUMZHQKCH-UHFFFAOYSA-N 2-methoxy-4-methyl-6-morpholin-4-yl-n-[(2-phenylphenyl)methyl]pyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC=C1C1=CC=CC=C1 NHQCCNUMZHQKCH-UHFFFAOYSA-N 0.000 description 1
- MDIJJRXFTPILBS-UHFFFAOYSA-N 2-methoxy-4-methyl-6-morpholin-4-yl-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 MDIJJRXFTPILBS-UHFFFAOYSA-N 0.000 description 1
- UYUQLIZCUOSRRQ-UHFFFAOYSA-N 2-methoxyethyl n-[2,6-dimethyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCOC)=C(C)C=C1CNC1=CC=C(C(F)(F)F)C=C1 UYUQLIZCUOSRRQ-UHFFFAOYSA-N 0.000 description 1
- NNJPKMLLSQRIQX-UHFFFAOYSA-N 2-methylpropyl n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)carbamate Chemical compound N1=C(C)C(NC(=O)OCC(C)C)=C(C)C=C1N1CCOCC1 NNJPKMLLSQRIQX-UHFFFAOYSA-N 0.000 description 1
- WJLXTOBWTZRKRD-UHFFFAOYSA-N 2-methylpropyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC(C)C)=CC=C1N(C)CC1=CC=C(Cl)S1 WJLXTOBWTZRKRD-UHFFFAOYSA-N 0.000 description 1
- SQSMFEQORFCPRQ-UHFFFAOYSA-N 2-morpholin-4-yl-1h-imidazole-5-carboxamide Chemical compound N1C(C(=O)N)=CN=C1N1CCOCC1 SQSMFEQORFCPRQ-UHFFFAOYSA-N 0.000 description 1
- KYTCOTKXTFPYLF-UHFFFAOYSA-N 2-morpholin-4-yl-4-(trifluoromethyl)-n-[1-[3-(trifluoromethyl)phenyl]ethyl]-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC(C(F)(F)F)=CC=1C(C)NC(=O)C(=C(N=1)C(F)(F)F)SC=1N1CCOCC1 KYTCOTKXTFPYLF-UHFFFAOYSA-N 0.000 description 1
- OIBVVFMODOYODL-UHFFFAOYSA-N 2-morpholin-4-yl-n-[1-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=CC(OC(F)(F)F)=CC=1C(C)NC(=O)C(=C(N=1)C(F)(F)F)SC=1N1CCOCC1 OIBVVFMODOYODL-UHFFFAOYSA-N 0.000 description 1
- FFFKQBAFVIXSEN-UHFFFAOYSA-N 2-morpholin-4-yl-n-[2-[3-(trifluoromethoxy)phenyl]ethyl]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound FC(F)(F)OC1=CC=CC(CCNC(=O)C2=C(N=C(S2)N2CCOCC2)C(F)(F)F)=C1 FFFKQBAFVIXSEN-UHFFFAOYSA-N 0.000 description 1
- TZXFYJTVNANMAX-UHFFFAOYSA-N 2-phenylmethoxyethyl n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]carbamate Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)OCCOCC=3C=CC=CC=3)C=C2CC1 TZXFYJTVNANMAX-UHFFFAOYSA-N 0.000 description 1
- YMRUQXQUIXXZSF-UHFFFAOYSA-N 2-phenylmethoxyethyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCCOCC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 YMRUQXQUIXXZSF-UHFFFAOYSA-N 0.000 description 1
- MTCGQUBUJCSAMO-UHFFFAOYSA-N 2-tert-butyl-n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC(C)(C)C1=C(C(=O)NCCCC(C)(C)C)C(C)=CC(N2CCOCC2)=N1 MTCGQUBUJCSAMO-UHFFFAOYSA-N 0.000 description 1
- KEEOMGLUZLLDDD-UHFFFAOYSA-N 2-tert-butyl-n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(C(C)(C)C)=C1C(=O)NCC1=CC=CC(F)=C1 KEEOMGLUZLLDDD-UHFFFAOYSA-N 0.000 description 1
- CDLDQUAWFKYYHV-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(3-methyl-1-benzothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound S1C2=CC=CC=C2C(C)=C1CN1C2=CC=C(NC(=O)CC(C)(C)C)C=C2CC1 CDLDQUAWFKYYHV-UHFFFAOYSA-N 0.000 description 1
- QSRVRUQGIKKYCG-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(3-methyl-5-phenyl-1,2-oxazol-4-yl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC=1C(C)=NOC=1C1=CC=CC=C1 QSRVRUQGIKKYCG-UHFFFAOYSA-N 0.000 description 1
- BLCITWFEHRSCKY-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(4-propan-2-ylphenyl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1=CC(C(C)C)=CC=C1CN1C2=CC=C(NC(=O)CC(C)(C)C)C=C2CC1 BLCITWFEHRSCKY-UHFFFAOYSA-N 0.000 description 1
- ZNSYHPCIMKYVPP-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(4-pyrrol-1-ylphenyl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC(C=C1)=CC=C1N1C=CC=C1 ZNSYHPCIMKYVPP-UHFFFAOYSA-N 0.000 description 1
- VUHQVXGVLVQCCE-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(5-methylthiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound S1C(C)=CC=C1CN1C2=CC=C(NC(=O)CC(C)(C)C)C=C2CC1 VUHQVXGVLVQCCE-UHFFFAOYSA-N 0.000 description 1
- VRZBOVWQXQFOCD-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[(6-phenoxypyridin-3-yl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC(C=N1)=CC=C1OC1=CC=CC=C1 VRZBOVWQXQFOCD-UHFFFAOYSA-N 0.000 description 1
- LPANCCTYLFDVAL-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(C(F)(F)F)C=C1 LPANCCTYLFDVAL-UHFFFAOYSA-N 0.000 description 1
- SPFJQCNWZDVROJ-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[[6-(4-methylphenoxy)pyridin-3-yl]methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1=CC(C)=CC=C1OC(N=C1)=CC=C1CN1C2=CC=C(NC(=O)CC(C)(C)C)C=C2CC1 SPFJQCNWZDVROJ-UHFFFAOYSA-N 0.000 description 1
- GKQIFKFAJUNJSB-UHFFFAOYSA-N 3,3-dimethyl-n-[1-[[6-(trifluoromethyl)pyridin-3-yl]methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(C(F)(F)F)N=C1 GKQIFKFAJUNJSB-UHFFFAOYSA-N 0.000 description 1
- WJLOXTPZZKOJPH-UHFFFAOYSA-N 3,3-dimethyl-n-[2-(trifluoromethyl)-4-[7-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]butanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=CC=C1N1CC2=CC(C(F)(F)F)=CC=C2CC1 WJLOXTPZZKOJPH-UHFFFAOYSA-N 0.000 description 1
- FUWZLYDFJFRKGG-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-4-[(2-phenylpyrimidin-5-yl)methylamino]phenyl]butanamide Chemical compound C1=C(NC(=O)CC(C)(C)C)C(C)=CC(NCC=2C=NC(=NC=2)C=2C=CC=CC=2)=C1 FUWZLYDFJFRKGG-UHFFFAOYSA-N 0.000 description 1
- YDSRFTJYQRXZCE-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]butanamide Chemical compound FC(F)(F)C1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CCOCC2)=C1 YDSRFTJYQRXZCE-UHFFFAOYSA-N 0.000 description 1
- VQCVVNXKJURFIV-UHFFFAOYSA-N 3,3-dimethyl-n-[2-methyl-6-morpholin-4-yl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]butanamide Chemical compound C=1C(N2CCOCC2)=C(NC(=O)CC(C)(C)C)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 VQCVVNXKJURFIV-UHFFFAOYSA-N 0.000 description 1
- XWLHXKMXYSTIJX-UHFFFAOYSA-N 3-(3,4-difluorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1=CC=C(F)C(F)=C1 XWLHXKMXYSTIJX-UHFFFAOYSA-N 0.000 description 1
- OESDYULIRWTQIK-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1=CC=CC(Cl)=C1 OESDYULIRWTQIK-UHFFFAOYSA-N 0.000 description 1
- XBLDZJXJCQTOHW-UHFFFAOYSA-N 3-(3-chlorophenyl)-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1=CC=CC(Cl)=C1 XBLDZJXJCQTOHW-UHFFFAOYSA-N 0.000 description 1
- HEYNGFXJGIIZLZ-UHFFFAOYSA-N 3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-1,1-di(propan-2-yl)urea Chemical compound C1CC2=CC(NC(=O)N(C(C)C)C(C)C)=CC=C2N1CC1=CC=C(Cl)S1 HEYNGFXJGIIZLZ-UHFFFAOYSA-N 0.000 description 1
- VVYOXVXPNLGNFB-UHFFFAOYSA-N 3-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-1-methyl-1-propylurea Chemical compound C1CC2=CC(NC(=O)N(C)CCC)=CC=C2N1CC1=CC=C(Cl)S1 VVYOXVXPNLGNFB-UHFFFAOYSA-N 0.000 description 1
- SJAIYFDQCITQLJ-UHFFFAOYSA-N 3-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-1-methyl-1-propylurea Chemical compound C1=C(Cl)C(NC(=O)N(C)CCC)=CC=C1N(C)CC1=CC=C(Cl)S1 SJAIYFDQCITQLJ-UHFFFAOYSA-N 0.000 description 1
- IOVOTFMCPZOTFH-UHFFFAOYSA-N 3-butan-2-yl-n-(2-cyclopentylethyl)-5-morpholin-4-ylpyrazine-2-carboxamide Chemical compound CCC(C)C1=NC(N2CCOCC2)=CN=C1C(=O)NCCC1CCCC1 IOVOTFMCPZOTFH-UHFFFAOYSA-N 0.000 description 1
- WOHZAQXIVKYOIU-UHFFFAOYSA-N 3-butan-2-yl-n-[(4-chlorophenyl)methyl]-5-morpholin-4-ylpyrazine-2-carboxamide Chemical compound CCC(C)C1=NC(N2CCOCC2)=CN=C1C(=O)NCC1=CC=C(Cl)C=C1 WOHZAQXIVKYOIU-UHFFFAOYSA-N 0.000 description 1
- NKRSJPBJRWPWTO-UHFFFAOYSA-N 3-chloropropyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCCCCl)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 NKRSJPBJRWPWTO-UHFFFAOYSA-N 0.000 description 1
- PVKGAFIBJUZLPW-UHFFFAOYSA-N 3-cyclohexyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1CCCCC1 PVKGAFIBJUZLPW-UHFFFAOYSA-N 0.000 description 1
- FFJSHGKHOFZMRC-UHFFFAOYSA-N 3-cyclohexyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1CCCCC1 FFJSHGKHOFZMRC-UHFFFAOYSA-N 0.000 description 1
- WHTGDXHISJRNKN-UHFFFAOYSA-N 3-cyclopentyl-n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CCC1CCCC1 WHTGDXHISJRNKN-UHFFFAOYSA-N 0.000 description 1
- FQHLBMKMJMGTSG-UHFFFAOYSA-N 3-cyclopentyl-n-(2,6-dimethyl-4-morpholin-4-ylphenyl)propanamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CCC1CCCC1 FQHLBMKMJMGTSG-UHFFFAOYSA-N 0.000 description 1
- YZRXQAFUIINKEG-UHFFFAOYSA-N 3-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-4-methyl-2h-1,6-naphthyridine-3-carboxamide Chemical compound C1N=C2C=CN=CC2=C(C)C1(SCC)C(=O)NCC1=CC=CC(F)=C1 YZRXQAFUIINKEG-UHFFFAOYSA-N 0.000 description 1
- QSJNXBHXRYAKBV-ZETCQYMHSA-N 4,4,4-trifluoro-3-hydroxy-N-[(1S)-1-[3-(trifluoromethoxy)phenyl]ethyl]-3-(trifluoromethyl)butanamide Chemical compound FC(C(CC(=O)N[C@@H](C)C1=CC(=CC=C1)OC(F)(F)F)(C(F)(F)F)O)(F)F QSJNXBHXRYAKBV-ZETCQYMHSA-N 0.000 description 1
- RVPHDOFIUXHDJE-UHFFFAOYSA-N 4-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCSC1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=CC(F)=C1 RVPHDOFIUXHDJE-UHFFFAOYSA-N 0.000 description 1
- YTWRXXXQMCFDPH-UHFFFAOYSA-N 4-ethylsulfanyl-n-[(3-fluorophenyl)methyl]-6-methyl-2-morpholin-4-ylpyrimidine-5-carboxamide Chemical compound CCSC1=NC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=CC(F)=C1 YTWRXXXQMCFDPH-UHFFFAOYSA-N 0.000 description 1
- YJLRIBZCRXKFJX-UHFFFAOYSA-N 4-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCSC1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(F)C=C1 YJLRIBZCRXKFJX-UHFFFAOYSA-N 0.000 description 1
- LZNUPNICZDUTMX-UHFFFAOYSA-N 4-fluoro-n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]benzamide Chemical compound C1=CC(F)=CC=C1CN1C2=CC=C(NC(=O)C=3C=CC(F)=CC=3)C=C2CC1 LZNUPNICZDUTMX-UHFFFAOYSA-N 0.000 description 1
- PXVPTTZRKHKSON-UHFFFAOYSA-N 4-methyl-6-morpholin-4-yl-2-propan-2-yl-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(F)(F)F)C(C(C)C)=NC(N2CCOCC2)=C1 PXVPTTZRKHKSON-UHFFFAOYSA-N 0.000 description 1
- HTPIMAFOIXXYJI-UHFFFAOYSA-N 4-methyl-6-morpholin-4-yl-2-propan-2-yl-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 HTPIMAFOIXXYJI-UHFFFAOYSA-N 0.000 description 1
- XKYDBVHRDUNUMU-UHFFFAOYSA-N 4-methyl-6-morpholin-4-yl-2-propyl-n-(4,4,4-trifluorobutyl)pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(F)(F)F)C(CCC)=NC(N2CCOCC2)=C1 XKYDBVHRDUNUMU-UHFFFAOYSA-N 0.000 description 1
- MARZPGHINVAPEJ-UHFFFAOYSA-N 4-methyl-6-morpholin-4-yl-2-propyl-n-[[4-(trifluoromethyl)phenyl]methyl]pyridine-3-carboxamide Chemical compound CCCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(C(F)(F)F)C=C1 MARZPGHINVAPEJ-UHFFFAOYSA-N 0.000 description 1
- UOTUGSGYFHMURV-UHFFFAOYSA-N 4-n-[(5-chlorothiophen-2-yl)methyl]-4-n,2-dimethylbenzene-1,4-diamine Chemical compound C=1C=C(N)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 UOTUGSGYFHMURV-UHFFFAOYSA-N 0.000 description 1
- OGABBSFCFIJRPK-UHFFFAOYSA-N 5-methyl-n-[2-methyl-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]hexanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 OGABBSFCFIJRPK-UHFFFAOYSA-N 0.000 description 1
- HKSAGXSXIWFXMH-UHFFFAOYSA-N 6-ethylsulfanyl-n-[(4-fluorophenyl)methyl]-4-methyl-1,7-naphthyridine-3-carboxamide Chemical compound C=1N=C2C=NC(SCC)=CC2=C(C)C=1C(=O)NCC1=CC=C(F)C=C1 HKSAGXSXIWFXMH-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010052075 Acquired epileptic aphasia Diseases 0.000 description 1
- 208000003116 Adie Syndrome Diseases 0.000 description 1
- 201000011452 Adrenoleukodystrophy Diseases 0.000 description 1
- 208000006888 Agnosia Diseases 0.000 description 1
- 241001047040 Agnosia Species 0.000 description 1
- 201000002882 Agraphia Diseases 0.000 description 1
- 208000024341 Aicardi syndrome Diseases 0.000 description 1
- 208000033237 Aicardi-Goutières syndrome Diseases 0.000 description 1
- 208000011403 Alexander disease Diseases 0.000 description 1
- 208000036022 Alpers' disease Diseases 0.000 description 1
- 208000031277 Amaurotic familial idiocy Diseases 0.000 description 1
- 208000009575 Angelman syndrome Diseases 0.000 description 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 description 1
- 206010003062 Apraxia Diseases 0.000 description 1
- 208000022316 Arachnoid cyst Diseases 0.000 description 1
- 206010003101 Arnold-Chiari Malformation Diseases 0.000 description 1
- 208000022211 Arteriovenous Malformations Diseases 0.000 description 1
- 208000036640 Asperger disease Diseases 0.000 description 1
- 201000006062 Asperger syndrome Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003594 Ataxia telangiectasia Diseases 0.000 description 1
- 102000007371 Ataxin-3 Human genes 0.000 description 1
- 102000014461 Ataxins Human genes 0.000 description 1
- 108010078286 Ataxins Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 208000031713 Autosomal recessive spastic paraplegia type 20 Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000005943 Barth syndrome Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000006373 Bell palsy Diseases 0.000 description 1
- 208000034577 Benign intracranial hypertension Diseases 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 201000004940 Bloch-Sulzberger syndrome Diseases 0.000 description 1
- 206010006074 Brachial plexus injury Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 206010048409 Brain malformation Diseases 0.000 description 1
- 206010006491 Brown-Sequard syndrome Diseases 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000010482 CADASIL Diseases 0.000 description 1
- 208000022526 Canavan disease Diseases 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000031464 Cavernous Central Nervous System Hemangioma Diseases 0.000 description 1
- 208000006569 Central Cord Syndrome Diseases 0.000 description 1
- 206010064012 Central pain syndrome Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008096 Cerebral atrophy Diseases 0.000 description 1
- 208000033221 Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 208000033935 Cerebral autosomal dominant arteriopathy-subcortical infarcts-leukoencephalopathy Diseases 0.000 description 1
- 208000032929 Cerebral haemangioma Diseases 0.000 description 1
- 206010053684 Cerebrohepatorenal syndrome Diseases 0.000 description 1
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 description 1
- 208000015321 Chiari malformation Diseases 0.000 description 1
- 206010008513 Child maltreatment syndrome Diseases 0.000 description 1
- 208000001353 Coffin-Lowry syndrome Diseases 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000023890 Complex Regional Pain Syndromes Diseases 0.000 description 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 description 1
- 102000012437 Copper-Transporting ATPases Human genes 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 208000009283 Craniosynostoses Diseases 0.000 description 1
- 206010049889 Craniosynostosis Diseases 0.000 description 1
- 208000012514 Cumulative Trauma disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 206010011831 Cytomegalovirus infection Diseases 0.000 description 1
- 201000003863 Dandy-Walker Syndrome Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 208000019246 Developmental coordination disease Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 201000007547 Dravet syndrome Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 201000008009 Early infantile epileptic encephalopathy Diseases 0.000 description 1
- 206010071545 Early infantile epileptic encephalopathy with burst-suppression Diseases 0.000 description 1
- 206010014567 Empty Sella Syndrome Diseases 0.000 description 1
- 206010052369 Encephalitis lethargica Diseases 0.000 description 1
- 206010049020 Encephalitis periaxialis diffusa Diseases 0.000 description 1
- 208000002403 Encephalocele Diseases 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 206010063006 Facial spasm Diseases 0.000 description 1
- 208000001441 Familial Periodic Paralyses Diseases 0.000 description 1
- 208000001948 Farber Lipogranulomatosis Diseases 0.000 description 1
- 208000002091 Febrile Seizures Diseases 0.000 description 1
- 208000024412 Friedreich ataxia Diseases 0.000 description 1
- 208000009796 Gangliosidoses Diseases 0.000 description 1
- 208000015872 Gaucher disease Diseases 0.000 description 1
- 208000007223 Gerstmann syndrome Diseases 0.000 description 1
- 208000003736 Gerstmann-Straussler-Scheinker Disease Diseases 0.000 description 1
- 206010072075 Gerstmann-Straussler-Scheinker syndrome Diseases 0.000 description 1
- 208000009119 Giant Axonal Neuropathy Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 208000021965 Glossopharyngeal Nerve disease Diseases 0.000 description 1
- 102100029458 Glutamate receptor ionotropic, NMDA 2A Human genes 0.000 description 1
- 101710195153 Glutamate receptor ionotropic, NMDA 2A Proteins 0.000 description 1
- 102100022630 Glutamate receptor ionotropic, NMDA 2B Human genes 0.000 description 1
- 101710195187 Glutamate receptor ionotropic, NMDA 2B Proteins 0.000 description 1
- 102100022631 Glutamate receptor ionotropic, NMDA 2C Human genes 0.000 description 1
- 101710195185 Glutamate receptor ionotropic, NMDA 2C Proteins 0.000 description 1
- 102100022626 Glutamate receptor ionotropic, NMDA 2D Human genes 0.000 description 1
- 101710195184 Glutamate receptor ionotropic, NMDA 2D Proteins 0.000 description 1
- 102100038942 Glutamate receptor ionotropic, NMDA 3A Human genes 0.000 description 1
- 101710195181 Glutamate receptor ionotropic, NMDA 3A Proteins 0.000 description 1
- 102100038958 Glutamate receptor ionotropic, NMDA 3B Human genes 0.000 description 1
- 101710195174 Glutamate receptor ionotropic, NMDA 3B Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032007 Glycogen storage disease due to acid maltase deficiency Diseases 0.000 description 1
- 206010053185 Glycogen storage disease type II Diseases 0.000 description 1
- 208000009396 Group II Malformations of Cortical Development Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 206010063491 Herpes zoster oticus Diseases 0.000 description 1
- 206010020352 Holmes-Adie pupil Diseases 0.000 description 1
- 208000016297 Holmes-Adie syndrome Diseases 0.000 description 1
- 206010020523 Hydromyelia Diseases 0.000 description 1
- 206010053712 Hypersomnia-bulimia syndrome Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 208000018127 Idiopathic intracranial hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 208000007031 Incontinentia pigmenti Diseases 0.000 description 1
- 208000008498 Infantile Refsum disease Diseases 0.000 description 1
- 206010021750 Infantile Spasms Diseases 0.000 description 1
- 208000017463 Infantile neuroaxonal dystrophy Diseases 0.000 description 1
- 206010022034 Iniencephaly Diseases 0.000 description 1
- 201000008450 Intracranial aneurysm Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- 208000000209 Isaacs syndrome Diseases 0.000 description 1
- 201000008645 Joubert syndrome Diseases 0.000 description 1
- 206010048804 Kearns-Sayre syndrome Diseases 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 201000008178 Kleine-Levin syndrome Diseases 0.000 description 1
- 208000006541 Klippel-Feil syndrome Diseases 0.000 description 1
- 201000005725 Kluver-Bucy Syndrome Diseases 0.000 description 1
- 208000006264 Korsakoff syndrome Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 description 1
- 201000005802 Landau-Kleffner Syndrome Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 201000006792 Lennox-Gastaut syndrome Diseases 0.000 description 1
- 208000009625 Lesch-Nyhan syndrome Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000010557 Lipid storage disease Diseases 0.000 description 1
- 208000008892 Lipoid Proteinosis of Urbach and Wiethe Diseases 0.000 description 1
- 206010048911 Lissencephaly Diseases 0.000 description 1
- 201000000251 Locked-in syndrome Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 102100033448 Lysosomal alpha-glucosidase Human genes 0.000 description 1
- 208000002569 Machado-Joseph Disease Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000005767 Megalencephaly Diseases 0.000 description 1
- 201000002571 Melkersson-Rosenthal syndrome Diseases 0.000 description 1
- 102000009030 Member 1 Subfamily D ATP Binding Cassette Transporter Human genes 0.000 description 1
- 108010049137 Member 1 Subfamily D ATP Binding Cassette Transporter Proteins 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000008948 Menkes Kinky Hair Syndrome Diseases 0.000 description 1
- 208000012583 Menkes disease Diseases 0.000 description 1
- 201000011442 Metachromatic leukodystrophy Diseases 0.000 description 1
- 201000002169 Mitochondrial myopathy Diseases 0.000 description 1
- 201000002983 Mobius syndrome Diseases 0.000 description 1
- 208000034167 Moebius syndrome Diseases 0.000 description 1
- 206010069681 Monomelic amyotrophy Diseases 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000009433 Moyamoya Disease Diseases 0.000 description 1
- 208000008955 Mucolipidoses Diseases 0.000 description 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 208000007379 Muscle Hypotonia Diseases 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- 206010028424 Myasthenic syndrome Diseases 0.000 description 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 description 1
- 208000009571 Myoclonic Cerebellar Dyssynergia Diseases 0.000 description 1
- 208000036572 Myoclonic epilepsy Diseases 0.000 description 1
- 208000002033 Myoclonus Diseases 0.000 description 1
- 201000002481 Myositis Diseases 0.000 description 1
- 206010061533 Myotonia Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- AZSUUBKZIUKMNP-AWEZNQCLSA-N N-[(1R)-2-cyclopropyloxy-1-[3-(difluoromethoxy)phenyl]ethyl]-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide Chemical compound C1(CC1)OC[C@@H](C1=CC(=CC=C1)OC(F)F)NC(CC1(CC(C1)(F)F)O)=O AZSUUBKZIUKMNP-AWEZNQCLSA-N 0.000 description 1
- WRUIJTRYCPBOMY-AWEZNQCLSA-N N-[(1R)-2-cyclopropyloxy-1-[3-(trifluoromethoxy)phenyl]ethyl]-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide Chemical compound C1(CC1)OC[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(CC1(CC(C1)(F)F)O)=O WRUIJTRYCPBOMY-AWEZNQCLSA-N 0.000 description 1
- QZVQHIRSOJNYBQ-LBPRGKRZSA-N N-[(1S)-2-cyano-1-[3-(trifluoromethoxy)phenyl]ethyl]-2-(3,3-difluoro-1-hydroxycyclobutyl)acetamide Chemical compound C(#N)C[C@@H](C1=CC(=CC=C1)OC(F)(F)F)NC(CC1(CC(C1)(F)F)O)=O QZVQHIRSOJNYBQ-LBPRGKRZSA-N 0.000 description 1
- 102000034570 NR1 subfamily Human genes 0.000 description 1
- 108020001305 NR1 subfamily Proteins 0.000 description 1
- 102000038100 NR2 subfamily Human genes 0.000 description 1
- 108020002076 NR2 subfamily Proteins 0.000 description 1
- 208000009905 Neurofibromatoses Diseases 0.000 description 1
- 201000005625 Neuroleptic malignant syndrome Diseases 0.000 description 1
- 208000002537 Neuronal Ceroid-Lipofuscinoses Diseases 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 206010068106 Occipital neuralgia Diseases 0.000 description 1
- 206010053854 Opsoclonus myoclonus Diseases 0.000 description 1
- 208000005225 Opsoclonus-Myoclonus Syndrome Diseases 0.000 description 1
- 206010069350 Osmotic demyelination syndrome Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 206010065657 Paroxysmal choreoathetosis Diseases 0.000 description 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 description 1
- 206010034701 Peroneal nerve palsy Diseases 0.000 description 1
- 208000012202 Pervasive developmental disease Diseases 0.000 description 1
- 208000008713 Piriformis Muscle Syndrome Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010036172 Porencephaly Diseases 0.000 description 1
- 206010052469 Postictal paralysis Diseases 0.000 description 1
- 208000010366 Postpoliomyelitis syndrome Diseases 0.000 description 1
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 description 1
- 208000032319 Primary lateral sclerosis Diseases 0.000 description 1
- 208000037534 Progressive hemifacial atrophy Diseases 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 206010071141 Rasmussen encephalitis Diseases 0.000 description 1
- 208000004160 Rasmussen subacute encephalitis Diseases 0.000 description 1
- 208000005587 Refsum Disease Diseases 0.000 description 1
- 208000005793 Restless legs syndrome Diseases 0.000 description 1
- 201000007981 Reye syndrome Diseases 0.000 description 1
- 229910006074 SO2NH2 Inorganic materials 0.000 description 1
- 208000007077 SUNCT syndrome Diseases 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 208000021235 Schilder disease Diseases 0.000 description 1
- 208000000729 Schizencephaly Diseases 0.000 description 1
- 206010073677 Severe myoclonic epilepsy of infancy Diseases 0.000 description 1
- 208000002108 Shaken Baby Syndrome Diseases 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 201000003696 Sotos syndrome Diseases 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 206010058571 Spinal cord infarction Diseases 0.000 description 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000036834 Spinocerebellar ataxia type 3 Diseases 0.000 description 1
- 206010072148 Stiff-Person syndrome Diseases 0.000 description 1
- 206010042265 Sturge-Weber Syndrome Diseases 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 208000027522 Sydenham chorea Diseases 0.000 description 1
- 206010043118 Tardive Dyskinesia Diseases 0.000 description 1
- 208000003664 Tarlov Cysts Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 208000035954 Thomsen and Becker disease Diseases 0.000 description 1
- 208000035317 Total hypoxanthine-guanine phosphoribosyl transferase deficiency Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000032109 Transient ischaemic attack Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010044696 Tropical spastic paresis Diseases 0.000 description 1
- 201000003397 Troyer syndrome Diseases 0.000 description 1
- 208000026911 Tuberous sclerosis complex Diseases 0.000 description 1
- 206010046298 Upper motor neurone lesion Diseases 0.000 description 1
- 208000036826 VIIth nerve paralysis Diseases 0.000 description 1
- 206010063661 Vascular encephalopathy Diseases 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 description 1
- 201000006791 West syndrome Diseases 0.000 description 1
- 208000027207 Whipple disease Diseases 0.000 description 1
- 206010049644 Williams syndrome Diseases 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 201000004525 Zellweger Syndrome Diseases 0.000 description 1
- 208000036813 Zellweger spectrum disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 208000030597 adult Refsum disease Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 208000011916 alternating hemiplegia Diseases 0.000 description 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002320 anencephaly Diseases 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 230000005744 arteriovenous malformation Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 201000004562 autosomal dominant cerebellar ataxia Diseases 0.000 description 1
- KAEMILXLUFFLSU-UHFFFAOYSA-N benzyl n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)carbamate Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)OCC1=CC=CC=C1 KAEMILXLUFFLSU-UHFFFAOYSA-N 0.000 description 1
- DDAWRADOFRFSCU-UHFFFAOYSA-N benzyl n-(2,6-dimethyl-4-morpholin-4-ylphenyl)carbamate Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)OCC1=CC=CC=C1 DDAWRADOFRFSCU-UHFFFAOYSA-N 0.000 description 1
- QIUJJJVRYWFJPB-UHFFFAOYSA-N benzyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 QIUJJJVRYWFJPB-UHFFFAOYSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 206010005159 blepharospasm Diseases 0.000 description 1
- 230000000744 blepharospasm Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
- GFLUXUNNWRGAJS-UHFFFAOYSA-N but-2-ynyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC#CC)=CC=C1N(C)CC1=CC=C(Cl)S1 GFLUXUNNWRGAJS-UHFFFAOYSA-N 0.000 description 1
- NTCMMLFINXWYDI-UHFFFAOYSA-N but-3-enyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OCCC=C)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 NTCMMLFINXWYDI-UHFFFAOYSA-N 0.000 description 1
- CSWQFUWZYDMBLR-UHFFFAOYSA-N butyl n-(2,6-dimethyl-4-morpholin-4-ylphenyl)carbamate Chemical compound C1=C(C)C(NC(=O)OCCCC)=C(C)C=C1N1CCOCC1 CSWQFUWZYDMBLR-UHFFFAOYSA-N 0.000 description 1
- RRBPKGFPYVBTPQ-UHFFFAOYSA-N butyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 RRBPKGFPYVBTPQ-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 208000009885 central pontine myelinolysis Diseases 0.000 description 1
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 1
- 208000016886 cerebral arteriopathy with subcortical infarcts and leukoencephalopathy Diseases 0.000 description 1
- 201000000760 cerebral cavernous malformation Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000003536 colpocephaly Diseases 0.000 description 1
- 201000011474 congenital myopathy Diseases 0.000 description 1
- 210000000877 corpus callosum Anatomy 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 208000013257 developmental and epileptic encephalopathy Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical compound C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 208000019479 dysautonomia Diseases 0.000 description 1
- 206010058319 dysgraphia Diseases 0.000 description 1
- 206010013932 dyslexia Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- YYIFYTOIDVFSJM-UHFFFAOYSA-N ethyl n-(4-bromo-2,6-dimethylphenyl)carbamate Chemical compound CCOC(=O)NC1=C(C)C=C(Br)C=C1C YYIFYTOIDVFSJM-UHFFFAOYSA-N 0.000 description 1
- ILASNVQYHYJIFT-UHFFFAOYSA-N ethyl n-[2,6-dimethyl-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=C(C)C=C1N1CC2=CC=C(C(F)(F)F)C=C2CC1 ILASNVQYHYJIFT-UHFFFAOYSA-N 0.000 description 1
- IECMFWSPQDIVPW-UHFFFAOYSA-N ethyl n-[2,6-dimethyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=C(C)C=C1CNC1=CC=C(C(F)(F)F)C=C1 IECMFWSPQDIVPW-UHFFFAOYSA-N 0.000 description 1
- LVDKVOBNMQQEAL-UHFFFAOYSA-N ethyl n-[2-(4-chlorophenyl)-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(Cl)=CC=2)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 LVDKVOBNMQQEAL-UHFFFAOYSA-N 0.000 description 1
- JBASQAITBFAGGZ-UHFFFAOYSA-N ethyl n-[2-(4-chlorophenyl)-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(Cl)=CC=2)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 JBASQAITBFAGGZ-UHFFFAOYSA-N 0.000 description 1
- AVLRKXVHQCYJLZ-UHFFFAOYSA-N ethyl n-[2-[4-(dimethylamino)phenyl]-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(=CC=2)N(C)C)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 AVLRKXVHQCYJLZ-UHFFFAOYSA-N 0.000 description 1
- TYFOODIYYYOWKK-UHFFFAOYSA-N ethyl n-[2-[4-(dimethylamino)phenyl]-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C=2C=CC(=CC=2)N(C)C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 TYFOODIYYYOWKK-UHFFFAOYSA-N 0.000 description 1
- KXYHFTARJIQOMA-UHFFFAOYSA-N ethyl n-[2-amino-4-(1-benzothiophen-3-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CSC2=CC=CC=C12 KXYHFTARJIQOMA-UHFFFAOYSA-N 0.000 description 1
- PAUMPFSSOXRDEJ-UHFFFAOYSA-N ethyl n-[2-amino-4-(anilinomethyl)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC=C1 PAUMPFSSOXRDEJ-UHFFFAOYSA-N 0.000 description 1
- CYVMSJCKTMVSRR-UHFFFAOYSA-N ethyl n-[2-amino-4-(thiophen-2-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=CS1 CYVMSJCKTMVSRR-UHFFFAOYSA-N 0.000 description 1
- WALRLVHHRQJWMT-UHFFFAOYSA-N ethyl n-[2-amino-4-(thiophen-3-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CSC=C1 WALRLVHHRQJWMT-UHFFFAOYSA-N 0.000 description 1
- XFNGDUVFJSECBN-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,3-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(Cl)=C1Cl XFNGDUVFJSECBN-UHFFFAOYSA-N 0.000 description 1
- SCOOTUMXCXKEAD-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4,6-trimethylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=C(C)C=C1C SCOOTUMXCXKEAD-UHFFFAOYSA-N 0.000 description 1
- MPNLUKUAXMXGGU-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1Cl MPNLUKUAXMXGGU-UHFFFAOYSA-N 0.000 description 1
- XVKFYUITXXYYEN-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2,4-difluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1F XVKFYUITXXYYEN-UHFFFAOYSA-N 0.000 description 1
- VDDRKSVFMCGVKS-UHFFFAOYSA-N ethyl n-[2-amino-4-[(2-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC=C1F VDDRKSVFMCGVKS-UHFFFAOYSA-N 0.000 description 1
- HFTMLRRJCMKHCO-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3,5-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC(Cl)=CC(Cl)=C1 HFTMLRRJCMKHCO-UHFFFAOYSA-N 0.000 description 1
- GXONDZRSDZSZRZ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-chloro-4-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C)C(Cl)=C1 GXONDZRSDZSZRZ-UHFFFAOYSA-N 0.000 description 1
- STCYUEYAARANPB-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(Cl)=C1 STCYUEYAARANPB-UHFFFAOYSA-N 0.000 description 1
- RAVCWWJMYAMNLK-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 RAVCWWJMYAMNLK-UHFFFAOYSA-N 0.000 description 1
- RNFBDOBYXLGUBY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(C)=C1 RNFBDOBYXLGUBY-UHFFFAOYSA-N 0.000 description 1
- QVJISOGPNWUYBI-UHFFFAOYSA-N ethyl n-[2-amino-4-[(3-methylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=CS1 QVJISOGPNWUYBI-UHFFFAOYSA-N 0.000 description 1
- BSQFTTSXMOOOGH-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-bromo-3-methoxythiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(OC)C(Br)=CS1 BSQFTTSXMOOOGH-UHFFFAOYSA-N 0.000 description 1
- HJHXJDJGCMMSGX-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-bromothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC(Br)=CS1 HJHXJDJGCMMSGX-UHFFFAOYSA-N 0.000 description 1
- PZWXBOANAHDGDV-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-butylanilino)methyl]phenyl]carbamate Chemical compound C1=CC(CCCC)=CC=C1NCC1=CC=C(NC(=O)OCC)C(N)=C1 PZWXBOANAHDGDV-UHFFFAOYSA-N 0.000 description 1
- UACNDMSYYWUJNP-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-chloro-3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 UACNDMSYYWUJNP-UHFFFAOYSA-N 0.000 description 1
- DWSPCTCHYKCYFR-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 DWSPCTCHYKCYFR-UHFFFAOYSA-N 0.000 description 1
- BYARLUNDODGUSF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-cyanoanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C#N)C=C1 BYARLUNDODGUSF-UHFFFAOYSA-N 0.000 description 1
- LLYSQBCINNSNKO-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-cyclohexylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C2CCCCC2)C=C1 LLYSQBCINNSNKO-UHFFFAOYSA-N 0.000 description 1
- NQNXMCDBIPXRFF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 NQNXMCDBIPXRFF-UHFFFAOYSA-N 0.000 description 1
- BSCJHOFVPMMXGC-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methoxyanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(OC)C=C1 BSCJHOFVPMMXGC-UHFFFAOYSA-N 0.000 description 1
- CIYWTQMAZIEXNG-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-methylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C)C=C1 CIYWTQMAZIEXNG-UHFFFAOYSA-N 0.000 description 1
- NVOFZLPWTFWFDQ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-phenylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C=2C=CC=CC=2)C=C1 NVOFZLPWTFWFDQ-UHFFFAOYSA-N 0.000 description 1
- OVMRYCWHBHWHDB-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-propan-2-ylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(C)C)C=C1 OVMRYCWHBHWHDB-UHFFFAOYSA-N 0.000 description 1
- YGDMFPQYDCZIMM-UHFFFAOYSA-N ethyl n-[2-amino-4-[(4-tert-butylanilino)methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(C)(C)C)C=C1 YGDMFPQYDCZIMM-UHFFFAOYSA-N 0.000 description 1
- WXSQDZHUDQVVFR-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-bromothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Br)S1 WXSQDZHUDQVVFR-UHFFFAOYSA-N 0.000 description 1
- IJHUAAPUXUHKRF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-chlorothiophen-2-yl)methyl-ethylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1N(CC)CC1=CC=C(Cl)S1 IJHUAAPUXUHKRF-UHFFFAOYSA-N 0.000 description 1
- OWMAWWXIMWNHSI-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(Cl)S1 OWMAWWXIMWNHSI-UHFFFAOYSA-N 0.000 description 1
- GKEWWXCUSGRKEY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 GKEWWXCUSGRKEY-UHFFFAOYSA-N 0.000 description 1
- OCOIXRNXFUKTKY-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-ethylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(CC)S1 OCOIXRNXFUKTKY-UHFFFAOYSA-N 0.000 description 1
- WIUHLNPDCTWFEH-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-fluoro-1-benzofuran-3-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=COC2=CC=C(F)C=C12 WIUHLNPDCTWFEH-UHFFFAOYSA-N 0.000 description 1
- ITKAHTLJWIBUCZ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-fluorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)S1 ITKAHTLJWIBUCZ-UHFFFAOYSA-N 0.000 description 1
- HNUMRLQROUPWNJ-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-methylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C)S1 HNUMRLQROUPWNJ-UHFFFAOYSA-N 0.000 description 1
- PNYDZEMORIWFHF-UHFFFAOYSA-N ethyl n-[2-amino-4-[(5-phenylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C=2C=CC=CC=2)S1 PNYDZEMORIWFHF-UHFFFAOYSA-N 0.000 description 1
- KKTKRODPSKTNPL-UHFFFAOYSA-N ethyl n-[2-amino-4-[(6-chloro-3-methoxy-1-benzothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(OC)C2=CC=C(Cl)C=C2S1 KKTKRODPSKTNPL-UHFFFAOYSA-N 0.000 description 1
- SHWHGZSYKAZUIB-UHFFFAOYSA-N ethyl n-[2-amino-4-[1-(4-chloroanilino)ethyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1C(C)NC1=CC=C(Cl)C=C1 SHWHGZSYKAZUIB-UHFFFAOYSA-N 0.000 description 1
- VRXUASWAYZPEHF-UHFFFAOYSA-N ethyl n-[2-amino-4-[1-[4-(trifluoromethyl)anilino]ethyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1C(C)NC1=CC=C(C(F)(F)F)C=C1 VRXUASWAYZPEHF-UHFFFAOYSA-N 0.000 description 1
- AEBTUIWNDWVQNE-UHFFFAOYSA-N ethyl n-[2-amino-4-[[3-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(C(F)(F)F)=C1 AEBTUIWNDWVQNE-UHFFFAOYSA-N 0.000 description 1
- PYVCGNWJTVIAMS-UHFFFAOYSA-N ethyl n-[2-amino-4-[[3-fluoro-4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C(F)=C1 PYVCGNWJTVIAMS-UHFFFAOYSA-N 0.000 description 1
- RJCPUTBLOULGBP-UHFFFAOYSA-N ethyl n-[2-amino-4-[[4-(4-chlorophenyl)sulfonyl-3-methylthiophen-2-yl]methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1NCC1=C(C)C(S(=O)(=O)C=2C=CC(Cl)=CC=2)=CS1 RJCPUTBLOULGBP-UHFFFAOYSA-N 0.000 description 1
- CBUCMNUGRUKIBK-UHFFFAOYSA-N ethyl n-[2-amino-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 CBUCMNUGRUKIBK-UHFFFAOYSA-N 0.000 description 1
- JFADARKTLVNWJT-UHFFFAOYSA-N ethyl n-[2-amino-4-[[4-fluoro-3-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C(C(F)(F)F)=C1 JFADARKTLVNWJT-UHFFFAOYSA-N 0.000 description 1
- AQQQGRCQQUTKHH-UHFFFAOYSA-N ethyl n-[2-amino-4-[methyl-[(5-methylthiophen-2-yl)methyl]amino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C)S1 AQQQGRCQQUTKHH-UHFFFAOYSA-N 0.000 description 1
- JFKOOJKAUOELLK-UHFFFAOYSA-N ethyl n-[2-amino-6-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCC)=C(C)C=C1NCC1=CC=C(C(F)(F)F)C=C1 JFKOOJKAUOELLK-UHFFFAOYSA-N 0.000 description 1
- PJQJLRQLLHQJMP-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(3,4-dichloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 PJQJLRQLLHQJMP-UHFFFAOYSA-N 0.000 description 1
- YZOXDNFQASBYLT-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-chloro-3-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 YZOXDNFQASBYLT-UHFFFAOYSA-N 0.000 description 1
- URAKWDASUSFXKH-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-chloroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 URAKWDASUSFXKH-UHFFFAOYSA-N 0.000 description 1
- XPAYAFCWAGCEME-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-fluoroanilino)methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 XPAYAFCWAGCEME-UHFFFAOYSA-N 0.000 description 1
- AMWAUBYTNYONBR-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 AMWAUBYTNYONBR-UHFFFAOYSA-N 0.000 description 1
- UJHAKAHMBMEMNW-UHFFFAOYSA-N ethyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 UJHAKAHMBMEMNW-UHFFFAOYSA-N 0.000 description 1
- YHALLHHMBWALKL-UHFFFAOYSA-N ethyl n-[2-chloro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YHALLHHMBWALKL-UHFFFAOYSA-N 0.000 description 1
- UVHHGQGCILHVPA-UHFFFAOYSA-N ethyl n-[2-chloro-4-[methyl-[(4-methylsulfanylphenyl)methyl]amino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(SC)C=C1 UVHHGQGCILHVPA-UHFFFAOYSA-N 0.000 description 1
- PXJYWPAJYQOYAU-UHFFFAOYSA-N ethyl n-[2-chloro-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 PXJYWPAJYQOYAU-UHFFFAOYSA-N 0.000 description 1
- MTYCZZYJZDRZKZ-UHFFFAOYSA-N ethyl n-[2-cyano-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 MTYCZZYJZDRZKZ-UHFFFAOYSA-N 0.000 description 1
- GRAKJGFHEIJYDP-UHFFFAOYSA-N ethyl n-[2-cyclopentyloxy-4-[(3-fluoro-2-methylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(OC2CCCC2)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(F)=C1C GRAKJGFHEIJYDP-UHFFFAOYSA-N 0.000 description 1
- QYUKOZHZSRWMNG-UHFFFAOYSA-N ethyl n-[2-cyclopentyloxy-4-[(4-methoxyphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(OC2CCCC2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(OC)C=C1 QYUKOZHZSRWMNG-UHFFFAOYSA-N 0.000 description 1
- FBWLGGCIJQPAGG-UHFFFAOYSA-N ethyl n-[2-fluoro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 FBWLGGCIJQPAGG-UHFFFAOYSA-N 0.000 description 1
- HIFLWUPIVYIOKB-UHFFFAOYSA-N ethyl n-[2-methoxy-4-[(3-methylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCC)=CC=C1NCC1=C(C)C=CS1 HIFLWUPIVYIOKB-UHFFFAOYSA-N 0.000 description 1
- DBGKFRUFUABFLM-UHFFFAOYSA-N ethyl n-[2-methoxy-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 DBGKFRUFUABFLM-UHFFFAOYSA-N 0.000 description 1
- GPLMHGDAOVFNCU-UHFFFAOYSA-N ethyl n-[2-methyl-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 GPLMHGDAOVFNCU-UHFFFAOYSA-N 0.000 description 1
- VLIKNAITKKRTJV-UHFFFAOYSA-N ethyl n-[2-methyl-4-[(5-phenylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C=2C=CC=CC=2)S1 VLIKNAITKKRTJV-UHFFFAOYSA-N 0.000 description 1
- YETJUQCNPAAANG-UHFFFAOYSA-N ethyl n-[2-methyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YETJUQCNPAAANG-UHFFFAOYSA-N 0.000 description 1
- FJGJSYHAKOHFMZ-UHFFFAOYSA-N ethyl n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 FJGJSYHAKOHFMZ-UHFFFAOYSA-N 0.000 description 1
- XYIVNKLPSJLTHT-UHFFFAOYSA-N ethyl n-[4-(1,3-benzodioxol-5-ylmethylamino)-2-propan-2-yloxyphenyl]carbamate Chemical compound C1=C(OC(C)C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(OCO2)C2=C1 XYIVNKLPSJLTHT-UHFFFAOYSA-N 0.000 description 1
- LBPNSUIVYSELKA-UHFFFAOYSA-N ethyl n-[4-(1-benzothiophen-2-ylmethylamino)-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1NCC1=CC2=CC=CC=C2S1 LBPNSUIVYSELKA-UHFFFAOYSA-N 0.000 description 1
- MBZCXPYDDKNMKD-UHFFFAOYSA-N ethyl n-[4-(1-benzothiophen-2-ylmethylamino)-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC2=CC=CC=C2S1 MBZCXPYDDKNMKD-UHFFFAOYSA-N 0.000 description 1
- DTOYTZIERSGENB-UHFFFAOYSA-N ethyl n-[4-(1-benzothiophen-3-ylmethylamino)-2-cyclopentyloxyphenyl]carbamate Chemical compound CCOC(=O)NC1=CC=C(NCC=2C3=CC=CC=C3SC=2)C=C1OC1CCCC1 DTOYTZIERSGENB-UHFFFAOYSA-N 0.000 description 1
- XDKSFHCRKBLVPN-UHFFFAOYSA-N ethyl n-[4-[(2,4-difluorophenyl)methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCC)=CC=C1NCC1=CC=C(F)C=C1F XDKSFHCRKBLVPN-UHFFFAOYSA-N 0.000 description 1
- PSRTZGHRXNJOEO-UHFFFAOYSA-N ethyl n-[4-[(3,4-difluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C(F)=C1 PSRTZGHRXNJOEO-UHFFFAOYSA-N 0.000 description 1
- DHNIHGLWXHLYGU-UHFFFAOYSA-N ethyl n-[4-[(3-fluoro-2-methylphenyl)methylamino]-2-(2-phenylethoxy)phenyl]carbamate Chemical compound C1=C(OCCC=2C=CC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(F)=C1C DHNIHGLWXHLYGU-UHFFFAOYSA-N 0.000 description 1
- DDLKIMUNVILAIR-UHFFFAOYSA-N ethyl n-[4-[(3-fluoro-2-methylphenyl)methylamino]-2-phenylmethoxyphenyl]carbamate Chemical compound C1=C(OCC=2C=CC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(F)=C1C DDLKIMUNVILAIR-UHFFFAOYSA-N 0.000 description 1
- CVTJQRXEUAZWTQ-UHFFFAOYSA-N ethyl n-[4-[(3-fluoro-2-methylphenyl)methylamino]-2-propan-2-yloxyphenyl]carbamate Chemical compound C1=C(OC(C)C)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(F)=C1C CVTJQRXEUAZWTQ-UHFFFAOYSA-N 0.000 description 1
- QEYNFGCIULPLPC-UHFFFAOYSA-N ethyl n-[4-[(3-fluoroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=C(C)C=C1CNC1=CC=CC(F)=C1 QEYNFGCIULPLPC-UHFFFAOYSA-N 0.000 description 1
- YFYLMPIYVCSHPH-UHFFFAOYSA-N ethyl n-[4-[(3-fluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=CC(F)=C1 YFYLMPIYVCSHPH-UHFFFAOYSA-N 0.000 description 1
- IMLUDSPLHDRIPO-UHFFFAOYSA-N ethyl n-[4-[(3-fluorophenyl)methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(F)=C1 IMLUDSPLHDRIPO-UHFFFAOYSA-N 0.000 description 1
- LCEODKNUZATZLW-UHFFFAOYSA-N ethyl n-[4-[(3-methoxyphenyl)methylamino]-2-phenylmethoxyphenyl]carbamate Chemical compound C1=C(OCC=2C=CC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=CC(OC)=C1 LCEODKNUZATZLW-UHFFFAOYSA-N 0.000 description 1
- TZNQYORNTRQEJV-UHFFFAOYSA-N ethyl n-[4-[(4-chloro-3-fluoroanilino)methyl]-2-fluorophenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 TZNQYORNTRQEJV-UHFFFAOYSA-N 0.000 description 1
- RUVLMXALVIBXME-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]-2-fluorophenyl]carbamate Chemical compound C1=C(F)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 RUVLMXALVIBXME-UHFFFAOYSA-N 0.000 description 1
- DPIDNSCETUXASM-UHFFFAOYSA-N ethyl n-[4-[(4-chloroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(Cl)C=C1 DPIDNSCETUXASM-UHFFFAOYSA-N 0.000 description 1
- QCEHDLKQWVGPFI-UHFFFAOYSA-N ethyl n-[4-[(4-chlorophenyl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)C=C1 QCEHDLKQWVGPFI-UHFFFAOYSA-N 0.000 description 1
- HCLUFHIOGAXFCC-UHFFFAOYSA-N ethyl n-[4-[(4-fluoroanilino)methyl]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1CNC1=CC=C(F)C=C1 HCLUFHIOGAXFCC-UHFFFAOYSA-N 0.000 description 1
- NWLXPWFNBKJVKX-UHFFFAOYSA-N ethyl n-[4-[(4-fluorophenyl)methyl-methylamino]-2-propan-2-yloxyphenyl]carbamate Chemical compound C1=C(OC(C)C)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(F)C=C1 NWLXPWFNBKJVKX-UHFFFAOYSA-N 0.000 description 1
- XKSCLMWYIAIGGH-UHFFFAOYSA-N ethyl n-[4-[(4-methylsulfanylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1NCC1=CC=C(SC)C=C1 XKSCLMWYIAIGGH-UHFFFAOYSA-N 0.000 description 1
- FUOWMPZQNQMKQJ-UHFFFAOYSA-N ethyl n-[4-[(4-methylsulfanylphenyl)methylamino]-2-phenylmethoxyphenyl]carbamate Chemical compound C1=C(OCC=2C=CC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(SC)C=C1 FUOWMPZQNQMKQJ-UHFFFAOYSA-N 0.000 description 1
- KKLHNPWQODPAQP-UHFFFAOYSA-N ethyl n-[4-[(4-tert-butylphenyl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 KKLHNPWQODPAQP-UHFFFAOYSA-N 0.000 description 1
- AYJLXGFLEJCNSS-UHFFFAOYSA-N ethyl n-[4-[(4-tert-butylphenyl)methyl-methylamino]-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 AYJLXGFLEJCNSS-UHFFFAOYSA-N 0.000 description 1
- JHNNJXNHEUWQQI-UHFFFAOYSA-N ethyl n-[4-[(4-tert-butylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 JHNNJXNHEUWQQI-UHFFFAOYSA-N 0.000 description 1
- LZCPHDBEDLLPCH-UHFFFAOYSA-N ethyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(Br)S1 LZCPHDBEDLLPCH-UHFFFAOYSA-N 0.000 description 1
- BNRZQCLVVKMSIW-UHFFFAOYSA-N ethyl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Br)S1 BNRZQCLVVKMSIW-UHFFFAOYSA-N 0.000 description 1
- URCRJUUPLVVVDL-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(Cl)S1 URCRJUUPLVVVDL-UHFFFAOYSA-N 0.000 description 1
- AKLXLTKONNDHHV-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-(6-methoxypyridin-3-yl)phenyl]carbamate Chemical compound C1=C(C=2C=NC(OC)=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 AKLXLTKONNDHHV-UHFFFAOYSA-N 0.000 description 1
- JBIFACVOFRVYLT-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 JBIFACVOFRVYLT-UHFFFAOYSA-N 0.000 description 1
- XXUITLDPXQQWMX-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-cyanophenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 XXUITLDPXQQWMX-UHFFFAOYSA-N 0.000 description 1
- ZWTUCGJBUWCVJO-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 ZWTUCGJBUWCVJO-UHFFFAOYSA-N 0.000 description 1
- BHONFRQFLYRMJR-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-pyridin-3-ylphenyl]carbamate Chemical compound C1=C(C=2C=NC=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 BHONFRQFLYRMJR-UHFFFAOYSA-N 0.000 description 1
- HWRLUDVUXQLMIH-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-pyridin-4-ylphenyl]carbamate Chemical compound C1=C(C=2C=CN=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 HWRLUDVUXQLMIH-UHFFFAOYSA-N 0.000 description 1
- KPERHISRLWKTQA-UHFFFAOYSA-N ethyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-quinolin-5-ylphenyl]carbamate Chemical compound C1=C(C=2C3=CC=CN=C3C=CC=2)C(NC(=O)OCC)=CC=C1NCC1=CC=C(Cl)S1 KPERHISRLWKTQA-UHFFFAOYSA-N 0.000 description 1
- NIEWPONKIRMTPH-UHFFFAOYSA-N ethyl n-[4-[(6-methoxy-1-benzothiophen-2-yl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC2=CC=C(OC)C=C2S1 NIEWPONKIRMTPH-UHFFFAOYSA-N 0.000 description 1
- KLNBESIFXRZEPF-UHFFFAOYSA-N ethyl n-[4-[[3-fluoro-4-(trifluoromethyl)phenyl]methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCC)=CC=C1NCC1=CC=C(C(F)(F)F)C(F)=C1 KLNBESIFXRZEPF-UHFFFAOYSA-N 0.000 description 1
- GCFCPEZENZTFAY-UHFFFAOYSA-N ethyl n-[4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 GCFCPEZENZTFAY-UHFFFAOYSA-N 0.000 description 1
- GAYMQGPGTVLOQU-UHFFFAOYSA-N ethyl n-[4-[methyl-[(4-methylsulfanylphenyl)methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(SC)C=C1 GAYMQGPGTVLOQU-UHFFFAOYSA-N 0.000 description 1
- IMUOXPRZLBQDQK-UHFFFAOYSA-N ethyl n-[4-[methyl-[(4-propan-2-ylphenyl)methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C(C)C)C=C1 IMUOXPRZLBQDQK-UHFFFAOYSA-N 0.000 description 1
- LUCIULMHEDDUDH-UHFFFAOYSA-N ethyl n-[4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 LUCIULMHEDDUDH-UHFFFAOYSA-N 0.000 description 1
- 208000002980 facial hemiatrophy Diseases 0.000 description 1
- 208000004967 femoral neuropathy Diseases 0.000 description 1
- 208000008487 fibromuscular dysplasia Diseases 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 201000011349 geniculate herpes zoster Diseases 0.000 description 1
- 201000005442 glossopharyngeal neuralgia Diseases 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 201000004502 glycogen storage disease II Diseases 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000020727 hemicrania continua Diseases 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- JLNYLDRCNCLJQY-UHFFFAOYSA-N hexyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCCCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 JLNYLDRCNCLJQY-UHFFFAOYSA-N 0.000 description 1
- 208000009624 holoprosencephaly Diseases 0.000 description 1
- 201000009075 hydranencephaly Diseases 0.000 description 1
- 208000003906 hydrocephalus Diseases 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 201000008319 inclusion body myositis Diseases 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000017476 juvenile neuronal ceroid lipofuscinosis Diseases 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 208000004343 lateral medullary syndrome Diseases 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000036546 leukodystrophy Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000014817 lissencephaly spectrum disease Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 208000014416 lysosomal lipid storage disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000032184 meralgia paresthetica Diseases 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- ZWBZSWWTAABAAW-UHFFFAOYSA-N methyl 3-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylanilino]-3-oxopropanoate Chemical compound C1=C(C)C(NC(=O)CC(=O)OC)=CC=C1N(C)CC1=CC=C(Cl)S1 ZWBZSWWTAABAAW-UHFFFAOYSA-N 0.000 description 1
- GIOTXFVSHZODRM-UHFFFAOYSA-N methyl 4-[[3-methyl-4-(propoxycarbonylamino)anilino]methyl]benzoate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(=O)OC)C=C1 GIOTXFVSHZODRM-UHFFFAOYSA-N 0.000 description 1
- ZRCLMLJAAYQKFH-UHFFFAOYSA-N methyl n-[4-(1-benzothiophen-2-ylmethylamino)-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OC)=CC=C1NCC1=CC2=CC=CC=C2S1 ZRCLMLJAAYQKFH-UHFFFAOYSA-N 0.000 description 1
- 208000004141 microcephaly Diseases 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 description 1
- 206010065579 multifocal motor neuropathy Diseases 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- JKSZZVSCRAVAHI-UHFFFAOYSA-N n-(1-benzyl-2,3-dihydroindol-5-yl)methanesulfonamide Chemical compound C1CC2=CC(NS(=O)(=O)C)=CC=C2N1CC1=CC=CC=C1 JKSZZVSCRAVAHI-UHFFFAOYSA-N 0.000 description 1
- YHCSKBDPRSOGPG-UHFFFAOYSA-N n-(1-benzylindol-5-yl)methanesulfonamide Chemical compound C1=CC2=CC(NS(=O)(=O)C)=CC=C2N1CC1=CC=CC=C1 YHCSKBDPRSOGPG-UHFFFAOYSA-N 0.000 description 1
- NSXYSIRPQHZGRS-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3,4-dimethylphenyl)acetamide Chemical compound C1=C(C)C(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C NSXYSIRPQHZGRS-UHFFFAOYSA-N 0.000 description 1
- QFXOZVHCESXJLE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3,5-dimethylphenyl)acetamide Chemical compound CC1=CC(C)=CC(CC(=O)NC=2C(=NC(=CC=2C)N2CCOCC2)C)=C1 QFXOZVHCESXJLE-UHFFFAOYSA-N 0.000 description 1
- LNHWKNMHQDEDHA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(F)=C1 LNHWKNMHQDEDHA-UHFFFAOYSA-N 0.000 description 1
- MTXSFPSKHDODED-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(CC(=O)NC=2C(=NC(=CC=2C)N2CCOCC2)C)=C1 MTXSFPSKHDODED-UHFFFAOYSA-N 0.000 description 1
- LXXQJPDIABMXEO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=C(F)C=C1 LXXQJPDIABMXEO-UHFFFAOYSA-N 0.000 description 1
- RVOCAYGOJGYTFK-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methoxy-3-methylphenyl)acetamide Chemical compound C1=C(C)C(OC)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C RVOCAYGOJGYTFK-UHFFFAOYSA-N 0.000 description 1
- ZWAWWLRQLGIARH-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C ZWAWWLRQLGIARH-UHFFFAOYSA-N 0.000 description 1
- ZZQZQXDYSRXASP-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C ZZQZQXDYSRXASP-UHFFFAOYSA-N 0.000 description 1
- OEMGVWLOWRPQLL-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 OEMGVWLOWRPQLL-UHFFFAOYSA-N 0.000 description 1
- GKDVUJSUFGQXKA-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-naphthalen-2-ylacetamide Chemical compound N=1C(C)=C(NC(=O)CC=2C=C3C=CC=CC3=CC=2)C(C)=CC=1N1CCOCC1 GKDVUJSUFGQXKA-UHFFFAOYSA-N 0.000 description 1
- LOCRXXVELNBLQE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-phenylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC=C1 LOCRXXVELNBLQE-UHFFFAOYSA-N 0.000 description 1
- MRNPWIWBKMYBTH-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-phenylcyclopropane-1-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)C1CC1C1=CC=CC=C1 MRNPWIWBKMYBTH-UHFFFAOYSA-N 0.000 description 1
- VRDZAGWZCGIZSC-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-thiophen-2-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CS1 VRDZAGWZCGIZSC-UHFFFAOYSA-N 0.000 description 1
- ZBQQCPVAXQILBE-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-2-thiophen-3-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=NC(C)=C1NC(=O)CC=1C=CSC=1 ZBQQCPVAXQILBE-UHFFFAOYSA-N 0.000 description 1
- WVSKXMHDWLIKIR-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3,5,5-trimethylhexanamide Chemical compound N1=C(C)C(NC(=O)CC(C)CC(C)(C)C)=C(C)C=C1N1CCOCC1 WVSKXMHDWLIKIR-UHFFFAOYSA-N 0.000 description 1
- KAKNMOGUWPXQFL-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3-(4-methoxyphenyl)propanamide Chemical compound C1=CC(OC)=CC=C1CCC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C KAKNMOGUWPXQFL-UHFFFAOYSA-N 0.000 description 1
- OFNMXZJAGVKVKO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-3-(4-methylphenyl)propanamide Chemical compound C1=CC(C)=CC=C1CCC(=O)NC1=C(C)C=C(N2CCOCC2)N=C1C OFNMXZJAGVKVKO-UHFFFAOYSA-N 0.000 description 1
- BLESCNKLEXGCBO-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-4-methylpentanamide Chemical compound N1=C(C)C(NC(=O)CCC(C)C)=C(C)C=C1N1CCOCC1 BLESCNKLEXGCBO-UHFFFAOYSA-N 0.000 description 1
- LRPPLNWCCXUMIQ-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)-5-methylhexanamide Chemical compound N1=C(C)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 LRPPLNWCCXUMIQ-UHFFFAOYSA-N 0.000 description 1
- RZPBJOUKSLGPAK-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)heptanamide Chemical compound N1=C(C)C(NC(=O)CCCCCC)=C(C)C=C1N1CCOCC1 RZPBJOUKSLGPAK-UHFFFAOYSA-N 0.000 description 1
- SAHHONAYVKIMTP-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)hexanamide Chemical compound N1=C(C)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 SAHHONAYVKIMTP-UHFFFAOYSA-N 0.000 description 1
- QHRDANBBSJKUAT-UHFFFAOYSA-N n-(2,4-dimethyl-6-morpholin-4-ylpyridin-3-yl)octanamide Chemical compound N1=C(C)C(NC(=O)CCCCCCC)=C(C)C=C1N1CCOCC1 QHRDANBBSJKUAT-UHFFFAOYSA-N 0.000 description 1
- UANXUOHOUIPKAT-UHFFFAOYSA-N n-(2,4-dimethyl-6-quinolin-3-ylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound C=1N=C2C=CC=CC2=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 UANXUOHOUIPKAT-UHFFFAOYSA-N 0.000 description 1
- QFBRGGLYIZJDNP-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2F)N2CCOCC2)F)=C1 QFBRGGLYIZJDNP-UHFFFAOYSA-N 0.000 description 1
- PCQHZOFRMZIDSO-UHFFFAOYSA-N n-(2,6-difluoro-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound C1=C(F)C(NC(=O)CC(C)(C)C)=C(F)C=C1N1CCOCC1 PCQHZOFRMZIDSO-UHFFFAOYSA-N 0.000 description 1
- RQMWEJOBHGLLHJ-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2,3-dihydro-1-benzofuran-2-carboxamide Chemical compound C=1C(C)=C(NC(=O)C2OC3=CC=CC=C3C2)C(C)=CC=1N1CCOCC1 RQMWEJOBHGLLHJ-UHFFFAOYSA-N 0.000 description 1
- RZHYJMWCLWAHFW-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(3,4-dimethylphenyl)acetamide Chemical compound C1=C(C)C(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)C=C1C RZHYJMWCLWAHFW-UHFFFAOYSA-N 0.000 description 1
- BWTFEOVRRVXFIS-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(F)=C1 BWTFEOVRRVXFIS-UHFFFAOYSA-N 0.000 description 1
- BHJCRISXCWZQNL-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(3-methylphenyl)acetamide Chemical compound CC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2C)N2CCOCC2)C)=C1 BHJCRISXCWZQNL-UHFFFAOYSA-N 0.000 description 1
- FQXJKHBCIJGCQO-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 FQXJKHBCIJGCQO-UHFFFAOYSA-N 0.000 description 1
- LWXZAWFLFOVWCD-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-(4-methylphenyl)acetamide Chemical compound C1=CC(C)=CC=C1CC(=O)NC1=C(C)C=C(N2CCOCC2)C=C1C LWXZAWFLFOVWCD-UHFFFAOYSA-N 0.000 description 1
- WZSQCEVOMHBPFJ-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-[3-(trifluoromethyl)phenyl]acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC(C(F)(F)F)=C1 WZSQCEVOMHBPFJ-UHFFFAOYSA-N 0.000 description 1
- DBQFAOANWIBIGE-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-naphthalen-2-ylacetamide Chemical compound C=1C(C)=C(NC(=O)CC=2C=C3C=CC=CC3=CC=2)C(C)=CC=1N1CCOCC1 DBQFAOANWIBIGE-UHFFFAOYSA-N 0.000 description 1
- IPQCETRADJWXPC-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-phenylacetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CC=C1 IPQCETRADJWXPC-UHFFFAOYSA-N 0.000 description 1
- IQZIDXSIVOBHBG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-2-thiophen-2-ylacetamide Chemical compound CC1=CC(N2CCOCC2)=CC(C)=C1NC(=O)CC1=CC=CS1 IQZIDXSIVOBHBG-UHFFFAOYSA-N 0.000 description 1
- UULFYDWHIRAODG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3,5,5-trimethylhexanamide Chemical compound C1=C(C)C(NC(=O)CC(C)CC(C)(C)C)=C(C)C=C1N1CCOCC1 UULFYDWHIRAODG-UHFFFAOYSA-N 0.000 description 1
- CPXXAHUMOPUBQF-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3-ethylpentanamide Chemical compound C1=C(C)C(NC(=O)CC(CC)CC)=C(C)C=C1N1CCOCC1 CPXXAHUMOPUBQF-UHFFFAOYSA-N 0.000 description 1
- QDYMTVOPTQMLIP-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-3-methylpentanamide Chemical compound C1=C(C)C(NC(=O)CC(C)CC)=C(C)C=C1N1CCOCC1 QDYMTVOPTQMLIP-UHFFFAOYSA-N 0.000 description 1
- TVSPKPCWJNRGPB-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-4-methylpentanamide Chemical compound C1=C(C)C(NC(=O)CCC(C)C)=C(C)C=C1N1CCOCC1 TVSPKPCWJNRGPB-UHFFFAOYSA-N 0.000 description 1
- FVUFQWDWZHWHQT-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)-5-methylhexanamide Chemical compound C1=C(C)C(NC(=O)CCCC(C)C)=C(C)C=C1N1CCOCC1 FVUFQWDWZHWHQT-UHFFFAOYSA-N 0.000 description 1
- WZMQBLIZLSZDTE-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)heptanamide Chemical compound C1=C(C)C(NC(=O)CCCCCC)=C(C)C=C1N1CCOCC1 WZMQBLIZLSZDTE-UHFFFAOYSA-N 0.000 description 1
- RPVLAQSRQQXWEJ-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)hex-5-enamide Chemical compound CC1=C(NC(=O)CCCC=C)C(C)=CC(N2CCOCC2)=C1 RPVLAQSRQQXWEJ-UHFFFAOYSA-N 0.000 description 1
- RJPNBZXKFWESKX-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(C)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 RJPNBZXKFWESKX-UHFFFAOYSA-N 0.000 description 1
- ZYQZHRXKSVPLEG-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)octanamide Chemical compound C1=C(C)C(NC(=O)CCCCCCC)=C(C)C=C1N1CCOCC1 ZYQZHRXKSVPLEG-UHFFFAOYSA-N 0.000 description 1
- FLNIDPUBPDBGTL-UHFFFAOYSA-N n-(2,6-dimethyl-4-morpholin-4-ylphenyl)pentanamide Chemical compound C1=C(C)C(NC(=O)CCCC)=C(C)C=C1N1CCOCC1 FLNIDPUBPDBGTL-UHFFFAOYSA-N 0.000 description 1
- JQAHNNUCWWVTBF-UHFFFAOYSA-N n-(2-amino-4-bromo-6-methylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=CC(Br)=CC(N)=C1NC(=O)CC(C)(C)C JQAHNNUCWWVTBF-UHFFFAOYSA-N 0.000 description 1
- LMHIKBQBDWYIPR-UHFFFAOYSA-N n-(2-bromo-4,6-dichlorophenyl)-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=C(Cl)C=C(Cl)C=C1Br LMHIKBQBDWYIPR-UHFFFAOYSA-N 0.000 description 1
- AYWFSTLPGFXGPN-UHFFFAOYSA-N n-(2-bromo-4,6-dichlorophenyl)-2-cyclopentylacetamide Chemical compound BrC1=CC(Cl)=CC(Cl)=C1NC(=O)CC1CCCC1 AYWFSTLPGFXGPN-UHFFFAOYSA-N 0.000 description 1
- VBTXCZKHCJLZGV-UHFFFAOYSA-N n-(2-bromo-4,6-dichlorophenyl)-3,3-dimethylbutanamide Chemical compound CC(C)(C)CC(=O)NC1=C(Cl)C=C(Cl)C=C1Br VBTXCZKHCJLZGV-UHFFFAOYSA-N 0.000 description 1
- KGYPPALBQMVEFK-UHFFFAOYSA-N n-(2-bromo-4,6-dimethylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound BrC1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 KGYPPALBQMVEFK-UHFFFAOYSA-N 0.000 description 1
- NOGJERYUQWFZSH-UHFFFAOYSA-N n-(2-bromo-4,6-dimethylphenyl)-2-cyclopentylacetamide Chemical compound BrC1=CC(C)=CC(C)=C1NC(=O)CC1CCCC1 NOGJERYUQWFZSH-UHFFFAOYSA-N 0.000 description 1
- OBGRLHUKTLMALQ-UHFFFAOYSA-N n-(2-bromo-4,6-dimethylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=CC(C)=C(NC(=O)CC(C)(C)C)C(Br)=C1 OBGRLHUKTLMALQ-UHFFFAOYSA-N 0.000 description 1
- JXZMYIPYHBOYME-UHFFFAOYSA-N n-(2-chloro-4-methoxy-6-morpholin-4-ylpyridin-3-yl)-2-cyclopentylacetamide Chemical compound COC1=CC(N2CCOCC2)=NC(Cl)=C1NC(=O)CC1CCCC1 JXZMYIPYHBOYME-UHFFFAOYSA-N 0.000 description 1
- PWTTZEIOVBSDKM-UHFFFAOYSA-N n-(2-chloro-4-methoxy-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(OC)=CC(N2CCOCC2)=N1 PWTTZEIOVBSDKM-UHFFFAOYSA-N 0.000 description 1
- ORMUPENLTSWLSB-UHFFFAOYSA-N n-(2-chloro-6-cyano-4-morpholin-4-ylphenyl)-3-cyclohexylpropanamide Chemical compound ClC1=CC(N2CCOCC2)=CC(C#N)=C1NC(=O)CCC1CCCCC1 ORMUPENLTSWLSB-UHFFFAOYSA-N 0.000 description 1
- CZXDPWCUNYIWRD-UHFFFAOYSA-N n-(2-chloro-6-methyl-4-morpholin-4-ylphenyl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=CC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1=CC=CC(F)=C1 CZXDPWCUNYIWRD-UHFFFAOYSA-N 0.000 description 1
- KWQRIEAEGLFRKZ-UHFFFAOYSA-N n-(2-chloro-6-methyl-4-morpholin-4-ylphenyl)-2-cyclopentylacetamide Chemical compound CC1=CC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1CCCC1 KWQRIEAEGLFRKZ-UHFFFAOYSA-N 0.000 description 1
- BZNCUGFPSDUISB-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(OC)=CC(N2CCOCC2)=C1 BZNCUGFPSDUISB-UHFFFAOYSA-N 0.000 description 1
- KIEKLHLDPVXZRI-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-4-methylpentanamide Chemical compound CC1=C(NC(=O)CCC(C)C)C(OC)=CC(N2CCOCC2)=C1 KIEKLHLDPVXZRI-UHFFFAOYSA-N 0.000 description 1
- LDGIJFPFNRCERN-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)-5-methylhexanamide Chemical compound CC1=C(NC(=O)CCCC(C)C)C(OC)=CC(N2CCOCC2)=C1 LDGIJFPFNRCERN-UHFFFAOYSA-N 0.000 description 1
- RUDPUVCWGIFSRS-UHFFFAOYSA-N n-(2-methoxy-6-methyl-4-morpholin-4-ylphenyl)hexanamide Chemical compound C1=C(OC)C(NC(=O)CCCCC)=C(C)C=C1N1CCOCC1 RUDPUVCWGIFSRS-UHFFFAOYSA-N 0.000 description 1
- DOUOPPDCDVPKHL-UHFFFAOYSA-N n-(3,3-dimethylbutyl)-2-[3-(4-fluorophenyl)propylsulfanyl]benzamide Chemical compound CC(C)(C)CCNC(=O)C1=CC=CC=C1SCCCC1=CC=C(F)C=C1 DOUOPPDCDVPKHL-UHFFFAOYSA-N 0.000 description 1
- MDAHIAVABNWZEZ-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-(1,4-oxazepan-4-yl)-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCCC(C)(C)C)=C(C(C)C)N=C1N1CCOCCC1 MDAHIAVABNWZEZ-UHFFFAOYSA-N 0.000 description 1
- IFAGCSHMNZPUED-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-(2-methoxyethoxy)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(OCCOC)=NC(N2CCOCC2)=C1 IFAGCSHMNZPUED-UHFFFAOYSA-N 0.000 description 1
- NTORCAHJPQKHBH-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-(2-methoxyethyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(CCOC)=NC(N2CCOCC2)=C1 NTORCAHJPQKHBH-UHFFFAOYSA-N 0.000 description 1
- XJYJWSWAIIXZQR-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-(3-methoxypropyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(CCCOC)=NC(N2CCOCC2)=C1 XJYJWSWAIIXZQR-UHFFFAOYSA-N 0.000 description 1
- GQNDEJRNWYEWJF-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-ethoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(OCC)=NC(N2CCOCC2)=C1 GQNDEJRNWYEWJF-UHFFFAOYSA-N 0.000 description 1
- GXVFJMOJOPATPH-OAHLLOKOSA-N n-(4,4-dimethylpentyl)-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(OC)=NC(N2[C@@H](COCC2)C)=C1 GXVFJMOJOPATPH-OAHLLOKOSA-N 0.000 description 1
- CNWVWJAMDPQCGY-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(OC)=NC(N2CCOCC2)=C1 CNWVWJAMDPQCGY-UHFFFAOYSA-N 0.000 description 1
- FMSQALQUUWIHJV-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-morpholin-4-yl-4-propan-2-yl-1,3-oxazole-5-carboxamide Chemical compound O1C(C(=O)NCCCC(C)(C)C)=C(C(C)C)N=C1N1CCOCC1 FMSQALQUUWIHJV-UHFFFAOYSA-N 0.000 description 1
- LEQXTPCTVKCFJQ-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-2-piperidin-1-yl-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound S1C(C(=O)NCCCC(C)(C)C)=C(C(C)C)N=C1N1CCCCC1 LEQXTPCTVKCFJQ-UHFFFAOYSA-N 0.000 description 1
- XBTZIJXKXQYDQK-QGZVFWFLSA-N n-(4,4-dimethylpentyl)-4-[(3r)-3-fluoropyrrolidin-1-yl]-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC(C)(C)CCCNC(=O)C=1C(C)=NC(N2CCOCC2)=CC=1N1CC[C@@H](F)C1 XBTZIJXKXQYDQK-QGZVFWFLSA-N 0.000 description 1
- SPLBAMAUUPNDNR-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-ethoxy-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(OCC)=CC(N2CCOCC2)=N1 SPLBAMAUUPNDNR-UHFFFAOYSA-N 0.000 description 1
- DLIOPSIJVGJPFE-OAHLLOKOSA-N n-(4,4-dimethylpentyl)-4-ethylsulfanyl-2-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(SCC)=CC(N2[C@@H](COCC2)C)=N1 DLIOPSIJVGJPFE-OAHLLOKOSA-N 0.000 description 1
- VJEXSONJBGTOCU-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-ethylsulfanyl-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(SCC)=CC(N2CCOCC2)=N1 VJEXSONJBGTOCU-UHFFFAOYSA-N 0.000 description 1
- VKOKEBSNHAJXPK-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-methyl-2-(2-methylbutan-2-yl)-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(C(C)(C)CC)=NC(N2CCOCC2)=C1 VKOKEBSNHAJXPK-UHFFFAOYSA-N 0.000 description 1
- PIZFEYMUYZNSQF-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-methyl-2-(2-methylbutyl)-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(CC(C)CC)=NC(N2CCOCC2)=C1 PIZFEYMUYZNSQF-UHFFFAOYSA-N 0.000 description 1
- IITKHCFJNGFJNA-QGZVFWFLSA-N n-(4,4-dimethylpentyl)-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(C(C)C)=NC(N2[C@@H](COCC2)C)=C1 IITKHCFJNGFJNA-QGZVFWFLSA-N 0.000 description 1
- RKPYDUJSIJQLGC-QGZVFWFLSA-N n-(4,4-dimethylpentyl)-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(CCC)=NC(N2[C@@H](COCC2)C)=C1 RKPYDUJSIJQLGC-QGZVFWFLSA-N 0.000 description 1
- GKVIRQLBDLCCQR-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-yl-2-(oxan-4-yl)pyridine-3-carboxamide Chemical compound CC(C)(C)CCCNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CCOCC1 GKVIRQLBDLCCQR-UHFFFAOYSA-N 0.000 description 1
- RZOZUDGCDZNAQK-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(C(C)C)=NC(N2CCOCC2)=C1 RZOZUDGCDZNAQK-UHFFFAOYSA-N 0.000 description 1
- JQACRGUVPKTFMW-UHFFFAOYSA-N n-(4,4-dimethylpentyl)-4-methyl-6-morpholin-4-yl-2-propylpyridine-3-carboxamide Chemical compound CC1=C(C(=O)NCCCC(C)(C)C)C(CCC)=NC(N2CCOCC2)=C1 JQACRGUVPKTFMW-UHFFFAOYSA-N 0.000 description 1
- CZEOTFCOTGFZPR-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-2-(3-fluorophenyl)acetamide Chemical compound CC1=NC(N2CCOCC2)=NC(C)=C1NC(=O)CC1=CC=CC(F)=C1 CZEOTFCOTGFZPR-UHFFFAOYSA-N 0.000 description 1
- BGZXWAKABKRXEW-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=NC(N2CCOCC2)=N1 BGZXWAKABKRXEW-UHFFFAOYSA-N 0.000 description 1
- CUYIVYGWYZOZCL-UHFFFAOYSA-N n-(4,6-dimethyl-2-morpholin-4-ylpyrimidin-5-yl)hexanamide Chemical compound N1=C(C)C(NC(=O)CCCCC)=C(C)N=C1N1CCOCC1 CUYIVYGWYZOZCL-UHFFFAOYSA-N 0.000 description 1
- CRNGWJTUEOBSCH-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-(4-chlorophenyl)acetamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)CC1=CC=C(Cl)C=C1 CRNGWJTUEOBSCH-UHFFFAOYSA-N 0.000 description 1
- GHQWOAYHLGEKSK-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-(4-fluorophenyl)acetamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 GHQWOAYHLGEKSK-UHFFFAOYSA-N 0.000 description 1
- YBULBCNOKRWWDW-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-phenylcyclopropane-1-carboxamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)C1C(C=2C=CC=CC=2)C1 YBULBCNOKRWWDW-UHFFFAOYSA-N 0.000 description 1
- BRSMPKRBMIMHTN-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)-2-thiophen-2-ylacetamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)CC1=CC=CS1 BRSMPKRBMIMHTN-UHFFFAOYSA-N 0.000 description 1
- INNYRLVBOHMVMN-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)cyclohexanecarboxamide Chemical compound CC1=CC(Br)=CC(C)=C1NC(=O)C1CCCCC1 INNYRLVBOHMVMN-UHFFFAOYSA-N 0.000 description 1
- HFNKFBFHZHFTGW-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)heptanamide Chemical compound CCCCCCC(=O)NC1=C(C)C=C(Br)C=C1C HFNKFBFHZHFTGW-UHFFFAOYSA-N 0.000 description 1
- MCBBKIXEHFOEKH-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)hexanamide Chemical compound CCCCCC(=O)NC1=C(C)C=C(Br)C=C1C MCBBKIXEHFOEKH-UHFFFAOYSA-N 0.000 description 1
- UQDDTPPOICDUBZ-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)octanamide Chemical compound CCCCCCCC(=O)NC1=C(C)C=C(Br)C=C1C UQDDTPPOICDUBZ-UHFFFAOYSA-N 0.000 description 1
- RWXAELOLLOUEEU-UHFFFAOYSA-N n-(4-bromo-2,6-dimethylphenyl)pentanamide Chemical compound CCCCC(=O)NC1=C(C)C=C(Br)C=C1C RWXAELOLLOUEEU-UHFFFAOYSA-N 0.000 description 1
- MVPLWTHYLWWKGV-UHFFFAOYSA-N n-(4-bromo-2-methyl-6-morpholin-4-ylphenyl)-3,3-dimethylbutanamide Chemical compound CC1=CC(Br)=CC(N2CCOCC2)=C1NC(=O)CC(C)(C)C MVPLWTHYLWWKGV-UHFFFAOYSA-N 0.000 description 1
- CTONPIFXRWAMMT-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)-2-cyclopentylacetamide Chemical compound COC1=NC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1CCCC1 CTONPIFXRWAMMT-UHFFFAOYSA-N 0.000 description 1
- OSHLKYWGTPRHND-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(OC)=NC(N2CCOCC2)=C1 OSHLKYWGTPRHND-UHFFFAOYSA-N 0.000 description 1
- FNGCWQBVWMPXRW-UHFFFAOYSA-N n-(4-chloro-2-methoxy-6-morpholin-4-ylpyridin-3-yl)propanamide Chemical compound N1=C(OC)C(NC(=O)CC)=C(Cl)C=C1N1CCOCC1 FNGCWQBVWMPXRW-UHFFFAOYSA-N 0.000 description 1
- UYJWNCUIBCLNDC-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-ethoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 UYJWNCUIBCLNDC-UHFFFAOYSA-N 0.000 description 1
- BUNBZNDNLJPPFY-CYBMUJFWSA-N n-[(3,4-difluorophenyl)methyl]-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 BUNBZNDNLJPPFY-CYBMUJFWSA-N 0.000 description 1
- OWNWFCCBOQFFOX-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 OWNWFCCBOQFFOX-UHFFFAOYSA-N 0.000 description 1
- AUURBWPETSEGJG-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-2-morpholin-4-yl-4-propyl-1,3-thiazole-5-carboxamide Chemical compound CCCC=1N=C(N2CCOCC2)SC=1C(=O)NCC1=CC=C(F)C(F)=C1 AUURBWPETSEGJG-UHFFFAOYSA-N 0.000 description 1
- IKTWGLWXFHAOPH-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 IKTWGLWXFHAOPH-UHFFFAOYSA-N 0.000 description 1
- PEROAAALFOPDSS-UHFFFAOYSA-N n-[(3,4-difluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C(F)=C1 PEROAAALFOPDSS-UHFFFAOYSA-N 0.000 description 1
- OEHWOISGCBTAIK-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2-ethoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 OEHWOISGCBTAIK-UHFFFAOYSA-N 0.000 description 1
- KRGXUWIYJXGBCZ-CYBMUJFWSA-N n-[(3,5-difluorophenyl)methyl]-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 KRGXUWIYJXGBCZ-CYBMUJFWSA-N 0.000 description 1
- OEHHINQQYDAYFA-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 OEHHINQQYDAYFA-UHFFFAOYSA-N 0.000 description 1
- SQCWGMWJOANZLX-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 SQCWGMWJOANZLX-UHFFFAOYSA-N 0.000 description 1
- DHRIDQQBLDZDQO-UHFFFAOYSA-N n-[(3,5-difluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC(F)=CC(F)=C1 DHRIDQQBLDZDQO-UHFFFAOYSA-N 0.000 description 1
- DASGGNBYGWWEHL-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-2-(methoxymethyl)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 DASGGNBYGWWEHL-UHFFFAOYSA-N 0.000 description 1
- VLOXSJOPIGBFFS-CQSZACIVSA-N n-[(3-fluorophenyl)methyl]-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 VLOXSJOPIGBFFS-CQSZACIVSA-N 0.000 description 1
- GCYRBQURLBDYIJ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 GCYRBQURLBDYIJ-UHFFFAOYSA-N 0.000 description 1
- OZPDOMJUSDYUJM-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-(oxetan-3-yloxy)pyridine-3-carboxamide Chemical compound C=1C=CC(F)=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1OC1COC1 OZPDOMJUSDYUJM-UHFFFAOYSA-N 0.000 description 1
- SQLBAILIXALTJY-HWKANZROSA-N n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-[(e)-prop-1-enyl]pyridine-3-carboxamide Chemical compound C\C=C\C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 SQLBAILIXALTJY-HWKANZROSA-N 0.000 description 1
- NNSVMZXPWHFNKQ-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 NNSVMZXPWHFNKQ-UHFFFAOYSA-N 0.000 description 1
- LGUWBRICNDIBKY-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propoxypyridine-3-carboxamide Chemical compound CCCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 LGUWBRICNDIBKY-UHFFFAOYSA-N 0.000 description 1
- ZWMVQBHKFYTOAR-UHFFFAOYSA-N n-[(3-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=CC(F)=C1 ZWMVQBHKFYTOAR-UHFFFAOYSA-N 0.000 description 1
- VPDBNBCEQUOMCC-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2,4-diethyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCC1=CC(N2CCOCC2)=NC(CC)=C1C(=O)NCC1=CC=C(Cl)C=C1 VPDBNBCEQUOMCC-UHFFFAOYSA-N 0.000 description 1
- PFNONEBWYHOGIF-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(1,4-oxazepan-4-yl)-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N2CCOCCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 PFNONEBWYHOGIF-UHFFFAOYSA-N 0.000 description 1
- QVVSLYSSGDANLP-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(2,2-difluoroethoxy)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(OCC(F)F)=C1C(=O)NCC1=CC=C(Cl)C=C1 QVVSLYSSGDANLP-UHFFFAOYSA-N 0.000 description 1
- USOIEUYYXNAUND-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(2-fluoroethoxy)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CC1=CC(N2CCOCC2)=NC(OCCF)=C1C(=O)NCC1=CC=C(Cl)C=C1 USOIEUYYXNAUND-UHFFFAOYSA-N 0.000 description 1
- CLMGEZUBXJIAII-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(cyclopropylmethoxy)-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1OCC1CC1 CLMGEZUBXJIAII-UHFFFAOYSA-N 0.000 description 1
- VOSIWSWCCUPWQI-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[2-(dimethylamino)ethoxy]-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CN(C)CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 VOSIWSWCCUPWQI-UHFFFAOYSA-N 0.000 description 1
- MQDATYASGBQOAI-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[methyl(oxan-4-yl)amino]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound N=1C(C(F)(F)F)=C(C(=O)NCC=2C=CC(Cl)=CC=2)SC=1N(C)C1CCOCC1 MQDATYASGBQOAI-UHFFFAOYSA-N 0.000 description 1
- VACMFWFEZVRKDV-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[methyl(oxan-4-yl)amino]-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N(C)C2CCOCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 VACMFWFEZVRKDV-UHFFFAOYSA-N 0.000 description 1
- DAHWMGNWTVSAQU-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[methyl(oxan-4-ylmethyl)amino]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound N=1C(C(F)(F)F)=C(C(=O)NCC=2C=CC(Cl)=CC=2)SC=1N(C)CC1CCOCC1 DAHWMGNWTVSAQU-UHFFFAOYSA-N 0.000 description 1
- YWTKSJFXDTUPCM-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-[methyl(oxan-4-ylmethyl)amino]-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N(C)CC2CCOCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 YWTKSJFXDTUPCM-UHFFFAOYSA-N 0.000 description 1
- PFWOJJLKAJDGDY-OAHLLOKOSA-N n-[(4-chlorophenyl)methyl]-2-cyclopropyl-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound C[C@@H]1COCCN1C(N=C1C2CC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 PFWOJJLKAJDGDY-OAHLLOKOSA-N 0.000 description 1
- NGCYKXQASBWLQZ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-cyclopropyl-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1CNC(=O)C=1C(C)=CC(N2CCOCC2)=NC=1C1CC1 NGCYKXQASBWLQZ-UHFFFAOYSA-N 0.000 description 1
- IWBRCYULBCUJNW-IBGZPJMESA-N n-[(4-chlorophenyl)methyl]-2-cyclopropyl-6-[(2s)-2-(methoxymethyl)morpholin-4-yl]-4-methylpyridine-3-carboxamide Chemical compound C1CO[C@H](COC)CN1C(N=C1C2CC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 IWBRCYULBCUJNW-IBGZPJMESA-N 0.000 description 1
- MFUQJASRIDNRGX-OAHLLOKOSA-N n-[(4-chlorophenyl)methyl]-2-ethoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CCOC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 MFUQJASRIDNRGX-OAHLLOKOSA-N 0.000 description 1
- PBKOPUQCFRHUNW-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-ethoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCOC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 PBKOPUQCFRHUNW-UHFFFAOYSA-N 0.000 description 1
- OMLIGMJYIYQKOB-CQSZACIVSA-N n-[(4-chlorophenyl)methyl]-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 OMLIGMJYIYQKOB-CQSZACIVSA-N 0.000 description 1
- MOXGPYRNYQKHGY-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 MOXGPYRNYQKHGY-UHFFFAOYSA-N 0.000 description 1
- OXBXEJPPDQRXKD-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-methyl-6-morpholin-4-yl-4-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 OXBXEJPPDQRXKD-UHFFFAOYSA-N 0.000 description 1
- HAFJDMVPUDYKSM-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-methyl-6-morpholin-4-yl-4-propylpyridine-3-carboxamide Chemical compound CCCC1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 HAFJDMVPUDYKSM-UHFFFAOYSA-N 0.000 description 1
- WVQYXGFINUKNRJ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-morpholin-4-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound FC(F)(F)C=1N=C(N2CCOCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 WVQYXGFINUKNRJ-UHFFFAOYSA-N 0.000 description 1
- ZWGUXNSYQUMVCF-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-morpholin-4-yl-4-propan-2-yl-1,3-oxazole-5-carboxamide Chemical compound CC(C)C=1N=C(N2CCOCC2)OC=1C(=O)NCC1=CC=C(Cl)C=C1 ZWGUXNSYQUMVCF-UHFFFAOYSA-N 0.000 description 1
- GCJQQNKJOSVBRE-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-morpholin-4-yl-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N2CCOCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 GCJQQNKJOSVBRE-UHFFFAOYSA-N 0.000 description 1
- JPPLSEBXFCWMDN-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-piperidin-1-yl-4-propan-2-yl-1,3-thiazole-5-carboxamide Chemical compound CC(C)C=1N=C(N2CCCCC2)SC=1C(=O)NCC1=CC=C(Cl)C=C1 JPPLSEBXFCWMDN-UHFFFAOYSA-N 0.000 description 1
- KFQMYEKKZWPJSF-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-3-methyl-2-morpholin-4-yl-5-propan-2-ylimidazole-4-carboxamide Chemical compound CN1C(C(=O)NCC=2C=CC(Cl)=CC=2)=C(C(C)C)N=C1N1CCOCC1 KFQMYEKKZWPJSF-UHFFFAOYSA-N 0.000 description 1
- IIFYEKIGYULSOH-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4,6-dimethoxy-2-morpholin-4-ylpyrimidine-5-carboxamide Chemical compound COC1=NC(N2CCOCC2)=NC(OC)=C1C(=O)NCC1=CC=C(Cl)C=C1 IIFYEKIGYULSOH-UHFFFAOYSA-N 0.000 description 1
- UBIPROYNHTWATQ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-(dimethylamino)-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CN(C)C1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 UBIPROYNHTWATQ-UHFFFAOYSA-N 0.000 description 1
- LKDXHIDATSIHQS-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-cyclopropyl-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound C=1C=C(Cl)C=CC=1CNC(=O)C=1C(C)=NC(N2CCOCC2)=CC=1C1CC1 LKDXHIDATSIHQS-UHFFFAOYSA-N 0.000 description 1
- NEZTVTSRLMHMGV-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-ethoxy-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCOC1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 NEZTVTSRLMHMGV-UHFFFAOYSA-N 0.000 description 1
- YIBGXYJKEPQZJK-CQSZACIVSA-N n-[(4-chlorophenyl)methyl]-4-ethylsulfanyl-2-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound CCSC1=CC(N2[C@@H](COCC2)C)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 YIBGXYJKEPQZJK-CQSZACIVSA-N 0.000 description 1
- UFASTUHMTQEIBS-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-ethylsulfanyl-2-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound CCSC1=CC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 UFASTUHMTQEIBS-UHFFFAOYSA-N 0.000 description 1
- KSDOMHBPLCHJDE-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-ethylsulfanyl-6-methyl-2-morpholin-4-ylpyrimidine-5-carboxamide Chemical compound CCSC1=NC(N2CCOCC2)=NC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 KSDOMHBPLCHJDE-UHFFFAOYSA-N 0.000 description 1
- AQMFSAHHVVUUIH-MRXNPFEDSA-N n-[(4-chlorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 AQMFSAHHVVUUIH-MRXNPFEDSA-N 0.000 description 1
- DXBVPZOGXVILSK-MRXNPFEDSA-N n-[(4-chlorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 DXBVPZOGXVILSK-MRXNPFEDSA-N 0.000 description 1
- VSXYQLIGAWKFRL-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 VSXYQLIGAWKFRL-UHFFFAOYSA-N 0.000 description 1
- AZBZSFOKKPDVIZ-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 AZBZSFOKKPDVIZ-UHFFFAOYSA-N 0.000 description 1
- NQYBSEDMQJZNKT-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-5-morpholin-4-yl-3-propan-2-ylpyrazine-2-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CN=C1C(=O)NCC1=CC=C(Cl)C=C1 NQYBSEDMQJZNKT-UHFFFAOYSA-N 0.000 description 1
- REPFMRQIVXRYGS-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-5-morpholin-4-yl-3-propan-2-ylpyridine-2-carboxamide Chemical compound CC(C)C1=CC(N2CCOCC2)=CN=C1C(=O)NCC1=CC=C(Cl)C=C1 REPFMRQIVXRYGS-UHFFFAOYSA-N 0.000 description 1
- GUVKTUZPIBHVTA-IBGZPJMESA-N n-[(4-chlorophenyl)methyl]-6-[(3s)-3-(methoxymethyl)morpholin-4-yl]-4-methyl-2-propan-2-ylpyridine-3-carboxamide Chemical compound COC[C@H]1COCCN1C(N=C1C(C)C)=CC(C)=C1C(=O)NCC1=CC=C(Cl)C=C1 GUVKTUZPIBHVTA-IBGZPJMESA-N 0.000 description 1
- RTXSSLVUHBREFX-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-6-morpholin-4-yl-2,4-di(propan-2-yl)pyridine-3-carboxamide Chemical compound CC(C)C1=CC(N2CCOCC2)=NC(C(C)C)=C1C(=O)NCC1=CC=C(Cl)C=C1 RTXSSLVUHBREFX-UHFFFAOYSA-N 0.000 description 1
- SCMDJAYXXJBFRG-CQSZACIVSA-N n-[(4-fluorophenyl)methyl]-2-methoxy-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]pyridine-3-carboxamide Chemical compound COC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 SCMDJAYXXJBFRG-CQSZACIVSA-N 0.000 description 1
- HBVWYWGWWSKZHE-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-2-methoxy-4-methyl-6-morpholin-4-ylpyridine-3-carboxamide Chemical compound COC1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 HBVWYWGWWSKZHE-UHFFFAOYSA-N 0.000 description 1
- IQHHBFVRGCJQPP-MRXNPFEDSA-N n-[(4-fluorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 IQHHBFVRGCJQPP-MRXNPFEDSA-N 0.000 description 1
- ABRHWJRZWHRDRG-MRXNPFEDSA-N n-[(4-fluorophenyl)methyl]-4-methyl-6-[(3r)-3-methylmorpholin-4-yl]-2-propylpyridine-3-carboxamide Chemical compound CCCC1=NC(N2[C@@H](COCC2)C)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 ABRHWJRZWHRDRG-MRXNPFEDSA-N 0.000 description 1
- FNOPHTPRAFLJEJ-ONEGZZNKSA-N n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-[(e)-prop-1-enyl]pyridine-3-carboxamide Chemical compound C\C=C\C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 FNOPHTPRAFLJEJ-ONEGZZNKSA-N 0.000 description 1
- JMVRJADNQNIYCS-UHFFFAOYSA-N n-[(4-fluorophenyl)methyl]-4-methyl-6-morpholin-4-yl-2-propan-2-ylpyridine-3-carboxamide Chemical compound CC(C)C1=NC(N2CCOCC2)=CC(C)=C1C(=O)NCC1=CC=C(F)C=C1 JMVRJADNQNIYCS-UHFFFAOYSA-N 0.000 description 1
- JBNREMLAUOUYRB-UHFFFAOYSA-N n-[1-(1-benzothiophen-2-ylmethyl)-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2SC3=CC=CC=C3C=2)CC2)C2=C1 JBNREMLAUOUYRB-UHFFFAOYSA-N 0.000 description 1
- YLOCKEYFOVMFIT-UHFFFAOYSA-N n-[1-(1-benzothiophen-2-ylmethyl)-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=CC=C2SC(CN3C4=CC=C(C=C4CC3)NC(=O)CC(C)(C)C)=CC2=C1 YLOCKEYFOVMFIT-UHFFFAOYSA-N 0.000 description 1
- ZMOKGMHZNZODRK-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethyl]-2-[methyl(oxan-4-yl)amino]-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(=O)C(=C(N=1)C(F)(F)F)SC=1N(C)C1CCOCC1 ZMOKGMHZNZODRK-UHFFFAOYSA-N 0.000 description 1
- OBJNPZDKXHLQBO-UHFFFAOYSA-N n-[1-(4-chlorophenyl)ethyl]-2-morpholin-4-yl-4-(trifluoromethyl)-1,3-thiazole-5-carboxamide Chemical compound C=1C=C(Cl)C=CC=1C(C)NC(=O)C(=C(N=1)C(F)(F)F)SC=1N1CCOCC1 OBJNPZDKXHLQBO-UHFFFAOYSA-N 0.000 description 1
- WRQSZMSXRSCLPP-UHFFFAOYSA-N n-[1-[(3,5-dimethyl-1-phenylpyrazol-4-yl)methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound CC1=NN(C=2C=CC=CC=2)C(C)=C1CN(C1=CC=2)CCC1=CC=2NC(=O)CC1=CC=C(F)C=C1 WRQSZMSXRSCLPP-UHFFFAOYSA-N 0.000 description 1
- PCAWYJLOTGGJDX-UHFFFAOYSA-N n-[1-[(3,5-dimethyl-1-phenylpyrazol-4-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(CN2C3=CC=C(NC(=O)CC(C)(C)C)C=C3CC2)C(C)=NN1C1=CC=CC=C1 PCAWYJLOTGGJDX-UHFFFAOYSA-N 0.000 description 1
- SCEJCGGUVNNWPA-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=CC(Cl)=CC=2)CC2)C2=C1 SCEJCGGUVNNWPA-UHFFFAOYSA-N 0.000 description 1
- NLELJHJOHHLRKY-UHFFFAOYSA-N n-[1-[(4-chlorophenyl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)C=C1 NLELJHJOHHLRKY-UHFFFAOYSA-N 0.000 description 1
- SQYQNUKBEUGHMW-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]-1-phenylmethanesulfonamide Chemical compound C1=CC(F)=CC=C1CN1C2=CC=C(NS(=O)(=O)CC=3C=CC=CC=3)C=C2CC1 SQYQNUKBEUGHMW-UHFFFAOYSA-N 0.000 description 1
- MLYGLHCJIUZCON-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]-2-thiophen-2-ylacetamide Chemical compound C1=CC(F)=CC=C1CN1C2=CC=C(NC(=O)CC=3SC=CC=3)C=C2CC1 MLYGLHCJIUZCON-UHFFFAOYSA-N 0.000 description 1
- ORDFNPXQFMYCJJ-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(F)C=C1 ORDFNPXQFMYCJJ-UHFFFAOYSA-N 0.000 description 1
- MBLHXGIQLLVTNK-UHFFFAOYSA-N n-[1-[(4-fluorophenyl)methyl]indol-5-yl]methanesulfonamide Chemical compound C1=CC2=CC(NS(=O)(=O)C)=CC=C2N1CC1=CC=C(F)C=C1 MBLHXGIQLLVTNK-UHFFFAOYSA-N 0.000 description 1
- OWLJBEFMBBKHDL-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-1-phenylmethanesulfonamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NS(=O)(=O)CC=3C=CC=CC=3)C=C2CC1 OWLJBEFMBBKHDL-UHFFFAOYSA-N 0.000 description 1
- NGSSGTOLCODPLL-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2,2-dimethylpropanamide Chemical compound C1CC2=CC(NC(=O)C(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 NGSSGTOLCODPLL-UHFFFAOYSA-N 0.000 description 1
- WCSJONOPHXDPQR-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2SC(Cl)=CC=2)CC2)C2=C1 WCSJONOPHXDPQR-UHFFFAOYSA-N 0.000 description 1
- NFZIHKNNXDBZMI-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2-phenoxyacetamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)COC=3C=CC=CC=3)C=C2CC1 NFZIHKNNXDBZMI-UHFFFAOYSA-N 0.000 description 1
- INBOWVFXGFYASA-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2-thiophen-2-ylacetamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)CC=3SC=CC=3)C=C2CC1 INBOWVFXGFYASA-UHFFFAOYSA-N 0.000 description 1
- VWDPGWVVUMGFBI-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 VWDPGWVVUMGFBI-UHFFFAOYSA-N 0.000 description 1
- LEFBMUAFQIOAKD-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-4-(dimethylamino)benzamide Chemical compound C1=CC(N(C)C)=CC=C1C(=O)NC1=CC=C(N(CC=2SC(Cl)=CC=2)CC2)C2=C1 LEFBMUAFQIOAKD-UHFFFAOYSA-N 0.000 description 1
- QPLBUHMKFJUHRV-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-4-fluorobenzamide Chemical compound C1=CC(F)=CC=C1C(=O)NC1=CC=C(N(CC=2SC(Cl)=CC=2)CC2)C2=C1 QPLBUHMKFJUHRV-UHFFFAOYSA-N 0.000 description 1
- INOQOCQMNCFZDG-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-6-(trifluoromethyl)pyridine-3-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C(=O)NC1=CC=C(N(CC=2SC(Cl)=CC=2)CC2)C2=C1 INOQOCQMNCFZDG-UHFFFAOYSA-N 0.000 description 1
- AINZRXMCTQLAAO-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]butanamide Chemical compound C1CC2=CC(NC(=O)CCC)=CC=C2N1CC1=CC=C(Cl)S1 AINZRXMCTQLAAO-UHFFFAOYSA-N 0.000 description 1
- KYXJYAWCKRGRPW-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]butane-1-sulfonamide Chemical compound C1CC2=CC(NS(=O)(=O)CCCC)=CC=C2N1CC1=CC=C(Cl)S1 KYXJYAWCKRGRPW-UHFFFAOYSA-N 0.000 description 1
- AUOZRASIFYBPPM-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]cyclopentanecarboxamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)C3CCCC3)C=C2CC1 AUOZRASIFYBPPM-UHFFFAOYSA-N 0.000 description 1
- UDLPJOIAOVEEPL-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]morpholine-4-carboxamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)N3CCOCC3)C=C2CC1 UDLPJOIAOVEEPL-UHFFFAOYSA-N 0.000 description 1
- CLUZVERVUJDLJR-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]pyridine-4-carboxamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)C=3C=CN=CC=3)C=C2CC1 CLUZVERVUJDLJR-UHFFFAOYSA-N 0.000 description 1
- XRJGFWOKHCXSEE-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]pyrrolidine-1-carboxamide Chemical compound S1C(Cl)=CC=C1CN1C2=CC=C(NC(=O)N3CCCC3)C=C2CC1 XRJGFWOKHCXSEE-UHFFFAOYSA-N 0.000 description 1
- QOQVAAXPPGQOFT-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-6-nitro-2,3-dihydroindol-5-yl]-2,2-dimethylpropanamide Chemical compound C1=2C=C([N+]([O-])=O)C(NC(=O)C(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 QOQVAAXPPGQOFT-UHFFFAOYSA-N 0.000 description 1
- IHUHNUOZZWHYEV-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-6-nitro-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1CC=2C=C(NC(=O)CC=3C=CC(F)=CC=3)C([N+](=O)[O-])=CC=2N1CC1=CC=C(Cl)S1 IHUHNUOZZWHYEV-UHFFFAOYSA-N 0.000 description 1
- TUEOQKMPHSSCKJ-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]-6-nitro-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C([N+]([O-])=O)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 TUEOQKMPHSSCKJ-UHFFFAOYSA-N 0.000 description 1
- IRNCNAXYARSFKH-UHFFFAOYSA-N n-[1-[(5-chlorothiophen-2-yl)methyl]indol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 IRNCNAXYARSFKH-UHFFFAOYSA-N 0.000 description 1
- XHCFARXUQBWVJQ-UHFFFAOYSA-N n-[1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C(=CC=3OCOC=3C=2)Cl)CC2)C2=C1 XHCFARXUQBWVJQ-UHFFFAOYSA-N 0.000 description 1
- YZKODOMNCLLXIE-UHFFFAOYSA-N n-[1-[(6-chloro-1,3-benzodioxol-5-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC(C(=C1)Cl)=CC2=C1OCO2 YZKODOMNCLLXIE-UHFFFAOYSA-N 0.000 description 1
- CHGPKEYXXUWPLC-UHFFFAOYSA-N n-[1-[(6-fluoro-4h-1,3-benzodioxin-8-yl)methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=3OCOCC=3C=C(F)C=2)CC2)C2=C1 CHGPKEYXXUWPLC-UHFFFAOYSA-N 0.000 description 1
- VVFNUEKZVPMLRO-UHFFFAOYSA-N n-[1-[(6-fluoro-4h-1,3-benzodioxin-8-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1OCOC2=C1C=C(F)C=C2CN1C2=CC=C(NC(=O)CC(C)(C)C)C=C2CC1 VVFNUEKZVPMLRO-UHFFFAOYSA-N 0.000 description 1
- ZXAIVTUUGYJSJH-UHFFFAOYSA-N n-[1-[[1-(4-fluorophenyl)-5-methylpyrazol-4-yl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound CC1=C(CN2C3=CC=C(NC(=O)CC(C)(C)C)C=C3CC2)C=NN1C1=CC=C(F)C=C1 ZXAIVTUUGYJSJH-UHFFFAOYSA-N 0.000 description 1
- WVTBISXVGWDRJU-UHFFFAOYSA-N n-[1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C(=CC=C(C=2)C(F)(F)F)Cl)CC2)C2=C1 WVTBISXVGWDRJU-UHFFFAOYSA-N 0.000 description 1
- UIPIUVZSTJLTJO-UHFFFAOYSA-N n-[1-[[2-chloro-5-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC(C(F)(F)F)=CC=C1Cl UIPIUVZSTJLTJO-UHFFFAOYSA-N 0.000 description 1
- SYJPKVCEZJKYPM-UHFFFAOYSA-N n-[1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(C(F)(F)F)C(F)=C1 SYJPKVCEZJKYPM-UHFFFAOYSA-N 0.000 description 1
- OGDBRAJYGVGTPX-UHFFFAOYSA-N n-[1-[[5-(4-chlorophenoxy)-1,3-dimethylpyrazol-4-yl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC=1C(C)=NN(C)C=1OC1=CC=C(Cl)C=C1 OGDBRAJYGVGTPX-UHFFFAOYSA-N 0.000 description 1
- MCAYBEOKXFMNSH-UHFFFAOYSA-N n-[1-[[6-(4-chlorophenyl)sulfanylpyridin-3-yl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC(C=N1)=CC=C1SC1=CC=C(Cl)C=C1 MCAYBEOKXFMNSH-UHFFFAOYSA-N 0.000 description 1
- VCHXEARYOTZKNN-UHFFFAOYSA-N n-[1-[[6-(4-cyanophenoxy)pyridin-3-yl]methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=CC=C(N(CC=2C=NC(OC=3C=CC(=CC=3)C#N)=CC=2)CC2)C2=C1 VCHXEARYOTZKNN-UHFFFAOYSA-N 0.000 description 1
- DLDPSEZMOLYRJJ-UHFFFAOYSA-N n-[1-[[6-(4-cyanophenoxy)pyridin-3-yl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(NC(=O)CC(C)(C)C)=CC=C2N1CC(C=N1)=CC=C1OC1=CC=C(C#N)C=C1 DLDPSEZMOLYRJJ-UHFFFAOYSA-N 0.000 description 1
- JRMUSINHKOFJFV-UHFFFAOYSA-N n-[2,4-dimethyl-6-(2,2,5-trimethyl-3h-1-benzofuran-7-yl)phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C(C)=CC=2CC(C)(C)OC=2C=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 JRMUSINHKOFJFV-UHFFFAOYSA-N 0.000 description 1
- XAONIUOGFLUMOE-UHFFFAOYSA-N n-[2,4-dimethyl-6-(4-propan-2-ylphenyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=CC(C(C)C)=CC=C1C1=CC(C)=CC(C)=C1NC(=O)CC(C)(C)C XAONIUOGFLUMOE-UHFFFAOYSA-N 0.000 description 1
- DNUHYUKYPLADFM-UHFFFAOYSA-N n-[2,4-dimethyl-6-[3-(trifluoromethoxy)phenyl]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=CC(OC(F)(F)F)=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 DNUHYUKYPLADFM-UHFFFAOYSA-N 0.000 description 1
- BUNUTIAYMZWFOP-UHFFFAOYSA-N n-[2,6-dimethyl-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=C1 BUNUTIAYMZWFOP-UHFFFAOYSA-N 0.000 description 1
- NWQBIMDKXBZSID-UHFFFAOYSA-N n-[2,6-dimethyl-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanethioamide Chemical compound CC1=C(NC(=S)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=C1 NWQBIMDKXBZSID-UHFFFAOYSA-N 0.000 description 1
- DAVKBZXKNMPEHG-UHFFFAOYSA-N n-[2,6-dimethyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]acetamide Chemical compound C1=C(C)C(NC(=O)C)=C(C)C=C1NCC1=CC=C(C(F)(F)F)C=C1 DAVKBZXKNMPEHG-UHFFFAOYSA-N 0.000 description 1
- BQIIVIXQLUJZJJ-UHFFFAOYSA-N n-[2,6-dimethyl-4-[[6-(trifluoromethyl)pyridin-3-yl]methylamino]phenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(NCC=2C=NC(=CC=2)C(F)(F)F)=C1 BQIIVIXQLUJZJJ-UHFFFAOYSA-N 0.000 description 1
- NPKGBLZCKDGMPK-UHFFFAOYSA-N n-[2,6-dimethyl-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]acetamide Chemical compound C=1C(C)=C(NC(C)=O)C(C)=CC=1N(C)CC1=CC=C(C(F)(F)F)C=C1 NPKGBLZCKDGMPK-UHFFFAOYSA-N 0.000 description 1
- ADEYHVVPEMWXKK-UHFFFAOYSA-N n-[2-(2,3-dihydro-1,4-benzodioxin-6-yl)-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C2OCCOC2=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 ADEYHVVPEMWXKK-UHFFFAOYSA-N 0.000 description 1
- HYADKSBTWYHMRC-UHFFFAOYSA-N n-[2-(3-acetamidophenyl)-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound CC(=O)NC1=CC=CC(C=2C(=C(C)C=C(C)C=2)NC(=O)CC=2C=CC(F)=CC=2)=C1 HYADKSBTWYHMRC-UHFFFAOYSA-N 0.000 description 1
- XYJIVBJRAKFODH-UHFFFAOYSA-N n-[2-(3-aminophenyl)-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=CC(N)=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 XYJIVBJRAKFODH-UHFFFAOYSA-N 0.000 description 1
- SXSIMUQLWHAEGS-UHFFFAOYSA-N n-[2-(3-cyanophenyl)-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=CC(C#N)=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 SXSIMUQLWHAEGS-UHFFFAOYSA-N 0.000 description 1
- KECGJWZRAYXEMQ-UHFFFAOYSA-N n-[2-(4-ethenylphenyl)-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(C=C)C=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 KECGJWZRAYXEMQ-UHFFFAOYSA-N 0.000 description 1
- LXGHGBFMMWWRPL-UHFFFAOYSA-N n-[2-[3,5-bis(trifluoromethyl)phenyl]-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 LXGHGBFMMWWRPL-UHFFFAOYSA-N 0.000 description 1
- ISMXZIBRJLAXBF-UHFFFAOYSA-N n-[2-[4-(dimethylamino)phenyl]-4,6-dimethylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC(C)=CC(C)=C1NC(=O)CC1=CC=C(F)C=C1 ISMXZIBRJLAXBF-UHFFFAOYSA-N 0.000 description 1
- ILXWQQLVKRBUAO-UHFFFAOYSA-N n-[2-amino-4-[(3-fluoroanilino)methyl]phenyl]-2,2-dimethylpropanamide Chemical compound C1=C(N)C(NC(=O)C(C)(C)C)=CC=C1CNC1=CC=CC(F)=C1 ILXWQQLVKRBUAO-UHFFFAOYSA-N 0.000 description 1
- GOXFPLZEUOSYNS-UHFFFAOYSA-N n-[2-amino-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(N)=CC=1NCC1=CC=C(Cl)S1 GOXFPLZEUOSYNS-UHFFFAOYSA-N 0.000 description 1
- SNQCBOUYAWFQCM-UHFFFAOYSA-N n-[2-amino-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(N)C(NC(=O)CC(C)(C)C)=CC=C1NCC1=CC=C(Cl)S1 SNQCBOUYAWFQCM-UHFFFAOYSA-N 0.000 description 1
- IOILGKDZUBZKAY-UHFFFAOYSA-N n-[2-bromo-4-[(5-chlorothiophen-2-yl)methylamino]-6-(trifluoromethyl)phenyl]-3-cyclohexylpropanamide Chemical compound C=1C(Br)=C(NC(=O)CCC2CCCCC2)C(C(F)(F)F)=CC=1NCC1=CC=C(Cl)S1 IOILGKDZUBZKAY-UHFFFAOYSA-N 0.000 description 1
- JXVMTGLEBIWOHI-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2Br)N2CCOCC2)C(F)(F)F)=C1 JXVMTGLEBIWOHI-UHFFFAOYSA-N 0.000 description 1
- RMGDROBIXZIMJN-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC1=C(Br)C=C(N2CCOCC2)C=C1C(F)(F)F RMGDROBIXZIMJN-UHFFFAOYSA-N 0.000 description 1
- VEZLUWKLAGYAPU-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-cyclopentylacetamide Chemical compound FC(F)(F)C1=CC(N2CCOCC2)=CC(Br)=C1NC(=O)CC1CCCC1 VEZLUWKLAGYAPU-UHFFFAOYSA-N 0.000 description 1
- ZAWSOIRSBNEJNI-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-3-cyclohexylpropanamide Chemical compound FC(F)(F)C1=CC(N2CCOCC2)=CC(Br)=C1NC(=O)CCC1CCCCC1 ZAWSOIRSBNEJNI-UHFFFAOYSA-N 0.000 description 1
- LNEODKACMQDIAF-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-3-cyclopentylpropanamide Chemical compound FC(F)(F)C1=CC(N2CCOCC2)=CC(Br)=C1NC(=O)CCC1CCCC1 LNEODKACMQDIAF-UHFFFAOYSA-N 0.000 description 1
- FPUGBBDCGLIOFN-UHFFFAOYSA-N n-[2-bromo-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]butanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CCC)=C(Br)C=C1N1CCOCC1 FPUGBBDCGLIOFN-UHFFFAOYSA-N 0.000 description 1
- IHLMAWNDSKTHJS-UHFFFAOYSA-N n-[2-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethoxy)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(OC(F)(F)F)C(NC(=O)CC(C)(C)C)=C(Cl)C=C1N1CC2=CC=CC=C2CC1 IHLMAWNDSKTHJS-UHFFFAOYSA-N 0.000 description 1
- JURDKTFYHWIOLE-UHFFFAOYSA-N n-[2-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=C(Cl)C=C1N1CC2=CC=CC=C2CC1 JURDKTFYHWIOLE-UHFFFAOYSA-N 0.000 description 1
- WSVPGQIOIVUVDN-UHFFFAOYSA-N n-[2-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethyl)phenyl]-3-cyclopentylpropanamide Chemical compound FC(F)(F)C1=CC(N2CC3=CC=CC=C3CC2)=CC(Cl)=C1NC(=O)CCC1CCCC1 WSVPGQIOIVUVDN-UHFFFAOYSA-N 0.000 description 1
- QEQSCTBTOWAMGI-UHFFFAOYSA-N n-[2-chloro-4-(3,4-dihydro-1h-isoquinolin-2-yl)-6-methylphenyl]-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=CC=C3CC2)=C1 QEQSCTBTOWAMGI-UHFFFAOYSA-N 0.000 description 1
- RHIVKINPKAPVFG-UHFFFAOYSA-N n-[2-chloro-4-(6-chloro-3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=C(Cl)C=C1N1CC2=CC=C(Cl)C=C2CC1 RHIVKINPKAPVFG-UHFFFAOYSA-N 0.000 description 1
- GVEWDAHCLFVWMC-UHFFFAOYSA-N n-[2-chloro-4-(6-chloro-3,4-dihydro-1h-isoquinolin-2-yl)-6-methylphenyl]-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(Cl)C=C3CC2)=C1 GVEWDAHCLFVWMC-UHFFFAOYSA-N 0.000 description 1
- AKMBUNDQKZOKEY-UHFFFAOYSA-N n-[2-chloro-4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethyl)phenyl]-3-cyclopentylpropanamide Chemical compound C1CC2=CC(F)=CC=C2CN1C(C=C1C(F)(F)F)=CC(Cl)=C1NC(=O)CCC1CCCC1 AKMBUNDQKZOKEY-UHFFFAOYSA-N 0.000 description 1
- XUHYQDMOGPLCHO-UHFFFAOYSA-N n-[2-chloro-4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-6-methylphenyl]-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 XUHYQDMOGPLCHO-UHFFFAOYSA-N 0.000 description 1
- ZXBSPGYOICSREC-UHFFFAOYSA-N n-[2-chloro-4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(Cl)C(NC(=O)CC(C)(C)C)=CC=C1N1CC2=CC=C(F)C=C2CC1 ZXBSPGYOICSREC-UHFFFAOYSA-N 0.000 description 1
- IMRNLRWJFWXHIF-UHFFFAOYSA-N n-[2-chloro-4-(7-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-6-(trifluoromethyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=C(Cl)C=C1N1CC2=CC(F)=CC=C2CC1 IMRNLRWJFWXHIF-UHFFFAOYSA-N 0.000 description 1
- BZACFVHATUEBMX-UHFFFAOYSA-N n-[2-chloro-4-(7-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-6-methylphenyl]-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC(F)=CC=C3CC2)=C1 BZACFVHATUEBMX-UHFFFAOYSA-N 0.000 description 1
- AOSDPVXNYCUYSW-UHFFFAOYSA-N n-[2-chloro-4-[(3,4-dichloroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 AOSDPVXNYCUYSW-UHFFFAOYSA-N 0.000 description 1
- HSXJTDIWKDHOPI-UHFFFAOYSA-N n-[2-chloro-4-[(3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 HSXJTDIWKDHOPI-UHFFFAOYSA-N 0.000 description 1
- DBLOEDMPCORMST-UHFFFAOYSA-N n-[2-chloro-4-[(4-chloro-3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 DBLOEDMPCORMST-UHFFFAOYSA-N 0.000 description 1
- SHXIJKYXFWJGDT-UHFFFAOYSA-N n-[2-chloro-4-[(4-chloroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 SHXIJKYXFWJGDT-UHFFFAOYSA-N 0.000 description 1
- HRQLXROTHVOVME-UHFFFAOYSA-N n-[2-chloro-4-[(4-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(F)C=C1 HRQLXROTHVOVME-UHFFFAOYSA-N 0.000 description 1
- DSPRNVSQYVZCFI-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2,2,2-trifluoroacetamide Chemical compound C=1C=C(NC(=O)C(F)(F)F)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 DSPRNVSQYVZCFI-UHFFFAOYSA-N 0.000 description 1
- RJIRJOHWLZOJNX-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2)N(C)CC=2SC(Cl)=CC=2)Cl)=C1 RJIRJOHWLZOJNX-UHFFFAOYSA-N 0.000 description 1
- KNCNOLISTQSDIB-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-(4-chlorophenyl)propanamide Chemical compound C=1C=C(Cl)C=CC=1C(C)C(=O)NC(C(=C1)Cl)=CC=C1N(C)CC1=CC=C(Cl)S1 KNCNOLISTQSDIB-UHFFFAOYSA-N 0.000 description 1
- QQMOLIHEOHSEJW-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 QQMOLIHEOHSEJW-UHFFFAOYSA-N 0.000 description 1
- NHGMMGIROLDGFV-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(N(C)CC=2SC(Cl)=CC=2)C=C1Cl NHGMMGIROLDGFV-UHFFFAOYSA-N 0.000 description 1
- BBUDPNLKZNMXMQ-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-phenylacetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 BBUDPNLKZNMXMQ-UHFFFAOYSA-N 0.000 description 1
- HJUMLZPJCRCVMP-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-2-thiophen-2-ylacetamide Chemical compound C=1C=C(NC(=O)CC=2SC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 HJUMLZPJCRCVMP-UHFFFAOYSA-N 0.000 description 1
- WREHPYPXQIMPCQ-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-3,3-dimethylbutanamide Chemical compound C=1C=C(NC(=O)CC(C)(C)C)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 WREHPYPXQIMPCQ-UHFFFAOYSA-N 0.000 description 1
- QOJZWSIRHHMUND-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-3-cyclohexylpropanamide Chemical compound C=1C=C(NC(=O)CCC2CCCCC2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 QOJZWSIRHHMUND-UHFFFAOYSA-N 0.000 description 1
- XEQYECZAIUQLSF-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]-3-phenylpropanamide Chemical compound C=1C=C(NC(=O)CCC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 XEQYECZAIUQLSF-UHFFFAOYSA-N 0.000 description 1
- ZXIJIODJNIISBC-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1N(C)CC1=CC=C(Cl)S1 ZXIJIODJNIISBC-UHFFFAOYSA-N 0.000 description 1
- ICTXQIPJUUCOJP-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]cyclobutanecarboxamide Chemical compound C=1C=C(NC(=O)C2CCC2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 ICTXQIPJUUCOJP-UHFFFAOYSA-N 0.000 description 1
- IEWASZTYXBKWSP-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]cyclohexanecarboxamide Chemical compound C=1C=C(NC(=O)C2CCCCC2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 IEWASZTYXBKWSP-UHFFFAOYSA-N 0.000 description 1
- GTFNEWRWVYJMGD-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]cyclopentanecarboxamide Chemical compound C=1C=C(NC(=O)C2CCCC2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 GTFNEWRWVYJMGD-UHFFFAOYSA-N 0.000 description 1
- KTVYZDPJAAPEAD-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]pentanamide Chemical compound C1=C(Cl)C(NC(=O)CCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 KTVYZDPJAAPEAD-UHFFFAOYSA-N 0.000 description 1
- UWLQXWWVEUDTNY-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2,2,2-trifluoroacetamide Chemical compound C1=C(Cl)C(NC(=O)C(F)(F)F)=CC=C1NCC1=CC=C(Cl)S1 UWLQXWWVEUDTNY-UHFFFAOYSA-N 0.000 description 1
- YFDSOWUYPDFCDA-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2,2-dimethylpropanamide Chemical compound C1=C(Cl)C(NC(=O)C(C)(C)C)=CC=C1NCC1=CC=C(Cl)S1 YFDSOWUYPDFCDA-UHFFFAOYSA-N 0.000 description 1
- BAZNEVZTWJPXMM-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2,3-dihydro-1-benzofuran-5-carboxamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)C1=CC=C(OCC2)C2=C1 BAZNEVZTWJPXMM-UHFFFAOYSA-N 0.000 description 1
- GZPCNLCZYOCMLW-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC=2C(=CC(NCC=3SC(Cl)=CC=3)=CC=2)Cl)=C1 GZPCNLCZYOCMLW-UHFFFAOYSA-N 0.000 description 1
- QPWADJHNRLEIQB-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(4-chlorophenyl)acetamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)CC1=CC=C(Cl)C=C1 QPWADJHNRLEIQB-UHFFFAOYSA-N 0.000 description 1
- VTUWOQKVXMNJRR-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC(C(=C1)Cl)=CC=C1NCC1=CC=C(Cl)S1 VTUWOQKVXMNJRR-UHFFFAOYSA-N 0.000 description 1
- BLZIGMLBKKOBNU-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC(C(=C1)Cl)=CC=C1NCC1=CC=C(Cl)S1 BLZIGMLBKKOBNU-UHFFFAOYSA-N 0.000 description 1
- BCGYFDWDTFWDIR-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-phenoxyacetamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)COC1=CC=CC=C1 BCGYFDWDTFWDIR-UHFFFAOYSA-N 0.000 description 1
- OOFJORNTRHEEFY-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-2-thiophen-2-ylacetamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)CC1=CC=CS1 OOFJORNTRHEEFY-UHFFFAOYSA-N 0.000 description 1
- GBUJVXQGXXEWHN-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(Cl)C(NC(=O)CC(C)(C)C)=CC=C1NCC1=CC=C(Cl)S1 GBUJVXQGXXEWHN-UHFFFAOYSA-N 0.000 description 1
- UHHGGSIKLWJNOT-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]-3-cyclohexylpropanamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)CCC1CCCCC1 UHHGGSIKLWJNOT-UHFFFAOYSA-N 0.000 description 1
- PDZFLRVABUEWSZ-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1NCC1=CC=C(Cl)S1 PDZFLRVABUEWSZ-UHFFFAOYSA-N 0.000 description 1
- WMRAUBJGYGJYFV-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]cyclobutanecarboxamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)C1CCC1 WMRAUBJGYGJYFV-UHFFFAOYSA-N 0.000 description 1
- PABXVNVCLLFEJC-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]cyclohexanecarboxamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)C1CCCCC1 PABXVNVCLLFEJC-UHFFFAOYSA-N 0.000 description 1
- AOFLYATWZBSEOS-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]cyclopentanecarboxamide Chemical compound S1C(Cl)=CC=C1CNC(C=C1Cl)=CC=C1NC(=O)C1CCCC1 AOFLYATWZBSEOS-UHFFFAOYSA-N 0.000 description 1
- HMSYDJFUVJCDSK-UHFFFAOYSA-N n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]pentanamide Chemical compound C1=C(Cl)C(NC(=O)CCCC)=CC=C1NCC1=CC=C(Cl)S1 HMSYDJFUVJCDSK-UHFFFAOYSA-N 0.000 description 1
- JLKZQPXSHYGHBK-UHFFFAOYSA-N n-[2-chloro-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(Cl)C(NC(=O)CC(C)(C)C)=CC=C1N1CC2=CC=C(C(F)(F)F)C=C2CC1 JLKZQPXSHYGHBK-UHFFFAOYSA-N 0.000 description 1
- SIONWVZOLMLQGG-UHFFFAOYSA-N n-[2-chloro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]butanamide Chemical compound C1=C(Cl)C(NC(=O)CCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 SIONWVZOLMLQGG-UHFFFAOYSA-N 0.000 description 1
- XSAPBUXDUGPCDB-UHFFFAOYSA-N n-[2-chloro-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-(3-fluorophenyl)acetamide Chemical compound FC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2Cl)N2CCOCC2)C(F)(F)F)=C1 XSAPBUXDUGPCDB-UHFFFAOYSA-N 0.000 description 1
- VRZOMCHSAMLLPJ-UHFFFAOYSA-N n-[2-chloro-4-morpholin-4-yl-6-(trifluoromethyl)phenyl]-2-cyclopentylacetamide Chemical compound FC(F)(F)C1=CC(N2CCOCC2)=CC(Cl)=C1NC(=O)CC1CCCC1 VRZOMCHSAMLLPJ-UHFFFAOYSA-N 0.000 description 1
- RMPCHGWCNFMAHK-UHFFFAOYSA-N n-[2-chloro-6-(trifluoromethyl)-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=C(Cl)C=C1N1CC2=CC=C(C(F)(F)F)C=C2CC1 RMPCHGWCNFMAHK-UHFFFAOYSA-N 0.000 description 1
- NUVDMQHUVICNHC-UHFFFAOYSA-N n-[2-chloro-6-(trifluoromethyl)-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-2-cyclopentylacetamide Chemical compound C1=CC(C(F)(F)F)=CC=C1CNC(C=C1C(F)(F)F)=CC(Cl)=C1NC(=O)CC1CCCC1 NUVDMQHUVICNHC-UHFFFAOYSA-N 0.000 description 1
- KEBOLMNDHWAEOH-UHFFFAOYSA-N n-[2-chloro-6-methyl-4-[6-(trifluoromethyl)-3,4-dihydro-1h-isoquinolin-2-yl]phenyl]-3,3-dimethylbutanamide Chemical compound ClC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(C=C3CC2)C(F)(F)F)=C1 KEBOLMNDHWAEOH-UHFFFAOYSA-N 0.000 description 1
- SRPRNABRIZJJKK-UHFFFAOYSA-N n-[2-chloro-6-methyl-4-[[6-(trifluoromethyl)pyridin-3-yl]methylamino]phenyl]-2-(3-fluorophenyl)acetamide Chemical compound C=1C(Cl)=C(NC(=O)CC=2C=C(F)C=CC=2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)N=C1 SRPRNABRIZJJKK-UHFFFAOYSA-N 0.000 description 1
- VNXLQHITRXDULI-UHFFFAOYSA-N n-[2-fluoro-4-[(3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 VNXLQHITRXDULI-UHFFFAOYSA-N 0.000 description 1
- YIJKAGUJZZPFTO-UHFFFAOYSA-N n-[2-fluoro-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(C(F)(F)F)C=C1 YIJKAGUJZZPFTO-UHFFFAOYSA-N 0.000 description 1
- GEUIQJWDQZWGRE-UHFFFAOYSA-N n-[2-methoxy-4-[(4-propan-2-ylphenyl)methylamino]phenyl]butanamide Chemical compound C1=C(OC)C(NC(=O)CCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 GEUIQJWDQZWGRE-UHFFFAOYSA-N 0.000 description 1
- TUXZGMKFRZJZSM-UHFFFAOYSA-N n-[2-methoxy-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]butanamide Chemical compound C1=C(OC)C(NC(=O)CCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 TUXZGMKFRZJZSM-UHFFFAOYSA-N 0.000 description 1
- JSYCSVLZYSFSBB-UHFFFAOYSA-N n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-2-morpholin-4-ylacetamide Chemical compound C=1C=C(NC(=O)CN2CCOCC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 JSYCSVLZYSFSBB-UHFFFAOYSA-N 0.000 description 1
- NDZPOHAYEUWMTA-UHFFFAOYSA-N n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-2-piperidin-1-ylacetamide Chemical compound C=1C=C(NC(=O)CN2CCCCC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 NDZPOHAYEUWMTA-UHFFFAOYSA-N 0.000 description 1
- AQDSFYZMSFHLTN-UHFFFAOYSA-N n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]-2-pyrrolidin-1-ylacetamide Chemical compound C=1C=C(NC(=O)CN2CCCC2)C(C)=CC=1NCC1=CC=C(C(F)(F)F)C=C1 AQDSFYZMSFHLTN-UHFFFAOYSA-N 0.000 description 1
- WGJUXKMIFGCNDM-UHFFFAOYSA-N n-[2-methyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 WGJUXKMIFGCNDM-UHFFFAOYSA-N 0.000 description 1
- AMEVBSOCKOSCAX-UHFFFAOYSA-N n-[4-(3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=CC=C3CC2)=C1 AMEVBSOCKOSCAX-UHFFFAOYSA-N 0.000 description 1
- WPUMBENDZFWLRX-UHFFFAOYSA-N n-[4-(3,4-dihydro-1h-isoquinolin-2-yl)-2-methoxy-6-methylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(OC)=CC(N2CC3=CC=CC=C3CC2)=C1 WPUMBENDZFWLRX-UHFFFAOYSA-N 0.000 description 1
- XTXQZLKZKXJJGF-UHFFFAOYSA-N n-[4-(6-chloro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(Cl)C=C3CC2)=C1 XTXQZLKZKXJJGF-UHFFFAOYSA-N 0.000 description 1
- FJNPZKZPWVVSON-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 FJNPZKZPWVVSON-UHFFFAOYSA-N 0.000 description 1
- ABTRCHMHHBOXFV-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2-(trifluoromethyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=CC=C1N1CC2=CC=C(F)C=C2CC1 ABTRCHMHHBOXFV-UHFFFAOYSA-N 0.000 description 1
- LWSAVPZPBLUVQM-UHFFFAOYSA-N n-[4-(6-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2-methylphenyl]-3,3-dimethylbutanamide Chemical compound C1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC=C(F)C=C3CC2)=C1 LWSAVPZPBLUVQM-UHFFFAOYSA-N 0.000 description 1
- ZIVMHLHITXTGRE-UHFFFAOYSA-N n-[4-(6-methoxy-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound C1CC2=CC(OC)=CC=C2CN1C1=CC(C)=C(NC(=O)CC(C)(C)C)C(C)=C1 ZIVMHLHITXTGRE-UHFFFAOYSA-N 0.000 description 1
- AYTUSFFMOMITAH-UHFFFAOYSA-N n-[4-(7-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2,6-dimethylphenyl]-3,3-dimethylbutanamide Chemical compound CC1=C(NC(=O)CC(C)(C)C)C(C)=CC(N2CC3=CC(F)=CC=C3CC2)=C1 AYTUSFFMOMITAH-UHFFFAOYSA-N 0.000 description 1
- MGZUTAIZUGWMSW-UHFFFAOYSA-N n-[4-(7-fluoro-3,4-dihydro-1h-isoquinolin-2-yl)-2-(trifluoromethyl)phenyl]-3,3-dimethylbutanamide Chemical compound C1=C(C(F)(F)F)C(NC(=O)CC(C)(C)C)=CC=C1N1CC2=CC(F)=CC=C2CC1 MGZUTAIZUGWMSW-UHFFFAOYSA-N 0.000 description 1
- YYXJEXZKPIYXQH-UHFFFAOYSA-N n-[4-(azepan-1-yl)-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound CC1=CC(N2CCCCCC2)=CC(C)=C1NC(=O)CC1CCCC1 YYXJEXZKPIYXQH-UHFFFAOYSA-N 0.000 description 1
- NHXHKDUACVRVPF-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 NHXHKDUACVRVPF-UHFFFAOYSA-N 0.000 description 1
- IIHYQCLDAORSCI-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 IIHYQCLDAORSCI-UHFFFAOYSA-N 0.000 description 1
- USVPVZBUNHDWDV-UHFFFAOYSA-N n-[4-[(3,4-dichloroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(Cl)=C1 USVPVZBUNHDWDV-UHFFFAOYSA-N 0.000 description 1
- SGOJPZRZKYMFBN-UHFFFAOYSA-N n-[4-[(3-chloroanilino)methyl]-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=CC(Cl)=C1 SGOJPZRZKYMFBN-UHFFFAOYSA-N 0.000 description 1
- AJURBOPYTAEEME-UHFFFAOYSA-N n-[4-[(3-fluoroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=CC(F)=C1 AJURBOPYTAEEME-UHFFFAOYSA-N 0.000 description 1
- QOUWPCGZCSHNRK-UHFFFAOYSA-N n-[4-[(4-amino-2-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1C QOUWPCGZCSHNRK-UHFFFAOYSA-N 0.000 description 1
- GLIFJWDTFOEGAR-UHFFFAOYSA-N n-[4-[(4-amino-3,5-dichloroanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC(Cl)=C(N)C(Cl)=C1 GLIFJWDTFOEGAR-UHFFFAOYSA-N 0.000 description 1
- VOOCWXWSNXHKBV-UHFFFAOYSA-N n-[4-[(4-amino-3-methylanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C(C)=C1 VOOCWXWSNXHKBV-UHFFFAOYSA-N 0.000 description 1
- IUICPWUFTFHFNJ-UHFFFAOYSA-N n-[4-[(4-aminoanilino)methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C(N)C=C1 IUICPWUFTFHFNJ-UHFFFAOYSA-N 0.000 description 1
- ANCSKQQFJNCGFC-UHFFFAOYSA-N n-[4-[(4-chloro-3-fluoroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 ANCSKQQFJNCGFC-UHFFFAOYSA-N 0.000 description 1
- KEJHLHSTFNWOIR-UHFFFAOYSA-N n-[4-[(4-chloro-3-fluoroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 KEJHLHSTFNWOIR-UHFFFAOYSA-N 0.000 description 1
- CKRMGYYYPLOCHM-UHFFFAOYSA-N n-[4-[(4-chloro-3-fluoroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C(F)=C1 CKRMGYYYPLOCHM-UHFFFAOYSA-N 0.000 description 1
- SWJZWKSJUDGALQ-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=C(Cl)C=C1 SWJZWKSJUDGALQ-UHFFFAOYSA-N 0.000 description 1
- HFOBLYQFMYXPKI-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2,6-dimethylphenyl]pentanamide Chemical compound C1=C(C)C(NC(=O)CCCC)=C(C)C=C1CNC1=CC=C(Cl)C=C1 HFOBLYQFMYXPKI-UHFFFAOYSA-N 0.000 description 1
- YNWPLUKYJAPYJQ-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2-fluorophenyl]butanamide Chemical compound C1=C(F)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 YNWPLUKYJAPYJQ-UHFFFAOYSA-N 0.000 description 1
- XFZWRYINWCHARH-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 XFZWRYINWCHARH-UHFFFAOYSA-N 0.000 description 1
- SESQTSCDOREBKJ-UHFFFAOYSA-N n-[4-[(4-chloroanilino)methyl]phenyl]butanamide Chemical compound C1=CC(NC(=O)CCC)=CC=C1CNC1=CC=C(Cl)C=C1 SESQTSCDOREBKJ-UHFFFAOYSA-N 0.000 description 1
- IMMNNWSVPCTHKC-UHFFFAOYSA-N n-[4-[(4-fluoroanilino)methyl]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1CNC1=CC=C(F)C=C1 IMMNNWSVPCTHKC-UHFFFAOYSA-N 0.000 description 1
- LJRXFNXMIQEJIO-UHFFFAOYSA-N n-[4-[(4-tert-butylphenyl)methylamino]-2-methoxyphenyl]butanamide Chemical compound C1=C(OC)C(NC(=O)CCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 LJRXFNXMIQEJIO-UHFFFAOYSA-N 0.000 description 1
- QXLDJYKVHQGGIE-UHFFFAOYSA-N n-[4-[(5-bromothiophen-2-yl)methylamino]-2-methoxyphenyl]butanamide Chemical compound C1=C(OC)C(NC(=O)CCC)=CC=C1NCC1=CC=C(Br)S1 QXLDJYKVHQGGIE-UHFFFAOYSA-N 0.000 description 1
- PUWKCSUQTQBIRA-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-2,2-dimethylpropanamide Chemical compound C=1C=C(NC(=O)C(C)(C)C)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 PUWKCSUQTQBIRA-UHFFFAOYSA-N 0.000 description 1
- BYMZSQYOOFBETO-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-2-(3-methoxyphenyl)acetamide Chemical compound COC1=CC=CC(CC(=O)NC=2C(=CC(=CC=2)N(C)CC=2SC(Cl)=CC=2)C)=C1 BYMZSQYOOFBETO-UHFFFAOYSA-N 0.000 description 1
- XFEGTPTVEMIAHI-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-2-(4-fluorophenyl)acetamide Chemical compound C=1C=C(NC(=O)CC=2C=CC(F)=CC=2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 XFEGTPTVEMIAHI-UHFFFAOYSA-N 0.000 description 1
- BBSKYLLMPFIUPS-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-2-(4-methoxyphenyl)acetamide Chemical compound C1=CC(OC)=CC=C1CC(=O)NC1=CC=C(N(C)CC=2SC(Cl)=CC=2)C=C1C BBSKYLLMPFIUPS-UHFFFAOYSA-N 0.000 description 1
- FZSKMPVDJNZYPW-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-2-thiophen-2-ylacetamide Chemical compound C=1C=C(NC(=O)CC=2SC=CC=2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 FZSKMPVDJNZYPW-UHFFFAOYSA-N 0.000 description 1
- ULWXUDKJPRSZJJ-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-3,3-dimethylbutanamide Chemical compound C=1C=C(NC(=O)CC(C)(C)C)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 ULWXUDKJPRSZJJ-UHFFFAOYSA-N 0.000 description 1
- PMDHTUCYTXCBRV-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-3-cyclohexylpropanamide Chemical compound C=1C=C(NC(=O)CCC2CCCCC2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 PMDHTUCYTXCBRV-UHFFFAOYSA-N 0.000 description 1
- ZANNEMGAMBXAJH-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]-3-phenylpropanamide Chemical compound C=1C=C(NC(=O)CCC=2C=CC=CC=2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 ZANNEMGAMBXAJH-UHFFFAOYSA-N 0.000 description 1
- MQGPHTBVVQWZAS-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]butanamide Chemical compound C1=C(C)C(NC(=O)CCC)=CC=C1N(C)CC1=CC=C(Cl)S1 MQGPHTBVVQWZAS-UHFFFAOYSA-N 0.000 description 1
- SBGPXKACAAELIX-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]cyclobutanecarboxamide Chemical compound C=1C=C(NC(=O)C2CCC2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 SBGPXKACAAELIX-UHFFFAOYSA-N 0.000 description 1
- ODIRDRIAAMZLCL-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]cyclopentanecarboxamide Chemical compound C=1C=C(NC(=O)C2CCCC2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 ODIRDRIAAMZLCL-UHFFFAOYSA-N 0.000 description 1
- CYGSZWQLHYXDPR-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]cyclopropanecarboxamide Chemical compound C=1C=C(NC(=O)C2CC2)C(C)=CC=1N(C)CC1=CC=C(Cl)S1 CYGSZWQLHYXDPR-UHFFFAOYSA-N 0.000 description 1
- VCUGNXTWGUQSIK-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methylphenyl]pentanamide Chemical compound C1=C(C)C(NC(=O)CCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 VCUGNXTWGUQSIK-UHFFFAOYSA-N 0.000 description 1
- RHEJEMHTZMPVHX-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-[4-(dimethylamino)phenyl]phenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(N(C)C)=CC=C1C1=CC(NCC=2SC(Cl)=CC=2)=CC=C1NC(=O)CC1=CC=C(F)C=C1 RHEJEMHTZMPVHX-UHFFFAOYSA-N 0.000 description 1
- TXYYXEJXGQEJQO-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-iodophenyl]-2-(4-fluorophenyl)acetamide Chemical compound C1=CC(F)=CC=C1CC(=O)NC(C(=C1)I)=CC=C1NCC1=CC=C(Cl)S1 TXYYXEJXGQEJQO-UHFFFAOYSA-N 0.000 description 1
- NFTGAJLMMXINJN-UHFFFAOYSA-N n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-methoxyphenyl]butanamide Chemical compound C1=C(OC)C(NC(=O)CCC)=CC=C1NCC1=CC=C(Cl)S1 NFTGAJLMMXINJN-UHFFFAOYSA-N 0.000 description 1
- TWOAAVBTWULEDV-UHFFFAOYSA-N n-[4-[2-(2-chlorophenyl)morpholin-4-yl]-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound CC1=CC(N2CC(OCC2)C=2C(=CC=CC=2)Cl)=CC(C)=C1NC(=O)CC1CCCC1 TWOAAVBTWULEDV-UHFFFAOYSA-N 0.000 description 1
- HYHPENAHMAZITK-UHFFFAOYSA-N n-[4-[2-(2-chlorophenyl)thiomorpholin-4-yl]-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound CC1=CC(N2CC(SCC2)C=2C(=CC=CC=2)Cl)=CC(C)=C1NC(=O)CC1CCCC1 HYHPENAHMAZITK-UHFFFAOYSA-N 0.000 description 1
- BDFMGMYOZMUMDN-UHFFFAOYSA-N n-[4-[[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)amino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=C2C(C)(C)CCC(C)(C)C2=C1 BDFMGMYOZMUMDN-UHFFFAOYSA-N 0.000 description 1
- HPSQCKGKVCFDOI-UHFFFAOYSA-N n-[4-[[(5-chloropyridin-2-yl)amino]methyl]-2,6-dimethylphenyl]-2-cyclopentylacetamide Chemical compound C=1C(C)=C(NC(=O)CC2CCCC2)C(C)=CC=1CNC1=CC=C(Cl)C=N1 HPSQCKGKVCFDOI-UHFFFAOYSA-N 0.000 description 1
- YXWRKVOHJVXRFZ-UHFFFAOYSA-N n-[4-[[3-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC1=CC=CC(CN2C=NC=C2)=C1 YXWRKVOHJVXRFZ-UHFFFAOYSA-N 0.000 description 1
- FCNULWHUEPGFAA-UHFFFAOYSA-N n-[4-[[4-(imidazol-1-ylmethyl)anilino]methyl]phenyl]acetamide Chemical compound C1=CC(NC(=O)C)=CC=C1CNC(C=C1)=CC=C1CN1C=NC=C1 FCNULWHUEPGFAA-UHFFFAOYSA-N 0.000 description 1
- MAABUWLWOVWWDB-UHFFFAOYSA-N n-[4-[[5-(4-chlorophenoxy)-1,3-dimethylpyrazol-4-yl]methylamino]-2-methylphenyl]-2,2-dimethylpropanamide Chemical compound C=1C=C(NC(=O)C(C)(C)C)C(C)=CC=1NCC=1C(C)=NN(C)C=1OC1=CC=C(Cl)C=C1 MAABUWLWOVWWDB-UHFFFAOYSA-N 0.000 description 1
- GIGOQAZYYLYRQV-UHFFFAOYSA-N n-[4-chloro-1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=C(Cl)C(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 GIGOQAZYYLYRQV-UHFFFAOYSA-N 0.000 description 1
- LOCLEXPLOMOTOG-UHFFFAOYSA-N n-[4-chloro-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1CC2=C(Cl)C(NC(=O)CC(C)(C)C)=CC=C2N1CC1=CC=C(C(F)(F)F)C=C1 LOCLEXPLOMOTOG-UHFFFAOYSA-N 0.000 description 1
- WMITZKMKKZVUOA-UHFFFAOYSA-N n-[6-amino-1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(N)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(F)C=C1 WMITZKMKKZVUOA-UHFFFAOYSA-N 0.000 description 1
- XFXDQNZGCOJIKK-UHFFFAOYSA-N n-[6-amino-1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-2,2-dimethylpropanamide Chemical compound C1=2C=C(N)C(NC(=O)C(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 XFXDQNZGCOJIKK-UHFFFAOYSA-N 0.000 description 1
- JNEYEYIXWBWWGG-UHFFFAOYSA-N n-[6-amino-1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(N)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 JNEYEYIXWBWWGG-UHFFFAOYSA-N 0.000 description 1
- PFXGSJZQUMCENI-UHFFFAOYSA-N n-[6-amino-1-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(N)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(C(F)(F)F)C(F)=C1 PFXGSJZQUMCENI-UHFFFAOYSA-N 0.000 description 1
- BDNMQAIDXMFIPX-UHFFFAOYSA-N n-[6-amino-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-2,2-dimethylpropanamide Chemical compound C1=2C=C(N)C(NC(=O)C(C)(C)C)=CC=2CCN1CC1=CC=C(C(F)(F)F)C=C1 BDNMQAIDXMFIPX-UHFFFAOYSA-N 0.000 description 1
- LEAGGTMYQUKNJZ-UHFFFAOYSA-N n-[6-amino-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-2-(4-fluorophenyl)acetamide Chemical compound C1CC=2C=C(NC(=O)CC=3C=CC(F)=CC=3)C(N)=CC=2N1CC1=CC=C(C(F)(F)F)C=C1 LEAGGTMYQUKNJZ-UHFFFAOYSA-N 0.000 description 1
- IAZYLAOKVSTMMF-UHFFFAOYSA-N n-[6-amino-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(N)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(C(F)(F)F)C=C1 IAZYLAOKVSTMMF-UHFFFAOYSA-N 0.000 description 1
- SJZUZZGCSNZQTD-UHFFFAOYSA-N n-[6-bromo-1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(Br)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(Cl)S1 SJZUZZGCSNZQTD-UHFFFAOYSA-N 0.000 description 1
- ZAXBJTRAIGCMSW-UHFFFAOYSA-N n-[6-bromo-1-[[4-(trifluoromethyl)phenyl]methyl]-2,3-dihydroindol-5-yl]-3,3-dimethylbutanamide Chemical compound C1=2C=C(Br)C(NC(=O)CC(C)(C)C)=CC=2CCN1CC1=CC=C(C(F)(F)F)C=C1 ZAXBJTRAIGCMSW-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 201000003631 narcolepsy Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000007431 neuroacanthocytosis Diseases 0.000 description 1
- 208000033510 neuroaxonal dystrophy Diseases 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 201000007601 neurodegeneration with brain iron accumulation Diseases 0.000 description 1
- 201000007599 neurodegeneration with brain iron accumulation 2a Diseases 0.000 description 1
- 201000004931 neurofibromatosis Diseases 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 201000007607 neuronal ceroid lipofuscinosis 3 Diseases 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 208000000288 neurosarcoidosis Diseases 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 201000003077 normal pressure hydrocephalus Diseases 0.000 description 1
- 208000031237 olivopontocerebellar atrophy Diseases 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 208000012111 paraneoplastic syndrome Diseases 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 208000007777 paroxysmal Hemicrania Diseases 0.000 description 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
- 239000004031 partial agonist Substances 0.000 description 1
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 201000005936 periventricular leukomalacia Diseases 0.000 description 1
- 208000020930 peroxisome biogenesis disorder 1B Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- QYNJALBPNQXKOG-UHFFFAOYSA-N phenyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C=1C=C(NC(=O)OC=2C=CC=CC=2)C(Cl)=CC=1N(C)CC1=CC=C(Cl)S1 QYNJALBPNQXKOG-UHFFFAOYSA-N 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 206010049433 piriformis syndrome Diseases 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 208000018290 primary dysautonomia Diseases 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 206010036807 progressive multifocal leukoencephalopathy Diseases 0.000 description 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 description 1
- 125000006238 prop-1-en-1-yl group Chemical group [H]\C(*)=C(/[H])C([H])([H])[H] 0.000 description 1
- MXUJFQOMTXBKEL-UHFFFAOYSA-N propan-2-yl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(NC(=O)OC(C)C)C(OC)=CC(NCC=2SC(Br)=CC=2)=C1 MXUJFQOMTXBKEL-UHFFFAOYSA-N 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- AQMMAJZBLIFENA-UHFFFAOYSA-N propyl n-(4-bromo-2,6-dimethylphenyl)carbamate Chemical compound CCCOC(=O)NC1=C(C)C=C(Br)C=C1C AQMMAJZBLIFENA-UHFFFAOYSA-N 0.000 description 1
- SIMHCLCXJNWNEF-UHFFFAOYSA-N propyl n-[1-[(4-fluorophenyl)methyl]-2,3-dihydroindol-5-yl]carbamate Chemical compound C1CC2=CC(NC(=O)OCCC)=CC=C2N1CC1=CC=C(F)C=C1 SIMHCLCXJNWNEF-UHFFFAOYSA-N 0.000 description 1
- PRTLUEMAYPPJKC-UHFFFAOYSA-N propyl n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]carbamate Chemical compound C1CC2=CC(NC(=O)OCCC)=CC=C2N1CC1=CC=C(Cl)S1 PRTLUEMAYPPJKC-UHFFFAOYSA-N 0.000 description 1
- YVNQJVUAEHJVSD-UHFFFAOYSA-N propyl n-[2,6-dimethyl-4-[(4-methyl-2-phenylpyrimidin-5-yl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CN=C(C=2C=CC=CC=2)N=C1C YVNQJVUAEHJVSD-UHFFFAOYSA-N 0.000 description 1
- SCZBYOLAIVJLAL-UHFFFAOYSA-N propyl n-[2,6-dimethyl-4-[[4-(trifluoromethyl)anilino]methyl]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC=C(C(F)(F)F)C=C1 SCZBYOLAIVJLAL-UHFFFAOYSA-N 0.000 description 1
- JRUNPSYYKOZIFI-UHFFFAOYSA-N propyl n-[2,6-dimethyl-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(C(F)(F)F)C=C1 JRUNPSYYKOZIFI-UHFFFAOYSA-N 0.000 description 1
- KAMAAAVPELJCKX-UHFFFAOYSA-N propyl n-[2,6-dimethyl-4-[[6-(4-methylphenoxy)pyridin-3-yl]methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC(C=N1)=CC=C1OC1=CC=C(C)C=C1 KAMAAAVPELJCKX-UHFFFAOYSA-N 0.000 description 1
- GUWWVMJPRYOTKR-UHFFFAOYSA-N propyl n-[2-(furan-2-yl)-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C=2OC=CC=2)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 GUWWVMJPRYOTKR-UHFFFAOYSA-N 0.000 description 1
- SNWAFDKDRJRUCS-UHFFFAOYSA-N propyl n-[2-(trifluoromethyl)-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 SNWAFDKDRJRUCS-UHFFFAOYSA-N 0.000 description 1
- KYYUTTNFUCOPCS-UHFFFAOYSA-N propyl n-[2-amino-4-(1-benzothiophen-2-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC=C2S1 KYYUTTNFUCOPCS-UHFFFAOYSA-N 0.000 description 1
- NHFRVRNKRNDFPO-UHFFFAOYSA-N propyl n-[2-amino-4-(1-benzothiophen-3-ylmethylamino)phenyl]carbamate Chemical compound C1=C(N)C(NC(=O)OCCC)=CC=C1NCC1=CSC2=CC=CC=C12 NHFRVRNKRNDFPO-UHFFFAOYSA-N 0.000 description 1
- QHMVGVWNQLCEIC-UHFFFAOYSA-N propyl n-[2-bromo-4-[(4-methylsulfanylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(SC)C=C1 QHMVGVWNQLCEIC-UHFFFAOYSA-N 0.000 description 1
- XSCQBIFKOLPBQP-UHFFFAOYSA-N propyl n-[2-bromo-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 XSCQBIFKOLPBQP-UHFFFAOYSA-N 0.000 description 1
- YLYPVBMLXLRFPR-UHFFFAOYSA-N propyl n-[2-bromo-4-[(4-tert-butylphenyl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 YLYPVBMLXLRFPR-UHFFFAOYSA-N 0.000 description 1
- CSVKGTLKBFHNBH-UHFFFAOYSA-N propyl n-[2-bromo-4-[(4-tert-butylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 CSVKGTLKBFHNBH-UHFFFAOYSA-N 0.000 description 1
- BWNNQSDXPGZXIU-UHFFFAOYSA-N propyl n-[2-bromo-4-[(5-bromothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 BWNNQSDXPGZXIU-UHFFFAOYSA-N 0.000 description 1
- RDVVIESVSGRXJS-UHFFFAOYSA-N propyl n-[2-bromo-4-[(5-bromothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 RDVVIESVSGRXJS-UHFFFAOYSA-N 0.000 description 1
- RFBPNVJIXZBIRC-UHFFFAOYSA-N propyl n-[2-bromo-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 RFBPNVJIXZBIRC-UHFFFAOYSA-N 0.000 description 1
- UJYLUVNQOIWRHI-UHFFFAOYSA-N propyl n-[2-bromo-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 UJYLUVNQOIWRHI-UHFFFAOYSA-N 0.000 description 1
- ZVJQBZOVZAKHCL-UHFFFAOYSA-N propyl n-[2-bromo-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(Br)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 ZVJQBZOVZAKHCL-UHFFFAOYSA-N 0.000 description 1
- CYWFLRNPZAOFSD-UHFFFAOYSA-N propyl n-[2-chloro-4-[(4-fluorophenyl)methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(F)C=C1 CYWFLRNPZAOFSD-UHFFFAOYSA-N 0.000 description 1
- YJOPZVBUMWERJC-UHFFFAOYSA-N propyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methyl-methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 YJOPZVBUMWERJC-UHFFFAOYSA-N 0.000 description 1
- AFEGKGPOQWHFQJ-UHFFFAOYSA-N propyl n-[2-chloro-4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 AFEGKGPOQWHFQJ-UHFFFAOYSA-N 0.000 description 1
- UGBFSKGLWGZLCW-UHFFFAOYSA-N propyl n-[2-chloro-4-[(5-methylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C)S1 UGBFSKGLWGZLCW-UHFFFAOYSA-N 0.000 description 1
- YEXHSLUGSAGMJM-UHFFFAOYSA-N propyl n-[2-chloro-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 YEXHSLUGSAGMJM-UHFFFAOYSA-N 0.000 description 1
- HMQPLANFTAPTBN-UHFFFAOYSA-N propyl n-[2-cyano-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 HMQPLANFTAPTBN-UHFFFAOYSA-N 0.000 description 1
- CPKOTQLROKZIHS-UHFFFAOYSA-N propyl n-[2-cyano-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 CPKOTQLROKZIHS-UHFFFAOYSA-N 0.000 description 1
- QMKMMGGJLUWMDT-UHFFFAOYSA-N propyl n-[2-iodo-4-[(4-methylsulfanylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(SC)C=C1 QMKMMGGJLUWMDT-UHFFFAOYSA-N 0.000 description 1
- BXPLVYLJBOHLAC-UHFFFAOYSA-N propyl n-[2-iodo-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 BXPLVYLJBOHLAC-UHFFFAOYSA-N 0.000 description 1
- FNIFMWOIQHIEBH-UHFFFAOYSA-N propyl n-[2-iodo-4-[[4-(4-methylpiperazin-1-yl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(N2CCN(C)CC2)C=C1 FNIFMWOIQHIEBH-UHFFFAOYSA-N 0.000 description 1
- NUIPDYRCSYMGEO-UHFFFAOYSA-N propyl n-[2-iodo-4-[[4-(trifluoromethyl)phenyl]methylamino]phenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(F)(F)F)C=C1 NUIPDYRCSYMGEO-UHFFFAOYSA-N 0.000 description 1
- RJBCLHKMVOWSML-UHFFFAOYSA-N propyl n-[2-methoxy-4-[methyl-[(5-methylthiophen-2-yl)methyl]amino]phenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C)S1 RJBCLHKMVOWSML-UHFFFAOYSA-N 0.000 description 1
- VACFMSSWACPZHI-UHFFFAOYSA-N propyl n-[2-methyl-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 VACFMSSWACPZHI-UHFFFAOYSA-N 0.000 description 1
- AAPHGYAVTQDBAX-UHFFFAOYSA-N propyl n-[2-methyl-4-[(5-methylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C)S1 AAPHGYAVTQDBAX-UHFFFAOYSA-N 0.000 description 1
- QVCSVXPJFKCBPU-UHFFFAOYSA-N propyl n-[2-methyl-4-[(5-phenylthiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C=2C=CC=CC=2)S1 QVCSVXPJFKCBPU-UHFFFAOYSA-N 0.000 description 1
- PINFNGLHVSTBBG-UHFFFAOYSA-N propyl n-[2-methyl-4-[methyl-[(4-methylsulfanylphenyl)methyl]amino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(SC)C=C1 PINFNGLHVSTBBG-UHFFFAOYSA-N 0.000 description 1
- GOJPEGLCQDFVPT-UHFFFAOYSA-N propyl n-[2-methyl-4-[methyl-[(4-propan-2-ylphenyl)methyl]amino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)C)C=C1 GOJPEGLCQDFVPT-UHFFFAOYSA-N 0.000 description 1
- QFDDBMBVVIVHEO-UHFFFAOYSA-N propyl n-[2-methyl-4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]phenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 QFDDBMBVVIVHEO-UHFFFAOYSA-N 0.000 description 1
- UZUYYMCKQDLORF-UHFFFAOYSA-N propyl n-[2-phenyl-4-[(4-propan-2-ylphenyl)methylamino]phenyl]carbamate Chemical compound C1=C(C=2C=CC=CC=2)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 UZUYYMCKQDLORF-UHFFFAOYSA-N 0.000 description 1
- CUZJSPJHSHZBAK-UHFFFAOYSA-N propyl n-[4-(1-benzofuran-2-ylmethylamino)-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC=C2O1 CUZJSPJHSHZBAK-UHFFFAOYSA-N 0.000 description 1
- NPXGSEYMDJBGGG-UHFFFAOYSA-N propyl n-[4-(1-benzofuran-2-ylmethylamino)-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC=C2O1 NPXGSEYMDJBGGG-UHFFFAOYSA-N 0.000 description 1
- OKURPJNOOJFAPL-UHFFFAOYSA-N propyl n-[4-(1-benzothiophen-2-ylmethylamino)-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC=C2S1 OKURPJNOOJFAPL-UHFFFAOYSA-N 0.000 description 1
- HIZHMAAIAJCCJA-UHFFFAOYSA-N propyl n-[4-(1-benzothiophen-2-ylmethylamino)-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC=C2S1 HIZHMAAIAJCCJA-UHFFFAOYSA-N 0.000 description 1
- UIDDHJYOJQKCBL-UHFFFAOYSA-N propyl n-[4-[(3,5-difluoroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC(F)=CC(F)=C1 UIDDHJYOJQKCBL-UHFFFAOYSA-N 0.000 description 1
- YDWHGGSSEKVEEC-UHFFFAOYSA-N propyl n-[4-[(3-fluoroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC=CC(F)=C1 YDWHGGSSEKVEEC-UHFFFAOYSA-N 0.000 description 1
- AQIFYVHPKXHKSC-UHFFFAOYSA-N propyl n-[4-[(4-chloroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC=C(Cl)C=C1 AQIFYVHPKXHKSC-UHFFFAOYSA-N 0.000 description 1
- MMKYWFRMYQWGMK-UHFFFAOYSA-N propyl n-[4-[(4-fluoroanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC=C(F)C=C1 MMKYWFRMYQWGMK-UHFFFAOYSA-N 0.000 description 1
- FCHLJBHFHBTVKP-UHFFFAOYSA-N propyl n-[4-[(4-fluorophenyl)methyl-methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(F)C=C1 FCHLJBHFHBTVKP-UHFFFAOYSA-N 0.000 description 1
- SMJVYXBKVNPKMX-UHFFFAOYSA-N propyl n-[4-[(4-fluorophenyl)methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(F)C=C1 SMJVYXBKVNPKMX-UHFFFAOYSA-N 0.000 description 1
- ZUMWFZLNACCXQY-UHFFFAOYSA-N propyl n-[4-[(4-fluorophenyl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(F)C=C1 ZUMWFZLNACCXQY-UHFFFAOYSA-N 0.000 description 1
- LFRNMSVOMBZWHX-UHFFFAOYSA-N propyl n-[4-[(4-fluorophenyl)methylamino]-2-phenylphenyl]carbamate Chemical compound C1=C(C=2C=CC=CC=2)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(F)C=C1 LFRNMSVOMBZWHX-UHFFFAOYSA-N 0.000 description 1
- BHLLLFQNDMQXGM-UHFFFAOYSA-N propyl n-[4-[(4-methoxyanilino)methyl]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1CNC1=CC=C(OC)C=C1 BHLLLFQNDMQXGM-UHFFFAOYSA-N 0.000 description 1
- WCEIYJJKLZBVFS-UHFFFAOYSA-N propyl n-[4-[(4-methylsulfanylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(SC)C=C1 WCEIYJJKLZBVFS-UHFFFAOYSA-N 0.000 description 1
- JZWNUSQHKDGSPL-UHFFFAOYSA-N propyl n-[4-[(4-propan-2-ylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)C)C=C1 JZWNUSQHKDGSPL-UHFFFAOYSA-N 0.000 description 1
- OAYSXZNFPMSWAG-UHFFFAOYSA-N propyl n-[4-[(4-tert-butylphenyl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 OAYSXZNFPMSWAG-UHFFFAOYSA-N 0.000 description 1
- VMODJIZIFUHEHH-UHFFFAOYSA-N propyl n-[4-[(4-tert-butylphenyl)methyl-methylamino]-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 VMODJIZIFUHEHH-UHFFFAOYSA-N 0.000 description 1
- GNWHHFNXSDFJRR-UHFFFAOYSA-N propyl n-[4-[(4-tert-butylphenyl)methyl-methylamino]-2-cyanophenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)(C)C)C=C1 GNWHHFNXSDFJRR-UHFFFAOYSA-N 0.000 description 1
- SIEUTMUKGSAJCV-UHFFFAOYSA-N propyl n-[4-[(4-tert-butylphenyl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 SIEUTMUKGSAJCV-UHFFFAOYSA-N 0.000 description 1
- HBJYCGYONGRNBT-UHFFFAOYSA-N propyl n-[4-[(4-tert-butylphenyl)methylamino]-2-iodophenyl]carbamate Chemical compound C1=C(I)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(C(C)(C)C)C=C1 HBJYCGYONGRNBT-UHFFFAOYSA-N 0.000 description 1
- UHEROFPUOURMRS-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 UHEROFPUOURMRS-UHFFFAOYSA-N 0.000 description 1
- PCQHVHNZUALPAY-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 PCQHVHNZUALPAY-UHFFFAOYSA-N 0.000 description 1
- FWDZPVMNVYWYDE-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-cyanophenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 FWDZPVMNVYWYDE-UHFFFAOYSA-N 0.000 description 1
- YQQGBVKAOAIQCU-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 YQQGBVKAOAIQCU-UHFFFAOYSA-N 0.000 description 1
- CUWJGDXDNIVHMT-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methyl-methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Br)S1 CUWJGDXDNIVHMT-UHFFFAOYSA-N 0.000 description 1
- VNMZPITYDDGRFI-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 VNMZPITYDDGRFI-UHFFFAOYSA-N 0.000 description 1
- BYUTZEHIGCHKBV-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-chlorophenyl]carbamate Chemical compound C1=C(Cl)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 BYUTZEHIGCHKBV-UHFFFAOYSA-N 0.000 description 1
- USVUDEJACSYFMY-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-cyanophenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 USVUDEJACSYFMY-UHFFFAOYSA-N 0.000 description 1
- QIOHVQFTNMAWDO-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 QIOHVQFTNMAWDO-UHFFFAOYSA-N 0.000 description 1
- ROLKYIHQDWATHN-UHFFFAOYSA-N propyl n-[4-[(5-bromothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCC)=CC=C1NCC1=CC=C(Br)S1 ROLKYIHQDWATHN-UHFFFAOYSA-N 0.000 description 1
- LWONAZIZWSZQPC-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 LWONAZIZWSZQPC-UHFFFAOYSA-N 0.000 description 1
- AQNFKJPGVQANSC-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methyl-methylamino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(Cl)S1 AQNFKJPGVQANSC-UHFFFAOYSA-N 0.000 description 1
- NFJFMYAGECOXQG-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(Cl)S1 NFJFMYAGECOXQG-UHFFFAOYSA-N 0.000 description 1
- PMQZVDCJFUVTHF-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-(furan-2-yl)phenyl]carbamate Chemical compound C1=C(C=2OC=CC=2)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 PMQZVDCJFUVTHF-UHFFFAOYSA-N 0.000 description 1
- DJUQASMTDBQSDU-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-cyanophenyl]carbamate Chemical compound C1=C(C#N)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 DJUQASMTDBQSDU-UHFFFAOYSA-N 0.000 description 1
- JTBGMUOYQQVBTC-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 JTBGMUOYQQVBTC-UHFFFAOYSA-N 0.000 description 1
- HXYZXAFZZIRHHL-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]-2-phenylphenyl]carbamate Chemical compound C1=C(C=2C=CC=CC=2)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 HXYZXAFZZIRHHL-UHFFFAOYSA-N 0.000 description 1
- AANRTTWSJLIBNU-UHFFFAOYSA-N propyl n-[4-[(5-chlorothiophen-2-yl)methylamino]phenyl]carbamate Chemical compound C1=CC(NC(=O)OCCC)=CC=C1NCC1=CC=C(Cl)S1 AANRTTWSJLIBNU-UHFFFAOYSA-N 0.000 description 1
- NUTZCWRUFKZYLV-UHFFFAOYSA-N propyl n-[4-[(6-methoxy-1-benzothiophen-2-yl)methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=C(OC)C=C2S1 NUTZCWRUFKZYLV-UHFFFAOYSA-N 0.000 description 1
- NREXXJQDOCMIGN-UHFFFAOYSA-N propyl n-[4-[(6-methoxypyridin-3-yl)methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(OC)N=C1 NREXXJQDOCMIGN-UHFFFAOYSA-N 0.000 description 1
- YGACWVPIOXYFMJ-UHFFFAOYSA-N propyl n-[4-[1-benzothiophen-2-ylmethyl(methyl)amino]-2-methoxyphenyl]carbamate Chemical compound C1=C(OC)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC2=CC=CC=C2S1 YGACWVPIOXYFMJ-UHFFFAOYSA-N 0.000 description 1
- PCCQSQGHSVUCBZ-UHFFFAOYSA-N propyl n-[4-[[3-fluoro-4-(trifluoromethyl)phenyl]methyl-methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1N(C)CC1=CC=C(C(F)(F)F)C(F)=C1 PCCQSQGHSVUCBZ-UHFFFAOYSA-N 0.000 description 1
- NEHSTGIZKPRPQM-UHFFFAOYSA-N propyl n-[4-[[3-fluoro-4-(trifluoromethyl)phenyl]methylamino]-2,6-dimethylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=C(C)C=C1NCC1=CC=C(C(F)(F)F)C(F)=C1 NEHSTGIZKPRPQM-UHFFFAOYSA-N 0.000 description 1
- PXPOVHBJPNEAIO-UHFFFAOYSA-N propyl n-[4-[[4-(4-chlorophenyl)sulfonyl-3-methylthiophen-2-yl]methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=C(C)C(S(=O)(=O)C=2C=CC(Cl)=CC=2)=CS1 PXPOVHBJPNEAIO-UHFFFAOYSA-N 0.000 description 1
- QQGCEBGXHWJPAE-UHFFFAOYSA-N propyl n-[4-[[4-(dimethylamino)phenyl]methylamino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1NCC1=CC=C(N(C)C)C=C1 QQGCEBGXHWJPAE-UHFFFAOYSA-N 0.000 description 1
- BXBONVDXYZLIRH-UHFFFAOYSA-N propyl n-[4-[[5-(dimethylamino)-3-methyl-1-benzothiophen-2-yl]methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=C(C)C2=CC(N(C)C)=CC=C2S1 BXBONVDXYZLIRH-UHFFFAOYSA-N 0.000 description 1
- PKMRTAMQCXTVMS-UHFFFAOYSA-N propyl n-[4-[[7-(dimethylamino)-1-benzothiophen-2-yl]methylamino]-2-methylphenyl]carbamate Chemical compound C1=C(C)C(NC(=O)OCCC)=CC=C1NCC1=CC2=CC=CC(N(C)C)=C2S1 PKMRTAMQCXTVMS-UHFFFAOYSA-N 0.000 description 1
- GKFDLOMGRKRKCN-UHFFFAOYSA-N propyl n-[4-[methyl-[(4-methylsulfanylphenyl)methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(SC)C=C1 GKFDLOMGRKRKCN-UHFFFAOYSA-N 0.000 description 1
- XJPFACYFAMERDR-UHFFFAOYSA-N propyl n-[4-[methyl-[(4-propan-2-ylphenyl)methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(C)C)C=C1 XJPFACYFAMERDR-UHFFFAOYSA-N 0.000 description 1
- DPDDVOFOYUWVOB-UHFFFAOYSA-N propyl n-[4-[methyl-[[4-(trifluoromethyl)phenyl]methyl]amino]-2-(trifluoromethyl)phenyl]carbamate Chemical compound C1=C(C(F)(F)F)C(NC(=O)OCCC)=CC=C1N(C)CC1=CC=C(C(F)(F)F)C=C1 DPDDVOFOYUWVOB-UHFFFAOYSA-N 0.000 description 1
- 201000006470 prosopagnosia Diseases 0.000 description 1
- 208000001381 pseudotumor cerebri Diseases 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- QXUAYTHTYPXRJX-UHFFFAOYSA-N s-ethyl n-[2-cyclopentyloxy-4-[(4-fluorophenyl)methyl-methylamino]phenyl]carbamothioate Chemical compound CCSC(=O)NC1=CC=C(N(C)CC=2C=CC(F)=CC=2)C=C1OC1CCCC1 QXUAYTHTYPXRJX-UHFFFAOYSA-N 0.000 description 1
- UVTVKEZLGLETEN-UHFFFAOYSA-N s-ethyl n-[4-[(4-fluorophenyl)methyl-methylamino]-2-phenylmethoxyphenyl]carbamothioate Chemical compound CCSC(=O)NC1=CC=C(N(C)CC=2C=CC(F)=CC=2)C=C1OCC1=CC=CC=C1 UVTVKEZLGLETEN-UHFFFAOYSA-N 0.000 description 1
- 208000002477 septooptic dysplasia Diseases 0.000 description 1
- 210000000145 septum pellucidum Anatomy 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000037959 spinal tumor Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 208000003755 striatonigral degeneration Diseases 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 208000002025 tabes dorsalis Diseases 0.000 description 1
- WHVIPUKUBIQKNK-UHFFFAOYSA-N tert-butyl n-[1-[(5-chlorothiophen-2-yl)methyl]-2,3-dihydroindol-5-yl]carbamate Chemical compound C1CC2=CC(NC(=O)OC(C)(C)C)=CC=C2N1CC1=CC=C(Cl)S1 WHVIPUKUBIQKNK-UHFFFAOYSA-N 0.000 description 1
- 201000006361 tethered spinal cord syndrome Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 231100000399 thyrotoxic Toxicity 0.000 description 1
- 230000001897 thyrotoxic effect Effects 0.000 description 1
- 201000010875 transient cerebral ischemia Diseases 0.000 description 1
- 208000009174 transverse myelitis Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 125000004950 trifluoroalkyl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- 208000006961 tropical spastic paraparesis Diseases 0.000 description 1
- 208000009999 tuberous sclerosis Diseases 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 208000018219 von Economo disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Definitions
- the present invention relates to combination therapies for treatment of various medical conditions. Specifically, the present invention relates to a combination of a metal channer activator and N-methyl-D-aspartate (NMDA) receptor antagonists for treatment of neurological and neurodegenerative disorders.
- NMDA N-methyl-D-aspartate
- Metal channel activators are associated with a wide range of physiological functions including the regulation of the electrical properties of excitable cells. Metal channels control the follow of metal ions such as Potassium (K + ) and Sodium (Na + ) across a cell membrane. A primary function of these channels in the brain is to regulate the neuronal action potential. Several neurologic disorders are potentially due to dysregulation of metal channels. [0004] Potassium (K + ) channels, present on the plasma membranes of most cell types, are the most diverse class of all ion channels.
- Potassium channels of the Kv7 family of voltage-gated potassium (K + ) channels are of particular therapeutic interest due to their importance in neurological conditions such as excitability disorders including Amyotrophic lateral sclerosis (ALS).
- ALS Amyotrophic lateral sclerosis
- Kv7 voltage-gated potassium
- K + voltage-gated potassium
- Metal channel activators have been reported to be useful for treatment of various neurological and neurodegenerative disorders. Thus far, only one metal channel activator, Retigabine, has been FDA approved. Retigabine is used as anticonvulsant for the treatment of epilepsy.
- Kv7 channel activators have been proposed for the treatment of many conditions including substance abuse and mood disorders (Vigil FA, Carver CM, Shapiro MS. Pharmacological Manipulation of K v 7 Channels as a New Therapeutic Tool for Multiple Brain Disorders. Front Physiol.2020 Jun 19;11:688. doi: 10.3389/fphys.2020.00688). There remains a need, however, for new therapies utilizing Kv7.
- One solution is combining metal channel activators with other therapeutic agents to significantly improve treatment outcomes.
- NDMA receptor antagonists target the NDMA receptor, a receptor which allows calcium efflux in the presence of glutamate or glycine when neurons are depolarized.
- NDMA receptor antagonists prevent calcium efflux and have been used as anesthetics. Recent research, primarily focused on Ketamine, has revealed an unexpected antidepressant effect. Lanicemine has been developed as an alternative antidepressant to Ketamine with reduced side effects but has not successfully treated depression as a single agent in randomized controlled trials. [0007] Described herein are compositions and methods for combination therapies of Kv7 openers with NMDA receptor antagonists.
- the combination therapies have treatment capabilities greater than Kv7 openers or NMDA receptor antagonists alone, and may be particularly useful for depressive disorders. Pharmaceutical compositions combining these agents may also be useful for treatment of a pain and neurological or neurodegenerative diseases.
- the present invention is directed to combination therapies including a metal channel activator and an NMDA receptor antagonist.
- a pharmaceutical composition including a metal channel activator and an NMDA receptor antagonist.
- a method of treating a depressive disorder including administering the pharmaceutical composition.
- a method of treating a pain disorder including administering the pharmaceutical composition.
- DETAILED DESCRIPTION [0013] The following detailed description is provided to aid those skilled in the art in practicing the present invention. Exemplary embodiments will hereinafter be described in detail. However, these embodiments are only exemplary, and the present disclosure is not limited thereto but rather is defined by the scope of the appended claims. Those of ordinary skill in the art may make modifications and variations in the embodiments described herein without departing from the spirit or scope of the present disclosure.
- the embodiments are merely described below, by referring to structures and schemes, to explain aspects of the present description.
- the term “and/or” includes any and all combinations of one or more of the associated listed items.
- the term “or” means “and/or.” Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list. [0015] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms.
- substituted refers to a group substituted with deuterium, a halogen (-F, -Cl, -Br, -I), a hydroxy group (-OH), an amino group (-NH 2 ), a carboxyl group (-CO 2 H), a substituted or unsubstituted C1-C10 amine group, a nitro group (-NO 2 ), a C1-C10 alkyl group, a C3-C10 cycloalkyl group, a C6-C12 aryl group, a C1-C10 alkoxy group, a C1 to C10 trifluoroalkyl group such as a trifluoromethyl group (-CF 3 ) and the like, or a cyano group (-CN) instead of at least one hydrogen of a substituting group or compound.
- modulator when describing compounds, describe compounds that may enact their effect through a number of mechanisms of action including but not limited to: binding to the active site of a protein, binding to a region of the protein away from the active site, causing relocalization of a protein, inducing degradation of a protein, inducing stabilization of a protein, causing a conformational change in a protein, decreasing the activation threshold for a protein, increasing the activation threshold for a protein, altering posttranslational modifications for a protein, reducing the transcription of a gene, increasing the transcription of a gene, reducing the translation of an mRNA transcript, increasing the translation of an mRNA transcript, disrupting an interaction between two proteins, and stabilizing an interaction between two proteins; wherein the protein may be the target of modulation or an intermediary protein which is associated with modulation
- Modulators of the targets described herein may each or both be small molecule compounds, proteins, antibody fragments or antibodies, or any other construct effecting modulation. It should be appreciated that an NMDA receptor antagonist is a type of modulator of the NMDA receptor. [0023] As used herein, “NMDA receptor antagonist” or alternatively “NMDA modulator” means any compound (small molecule, peptide, etc.) effecting modulation or desired change in biological activity of the NMDA receptor.
- NMDA receptor antagonists may target particular portions of an NMDA receptor, such as GluN1 (alternatively NR1) or GluN2 (alternatively NR2) subunits, or additionally or alternatively GluN3 subunits.
- NMDA receptor antagonist target GluN1 subunits, in some cases selectively.
- NMDA receptor antagonists target one or more GluN2 subtypes GluN2A, GluN2B, GluN2C, and/or GluN2D, in some cases selectively.
- NMDA receptor antagonists may target one or more GluN3 subtypes GluN3A, GluN3B, and/or GluN3C, in some cases selectively. In some embodiments, NMDA receptor antagonists may target an allosteric site. In some embodiments, NMDA receptor antagonists may include partial agonists which exert dual (agonist/antagonist) effects on NMDA receptors. In certain embodiments, NMDA receptor antagonists may include agents which have a target other than the NMDA receptor which result in an NMDA receptor antagonist-like physiologic effect. [0024] As used herein, “neurological disease” refers to a disease or disorder which affects the brain and/or nerves found elsewhere in the body.
- Such neurologic diseases may include: Absence of the Septum Pellucidum, Acid Lipase Disease, Acute Disseminated Encephalomyelitis, Adrenoleukodystrophy, Agenesis of the Corpus Callosum, Agnosia, Aicardi Syndrome, Aicardi-Goutieres Syndrome, Alexander Disease, Alpers' Disease, Alternating Hemiplegia, Alzheimer's Disease, Amyotrophic Lateral Sclerosis (ALS), Anencephaly, Angelman Syndrome, Antiphospholipid Syndrome, Aphasia, Apraxia, Arachnoid Cysts, Arachnoiditis, Arteriovenous Malformation, Asperger Syndrome, Ataxia Telangiectasia, Ataxias and Cerebellar or Spinocerebellar Degeneration, Atrial Fibrillation and Stroke, Attention Deficit-Hyperactivity Disorder, Autism Spectrum Disorder, Back Pain, Barth Syndrome, Batten Disease, Behcet's Disease, Bell's Palsy, Benign Essential Blepharospasm, Bin
- the term “metal channel activator” is construed to include both metal channel activator and pharmaceutically acceptable salt thereof.
- NMDA receptor antagonist or “NMDA modulator” is construed to include both NMDA receptor antagonist and pharmaceutically acceptable salt thereof.
- AUC is the definite integral of the concentration of a drug in blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given as a function of time. AUC in this context is used to measure the total exposure to the drug across time.
- AUC can be evaluated over a definite time interval or estimated based on the integral drug concentrations measured over a time interval extrapolated to infinite time.
- Cmax is the highest concentration of a drug in the blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given.
- Tmax is the time taken after administration for a drug to reach its highest concentration in the blood, cerebrospinal fluid, target organ, or any other physiologically relevant site after a dose is given.
- proteinopathies refers to diseases characterized by an accumulation or aggregation of a single protein, or multiple proteins.
- Proteinopathies include but are not limited to: Creutzfeldt–Jakob disease and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, Amyotrophic lateral sclerosis (ALS), Frontotemporal Lobar Degeneration, and Lewy Body Dementia.
- ALS Amyotrophic lateral sclerosis
- ALS Frontotemporal Lobar Degeneration
- Lewy Body Dementia Proteinopathies include but are not limited to: Creutzfeldt–Jakob disease and other prion diseases, Alzheimer's disease, Parkinson's disease, amyloidosis, multiple system atrophy, Amyotrophic lateral sclerosis (ALS), Frontotemporal Lobar Degeneration, and Lewy Body Dementia.
- Kv7 channel activator may be selected from one of the following compounds according to Formula 1. Such compounds are described in US Patent No 9,481,653, issued November 1, 2016, and corresponding to US Application No.
- the Kv7 channel activator is a compound according to formula 1: Formula 1 , wherein D is optionally substituted C 3-6 carbocyclyl, optionally substituted C 2-5 heterocyclyl, isopropyl, or t-butyl; Bz is optionally substituted benzoimidazol-1,2-diyl; A is C 1-8 alkyl; X is F; and Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br.
- D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t- butyl.
- D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t- butyl, wherein each substituent of D and Y, if present, independently has a molecular weight of 15 Da to 200 Da and consists of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br.
- the Kv7 channel activator is a compound according to formula 1 wherein, D is optionally substituted C 3-6 carbocyclyl, optionally substituted C 2-5 heterocyclyl, isopropyl, or t-butyl; Bz is optionally substituted benzoimidazol-1,2-diyl; A is C 1-8 alkyl; X is H, F, CF 3 , optionally substituted phenyl, or optionally substituted pyridinyl; and Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br.
- D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t- butyl.
- each substituent of D, X, and Y independently has a molecular weight of 15 Da to 200 Da and consists of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br.
- R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , —CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl.
- X is optionally substituted phenyl.
- X is CF 3 .
- X is optionally substituted pyridinyl.
- X is H.
- Y is H.
- Y is OH.
- the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 2.
- Such compounds are described in US Patent No.9,481,653 issued November 1, 2016 and corresponding to US Application No. US14/853,815 filed September 14, 2015; US Patent No.9,914,708, issued March 13, 2018 and corresponding to US Application No.15/339,590 filed October, 31; US patent No 10,385,025, issued August 20, 2019 and corresponding to US Application No.15/879,792 filed January 25, 2018; US Patent No.10,906,877 issued on February 2, 2021 and corresponding to US Application No.16/460,449 filed July 2, 2019; US Patent No. 10,851,067 issued on December 1, 2020 and corresponding to US Application No.
- the Kv7 channel activator is a compound according to formula 2: Formula 2 , wherein D is optionally substituted cyclobutyl, optionally substituted phenyl, optionally substituted isoxazolyl, optionally substituted pyridinyl, isopropyl, or t-butyl; A is C 2-8 alkyl; X is H, F, CF 3 optionally substituted phenyl, or optionally substituted pyridinyl; Y is H, F, Cl, Br, I, or a moiety having a molecular weight of 15 Da to 300 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; R 1 is F, Cl, Br, CN, OCH 3 , CHF 2 , CF 3 , C 1-4 —CO 2 -alkyl, C 1-4 alkyl, —CH 2 CO 2 H, — CH 2 CO 2 CH
- Y is H, F, CF 3 , OH, C 1-5 O-alkyl, C 0-6 alkylamino, optionally substituted tetrahydropyranyl, or C 0-6 fluoroalkylamino.
- R 1 is Cl, Br, —OCH 3 , —CN, —CF 3 , —CH 2 OH, — COOCH 2 CH 3 , —C(CH 3 ) 2 OH, —CHOHCH 2 CH 3 , —CHOHCH 3 , —CHF 2 , —CH(CH 3 ) 2 , — C(CH 2 CH 3 ) 2 OH, —CH 2 COOCH 2 CH 3 , —CH 2 C(CH 3 ) 2 OH, —CH 2 COOH, or — CH 2 CON(CH 3 ) 2 .
- R 2 is H, F, —CH 2 OH, —CO 2 Me, or —C(CH 3 ) 2 OH.
- R 3 is H.
- R 4 is H, —CH 3 , or —CF 3 .
- R 1 is Cl, Br, CN, OCH 3 , CF 3 , —CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl.
- X is optionally substituted phenyl.
- X is CF 3 .
- X is optionally substituted pyridinyl.
- X is H.
- Y is H.
- Y is OH.
- the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator is a compound according to formula 2 wherein, D is optionally substituted cyclobutyl, or t-butyl; A is C 2-8 alkyl; X is H, CF 3 , or optionally substituted phenyl; Y is H or OH; R 1 is CN or C 1-4 hydroxyalkyl; and R 2 , R 3 , and R 4 are independently H, or F. [0065] In further embodiments, R 1 is CN, —C(CH 3 ) 2 OH, or —CH 2 C(CH 3 ) 2 OH. [0066] In further embodiments, R 2 is F. [0067] In further embodiments, R 3 is H.
- R 4 is H.
- R 1 is CN.
- R 1 is C 1-4 hydroxyalkyl.
- X is optionally substituted phenyl.
- X is CF 3 .
- X is H.
- Y is H. [0075] In further embodiments, Y is OH.
- the Kv7 channel activator is a compound according to formula 2 wherein, D is cyclobutyl; A is C 1-8 alkyl; X is CF 3 ; Y is H; R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , —CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl; R 2 is H, F, —CH 2 OH, — CO 2 Me, or —C(CH 3 ) 2 OH; R 3 is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and R 4 is H, —CH 3 , or —CF 3 ; or D is optionally substituted cyclobutyl; A is C 1-8 alkyl; X is CF 3 ;
- R 1 , R 2 , R 3 , and R 4 are independently H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br.
- Y is H, F, CF 3 , OH, C 1-5 O-alkyl, C 0-6 alkylamino, optionally substituted tetrahydropyranyl, or C 0-6 fluoroalkylamino.
- R 1 is H, Cl, Br, —OCH 3 , —CN, —CF 3 , —CH 2 OH, — COOCH 2 CH 3 , —C(CH 3 ) 2 OH, —CHOHCH 2 CH 3 , —CHOHCH 3 , —CHF 2 , —CH(CH 3 ) 2 , — C(CH 2 CH 3 )OH, —CH 2 COOCH 2 CH 3 , —CH 2 C(CH 3 ) 2 OH, —CH 2 COOH, or — CH 2 CON(CH 3 ) 2 .
- R 2 is H, F, —CH 2 OH, —CO 2 Me, or —C(CH 3 ) 2 OH.
- R 3 is H.
- R 4 is H, —CH 3 , or —CF 3 .
- the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
- the Kv7 channel activator is a compound selected from the group consisting of: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof. [0093] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0094] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0095] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0096] In further embodiments, the compound is: or a pharmaceutically acceptable salt thereof. [0097] In further embodiments, the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator is a compound selected from the group consisting of:
- the Kv7 channel activator is a compound selected from the group consisting of:
- the compound is:
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is:
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is:
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is: or a pharmaceutically acceptable salt thereof.
- the compound is:
- D is optionally substituted cyclobutyl, or t-butyl; A is C 2-8 alkyl, X is H, CF 3 , or optionally substituted phenyl, Y is H or OH, R 1 is CN or C 1-4 hydroxyalkyl; and R 2 , R 3 , and R 4 are independently H, or F.
- R 1 is CN, -C(CH 3 ) 2 OH, or -CH 2 C(CH 3 ) 2 OH.
- R 2 is F.
- R 3 is H.
- R 4 is H.
- R 1 is CN.
- R 1 is C 1-4 hydroxyalkyl.
- X is optionally substituted phenyl.
- X is CF 3 .
- X is H.
- Y is H. In a further embodiment, Y is OH.
- D is cyclobutyl;
- A is C 1-8 alkyl, X is CF 3 , Y is H,
- R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , -CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl;
- R 2 is H, F, - CH 2 OH, -CO 2 Me, or -C(CH 3 ) 2 OH;
- R 3 is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl or B; and
- R 4 is H, -CH 3 , or -CF 3 .
- D is optionally substituted cyclobutyl
- A is C 1-8 alkyl
- X is CH 3
- Y is H
- R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , -CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl
- R 2 is H, F, -CH 2 OH, -CO 2 Me, or -C(CH 3 ) 2 OH
- R 3 is H
- R 4 is H, -CH 3 , or - CF 3 .
- D is t-butyl;
- A is C 1-8 alkyl;
- X is H;
- Y is H;
- R 1 is Cl, Br, CN, OCH 3 , CF 3 , -CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl;
- R 2 is H, F, -CH 2 OH, - CO 2 Me, or -C(CH 3 ) 2 OH;
- R 3 is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and
- R 4 is H, -CH 3 , or -CF 3 .
- D is t-butyl;
- A is C 1-8 alkyl;
- X is CF 3 ;
- Y is H;
- R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , -CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl;
- R 2 is H, F, - CH 2 OH, -CO 2 Me, or -C(CH 3 ) 2 OH;
- R 3 is H, F, Cl, Br, I, or a substituent having a molecular weight of 15 Da to 200 Da and consisting of 2 to 5 chemical elements, wherein the chemical elements are independently C, H, O, N, S, F, Cl, or Br; and
- R 4 is H, CH 3 , or CF 3 .
- D is cyclobutyl; A is C 1-8 alkyl; X is H; Y is methyl(2,2,2-trifluoroethyl)amino; R 1 is H, Cl, Br, CN, OCH 3 , CF 3 , -CO 2 CH 2 CH 3 , C 1-4 alkyl, or C 1-4 hydroxyalkyl; R 2 is H, F, -CH 2 OH, -CO 2 Me, or -CH(CH 3 ) 2 OH; R 3 is H; and R 4 is H, - CH 3 , or -CF 3 .
- D is optionally substituted cyclobutyl, optionally substituted phenyl, or optionally substituted C 2-5 alkyl, wherein the optional substituents are selected from -CH 3 and F;
- A is C 1 alkyl, X is substituted cyclobutyl, wherein the substituent is F;
- Y is H;
- R 1 is selected from H, C 3 hydroxyalkyl, CN, F, or Cl;
- R 2 is selected from H, CN, F, Br, or -OCF 3 ;
- R 3 is selected from H, F, or -OCH 3 ;
- R 4 is H or F; and wherein when X is substituted with 2 fluorine atoms, the fluorine atoms are not geminal; or a pharmaceutically acceptable salt thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 3. Such compounds are described in US Patent No. 8,293,911 issued on October 23, 2012 and corresponding to US Application No.11/894,877 filed August 22, 2007; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 3, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 3: Formula 3 , wherein, R 1 and R 2 , vary independently, and are selected from the group consisting of H, CN, halogen, CH 2 CN, OH, CH 2 F, CHF 2 , CF 3 , CF 2 CF 3 , C 1 -C 6 alkyl, C( ⁇ O)C 1 -C 6 alkyl; NH—C 1 - C 6 alkyl; N(C 1 -C 6 alkyl)-C 1 -C 6 alkyl, NHC( ⁇ O)C 1 -C 6 alkyl, C( ⁇ O)N(CH 3 ) 2 , C( ⁇ O)N(Et) 2 , C( ⁇ O)NH 2 , C( ⁇ O)NH—C 1 -C 6 alkyl, SO 2 NH 2 , NHSO 2 —C 1 -C 6 alkyl; C( ⁇ O)OC 1 -C 6 alkyl
- R 1 and R 2 vary independently, and are selected from the group consisting of H, halogen, CF 3 , C 1 -C 6 alkyl, C( ⁇ O)C 1 -C 6 alkyl, C( ⁇ O)OC 1 -C 6 alkyl, OC( ⁇ O)C 1 -C 6 alkyl, OC 1 -C 6 alkyl, SCH 3 , C 3 -C 6 cycloalkyl, (CH 2 ) m C 3 -C 6 cycloalkyl, phenyl, pyridyl, pyrrolyl, thienyl, (CH 2 ) m phenyl, (CH 2 ) m pyrrolyl, and (CH 2 ) m pyridyl; wherein said cycloalkyl groups optionally contain one or two heteroatoms selected independently from the group consisting of O, N, and S; wherein said alkyl, cycloalkyl groups optionally contain one or two heteroatoms
- R 1 and R 2 vary independently, and are selected from the group consisting of H, halogen, CF 3 , C 1 -C 6 alkyl, C( ⁇ O)C 1 -C 6 alkyl, C( ⁇ O)OC 1 -C 6 alkyl, OC( ⁇ O)C 1 -C 6 alkyl, OC 1 -C 6 alkyl, SCH 3 , (CH 2 ) m cyclopropyl, (CH 2 ) m cyclobutyl, (CH 2 ) m cyclopentyl, (CH 2 ) m cyclohexyl, (CH 2 ) m oxazolyl, (CH 2 ) m isoxazolyl, (CH 2 ) m thiazolyl, (CH 2 ) m isothiazolyl, (CH 2 ) m phenyl, (CH 2 ) m pyrrolyl, (CH 2 ) m
- R 1 and R 2 vary independently, and are selected from the group consisting of H, halogen, CF 3 , OC 1 -C 3 alkyl, C 1 -C 6 alkyl, C( ⁇ O)OC 1 -C 3 alkyl, OC( ⁇ O)C 1 -C 3 alkyl, and C( ⁇ O)C 1 -C 3 alkyl;
- R′ is selected from the group consisting of H, F, CH 3 , and ethyl;
- R 3 and R 4 vary independently, and are selected from the group consisting of H, F, Cl, CF 3 , OCF 3 , OC 1 -C 3 alkyl, and C 1 -C 3 alkyl; and
- R 5 is C 1 -C 6 alkyl, (CHR 6 ) w C 3 - C 6 cycloalkyl, (CHR 6 ) w CH 2 C 3 -C 6 cycloalkyl, CH 2 (CHR 6 ) w
- R 2 is H or F;
- R′ is H;
- R 3 is selected from the group consisting of H, CH 3 , OCH 3 , CF 3 , OCF 3 , and Cl;
- R 4 is selected from the group consisting of CH 3 , OCH 3 , CF 3 , OCF 3 , and Cl;
- R 5 is C 3 -C 6 alkyl or (CH 2 ) w C 3 -C 6 cycloalkyl.
- R 1 is halogen or CF 3 ;
- R 2 is H or F;
- R′ is H;
- R 3 and R 4 vary independently, and are selected from the group consisting of H, CH 3 , OCH 3 , CF 3 , OCF 3 , or Cl;
- R 5 is selected from the group consisting of C 1 -C 6 alkyl, (CHR 6 ) w C 3 -C 6 cycloalkyl, (CHR 6 ) w CH 2 C 3 -C 6 cycloalkyl, CH 2 (CHR 6 ) w C 3 -C 6 cycloalkyl, CR 6 ⁇ CH—C 3 -C 6 cycloalkyl, CH ⁇ CR 6 —C 3 -C 6 cycloalkyl, (CHR 6 ) w C 5 -C 6 cycloalkenyl, CH 2 (CHR 6 ) w C 5 -C 6 cycloalkenyl, C 2 -C 6 alken
- R 1 is halogen or CF 3 ;
- R 2 is H or F;
- R′ is H;
- R 3 and R 4 vary independently, and are selected from the group consisting of H, CH 3 , OCH 3 , CF 3 , OCF 3 , or Cl;
- R 5 is selected from the group consisting of C 1 -C 6 alkyl, (CHR 6 ) w C 3 -C 6 cycloalkyl, (CHR 6 ) w CH 2 C 3 -C 6 cycloalkyl, CH 2 (CHR 6 ) w C 3 -C 6 cycloalkyl, CR 6 ⁇ CH—C 3 -C 6 cycloalkyl, CH ⁇ CR 6 —C 3 -C 6 cycloalkyl, (CHR 6 ) w C 5 -C 6 cycloalkenyl, CH 2 (CHR 6 ) w C 5 -C 6 cycloalkenyl, C 2 -C 6 alken
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 4. Such compounds are described in US Patent No.8,293,911 issued on October 23, 2012 and corresponding to US Application No. 11/894,877; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 4, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 4: Formula 4 , wherein, R 1 is selected from the group consisting of H, halogen, CN, CH 2 CN, CF 3 , C 1 - C 6 alkyl, OCH 3 , (C ⁇ O)OCH 3 , O(C ⁇ O)CH 3 , OCF 3 , (CH 2 ) m C 3 -C 6 cycloalkyl, phenyl, and pyridyl; R 2 is selected from the group consisting of H, F, OCH 3 , CH 3 , and CF 3 ; R 3 and R 4 vary independently, and are selected from the group consisting of H, F, Cl, CF 3 , OCF 3 , OC 1 -C 3 alkyl, or C 1 -C 3 alkyl; and R 5 is selected from the group consisting of C 1 -C 6 alkyl, (CHR 6 ) w C 3 -C 6 cyclo
- R 1 is selected from the group consisting of H, F, Cl, Br, CF 3 , C 1 -C 6 alkyl, OCH 3 , CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , and OCH 2 CH 3 ;
- R′ is selected from the group consisting of H, CH 3 , CH 2 CH 3 , or halogen;
- R3 and R4 vary independently, and are selected from the group consisting of H, F, Cl, CF 3 , OCF 3 , OCH 3 , and CH 3 ;
- R 5 is selected from the group consisting of C 1 -C 6 alkyl, CH 2 C 3 -C 6 cycloalkyl, CH 2 CH 2 C 3 - C 6 cycloalkyl, CH ⁇ CH—C 3 -C 6 cycloalkyl, CH ⁇ CH—C 5 -C 6 cycloalkenyl, CH 2 C 5 - C 6 cycloalkenyl, CH 2 C 5
- R 1 is selected from the group consisting of H, F, Cl, Br, CF 3 , C 1 -C 6 alkyl, OCH 3 , CH 2 OCH 3 , CH 2 CH 2 OCH 3 , CH 2 OCH 2 CH 3 , and OCH 2 CH 3 ;
- R′ is selected from the group consisting of H, CH 3 , CH 2 CH 3 , or halogen;
- R 3 and R 4 vary independently, and are selected from the group consisting of H, F, Cl, CF 3 , OCF 3 , OCH 3 , and CH 3 ;
- R 5 is selected from the group consisting of C 1 -C 6 alkyl, CH 2 C 3 -C 6 cycloalkyl, CH 2 CH 2 C 3 - C 6 cycloalkyl, CH ⁇ CH—C 3 -C 6 cycloalkyl, CH ⁇ CH—C 5 -C 6 cycloalkenyl, CH 2 C 5 - C 6 cycloalkenyl, CH 2 C 5
- R 1 is selected from the group consisting of F, CF 3 , Cl, CH 3 , CH 2 CH 3 , SCH 3 , OCH 3 , CH 2 OCH 3 , CH 2 OCH 2 CH 3 , OCF 3 , phenyl, thienyl, and H;
- R 2 is selected from the group consisting of H, F, Cl, and OCH 3 ;
- R′ is selected from the group consisting of H, F, CH 2 CH 3 , and CH 3 ;
- R 3 and R 4 vary independently, and are selected from the group consisting of H, Cl, CH 3 , CF 3 , OCH 3 , and OCF 3 ;
- R 5 is selected from the group consisting of C 4 -C 6 alkyl, (CH 2 ) w Ar, and (CH 2 ) w C 5 -C 6 cycloalkyl; wherein w is 1, 2, or 3.
- R 1 is selected from the group consisting of F, CF 3 , Cl, CH 3 , OCH 3 , CH 2 OCH 3 , and H;
- R 2 is selected from the group consisting of H, F, CH 3 , and Cl;
- R′ is H;
- R 3 is selected from the group consisting of H, Cl, CH 3 , CF 3 , OCH 3 , and OCF 3 ;
- R 4 is selected from the group consisting of Cl, OCH 3 , and CH 3 ; and
- R 5 is C 4 -C 6 alkyl or 2- cyclopentyl ethyl.
- R 3 and R 4 are both CH 3 or both OCH 3 ; and R 5 is C 5 -C 6 alkyl.
- R′ and R 2 are H; R 3 and R 4 are both methyl; and R 5 is C 5 - C 6 alkyl or (CH 2 ) w C 5 -C 6 cycloalkyl; wherein w is 1, 2, or 3.
- the compound is selected from the group consisting of: N-(2- chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethyl)phenyl)-3,3- dimethylbutanamide; N-(4-(3,4-dihydroisoquinolin-2(1H)-yl)-2,6-dimethylphenyl)-3,3- dimethylbutanamide; N-(2-chloro-4-(3,4-dihydroisoquinolin-2(1H)-yl)-6- (trifluoromethyl)phenyl)-3-cyclopentylpropanamide; N-(2-chloro-4-(6-fluoro-3,4- dihydroisoquinolin-2(1H)-yl)-6-(trifluoromethylphenyl)-3,3-dimethylbutanamide; N-[2- chloro-4-(3,4-dihydro-1H-isoquinolin-2(1H
- the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in US Patent No.8,993,593 issued on March 31, 2015 and corresponding to US Application No.12/698,070 filed February 1, 2010; US Publication No. US20220265634A1, published August 25, 2022 and corresponding to US Application No.17/668,340 filed February 9, 2022;which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 5, these references incorporated by reference herein control. [0134]
- the Kv7 channel activator is a compound according to formula 5: Formula 5 , optionally wherein the compound is substituted at any position.
- the Kv7 channel activator may be the following compound (ezogabine, also known as retigabine) or a pharmaceutically acceptable salt thereof.
- Ezogabine is a compound according to formula 6: In the case of any conflict of terminology in the context of Formula 6, these references incorporated by reference herein control.
- Formula 6 or, optionally, wherein the compound is substituted at any position.
- Formula 7 In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 7. Such compounds are described in US Patent No.
- the Kv7 channel activator is a compound according to formula 7: Formula 7 , wherein, L is CH 2 ; R 1 is optionally substituted cyclic C 3 H 5 , wherein the optional substituent of R 1 is CF 3 ; R 2 is optionally substituted cyclobutyl; R 3 is optionally substituted C 3 alkyl, wherein the optional substituent of R 3 is OH; R 4 is H; and R 5 is H; or wherein, L is CH 2 ; R 1 is optionally substituted C 2 alkyl, wherein the optional substituents of R 1 are independently CF 3 or CH 3 ; R 2 is optionally substituted cyclobutyl; R 3 is optionally substituted C 3 alkyl, wherein the optional substituent of R 3 is OH; R 4 is H; and R 5 is H; or wherein, wherein L is CH 2 , CF 2 , CHCH 3 , CH 2 CH 2 , C 3 H 6 , CH 2 O, C 2 H 4
- R 2 is optionally substituted C 4 H 9 , optionally substituted cyclobutyl, optionally substituted C 6-10 aryl, or optionally substituted C 2-9 heterocyclyl. [0138] In further embodiments, R 2 is optionally substituted C 4 H 9 , or optionally substituted cyclobutyl. [0139] In further embodiments, R 2 is optionally substituted phenyl, or optionally substituted C 2-9 heterocyclyl. [0140] In further embodiments, R 1 is optionally substituted phenyl. [0141] In further embodiments, R 1 is optionally substituted phenyl.
- R 1 is optionally substituted cyclopentyl or optionally substituted cyclohexyl. [0143] In further embodiments, R 1 is C 2-4 —O-alkyl. [0144] In further embodiments, R 1 is optionally substituted tetrahydrofuranyl or optionally substituted tetrahydro-2H-pyranyl. [0145] In further embodiments, R 1 is selected from the group consisting of:
- R 2 is selected from the group consisting of: [0147] In further embodiments, R 3 is CF 3 , Cl, CN, OCH 3 , or H. [0148] In further embodiments, R 1 is selected from the group consisting of:
- R 4 is CH 3 , CF 3 , Cl, or H.
- R 2 is selected from the group consisting of:
- the Kv7 channel activator is selected from the group consisting of:
- the Kv7 channel activator is selected from the group consisting of: Formula 8
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 8. Such compounds are described in US Patent No. 9,650,376, published on February 4, 2014 and corresponding to US Application No. 14/776,271 filed March 17, 2014; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 8, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 8: Formula 8 , wherein, L is CH 2 , CF 2 , CHCH 3 , CH 2 CH 2 , C 3 H 6 , CH 2 O, C 2 H 4 O, or C 3 H 6 O with the O of CH 2 O, C 2 H 4 O, or C 3 H 6 O bonded with R 1 ; wherein R 1 is optionally substituted C 1-2 alkyl, optionally substituted C 5-10 cycloalkyl, optionally substituted C 1-12 —O-alkyl, optionally substituted C 6-10 aryl, optionally substituted C 6-10 —O-aryl, or optionally substituted C 2- 9 heterocyclyl, wherein the optional substituents of R 1 are independently R A , F, Cl, CN, OR A , CF 3 , NR A R B , COR A , CO 2 R A , OCOR A , NR A COR B , CONR A R B ,
- R 2 is optionally substituted C 4 H 9 , optionally substituted cyclobutyl, optionally substituted C 6-10 aryl, or optionally substituted C 2-9 heterocyclyl. [0155] In further embodiments, R 2 is optionally substituted C 4 H 9 , or optionally substituted cyclobutyl. [0156] In further embodiments, R 2 is optionally substituted phenyl, or optionally substituted C 2-9 heterocyclyl. [0157] In further embodiments, R 1 is optionally substituted phenyl. [0158] In further embodiments, R 1 is optionally substituted phenyl.
- R 1 is optionally substituted cyclopentyl or optionally substituted cyclohexyl.
- R 1 is C 2-4 —O-alkyl.
- R 1 is optionally substituted tetrahydrofuranyl or optionally substituted tetrahydro-2H-pyranyl.
- R 1 is selected from the group consisting of:
- R 2 is selected from the group consisting of: [0164] In further embodiments, R 3 is CF 3 , Cl, CN, OCH 3 , or H. [0165] In further embodiments, R 1 is selected from the group consisting of:
- R 4 is CH 3 , CF 3 , Cl, or H.
- R 2 is selected from the group consisting of: Formula 9
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 9. Such compounds are described in International Publication No. WO2021023616A1, published February 11, 2021 and corresponding to International Application No. PCT/EP2020/071514 filed July 30, 2020; International Publication No. WO2019161877A1, published August 29, 2019 and corresponding to International Application No. PCT/EP2018/054057 filed February 20, 2018; US Publication No.
- the Kv7 channel activator is a compound according to formula 9: Formula 9 wherein, R1 is selected from the group consisting of C 1 -C 6 alkyl, CF 3 , CH 2 CF 3 , CF 2 CHF 2 , C 3 -C 8 cycloalkyl, wherein said C 3 -C 8 cycloalkyl may be substituted with 1 or 2 substituents selected from the group consisting of C 1 -C 3 alkyl, F, CHF 2 and CF 3 ; and R2 is H, C 1 -C 6 alkyl or CF 3 ; or R1 and R2 combine to form C 3 -C 5 cycloalkyl optionally substituted with 1 or 2 F, CHF 2 or CF 3 ; and R3 is C 1 -C 3 alkyl or CH 2 O—C 1-3 alkyl, said C 1 -C 3 alkyl or CH 2 O—C 1 -C 3 is alkyl substituted with C ⁇ N, 3
- R3 is selected from the group consisting of CH 2 —O—CF 3 , CH 2 —O— cyclopropyl, CH 2 —C ⁇ N.
- R1 is C 3 -C 4 cycloalkyl optionally substituted with 1 or 2 C 1 - C 3 alkyl, F, CHF 2 or CF 3 .
- R1 and R2 combine to form cyclobutyl optionally substituted with 1 or 2 F and R4 is OCF 3 or OCHF 2 .
- the Kv7 channel activator is selected from the group consisting of: (S)—N—((R)-2-cyclopropoxy-1-(3-(difluoromethoxy) phenyl)ethyl)-3- hydroxy-4,4-dimethylpentanamide; (S)—N—((R)-1-(3-(difluoromethoxy)phenyl)-2- (trifluoromethoxy)ethyl)-3-hydroxy-4,4-dimethylpentanamide; (S)—N—((R)-1-(3- (trifluoromethoxy)phenyl)-2-(trifluoromethoxy)ethyl)-3-hydroxy-4,4-dimethylpentanamide; (S)—N—((S)-2-cyano-1-(3-(trifluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4- dimethylpentanamide; (S)—N—((S)—N—((S)
- the Kv7 channel activator is selected from the group consisting of (R)—N—((R)-2-(difluoromethoxy)-1-(3-(difluoromethoxy)phenyl)ethyl)-3- hydroxy-4,4-dimethylpentanamide; (S)—N—((R)-2-(difluoromethoxy)-1-(3- (difluoromethoxy)phenyl)ethyl)-3-hydroxy-4,4-dimethylpentanamide; (S)-3-hydroxy-4,4- dimethyl-N—((S)-1-(3-(2,2,2-trifluoroethoxy)phenyl)ethyl) pentanamide; (R)-3-hydroxy-4,4- dimethyl-N—((S)-1-(3-(2,2,2-trifluoroethoxy) phenyl)ethyl)pentanamide; (R)—N—((R)-2-(difluorometh
- the Kv7 channel activator is a compound according to formula 8 wherein R 1 is selected from the group consisting of C 1 -C 6 alkyl, CF 3 , CH 2 CF 3 , CF 2 CHF 2 , C 3 -C 8 cycloalkyl, wherein said C 3 -C 8 cycloalkyl may be substituted with 1 or 2 F, CHF 2 or CF 3 , and R 2 is H, C 1 -C 6 alkyl or CF 3 ; or R 1 and R 2 combine to form C 3 -C 5 cycloalkyl optionally substituted with 1 or 2 F, CHF 2 or CF 3 ; R 3 is C1-C3 alkyl or CH 2 O—C1-3 alkyl, said C 1 -C 3 alkyl or CH 2 O—C 1-3 alkyl may optionally be substituted with 1 or 2 F; and R 4 is selected from the group consisting of OCF 3 , OCH 2 CF 3 or OCHF
- R 4 is OCF 3 or OCHF 2 .
- R 2 is H or CH 3 .
- R 3 is CH 2 O—C 1-3 alkyl.
- R 1 is C 3 -C 4 cycloalkyl optionally substituted with 1 or 2 F, CHF 2 or CF 3 .
- R 1 is t-butyl and R 2 is H and R 4 is OCF 3 , OCH 2 CF 3 , OCHF 2 or CF 3 .
- R 1 and R 2 combine to form cyclobutyl optionally substituted with 1 or 2 F and R 4 is OCF 3 , OCH 2 CF 3 , OCHF 2 or CF 3 .
- the Kv7 channel activator is selected from the group consisting of: (S)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3- (trifluoromethoxy)phenyl]ethyl]pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-[(1S)-1-[3- (trifluoromethoxy)phenyl]ethyl]pentanamide, (S)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3- (2,2,2- trifluoroethoxy)phenyl) ethyl)pentanamide, (R)-3-hydroxy-4,4-dimethyl-N-((S)-1-(3- (2,2,2- trifluoroethoxy)phen
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 10.
- Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2004058739A1, published July 15, 2004 and corresponding to International Application No. PCT/DK2003/000906 filed December 18, 2003; US patent No.7,368,472 issued May 6, 2008 and corresponding to US Application No.10/540,075 filed December 18, 2003; US Publication No.
- the Kv7 channel activator is a compound according to formula 10: wherein R 1 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 - cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, acyl, hydroxy-C 1-6 -alk(en/yn)yl and hydroxy-C 3-8 -Cycloalk(en)yl; R 2 and R 2′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, aryl, C 3-8 -cycloalk(en)yl-C 1-6 - alk(en/yn)yl, aryl-C 1-6 -alk(en/yn)yl, acyl, hydroxy-C
- the Kv7 channel activator is selected from the group consisting of: ⁇ 2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-methyl-amino]-phenyl ⁇ - carbamic acid ethyl ester; ⁇ 2-Amino-4-[(5-chloro-thiophen-2-ylmethyl)-amino]-phenyl ⁇ - carbamic acid ethyl ester; ⁇ 2-Amino-4-[(5-methyl-thiophen-2-ylmethyl)-methyl-amino]- phenyl ⁇ -carbamic acid ethyl ester; ⁇ 2-Amino-4-[(5-bromo-thiophen-2-ylmethyl)-amino]- phenyl ⁇ -carbamic acid ethyl ester; ⁇ 2-Amino-4-[(6-chloro-3-methoxy-benzo[b]thiophen-2- yl
- the Kv7 channel activator is a compound according to the formula: or a pharmaceutically acceptable salt thereof.
- the Kv7 channel activator is selected from the group consisting of: 2-Cyclopentyl-N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-acetamide; N-(2,6- Dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide; N-(4,6-Dimethyl-2- morpholin-4-yl-pyrimidin-5-yl)-2-(4-fluoro-phenyl)-acetamide; Hexanoic acid (2,6-difluoro- 4-morpholin-4-yl-phenyl)-amide; 2-Cyclopentyl-N-(4,6-dimethyl-2-morpholin-4-yl- pyrimidin-5-yl)-acetamide; N-(2-Bromo-4-
- the Kv7 channel activator is a compound according to formula 10 wherein: R 1 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, acyl, hydroxy-C 1-6 -alk(en/yn)yl and hydroxy-C 3-8 -cycloalk(en)yl; R 2 and R 2′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, aryl, C 3-8 -cycloalk(en)yl-C 1-6 - alk(en/yn)yl, aryl-C 1-6 -alk(en/yn)yl, acyl, hydroxy-C 1-6
- R 1 is selected from the group consisting of hydrogen and C 1- 6 -alk(en/yn)yl.
- at least one of the substituents R 2 and R 2′ is a hydrogen atom.
- both R 2 and R 2′ are hydrogen atoms.
- X is CO.
- q is 0.
- q is 1 and Z is an oxygen atom.
- R 3 is selected from the group consisting of C 1-6 -alk(en/yn)yl and aryl-C 1-6 -alk(en/yn)yl.
- R 3 is C 1-6 -alk(en/yn)yl. [0198] In further embodiments, R 3 is aryl-C 1-6 -alk(en/yn)yl. [0199] In further embodiments, W is a sulfur atom.
- Y is of formula: , wherein: W is S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R 5 is independently selected from the group consisting of C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, aryl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, aryl-C 1-6 -alk(en/yn)yl, acyl, halogen, halo-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, —CO—NR 6 R 6′ , cyano, nitro, —NR 7 R 7′ , —S—R 8 , —SO 2 R 8 , and SO 2 OR 8 , wherein: R 6 and R 6′
- Y is of formula: , wherein: W is S; m is 0, 1, 2 or 3; n is 0, 1, 2, 3 or 4; p is 0 or 1; and each R 5 is independently selected from the group consisting of C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, aryl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, aryl-C 1-6 -alk(en/yn)yl, acyl, halogen, halo-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, —CO—NR 6 R 6′ , cyano, nitro, —NR 7 R 7′ , —S—R 8 , —SO 2 R 8 , and SO 2 OR 8 , wherein: R 6 and R 6′
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 11.
- Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2004058739A1, published July 15, 2004 and corresponding to International Application No. PCT/DK2003/000906 filed December 18, 2003; US patent No. 7,368,472 issued May 6, 2008 and corresponding to US Application No.10/540,075 filed December 18, 2003; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; International Publication No.
- the Kv7 channel activator is a compound according to formula 11: Formula 11 wherein: s is 0 or 1; U is O, S, SO 2 , SO 2 NR 11 , CO—O or CONR 11 ; wherein: R 11 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, and C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl; or R 2 and R 11 together with the nitrogen atom to which R 11 is attached form a 5-8 membered saturated or unsaturated ring that optionally contains 1, 2 or 3 further heteroatoms; q is 0 or 1; X is CO or SO 2 ; with the proviso when X is SO 2 , then q is 0; Z is O or S; R 1 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn
- the Kv7 channel activator is selected from the group consisting of: ⁇ 4-[(Benzofuran-2-ylmethyl)-amino]-2-methylphenyl ⁇ -carbamic acid propyl ester; ⁇ 4-[(5-Chloro-thiophen-2-ylmethyl)-amino]-2-methylphenyl ⁇ -carbamic acid ethyl ester; ⁇ 4-[(Benzo[b]thiophen-2-ylmethyl)-amino]-2-methylphenyl ⁇ -carbamic acid ethyl ester; ⁇ 2-Methyl-4-[(5-phenyl-thiophen-2-ylmethyl)-amino]-phenyl ⁇ -carbamic acid ethyl ester; [4- (4-Isopropyl-benzylamino)-2-methylphenyl]-carbamic acid ethyl ester; [4-(4-Fluoro-
- the Kv7 channel activator is a compound according to formula 11, wherein: s is 0 or 1; U is O, S, SO 2 , SONR 11 , or CONR 11 ; wherein: R 11 is hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, or C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl; or R 2 and R 11 taken together with the nitrogen atom form a 5-8 membered saturated or unsaturated ring, which optionally contains 1, 2 or 3 further heteroatoms; q is 0 or 1; X is CO or SO 2 ; with the proviso that q is 0 when X is SO 2 ; Z is O or S; R 1 is hydrogen, C 1-6 - alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cyclo
- R 1 is C 1-6 -alk(en/yn)yl or a hydrogen atom.
- s is 0.
- s is 1.
- U is an oxygen atom.
- R 2 is hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, Ar, Ar—C 1-6 -alk(en/yn)yl, halogen, halo-C 1-6 -alk(en/yn)yl or cyano; with the provisos that when R 2 is halogen or cyano, then s is 0; and when s is 1 and R 2 is a hydrogen atom, then U is O or S.
- Z is an oxygen atom.
- Z is a sulfur atom.
- q is 0.
- R 3 is C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, heterocycloalk (en)yl-C 1 -6 -alk(en/yn)yl, heterocycloalk(en)yl, Ar, Ar—C 1-6 -alk(en/yn)yl, Ar-oxy-C 1-6 -alk (en/yn)yl, Ar—C 1-6 - alk(en/yn)yloxy-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy-carbonyl-C 1-6 -alk(en/yn)yl, hal
- R 12 and R 12′ are each independently hydrogen, C 1-6 - alk(en/yn)yl or Ar.
- V is CH.
- each R 5 is independently C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yl- heterocycloalk(en)yl, Ar, C 1-6 -alk(en/yn)yloxy, Ar-oxy, C 1-6 -alk(en/yn)yloxy-carbonyl, halogen, halo-C 1-6 -alk(en/yn)yl, NR 7 R 7′ , S—R 8 or SO 2 R 8 ; or two adjacent R 5 groups taken together with the aromatic group form a 5-8 membered ring, which optionally contains one or two heteroatoms.
- both R 7 and R 7′ are C 1-6 -alk(en/yn)yl.
- R 8 is C 1-6 -alk(en/yn)yl or Ar.
- the Kv7 channel activator is selected from the group consisting of: 2-(4-Fluorophenyl)-N- ⁇ 2-methyl-4-[(6-p-tolyloxypyridin-3-ylmethyl)-amino]- phenyl ⁇ -acetamide; 2-(4-Fluorophenyl)-N- ⁇ 2-methyl-4-[(6-trifluoromethylpyridin-3- ylmethyl)-amino]-phenyl ⁇ -acetamide; 3,3-Dimethyl-N- ⁇ 2-methyl-4-[(6-p-tolyloxypyridin-3- ylmethyl)-amino]-phenyl ⁇ -butyramide; 3,3-Di
- the Kv7 channel activator is a compound according to formula 11 wherein: U is O, S or NR 2′ ; s is 0 or 1; X is CO or SO 2 ; Z is O, S or NR 4 ; wherein R 4 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, hydroxy-C 1-6 -alk(en/yn)yl and hydroxy-C 3-8 - cycloalk(en)yl; q is 0 or 1; R 1 and R 1′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6
- R 1 and R 1 ' are independently selected from the group consisting of hydrogen and C 1-6 -alk(en/yn)yl. [0224] In further embodiments, at least one of R 1 and R 1 ' is a hydrogen atom. In further embodiments, s is 1. [0225] In further embodiments, s is 0. [0226] In further embodiments, R 2 is selected from the group consisting of hydrogen, C 1-6 - alk(en/yn)yl, Ar and halogen, provided that when R is halogen, then s is 0. [0227] In further embodiments, U is NR 2 ' and at least one of R and R 2 ' is a hydrogen atom.
- both R 2 and R 2 are hydrogen atoms.
- X is CO.
- q is 0.
- q is 1.
- Z is an oxygen atom.
- R 3 is C 1-6 - alk(en/yn)yl.
- each R 5 is independently selected from the group consisting of a C 1-6 -alk(en yn)yl, C 3-8 - cycloalk(en)yl, Ar, cyano, halogen, halo-C ⁇ -6 -alk(en/yn)yl and C 1- 6 - alk(an/en/yn)yloxy or two adjacent substituents together form a 5-8 membered saturated or unsaturated ring which optionally contains one or two heteroatoms.
- the Kv7 channel activator is selected from the group consisting of: ⁇ 2-Amino-4-[(4-tert-butyl phenylamino)-methyl]-phenyl ⁇ -carbamic acid ethyl ester; (2-Amino-4-phenylaminomethyl-phenyl)-carbamic acid ethyl ester; [2-Amino-4- (aphthalene-2-ylaminomethyl)-phenyl]carbamic acid ethyl ester; [2-Amino-4-(p-tolylamino- methyl)-phenyl]carbamic acid ethyl ester; ⁇ 2-Amino-4-[(4-trifluoromethylphenylamino)- methyl]-phenyl ⁇ -carbamic acid ethyl ester; ⁇ 2-Amino-4-[(4-chlorophenylamino)-methyl]- phenyl ⁇ -carbamic acid
- the Kv7 channel activator is a compound according to formula 11 wherein: U is O, S or C s is O or 1; X is CO or SO 2 ; Z is O, S or NR. , wherein R 4 is selected from the group consisting of hydrogen, C ⁇ -6-alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, hydroxy-C 1-6 -alk(en yn)yl and hydroxy-C 3-8 - cycloalk(en)yl; q is O or 1; R 1 and R 1 ' are independently selected from the group consisting of hydrogen, C ⁇ .
- R is selected from the group consisting of hydrogen, halogen, C 1-6 - alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C ⁇ -6 -alk(en/yn)yl, Ar, Ar-C 1-6 - alk(en/yn)yl, Ar-C 3-8 -cycloalk(en)yl-
- R 3 is selected from the group consisting of C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C ⁇ -6 -alk(en/yn)yl, Ar, Ar-C 1-6 - alk(en/yn)yl, Ar-C 3-8 - cycloalk(en)yl, hydroxy-C ⁇ -6 -alk(en/yn)yl, hydroxy-C 3-8 - cycloalk(en)yl,
- Y is selected from groups according to a formula selected from the group consisting of: wherein: the line represents a bond attaching the group represented by Y to the nitrogen atom; W is O or S; a is 0, 1, 2 or 3; b is O, 1, 2, 3 or 4; c is 0 or 1; d is 0, 1, 2 or 3; e is 0, 1 or 2; f is O, 1, 2, 3, 4 or 5; g is 0, 1, 2, 3 or 4; h is 0, 1, 2 or 3; and each R 5 is independently selected from the group consisting of a C 1-6 - alk(en yn)yl, C 3-8 -cycloalk(en)yl, Ar, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en yn)yl, Ar- C ⁇ -6 -alk(en/yn)y
- R 7 and R 7 ' are independently selected from the group consisting of hydrogen, C ⁇ .
- R 8 is selected from the group consisting of hydrogen, C 1-6 - alk(en/yn)yl, C 3-8 - cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C ⁇ -6 -alk(en/yn)yl, Ar and -NR 9 R 9 ; wherein R 9 and R 9 ' are independently selected from the group consisting of hydrogen, C 6 - alk(en/yn)yl, C 3-8 -cycloalk(en)yl and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl; with the provisos that when R 5 is SO 2 OR 8 then R 8 is not
- the Kv7 channel activator is a compound according to formula 11 wherein: wherein U is O, S or NR 2 s is O or 1; X is CO or SO 2 ; Z is O, S or NR , wherein R is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 - cycloalk(en)yl, C 3 -s-cycloaUc(en)yl-C ⁇ -6 -alk(en/yn)yl, hydroxy-C ⁇ -6 -alk(en/yn)yl and hydroxy-C 3-8 -cycloalk(en)yl; q is O or 1; 11 ' R and R are independently selected from the group consisting of hydrogen, C ⁇ _ 6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl- C 1;
- R is selected from the group consisting of hydrogen, halogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C ⁇ -6 -alk(en yn)yl, Ar, Ar-C ⁇ -6 - alk(en yn)yl, Ar-C 3-8 -cycloalk(en)yl, acyl, hydroxy-C 1-6 -alk(en/yn)yl, hydroxy- C 3-8 -cycloalk(en)yl, halo-C ⁇ -6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl and cyano; provided that when R 2 is halogen or cyano then s is 0; when s is 1 and U is NR 2 then R 2' is selected from the group consisting of hydrogen, halogen or cyano then
- R and R together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;
- R 3 is selected from the group consisting of C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en yn)yl, Ar, Ar-C 1-6 -alk(en/yn)yl, Ar-C 3 . 8 -cycloalk(en)yl, acyl, hydroxy-C ⁇ 6 -alk(en/yn)yl, hydroxy-C 3-8 -cycloalk(en)yl, halo-C 1-6 -alk(en/yn)yl and halo-C 3- 8 - cycloalk(en)yl; or R and R together form a 5-8 membered saturated or unsaturated ring which optionally contains one further heteroatom;
- the line represents a bond attaching the group represented by Y to the nitrogen atom;
- W is O or S;
- a is 0, 1, 2 or 3;
- h is 0, 1, 2, 3 or 4;
- c is 0 or 1;
- d is 0, 1, 2 or 3;
- e is 0, 1 or 2;
- f is O, 1, 2, 3, 4 or 5; is 0, 1, 2, 3 or 4;
- h is 0, 1, 2 or 3; and each R 5 is independently selected from the group consisting of a C ⁇ -6 - alk(en/yn)yl, C 3 .
- R 7 and R 7 ' are independently selected from the group consisting of hydrogen, Cj.
- R 8 is selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 - cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, Ar and -NR 9 R 9 ; wherein R 9 and R 9 ' are independently selected from the group consisting of hydrogen, Q.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 12. Such compounds are described in International Publication No.
- the Kv7 channel activator is a compound according to formula 12: Formula 12 wherein, the dotted line represents an optional bond; R 1 and R 1′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, hydroxy-C 1-6 -alk(en/yn)yl, hydroxy-C 3-8 -cycloalk(en)yl, hydroxy-C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 - cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl-C 1-6 -alk
- the compound of formula I is not: N-[1-(phenylmethyl)-1H- indol-5-yl]-Methanesulfonamide; N-[1-[(4-fluorophenyl)methyl]-1H-indol-5-yl]- Methanesulfonamide; N-[2,3-dihydro-1-(phenylmethyl)-1H-indol-5-yl]- Methanesulfonamide; N-[1-(phenylmethyl)-1H-indol-5-yl]-N′-4-quinolinyl-Urea; N-[1- (phenylmethyl)-1H-indol-5-yl]-N′-4-quinolinyl-Urea; or 1-(1-benzyl-5-indolinyl)-3-phenyl- Urea; or salts thereof.
- R 1 or R 1′ is a hydrogen atom.
- R 1 and R 1′ are hydrogen atoms.
- s is 0.
- s is 1.
- R 2 is a hydrogen atom.
- R 2 is NO 2 or a halogen atom.
- U is NR 11 .
- R 11 is a hydrogen atom.
- X is CO.
- X is SO 2 .
- q is 0.
- R 3 is selected from the group consisting of C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, Ar, Ar—C 1-6 -alk(en/yn)yl, Ar-oxy-C 1-6 -alk(en/yn)yl, Ar—C 1-6 - alk(en/yn)yloxy-C 1-6 -alk(en/yn)yl and —NR 12 R 12′ ; with the proviso that when R 3 is NR 12 R 12′ then q is 0.
- R 3 is NR 12 R 12′ , q is 0 and R 12 and R 12′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, Ar and Ar—C 1-6 - alk(en/yn)yl, or R 12 and R 12′ together with the nitrogen atom to which they are attached form a 4-8 membered saturated or unsaturated ring which optionally contains 1, 2 or 3 further heteroatoms.
- each R 5 is independently selected from the group consisting of C 1-6 -alk(en/yn)yl, Ar, Ar-thio, Ar-oxy, halogen and halo-C 1-6 -alk(en/yn)yl or two adjacent R 5 together with the aromatic group to which they are attached form a 4-8 membered ring which optionally contains one or two heteroatoms.
- the Kv7 channel activator is selected from the group consisting of: N-[4-Chloro-1-(4-trifluoromethylbenzyl)-2,3-dihydro-1H-indol-5-yl]-3,3- dimethylbutyramide; N-[4-Chloro-1-(5-chlorothiophen-2-ylmethyl)-2,3-dihydro-1H-indol-5- yl]-3,3-dimethylbutyramide; [1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-carbamic acid propyl ester; N-[1-(4-Fluorobenzyl)-2,3-dihydro-1H-indol-5-yl]-C-phenyl- methanesulfonamide; 4-Fluoro-N-[1-(4-fluorobenzyl)
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 13. Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009, and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 13, these references incorporated by reference herein control. [0259] In an embodiment, the Kv7 channel activator is a compound according to formula 13.
- R1 is selected from the group consisting of halogen, cyano, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yloxy; R2 is selected from the group consisting of halogen, cyan
- the Kv7 channel activator is selected from the group consisting of: N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-2-(4-fluoro-phenyl)- acetamide; 2-Cyclopentyl-N-(2-bromo-6-trifluoromethyl-4-morpholin-4-yl-phenyl)- acetamide; N-(2-Bromo-4-morpholin-4-yl-6-trifluoromethyl-phenyl)-3-cyclopentyl- propionamide; N-(2-Chloro-6-cyano-4-morpholin-4-yl-phenyl)-3-cyclohexyl-propionamide; 2-Cyclopentyl-N-(2,6-dimethyl-4-thiomorpholin-4-yl-phenyl)-acetamide; 2-Cyclopentyl-N- [2,6-dimethyl-4-(2-phenyl-morpholin
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 14.
- Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2008 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2006029623A1, published March 23, 2006 and corresponding to International Application No. PCT/DK2005/000560 filed September 2, 2005; US Patent No.7,601,870, issued October 13, 2009 and corresponding to US Application No.11/312,664 filed December 20, 2005; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.
- the Kv7 channel activator is a compound according to formula 14: Formula 14 wherein, Z is O or S; q is 0 or 1; each of R 1 and R 2 is independently selected from the group consisting of halogen, cyano, amino, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 3-8 -heterocycloalk(en)yl, Aryl, Heteroaryl, halo-C 1-6 - alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycl
- the Kv7 channel activator is selected from the group consisting of: Hexanoic acid (4-bromo-2,6-dimethyl-phenyl)-amide; N-(4-Bromo-2,6- dimethyl-phenyl)-2-(4-fluoro-phenyl)-acetamide; N-(2-Bromo-4,6-dimethyl-phenyl)-2-(4- fluoro-phenyl)-acetamide; N-(2-Bromo-4,6-dimethyl-phenyl)-3,3-dimethyl-butyramide; N- (2-Bromo-4,6-dimethyl-phenyl)-2-cyclopentyl-acetamide; N-(2-Bromo-4,6-dichloro-phenyl)- 3,3-dimethyl-butyramide; N-(2-Bromo-4,6-dichloro-phenyl)-2-(4-fluoro-phenyl)-
- Z is O or S; q is 0; R 1 and R 2 are each independently selected from the group consisting of halogen, cyano, amino, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, Aryl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy, and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yloxy; R 3 is selected
- R 1 and R 2 are each independently selected from the group consisting of halogen, amino, C 1-6 -alk(en/yn)yl, Aryl, and halo-C 1-6 -alk(en/yn)yl.
- R 3 is selected from the group consisting of C 1-8 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, Aryl-C 1-6 -alk(en/yn)yl, Aryl-C 3-8 - cycloalk(en)yl, and amino-C 1-6 -alk(en/yn)yl.
- R 4 is selected from the group consisting of halogen, C 1-6 - alk(en/yn)yl, NR 5 R 6 and R 7 NH—C 1-6 -alk(en/yn)yl, wherein R 5 , R 6 and R 7 are as previously defined.
- R 4 is NR 5 R 6 , wherein R 5 and R 6 are independently selected from the group consisting of hydrogen, Aryl-C 1-6 -alk(en/yn)yl, and C 1-6 -alk(en/yn)yl, with the proviso that R 5 and R 6 cannot both be hydrogen.
- R 4 is R 7 NH—C 1-6 -alk(en/yn)yl, wherein R 7 is Aryl.
- any Aryl is optionally substituted with one or more substituents independently selected from the group consisting of amino, halogen, cyano, C 1-6 - alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, hydroxy, C 1-6 -alk(en/yn)yloxy, halo-C 1-6 - alk(en/yn)yloxy, di-(C 1-6 -alk(en/yn)yl)amino, C 1-6 -alk(en/yn)yl-CO—NH— and C 1-6 - alk(en/yn)yl-sulfonamide; or two adjacent substituents may together with the Aryl group to which they are attached form a 4-8 membered ring,
- the Kv7 channel activator is a compound according to formula 14, wherein: Z is O or S; q is 0; R 1 and R 2 are each independently selected from the group consisting of halogen, cyano, amino, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, Aryl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo- C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy, and C 3-8 - cycloalk(en)yl-C
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 15.
- Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; International Publication No. WO2006092143A1, published September 8, 2006 and corresponding to International Application No. PCT/DK2006/000123 filed March 2, 2006; US Patent No.7,812,020, issued October 12, 2010 and corresponding to US Application No. 11/817,340 filed March 2, 2006; US Publication No.
- the Kv7 channel activator is a compound according to formula 15: Formula 15 wherein, q is 0 or 1; each of R 1 and R 2 is independently selected from the group consisting of halogen, cyano, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy and C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/
- the Kv7 channel activator is selected from the group consisting of: (2,4-Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid benzyl ester; (2,4- Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-carbamic acid 2-chloro-benzyl ester; 2-(4-Chloro- phenyl)-(2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-acetamide; 2-Phenyl- cyclopropanecarboxylic acid (2,4-dimethyl-6-morpholin-4-yl-pyridin-3-yl)-amide; N-(2,4- Dimethyl-6-morpholin-4-yl-pyridin-3-yl)-2-thiophen-2-yl-acetamide; 3-Cyclohexyl-N-(2,4- dimethyl-6-morpholin-4-yl-pyridin
- R 1 and R 2 each is independently selected from the group consisting of halogen, cyano, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, halo-C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy and C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yloxy; and R 3 is selected from the group consisting of
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 16.
- Such compounds are described in International Publication No. WO2009015667A1, published February 5, 2009 and corresponding to International Application No. PCT/DK2008/050191 filed July 31, 2008; US Publication No. US20100256145A1, published October 7, 2010 and corresponding to US Application No.12/671,505 filed July 31, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 16, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 16: Formula 16 wherein: q is 0 or 1; R 1 and R 2 are independently selected from the group consisting of hydrogen and optionally substituted aryl-C 1-6 -alk(en/yn)yl, provided that R 1 and R 2 are not both hydrogen; or R 1 and R 2 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further heteroatom; R 2 and R 4 are independently selected from hydrogen, halogen, cyano, amino, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, halo- C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy, C 3- 8 -cycl
- the Kv7 channel activator is selected from the group consisting of: N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimidin-5-yl]-2- cyclopentylacetamide; N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimidin-5- yl]-3,3-dimethylbutyramide; N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)- pyrimidin-5-yl]-2-(4-fluorophenyl)-acetamide; Hexanoic acid [4-amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-amide; N-[4-Amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-2
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 17.
- Such compounds are described in International Publication No. WO2007065449A1, published June 14, 2007 and corresponding to International Application No. PCT/DK2006/050039 filed September 7, 2006; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 17, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 17: Formula 17 , wherein: q is 0 or 1; R 1 and R 2 are independently selected from the group consisting of hydrogen and optionally substituted aryl-C 1-6 -alk(en/yn)yl, provided that R 1 and R 2 are not both hydrogen, or R 1 and R 2 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further heteroatom;R 3 and R 4 are independently selected from hydrogen, halogen, cyano, amino, C 1-6 - alk(en/yn)yl, C 3-8 -cycloalk(en)yl, halo- C 1-6 -alk(en/yn)yl, halo-C 3-8 -cycloalk(en)yl, C 1-6 -alk(en/yn)yloxy, C 3-8 -cycloalk(en)yloxy, C 3- 8 -cycloalk(en
- q is 0. [0281] In further embodiments, q is 1. [0282] In further embodiments, R 1 and R 2 are independently selected from hydrogen and optionally substituted aryl-C 1-6 -alk(en/yn)yl, provided that R 1 and R 2 are not both hydrogen. [0283] In further embodiments, R 1 and R 2 together with the nitrogen to which they are attached form a 5 to 7 membered ring optionally containing a further hetero atom. [0284] In further embodiments, said further hetero atom is oxygen. [0285] In further embodiments, said ring is a 6 membered ring. [0286] In further embodiments, said ring is a morpholine ring.
- R 3 and R 4 are independently selected from amino and C 1-6 - alk(en/yn)yl, preferably methyl.
- R 5 is selected from the group consisting of C 1-10 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, optionally substituted aryl-C 1-6 -alk(en/yn)yl and optionally substituted aryl.
- the Kv7 Channel activator is selected from the group consisting of: N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimidin-5-yl]-2- cyclopentylacetamide, N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)-pyrimidin-5- yl]-3,3- dimethylbutyramide, N-[4-Amino-6-methyl-2-(4-trifluoromethylbenzylamino)- pyrimidin-5-yl]-2-(4- fluorophenyl)-acetamide, Hexanoic acid [4-amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]- amide, N-[4-Amino-6-methyl-2-(4- trifluoromethylbenzylamino)-pyrimidin-5-yl]-2, N-[4-Amin
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 18.
- Such compounds are described in International Publication No. WO2004096767A1, published November 11, 2004 and corresponding to International Application No. PCT/DK2004/000283 filed April 23, 2004; US Publication No. US20060264496A1, published November 23, 2006 and corresponding to US Application No. 10/551,783 filed April 23, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 18, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 18: Formula 18 , wherein, the dotted line represents an optional bond; R 1 and R 1′ are independently selected from the group consisting of hydrogen, C 1-6 -alk(en/yn)yl, C 3-8 -cycloalk(en)yl, C 3-8 - cycloalk(en)yl-C 1-6 -alk(en/yn)yl, hydroxy-C 1-6 -alk(en/yn)yl, hydroxy-C 3-8 -cycloalk(en)yl, hydroxy-C 3-8 -cycloalk(en)yl-C 1-6 -alk(en/yn)yl, halo-C 1-6 -alk(en/yn)yl, halo-C 3-8 - cycloalk(en)yl, halo-C 3-8 -cycloalk(en)yl-C 1-6 -C -cycloalk
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 19. Such compounds are described in US Patent No. 9,248,122, issued February 2, 2016 and corresponding to US Application No.14/091,395 filed November 27, 2013; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 19, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 19: Formula 19 wherein, A 1 , A 2 and A 3 independently of each other represent CR 4 , N, O, S or N(CH 3 ), A 4 represents CR 4 or N, and n denotes 0 or 1, with the proviso, that at least one of A 1 , A 2 , A 3 and A 4 does not represent CR 4 , and with the proviso, that if n denotes 0, then precisely one of A 1 , A 2 and A 3 represents O, S or N(CH 3 ), or if n denotes 1, then A 1 , A 2 and A 3 independently of each other represent CR 4 or N, R 1 represents C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted;
- a 1 , A 2 and A 3 independently of each other represent CR 4 , N, O, S or N(CH 3 ), A 4 represents CR 4 or N, and n denotes 0 or 1, with the proviso, that at least one of A 1 , A 2 , A 3 and A 4 does not represent CR 4 , and with the proviso, that if n denotes 0, then precisely one of A 1 , A 2 and A 3 represents O, S or N(CH 3 ), or if n denotes 1, then A 1 , A 2 and A 3 independently of each other represent CR 4 or N, R 1 denotes C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , NH(C 1-4 -aliphatic residue), N(C 1-4 -aliphatic residue) 2 , OH, ⁇
- n denotes 1 and A 1 represents N
- a 2 represents CR 4
- a 3 represents CR 4 and A 4 represents CR 4
- n denotes 1 and A 1 represents CR 4
- a 2 represents N
- a 3 represents CR 4 and A 4 represents CR 4
- n denotes 1 and A 1 represents CR 4
- a 2 represents CR 4
- a 3 represents N and A 4 represents CR 4
- n denotes 1 and A 1 represents CR 4
- a 2 represents CR 4
- a 3 represents N and A 4 represents CR 4
- N or n denotes 1 and A 1 represents N
- a 2 represents N
- a 3 represents CR 4 and A 4 represents CR 4
- n denotes 1 and A 1 represents N
- a 2 represents CR 4
- a 3 represents N and A 4 represents CR 4
- n denotes 1 and A 1 represents N
- a 2 represents CR 4
- a 3 represents N and A 4 represents CR 4
- n denotes 1
- R 2 represents F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; C 1-4 - aliphatic residue, S—C 1-4 -aliphatic residue or O—C 1-4 -aliphatic residue, wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH and O—C 1-4 - aliphatic residue.
- R 2 represents C 1-4 -aliphatic residue.
- each R 4 independently represents H; F; Cl; Br; CN; CF 3 ; OCF 3 ; CH 3 , OCH 3 or S( ⁇ O) 2 CH 3 .
- R 1 represents the partial structure: wherein, m denotes 0, 1, or 2, R 1a and R 1b each independently of one another represent H, F, Cl, Br, I, O—C 1-4 -aliphatic residue or C 1-4 -aliphatic residue, R 1c denotes C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl,
- m denotes 1 or 2
- R 1a and R 1b represent H
- R 1c denotes C 1-4 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 - aliphatic residue, or denotes C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 -aliphatic residue
- m denotes 0 and R 1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the
- R 3 denotes a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , S—C 1-4 -aliphatic residue, CF 3 , CN and C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3 and O—C 1-4 -aliphatic residue, or denotes C 3-6 -cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group
- R 3 denotes C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ⁇ O, O—C 1-4 -aliphatic residue, OCF 3 , SCF 3 , CF 3 and C 1-4 -aliphatic residue, or denotes C 3-6 - cycloaliphatic residue or 3 to 7 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, OH, ⁇ O, O—C 1-4 -aliphatic residue, OCF 3 , SCF 3 , CF 3 and C 1-4 - aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with OH or O—C 1-4 -
- a 1 , A 2 and A 3 independently of each other represent CR 4 , N, O, S or N(CH 3 ), A 4 represents CR 4 or N, and n denotes 0 or 1, with the proviso, that at least one of A 1 , A 2 , A 3 and A 4 does not represent CR 4 , and with the proviso, that if n denotes 0, then precisely one of A 1 , A 2 and A 3 represents O, S or N(CH 3 ), or if n denotes 1, then A 1 , A 2 and A 3 independently of each other represent CR 4 or N, R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 1a and R 1b each independently of one another represent H, F, Cl, O—C 1-4 -aliphatic residue or C 1-4 -aliphatic residue, R 1c denotes C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at
- the Kv7 channel activator is selected from the group consisting of:12-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-[1,5]naphthyridine-3- carboxylic acid amide; 22-Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl- [1,5]naphthyridine-3-carboxylic acid amide; 3-Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4- methyl-[1,6]naphthyridine-3-carboxylic acid amide; 42-Ethylsulfanyl-N-[(4-fluorophenyl)- methyl]-4-methyl-[1,6]naphthyridine-3-carboxylic acid amide; 52-Ethylsulfanyl-N-[(3-fluorophen
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 20.
- Such compounds are described in US Patent No. 9,284,286 issued March 15, 2016 and corresponding to US Application No.14/091.373 filed November 27, 2013; International Publication No. WO2014082737A1, published June 5, 2014 and corresponding to International Application No. PCT/EP2013/003572 filed November 27, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 20, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 20: Formula 20 wherein: A 1 represents CR 10 R 11 or S; A 2 represents CR 12 R 13 , C( ⁇ O), O, S, S( ⁇ O) or S( ⁇ O) 2 ; A 3 , A 4 and A 5 independently of each other represent CR 7 , N, O, S or NR 8 , A 6 represents CR 7 or N, and n denotes 0 or 1, with the proviso, that if n denotes 0, then precisely one of A 3 , A 4 and A 5 represents O, S or NR 8 , or if n denotes 1, then A 3 , A 4 and A 5 independently of each other represent CR 7 or N; and with the proviso, that if n denotes 1 and A 3 , A 4 and A 5 each represent CR 7 , then A 6 does not represent N; R 1 represents C 1-10 -aliphatic residue, unsubstituted or mono- or poly
- a 1 represents CR 10 R 11 or S
- a 2 represents CR 12 R 13 , C( ⁇ O), O, S, S( ⁇ O) or S( ⁇ O) 2
- a 3 , A 4 and A 5 independently of each other represent CR 7 , N, O, S or NR 8
- a 6 represents CR 7 or N
- n denotes 0 or 1, with the proviso, that if n denotes 0, then precisely one of A 3 , A 4 and A 5 represents O, S or NR 8 , or if n denotes 1, then A 3 , A 4 and A 5 independently of each other represent CR 7 or N; and with the proviso, that if n denotes 1 and A 3 , A 4 and A 5 each represent CR 7 , then A 6 does not represent N;
- R 1 denotes a C 1-10 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group
- R 8 represents H or C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and O—C 1-4 -aliphatic residue.
- a 1 represents S; and
- a 2 represents S, S( ⁇ O) 2 or CR 12 R 13 , wherein R 12 and R 13 both represent H or both represent F.
- n denotes 1 and A 3 represents CR 7 , A 4 represents CR 7 , A 5 represents CR 7 and A 6 represents CR 7 ; or n denotes 1 and A 3 represents N, A 4 represents CR 7 , A 5 represents CR 7 and A 6 represents CR 7 ; or n denotes 1 and A 3 represents CR 7 , A 4 represents N, A 5 represents CR 7 and A 6 represents CR 7 ; or n denotes 1 and A 3 represents CR 7 , A 4 represents CR 7 , A 5 represents N and A 6 represents CR 7 ; or n denotes 1 and A 3 represents N, A 4 represents N, A 5 represents CR 7 and A 6 represents CR 7 ; or n denotes 1 and A 3 represents N, A 4 represents N, A 5 represents CR 7 and A 6 represents CR 7 ; or n denotes 1 and A 3 represents N, A 4 represents CR 7 , A 5 represents N and A 6 represents CR 7 ; or n denotes 1
- R 1 represents the partial structure: wherein: R 14a and R 14b each independently of the other represent H; F; Cl; Br; CF 3 ; CN; OH; OCF 3 ; NH 2 ; C 1-4 -aliphatic residue, O—C 1-4 -aliphatic residue, NH(C 1-4 -aliphatic residue), N(C 1-4 -aliphatic residue) 2 , in each case saturated or unsaturated, branched or unbranched, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, OH and OCF 3 ; or independently represent C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each
- R 14a and R 14b each independently of the other represents H; F; Cl; CH 3 ; CH 2 CH 3 ; (CH 2 ) 2 CH 3 ; CH(CH 3 ) 2 ; (CH 2 ) 3 CH 3 ; CH(CH) 3 CH 2 CH 3 ; C(CH 3 ) 3 ; OH; OCH 3 ; OCH 2 CH 3 ; O(CH 2 ) 2 OCH 3 or O(CH 2 ) 2 OH; m represents 0, 1 or 2 and represents 0 and B represents CH 3 ; CH 2 CH 3 ; (CH 2 ) 2 CH 3 ; CH(CH 3 ) 2 ; (CH 2 ) 3 CH 3 ; CH(CH 3 )CH 2 CH 3 ; C(CH 3 ) 3 ; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; cycloheptyl; adamantyl; bicyclo[2.2.1]heptyl; bicycl
- R 2 ; R 3 ; R 4 ; R 5 ; R 10 , R 11 , R 12 and R 13 each independently of the others represents H; F; Cl; CF 3 ; CN; OH; OCF 3 ; SCF 3 ; CH 3 ; CH 2 CH 3 ; (CH 2 ) 2 CH 3 ; CH(CH 3 ) 2 ; (CH 2 ) 3 CH 3 ; CH(CH) 3 CH 2 CH 3 ; C(CH 3 ) 3 ; OCH 3 ; OCH 2 CH 3 ; O(CH 2 ) 2 OCH 3 ; O(CH 2 ) 2 OH; SCH 3 ; SCH 2 CH 3 ; cyclopropyl; cyclobutyl; cyclopentyl; cyclohexyl; or R 2 and R 3 or R 4 and R 5 or R 10 and R 11 or R 12 and R 13 or R 2 and R 11 or R 2 and R 4 or R 2 and R 13 or R 4 and R 13 or R
- each R 7 represents H, F; Cl; CN; CF 3 ; CHF 2 ; CH 2 F; OCF 3 ; OCHF 2 ; OCH 2 F; SCF 3 ; CH 3 ; CH 2 CH 3 ; CH 2 CH 2 CH 3 ; CH(CH 3 ) 2 ; OH 2 CH 2 CH 2 CH 3 ; CH(CH) 3 CH 2 CH 3 ; CH 2 CH(CH 3 ) 2 ; O(CH 3 ) 3 ; OCH 3 ; OCH 2 CH 3 ; O(CH 2 ) 2 OCH 3 ; O(CH 2 ) 2 OH; S( ⁇ O) 2 CH 3 S( ⁇ O) 2 CH 2 CH 3 S( ⁇ O) 2 CH(CH 3 ) 2 or S( ⁇ O) 2 CH 2 CH 2 CH 3 ; and R 8 represents H or CH 3 or CH 2 CH 3 or CH(CH 3 ) 2 .
- R 6 represents a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case saturated or unsaturated, unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO 2 , CN, OH, ⁇ O, O—C 1-4 -aliphatic residue, OCF 3 , C 1-4 -aliphatic residue, CF 3 , SH, S—C 1-4 -aliphatic residue and SCF 3 ; or an aryl or a heteroaryl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, I, NO 2 , CN, OH, O—C 1-4 -aliphatic residue, OCF 3 , C 1-4 -aliphatic residue
- R 6 represents phenyl, pyridyl or thienyl, in each case unsubstituted or mono- or poly-substituted by one or more substituents each selected independently of one another from the group consisting of F, Cl, Br, CN, OH, O—C 1-4 - aliphatic residue, OCF 3 , C 1-4 -aliphatic residue, CF 3 and SCF 3 .
- the Kv7 channel activator is selected from the group consisting of: 12-[[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methyl-butyl)- benzamide; 2 N-(3,3-Dimethyl-butyl)-2-[3-(4-fluorophenyl)-propylsulfanyl]-benzamide; 33- [[3,3-Difluoro-3-(4-fluorophenyl)-propyl]sulfanyl]-N-(3-methyl-butyl)-pyridine-2-carboxylic acid amide; 43-[2-(Benzenesulfonyl)-ethylsulfanyl]-N-(thiophen-2-yl-methyl)-pyridine-2- carboxylic acid amide; 54-[[3,3-Difluoro-3-(4-fluorophenyl
- the Kv7 channel activator may be selected from one of the following compounds.
- Such compounds are described in US Publication No. US20140148454A1, published May 29, 2014 and corresponding to US Application No. 14/091,378 filed November 27, 2013; International Publication No. WO2014082739A1, published June 5, 2014 and corresponding to International Application No. PCT/EP2013/003574 filed November 27, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 21, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 21: Formula 21 wherein, A 1 represents CR 5 or N; A 2 represents CR 6 , N, O, S or NR 7 ; A 3 represents CR 8 or N, and n denotes 0 or 1, on the condition, that if n denotes 0, then A 2 represents O, S or NR 7 , or if n denotes 1, then A 2 represents CR 6 or N, wherein R 5 is selected from F, Cl, Br, CN, CH 3 , CF 3 , CHF 2 , CH 2 F, OCH 3 , C 2 H 5 , SCH 3 , OCF 3 , OCHF 2 or OCH 2 F; R 6 is selected from H, F, Cl, Br, CN, CH 3 , CF 3 , CHF 2 , CH 2 F, OCH 3 , C 2 H 5 , SCH 3 , OCF 3 , OCHF 2 or OCH 2 F; R 7 represents C
- a 1 represents CR 5 or N
- a 2 represents CR 6 , N, O, S or NR 7
- a 3 represents CR 8 or N
- n denotes 0 or 1, on the condition, that if n denotes 0, then A 2 represents O, S or NR 7 , or if n denotes 1, then A 2 represents CR 6 or N
- R 5 is selected from F, Cl, Br, CN, CH 3 , CF 3 , CHF 2 , CH 2 F, OCH 3 , C 2 H 5 , SCH 3 , OCF 3 , OCHF 2 or OCH 2 F
- R 6 is selected from H, F, Cl, Br, CN, CH 3 , CF 3 , CHF 2 , CH 2 F, OCH 3 , C 2 H 5 , SCH 3 , OCF 3 , OCHF 2 or OCH 2 F
- R 7 represents C 1-4 -aliphatic residue or C 3-5 -cycloaliphatic residue
- a 2 represents O and A 3 represents CR 8 ; or A 2 represents S and A 3 represents CR 8 ; or A 2 represents NR 7 and A 3 represents CR 8 ; or A 2 represents O and A 3 represents N; or A 2 represents S and A 3 represents N; or A 2 represents NR 7 and A 3 represents N.
- the compound is according to formula 21 wherein n denotes 1 and is according to the formula: wherein: A 1 represents N and A 2 represents CR 6 and A 3 represents CR 8 ; or A 1 represents CR 5 and A 2 represents N and A 3 represents CR 8 ; or A 1 represents N and A 2 represents N and A 3 represents CR 8 ; or A 1 represents N and A 2 represents CR 6 and A 3 represents N; or A 1 represents CR 5 and A 2 represents N and A 3 represents N; or A 1 represents N and A 2 represents N and A 3 represents N.
- R 5 denotes F, Cl, CH 3 , OCH 3 or CH 2 CH 3 ; and/or R 6 denotes H; and/or R 7 denotes CH 3 , CH 2 CH 3 or cyclopropyl; and/or R 8 denotes H.
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 1a and R 1b each independently of one another represent H, F, Cl, Br, I, O—C 1-4 -aliphatic residue or C 1-4 -aliphatic residue, R 1c denotes C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and O—C 1-4 -aliphatic residue, or denotes C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstit
- m denotes 1 or 2
- R 1a and R 1b represent H
- R 1c denotes C 1-4 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 - aliphatic residue, or denotes C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 -aliphatic residue
- m denotes 0 and R 1c denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the
- R 2 is selected from the group consisting of CH 3 , C 2 H 5 , CH 2 CH 2 CH 3 , CH(CH 3 ) 2 , CH 2 CH 2 CH 2 CH 3 , CH 2 CH(CH 3 ) 2 , CH(CH 3 )CH 2 CH 3 , C(CH 3 ) 3 , CH 2 -cyclopropyl, OCH 3 , OC 2 H 5 , OCH 2 CH 2 CH 3 , OCH(CH 3 ) 2 , O-cyclopropyl, SCH 3 , SC 2 H 5 , SCH 2 CH 2 CH 3 , SCH(CH 3 ) 2 , S-cyclopropyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, N(CH 3 ) 2 , N(CH 3 )C 2 H 5 , N(CH 3 )CH 2 CH 2 CH 3 , N(CH 3 )CH(CH 3 ) 2 , N
- R 3 represents the partial structure: wherein: o denotes 0, 1, 2 or 3, R 3a and R 3b each independently of one another represent H, F, Cl, Br, I, O—C 1-4 -aliphatic residue or C 1-4 -aliphatic residue or together denote ⁇ O, and R 3c denotes C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, O—C 1-4 -aliphatic residue, CF 3 and C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and O—C 1-4 -aliphatic residue, or denotes C 3-10 -cycloaliphatic residue or 3 to 10 membered heterocycl
- R 3 represents the partial structure: Wherein, o denotes 0, 1, 2 or 3, R 3a and R 3b each independently of one another represent H, F, CH 3 or OCH 3 , or together denote ⁇ O, R 3c denotes C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, O—C 1-4 -aliphatic residue, and CF 3 , or denotes cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl or tetrahydropyranyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, O—C 1-4 -alipha
- a 1 represents CR 5 , N;
- a 2 represents CR 6 , N, O, S or NR 7 ;
- a 3 represents CR 8 or N, and n denotes 0 or 1, on the condition, that if n denotes 0, then A 2 represents O, S or NR 7 , or if n denotes 1, then A 2 represents CR 6 or N, wherein R 5 denotes F, Cl, CH 3 , OCH 3 or CH 2 CH 3 ; and/or R 6 denotes H; and/or R 7 denotes CH 3 , CH 2 CH 3 or cyclopropyl; and/or R 8 denotes H; with the proviso, that, if n denotes 1, then at least one of A 1 , A 2 and A 3 denotes N, with the proviso, that if n denotes 1 and A 3 denotes N, then A 1 and/or A 2 denotes N, and with the proviso, that if n denotes if
- the Kv7 channel activator is selected from the group consisting of: N-[(4-Chlorophenyl)-methyl]-4-ethylsulfanyl-6-methyl-2-morpholin-4-yl- pyrimidine-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4,6-dimethoxy-2- morpholin-4-yl-pyrimidine-5-carboxylic acid amide; N-[(4-Chlorophenyl)-methyl]-4- ethylsulfanyl-2-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(4- Chlorophenyl)-methyl]-2-methyl-6-morpholin-4-yl-4-propyl-pyridine-3-carboxylic acid amide; N-(4,4-Dimethyl-pentyl)-4-ethoxy-2-methyl-6-morpholin-4-yl-pyr
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 22.
- Such compounds are described in Patent No. 9,278,103 issued March 8, 2016 and corresponding to US Application No.14/230,572 filed March 31, 2014; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 22, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 22: Formula 22 , wherein, R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1- 8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3
- R 1 represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R 12a and R 12b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1- 4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, and R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1- 4 aliphatic residue)
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2 or 3, R 12a and R 12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue or together denote ⁇ O, and R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C 1- 4 aliphatic residue, CN, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubsti
- R 2 represents F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1- 4 -aliphatic residue, a S—C 1-4 -aliphatic residue, or a O—C 1-4 -aliphatic residue, wherein the C 1- 4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted O—C 1-4 -aliphatic residue, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from
- R 3 represents H; F; Cl; Br; I; CN; CF 3 ; SCF 3 ; NO 2 ; OCF 3 ; a C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, or a S—C 1-4 -aliphatic residue, wherein the C 1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted O—C 1-4 aliphatic residue.
- R 6 denotes a C 2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycl
- R 6 denotes a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case is unsubstituted, or denotes a C 3-10 -cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 alipha
- R 1 represents the partial structure: wherein: m is 0, 1 or 2, and R 12a and R 12b each independently of one another represent H, F, OH, CH 3 or OCH 3 , or together denote ⁇ O, R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S( ⁇ O) 2 —CH 3 , an unsubstituted O—C 1-4 aliphatic residue, and CF 3 , or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3
- the Kv7 channel activator is selected from the group consisting of: N-[(3,5-Difluoro-phenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 9 N-[(3-Fluorophenyl)-methyl]-4-methyl-6-morpholin-4- yl-2-[(E)-prop-1-enyl]-pyridine-3-carboxylic acid amide; 10 N-[(3-Fluorophenyl)-methyl]-4- methyl-6-morpholin-4-yl-2-propyl-pyridine-3-carboxylic acid amide; 19 N-[(3- Fluorophenyl)-methyl]-2-methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[3-Fluorophenyl)-methyl]-2-(2-methoxy-eth
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 23.
- Such compounds are described in US Patent No.9,168,259 issued March 8, 2016 and corresponding to US Application No.13/449,472 filed April 18, 2012; US Patent No.8,552,200 issued December 12, 2013 and corresponding to US Application No.13/276,464 filed October 19, 2011; International Publication No. WO2012052167A1, published April 26, 2012 and corresponding to International Application No. PCT/EP2011/005265 filed April 26, 2012; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 23, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 23: Formula 23 wherein, R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1- 8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF 3
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3
- R 1 represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R 12a and R 12b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1- 4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, and R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1- 4 aliphatic residue)
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2 or 3, R 12a and R 12b each independently of one another represent H, F, Cl, Br, I, OH, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue or together denote ⁇ O, and R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C 1- 4 aliphatic residue, CN, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubsti
- R 2 represents F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1- 4 -aliphatic residue, a S—C 1-4 -aliphatic residue, or a O—C 1-4 -aliphatic residue, wherein the C 1- 4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted aliphatic residue, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, pyrrolidinyl, piperazinyl, 4-methylpiperazinyl, morpholinyl, or piperidinyl, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F
- R 3 represents H; F; Cl; Br; I; CN; CF 3 ; SCF 3 ; NO 2 ; OCF 3 ; a C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, or a S—C 1-4 -aliphatic residue, wherein the C 1-4 aliphatic residue may be in each case be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted O—C 1-4 -aliphatic residue.
- R 4 represents the partial structure: wherein: n denotes 0, 1, 2, or 3, R 13a and R 13b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O— C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, and R 13c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2
- R 4 represents the partial structure: wherein: n denotes 0, 1, 2 or 3, R 13a and R 13b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue or together denote ⁇ O, and R 13c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -
- R 6 denotes a C 2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycl
- R 6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R 6 denotes S—R 7 or O—R 8 wherein R 7 and R 8 in each case denote a C 1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, an NH(C 1-4 aliphatic residue), an N(C 1- 4 aliphatic residue) 2 , CF 3 , a C( ⁇ O)—O—C 1-4 -aliphatic residue, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be un
- R 6 denotes a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case is unsubstituted, or denotes a C 3-10 -cycloaliphatic residue, or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C
- C 3-10 -cycloaliphatic residue or the 3 to 10 membered heterocycloaliphatic residue may in each case optionally bridged via a unsubstituted C 1-4 aliphatic group, on the condition that if R 6 denotes a 3 to 10 membered heterocycloaliphatic residue, the 3 to 10 membered heterocycloaliphatic residue is linked via a carbon atom, or R 6 denotes S—R 7 or O—R 8 wherein R 7 and R 8 in each case denote a C 1-8 - aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, an NH(C 1-4 aliphatic residue), an N(C 1- 4 aliphatic residue) 2
- R 1 represents the partial structure: wherein: m is 0, 1 or 2, and R 12a and R 12b each independently of one another represent H, F, OH, CH 3 or OCH 3 , or together denote ⁇ O, R 12c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, CN, OH, S( ⁇ O) 2 —CH 3 , an unsubstituted O—C 1-4 aliphatic residue, and CF 3 , or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3
- the Kv7 channel activator is selected from the group consisting of: N-[(3,5-Difluoro-phenyl)-methyl]-2-ethylsulfanyl-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; Ethylsulfanyl-N-[(3-fluorophenyl)-methyl]-4-methyl-6- morpholin-4-yl-pyridine-3-carboxylic acid amide; N-[(3,5-Difluoro-phenyl)-methyl]-2- methoxy-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Ethylsulfanyl-N- [(4-fluorophenyl)-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2- Ethylsulfanyl-N-[(4-fluorophenyl)-methyl]-4-methyl-6
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 24.
- Such compounds are described in US Patent No.9,168,259 issued March 8, 2016 and corresponding to US Application No.13/449,472 filed April 18, 2012; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 24, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 24: Formula 24 wherein, X 1 represents a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; or a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted, and in each case optionally bridged via a C 1- 4 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; or represents OX 6 , wherein X 6 represents a C 1-6 -aliphatic residue, unsubstituted or mono- or polysubstituted; or a C 3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted; X 2 and X 3 independently of one another represent H; F; Cl; Br; I; CN; CH
- X 1 represents a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCH 2 F, OCHF 2 , OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a S( ⁇ O)—C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CN, and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting
- X 1 represents a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCH 2 F, OCHF 2 , OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a S( ⁇ O)—C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CN, and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting
- X 1 represents a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCH 2 F, OCHF 2 , OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a S( ⁇ O)—C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, CN, and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue is in each case unsubstituted, or represents a C 3-6 - cycloaliphatic residue, unsubstitute
- X 1 represents a C 2-6 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C 1-4 -aliphatic residue, or represents a C 3-6 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C 1-4 -aliphatic residue, or represents OX 6 , wherein X 6 represents a C 1-4 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C 1-4 -aliphatic residue.
- X 1 represents ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH 2 —CH(CH 3 )(C 2 H 5 ), C(CH 3 ) 2 (C 2 H 5 ), ethenyl or propenyl (—CH 2 CH ⁇ CH 2 , —CH ⁇ CH—CH 3 , —C( ⁇ CH 2 )— CH 3 ), cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or represents OX 6 , wherein X 6 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-
- X 2 and X 3 independently of one another represent H; F; Cl; Br; I; CH 2 F; CHF 2 ; CF 3 ; OH; OCH 2 F; OCHF 2 ; OCF 3 ; a C 1-4 -aliphatic residue, or an O—C 1- 4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted O—C 1-4 -aliphatic residue, or represent a C 3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C 1-4 -aliphatic residue,
- X 2 and X 3 independently of one another represent H; F; Cl; Br; I; CH 2 F; CHF 2 ; CF 3 ; OH; a C 1-4 -aliphatic residue, or an O—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue is in each case unsubstituted, or represent a C 3-6 - cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted, with the proviso that at least one of X 2 and X 3 denotes H or is linked via a carbon atom, X 4 and X 5 independently of one another represent H; CH 2 F; CHF 2 ; CF 3 ; a C 1-4 - aliphatic residue, wherein the C 1-4 -aliphatic residue is unsubstituted, or represent a C 3-6 - cycloaliphatic residue or a 3 to 6 membere
- X 2 and X 3 independently of one another represent H; OH; an unsubstituted C 1-4 -aliphatic residue, or an unsubstituted O—C 1-4 aliphatic residue, with the proviso that at least one of X 2 and X 3 denotes H or is linked via a carbon atom, X 4 and X 5 independently of one another represent H; CH 2 F; CHF 2 ; CF 3 ; an unsubstituted C 1-4 - aliphatic residue, or X 2 and X 3 or X 4 and X 5 in pairs, in each case independently of one another, together with the carbon atom connecting them, form a C 3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CH 2 F, CHF 2 , CF 3 , an unsubstituted O—C
- X 2 and X 3 independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, CH 2 —CH(CH 3 )(C 2 H 5 ), C(CH 3 ) 2 (C 2 H 5 ), OCH 3 or OCH 2 CH 3 , with the proviso that at least one of X 2 and X 3 denotes H or is linked via a carbon atom, X 4 and X 5 independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, n-pentyl, isopentyl,
- X 1 represents ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, tert.-butyl, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl, or represents OX 6 , wherein X 6 represents methyl, ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.- butyl, X 2 and X 3 in dependently of one another represent H; methyl; ethyl, n-propyl, 2-propyl, n-butyl, isobutyl, sec.-butyl, or tert.-butyl, X 4 and X 5 independently of one another represent H; methyl; ethyl, n-propyl, 2-propyl
- the Kv7 cannel activator is selected from the group consisting of: 2-Cyclopropyl-N-(3-hydroxy-4,4-dimethyl-pentyl)-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-[[(1S,2R)-2-hydroxy-cyclohexyl]- methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N- [[(1R,2S)-2-hydroxy-cyclohexyl]-methyl]-4-methyl-6-morpholin-4-yl-pyridine-3-carboxylic acid amide; 2-Cyclopropyl-N-([2-hydroxy-cyclopentyl]-methyl)-4-methyl-6-morpholin-4-yl- pyridine-3-carboxylic acid amide; N-(3-Hydroxy-4
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 25. Such compounds are described in US Patent No.8,653,101 issued February 18, 2014 and corresponding to US Application No. 10/992,118 filed November 18, 2005; International Publication No. WO2012025236A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004277 filed August 26, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 25, these references incorporated by reference herein control. [0364] In an embodiment, the Kv7 channel activator is a compound according to formula 25.
- R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1- 8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents H; F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF 3 ; SCF 3 ; a C 1-4 - aliphatic residue, a C
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue
- R 2 represents H; F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1-4 -aliphatic residue, a S—C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted aliphatic residue, a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, a C 1-4 - aliphatic residue and a O—C
- R 3 , R 4 , R 5 and R 6 each independently of one another represent H; F; Cl; Br; I; CN; CF 3 ; OCF 3 ; SCF 3 ; C( ⁇ O)H; C( ⁇ O)—OH; C( ⁇ O)—NH 2 ; S( ⁇ O) 2 —OH; NO 2 ; a C 1-4 -aliphatic residue, a C( ⁇ O)—C 1-4 aliphatic residue, a C( ⁇ O)—O— C 1-4 aliphatic residue, a O—C 1-4 -aliphatic residue, a O—C( ⁇ O)—C 1-4 -aliphatic residue, a S— C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consist
- R 3 , R 4 , R 5 and R 6 each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; OCF 3 ; SCF 3 ; a (C ⁇ O)— C 1-4 aliphatic residue, a C 1-4 aliphatic residue, O—C 1-4 aliphatic residue, a S—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH 3 .
- R 1 represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O— C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 ,
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 member
- R 7 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , CN, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue
- R 7 denotes a C 1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF
- R 1 represents the partial structure: wherein: m is 0, 1 or 2 and R 8a and R 8b each independently of one another represent H, F, a O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue; R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue,
- the Kv7 channel activator is selected from the group consisting of: N-(3,3-dimethyl-butyl)-2-methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3- carboxylic acid amide; 2-ethoxy-4-methyl-N-(thiophene-2-yl-methyl)-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; 2-ethoxy-N-[(4-fluorophenyl)-methyl]-4-methyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-2- methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4- fluorophenyl)-methyl]-2-methoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethoxy
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 26.
- Such compounds are described in International Publication No. WO2012025236A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004277 filed August 26, 2011; US Patent No.9,073,862 issued July 7, 2015 and corresponding to US Application No. 14/098,842 filed November 26, 2013; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 26, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 26: Formula 26 wherein, R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1- 8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents H; F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue
- R 2 represents H; F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1-4 -aliphatic residue, a S—C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted O—C 1-4 -aliphatic residue, a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, a C 1-4 - aliphatic residue and
- R 3 , R 4 , R 5 and R 6 each independently of one another represent H; F; Cl; Br; I; CN; CF 3 ; OCF 3 ; SCF 3 ; C( ⁇ O)H; C( ⁇ O)—OH; C( ⁇ O)—NH 2 ; S( ⁇ O) 2 —OH; NO 2 ; a C 1-4 -aliphatic residue, a C( ⁇ O)—C 1-4 aliphatic residue, a C( ⁇ O)—O— C 1-4 aliphatic residue, a O—C 1-4 -aliphatic residue, a O—C( ⁇ O)—C 1-4 -aliphatic residue, a S— C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consist
- R 3 , R 4 , R 5 and R 6 each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; OCF 3 ; SCF 3 ; a (C ⁇ O)— C 1-4 aliphatic residue, a C 1-4 aliphatic residue, O—C 1-4 aliphatic residue, a S—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH 3 .
- R 1 represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O— C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 ,
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 member
- R 7 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , CN, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue
- R 7 denotes a C 1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocyclo
- R 1 represents the partial structure: wherein: m is 0, 1 or 2 and R 8a and R 8b each independently of one another represent H, F, a O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue; R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue,
- the Kv7 channel activator may be selected from the group consisting of: [0389] N-[(3-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4-methyl-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-(2-methoxy-ethoxy)-4- methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]- 2-(2-hydroxy-ethoxy)-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N- [(3-fluorophenyl)-methyl]-2-isopropoxy-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-2-isopropoxy-4-methyl-7-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 27.
- Such compounds are described in International Publication No. WO2012025238A1, published March 1, 2012 and corresponding to International Application No. PCT/EP2011/004279 filed August 26, 2011; US Patent No.8,445,512 issued May 21, 2013 and corresponding to US Application No. 13/218,556 filed August 26, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 27, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 27: Formula 27 wherein: R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1- 8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents H; F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, ⁇ O, an O— C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue
- R 2 represents H; F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1-4 -aliphatic residue, a S—C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted aliphatic residue, a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, a C 1-4 - aliphatic residue and a O—C
- R 2 is ⁇ H.
- R 3 , R 4 , R 5 and R 6 each independently of one another represent H; F; Cl; Br; I; CN; CF 3 ; OCF 3 ; SCF 3 ; C( ⁇ O)H; C( ⁇ O)—OH; C( ⁇ O)—NH 2 ; S( ⁇ O) 2 —OH; NO 2 ; a C 1-4 -aliphatic residue, a C( ⁇ O)—C 1-4 aliphatic residue, a C( ⁇ O)—O— C 1-4 aliphatic residue, a O—C 1-4 -aliphatic residue, a O—C( ⁇ O)—C 1-4 -aliphatic residue, a S— C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or poly
- R 3 , R 4 , R 5 and R 6 each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; OCF 3 ; SCF 3 ; a (C ⁇ O)— C 1-4 aliphatic residue, a C 1-4 aliphatic residue, O—C 1-4 aliphatic residue, a S—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH 3 , on the condition that at least one of R 3 , R 4 , R 5 and R 6 is ⁇ H.
- R 1 represents the partial structure: [0398] Wherein, m denotes 0, 1, 2, 3 or 4, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), an N(C 1-4 aliphatic residue) 2 , OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), an N(C 1- 4 alipha
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 member
- R 7 denotes a C 2-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , CN, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue
- R 7 denotes a C 2-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH,
- R 1 represents the partial structure: wherein: m is 0, 1 or 2 and R 8a and R 8b each independently of one another represent H, F, a O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue; R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue,
- the Kv7 channel activator is selected from the group consisting of: 4-methyl-2-propyl-N-(thiophene-2-yl-methyl)-7-(trifluoromethyl)-quinoline-3- carboxylic acid amide; N-(cycloheptyl-methyl)-4-methyl-2-propyl-7-(trifluoromethyl)- quinoline-3-carboxylic acid amide; N-[(4-fluorophenyl)-methyl]-4-methyl-2-propyl-7- (trifluoromethyl)-quinoline-3-carboxylic acid amide; N-[(3-fluorophenyl)-methyl]-4-methyl- 2-propyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethyl-N-[(4-fluorophenyl)- methyl]-4-methyl-7-(trifluoromethyl)-quinoline-3-carboxylic acid amide; 2-ethyl-N-[(4-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 28.
- Such compounds are described in International Publication No. WO2012028300A1, published March 8,2012 and corresponding to International Application No. PCT/EP2011/004369 filed August 31, 2011; US Patent No.8,618,129 issued December 31, 2013 and corresponding to US Application No.13/222,023 filed August 31, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 28, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 28: Formula 28 wherein, R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted and optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO 2 ; OCF 3 ; SCF 3 ; a C 1-4 - aliphatic residue, a C
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , OH, ⁇ O, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O— C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue, unsubstituted or mono- or poly
- R 2 represents F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1- 4 -aliphatic residue, a S—C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, and an unsubstituted O—C 1-4 -aliphatic residue, a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, a C 1-4 - aliphatic residue and
- R 3 , R 4 , R 5 and R 6 each independently of one another represent H; F; Cl; Br; I; CN; CF 3 ; OCF 3 ; SCF 3 ; C( ⁇ O)H; C( ⁇ O)—OH; C( ⁇ O)—NH 2 ; S( ⁇ O) 2 —OH; NO 2 ; a C 1-4 -aliphatic residue, a C( ⁇ O)—C 1-4 aliphatic residue, a C( ⁇ O)—O— C 1-4 aliphatic residue, a O—C 1-4 -aliphatic residue, a O—C( ⁇ O)—C 1-4 -aliphatic residue, a S— C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consist
- R 3 , R 4 , R 5 and R 6 each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; OCF 3 ; SCF 3 ; a (C ⁇ O)— C 1-4 aliphatic residue, a C 1-4 aliphatic residue, O—C 1-4 aliphatic residue, a S—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH 3 .
- R 1 represents the partial structure: wherein: m denotes 0, 1, 2, 3 or 4, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, NO 2 , OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, or together denote ⁇ O, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , ⁇ O, OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S
- R 1 represents the partial structure wherein, m denotes 0, 1, or 2, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue, unsubstituted or
- R 7 denotes a C1-10-aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , ⁇ O, OH, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, CF 3 , CN, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloali
- R 7 denotes a C 1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3 and an un
- R 1 represents the partial structure: wherein: m is 0, 1 or 2 and R 8a and R 8b each independently of one another represent H, F, a O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue; R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue;
- the Kv7 channel activator is selected from the group consisting of: N-(3-fluorobenzyl)-2,4-dimethyl-1-oxo-7-(trifluoromethyl)-1,2- dihydroisoquinoline-3-carboxamide; N-(3-fluorobenzyl)-4-methyl-1-oxo-2-propyl-7- (trifluoromethyl)-1,2-dihydroisoquinoline-3-carboxamide; 2-ethyl-N-(3-fluorobenzyl)-4- methyl-1-oxo-7-(trifluoromethyl)-1,2-dihydroisoquinoline-3-carboxamide; N-(3- fluorobenzyl)-2-isopropyl-4-methyl-1-oxo-7-(trifluoromethyl)-1,2 dihydroisoquinoline-3- carboxamide; andN-(3-fluorobenzyl)-2-(2-methoxyethyl)
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 29.
- Such compounds are described in US Patent No.8,653,102 issued February 18, 2014and corresponding to US Application No.13/218,579 filed August 26, 2011; International Publication No. PCT/EP2011/004280, published March 1, 2012, and corresponding to International Application No. WO2012025239A1filed August 25, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 29, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 29: wherein: X denotes O or S, R 1 represents a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted; a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted and in each case optionally bridged via a C 1-8 aliphatic group, which in turn may be unsubstituted or mono- or polysubstituted; R 2 represents F; Cl; Br; I; CN; CF 3 ; C( ⁇ O)H; NO
- R 1 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1-4 aliphatic residue), OH, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , CN, a C 1-4 -aliphatic residue and C( ⁇ O)—OH, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 - cycloali
- R 2 represents F; Cl; Br; I; CN; CF 3 ; NO 2 ; OCF 3 ; SCF 3 ; a C 1- 4 -aliphatic residue, a S—C 1-4 -aliphatic residue, a O—C 1-4 -aliphatic residue, wherein the C 1-4 - aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, and an unsubstituted aliphatic residue, a C 3-6 -cycloaliphatic residue or a 3 to 6 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, ⁇ O, OH, a C 1-4 -aliphatic residue and a O— C 1-4 -aliphatic
- R 3 , R 4 , R 5 and R 6 each independently of one another represent H; F; Cl; Br; I; CN; CF 3 ; OCF 3 ; SCF 3 ; C( ⁇ O)H; C( ⁇ O)—OH; C( ⁇ O)—NH 2 ; S( ⁇ O) 2 —OH; NO 2 ; a C 1-4 -aliphatic residue, a C( ⁇ O)—C 1-4 aliphatic residue, a C( ⁇ O)—O— C 1-4 aliphatic residue, a O—C 1-4 -aliphatic residue, a O—C( ⁇ O)—C 1-4 -aliphatic residue, a S— C 1-4 -aliphatic residue, a S( ⁇ O) 2 —C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consist
- R 3 , R 4 , R 5 and R 6 each independently of one another are selected from the group consisting of H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; OCF 3 ; SCF 3 ; a (C ⁇ O)— C 1-4 aliphatic residue, a C 1-4 aliphatic residue, O—C 1-4 aliphatic residue, a S—C 1-4 aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, and O—CH 3 .
- R 1 represents the partial structure: wherein, m denotes 0, 1, 2, 3 or 4, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, NO 2 , NH 2 , a NH(C 1-4 aliphatic residue), OH, an O—C 1-4 aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 aliphatic residue, CF 3 , CN, a C 1-4 aliphatic residue or C( ⁇ O)—OH, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , NH 2 , an NH(C 1- 4 aliphatic residue), OH, an O
- R 1 represents the partial structure: wherein: m denotes 0, 1, or 2, R 8a and R 8b each independently of one another represent H, F, Cl, Br, I, an O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue, R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an O—C 1-4 aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue, wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 member
- R 7 denotes a C 1-10 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, NO 2 , OH, an O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, a C( ⁇ O)—O—C 1-4 -aliphatic residue, COOH, CF 3 , CN, and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, OCF 3 , CF 3 and an unsubstituted O—C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or
- R 7 denotes a C 1-8 -aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, an O—C 1-4 -aliphatic residue, COOH, a C( ⁇ O)—O—C 1-4 -aliphatic residue, OCF 3 , SH, SCF 3 , a S—C 1-4 -aliphatic residue, CF 3 , and a C 1-4 -aliphatic residue wherein the C 1-4 -aliphatic residue in each case may be unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, OH, CF 3
- R 1 represents the partial structure: wherein: m is 0, 1 or 2 and R 8a and R 8b each independently of one another represent H, F, a O—C 1-4 aliphatic residue or a C 1-4 aliphatic residue; R 8c denotes a C 1-4 aliphatic residue, unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue, CF 3 , and an unsubstituted C 1-4 -aliphatic residue, or denotes a C 3-10 -cycloaliphatic residue or a 3 to 10 membered heterocycloaliphatic residue, in each case unsubstituted or mono- or polysubstituted with at least one substituent selected from the group consisting of F, Cl, Br, I, an unsubstituted O—C 1-4 aliphatic residue,
- the Kv7 channel activator is selected from the group consisting of: N-[(3-Fluorophenyl)-methyl]-1,4-dimethyl-2-oxo-7-(trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; 1-Butyl-N-[(3-fluorophenyl)-methyl]-4-methyl-2-oxo-7- (trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3-Fluorophenyl)-methyl]-1,4- dimethyl-2-thioxo-7-(trifluoromethyl)-1H-quinoline-3-carboxylic acid amide; N-[(3- Fluorophenyl)-methyl]-1-(2-methoxy-ethyl)-4-methyl-2-oxo-7-(trifluoromethyl)-1H- quinoline-3-carboxylic acid amide; 1-Ethyl-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 30.
- Such compounds are described in International Publication No. WO2010075973A1, published July 8, 2010, and corresponding to International Application No. PCT/EP2009/009040 filed December 16, 2009; US Patent No.8,367,700 issued February 5, 2013 and corresponding to US Application No.12/635,800 filed December 11, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 30, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 30: Formula 30 , wherein, R 0 stands for C 1-10 alkyl or C 2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C 3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C 1-8 alkyl-bridged C 3-7 cycloalkyl or heterocyclyl, each saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; or C 1-8 alkyl-bridged aryl or heteroary
- R 1 stands for C 1-10 alkyl or C 2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C 3- 7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, each unsubstituted or mono- or polysubstituted; C 1-8 alkyl-bridged C 3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted, mono- or polysubstituted; C 1-8 alkyl-bridged heteroaryl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted, mono-
- R 3 , R 4 , R 5 and R 6 each mutually independently denote H; F; Cl; Br; I; NO 2 ; CF 3 ; CN; R 0 ; C( ⁇ O)(R 0 or H); C( ⁇ O)O(R 0 or H); C( ⁇ O)N(R 0 or H) 2 ; OH; OR 0 ; —O—(C 1-8 alkyl)-O—; O—(C 1-8 alkyl)-O—C 1-8 alkyl; OCF 3 ; N(R 0 or H) 2 ; N(R 0 or H)—C( ⁇ O)—R 0 ; N(R 0 or H)—C( ⁇ O)—N(R 0 or H) 2 ; SH; SCF 3 ; SR 0 ; S( ⁇ O) 2 R 0 ; S( ⁇ O) 2 O(R 0 or H); S( ⁇ O) 2 —N(R 0 or H
- R 7 , R 8 , R 9 , R 10 mutually independently stand for H; or C 1- 10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted.
- R 11 stands for H; F; Cl; Br; CN; C 1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted; or C 1-4 alkyl-bridged phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted or mono- or polysubstituted; R 13 stands for H; F; Cl; Br; CN; C 1-10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; phenyl or heteroaryl, each unsubstituted or mono- or polysubstituted; or C 2-4 alky
- R 12 and R 14 each mutually independently stand for H; or C 1- 10 alkyl, saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted.
- R 15 stands for C 3-10 alkyl or C 2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C 3- 7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; aryl or heteroaryl, unsubstituted or mono- or polysubstituted; C 1-8 alkyl-bridged C 3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can in each case be branched or unbranched, saturated or unsaturated, unsubstituted, mono
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 31.
- Such compounds are described in International Publication No. WO2010075973A1, published July 8, 2010, and corresponding to International Application No. PCT/EP2009/009040 filed December 16, 2009; US Patent No.8,367,700 issued February 5, 2013, and corresponding to US Application No.12/635,800 filed December 11, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 31, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 31: wherein, R 1 stands for C 1-10 alkyl or C 2-10 heteroalkyl, each saturated or unsaturated, branched or unbranched, unsubstituted or mono- or polysubstituted; C 3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; phenyl or thienyl, each unsubstituted or mono- or polysubstituted; C 1-8 alkyl-bridged C 3-7 cycloalkyl, saturated or unsaturated, unsubstituted or mono- or polysubstituted; C 1-8 alkyl-bridged phenyl, unsubstituted or mono- or polysubstituted, wherein the alkyl chain can be branched or unbranched, saturated or unsaturated, unsubstituted; or C 1-8 alkyl-bridged thi
- the Kv7 channel activator is selected from the group consisting of: 4-Oxo-4-(1-phenyl-3,4-dihydroisoquinolin-2(1H)-yl)-N-(3- (trifluoromethyl)benzyl)butyric acid amide; 4-(1-Methyl-3,4-dihydro-1H-isoquinolin-2-yl)-4- oxo-N-[[3-(trifluoromethyl)phenyl]methyl]butyric acid amide; 4-Oxo-4-(1-thien-2-yl-3,4- dihydroisoquinolin-2(1H)-yl)-N-(3-(trifluoromethyl)benzyl)butyric acid amide; 4-Oxo-4-[1- (4-pyridyl)-3,4-dihydro-1H-isoquinolin-2-yl]-N-[[3-(trifluoro
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 32.
- Such compounds are described in International Publication No. WO2010037863A1, published April 8, 2010, and corresponding to International Application No. PCT/EP2009/062859 filed October 2, 2009; US Publication No. US20120238547A1, published September 20, 2012 and corresponding to US Application No.13/394,345 filed September 2, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 32, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 32: Formula 32 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol- 1-yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo and trifluoromethyl; R 3 represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl which is optionally substituted one or more times with halo.
- R 3 represents furanyl which is optionally substituted with C 1- 6 -alkyl.
- R 4 represents C 1-6 -alkyl.
- R 5 and R 6 together with the nitrogen to which they are attached, represents morpholinyl.
- the compound is 3-Methyl-furan-2-carboxylic acid [2-((R)-3- fluoro-pyrrolidin-1-yl)-4-methyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl]-amide. [0449] In further embodiments, the compound is 3-Methyl-furan-2-carboxylic acid [2-((R)-3- fluoro-pyrrolidin-1-yl)-4-methyl-6-morpholin-4-yl-pyridin-3-yl]-amide; Formula 33 [0450] In an embodiment, the Kv7 channel activator may be selected from one of the following compounds according to Formula 33. Such compounds are described in US Publication No.
- the Kv7 channel activator is a compound according to formula 33: Formula 33 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents C 1-6 -alkyl; R 3 represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one or more times with substituents selected from C 1-6 -alkyl, C 1 -6 -alkoxy, halo and trifluoromethyl; R 4 represents C 1-6 -alkyl; and R 5 and R 6 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from morpholinyl and 1,4- oxazepanyl.
- R 1 represents metyl or iso-propyl.
- R 3 represents furanyl which is optionally substituted with C 1- 6 -alkyl.
- R 4 represents C 1-6 -alkyl.
- R 5 and R 6 together with the nitrogen to which they are attached, represents 1,4-oxazepanyl.
- the compound is 3-Methyl-furan-2-carboxylic acid(2- isopropyl-4-methyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide; or 3-Methyl-furan-2- carboxylic acid(2,4-dimethyl-6-[1,4]oxazepan-4-yl-pyridin-3-yl)-amide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 34. Such compounds are described in International Publication No.
- the Kv7 channel activator is a compound according to formula 34: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol- 1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo, hydroxy, amino, C 1-6 -alkyl, trifluoromethyl, C 1-6 - alkoxy, hydroxy-C 1-6 -alkyl and C 1-6 -alkoxy-C 1 -C 6 -alkyl; L
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl or piperidinyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with halo.
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halo.
- L represents —CH 2 —.
- R 3 represents C 1-6 -alkyl.
- R 3 represents phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, or C 3-6 -cycloalkyl, which phenyl, pyridyl, furanyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl and isothiazolyl is optionally substituted one or more times with substituents selected from C 1-6 -alkyl and halo.
- R 4 represents C 1-6 -alkyl.
- R 5 represents hydrogen.
- the Kv7 channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-[6-(7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-4- methyl-2-pyrrolidin-1-yl-pyridin-3-yl]-acetamide N-[6-(7,8-Dihydro-5H-[1,6]naphthyridin-6- yl)-4-methyl-2-pyrrolidin-1-yl-pyridin-3-yl]-3,3-dimethyl-butyramide; N-[6-(7,8-Dihydro- 5H-[1,6]naphthyridin-6-yl)-4-methyl-2-pyrrolidin-1-yl-pyridin-3-yl]-3-fluoro-benzamide; N- [6-(7,8-dihydro-5H-1
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 35.
- Such compounds are described in US Publication No. US20120059037A1, published March 8, 2012, and corresponding to US Application No.13/256,893 filed March 11, 2010; International Publication No. WO2010105960A1, published September 23, 2010 and corresponding to International Application No. PCT/EP2010/053072 filed March 11, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 35, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 35: Formula 35 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent hydrogen, C 1-6 -alkyl, hydroxy-C 1-6 -alkyl or C 1-6 -alkoxy-C 1-6 -alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, C
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen.
- L represents —CH 2 —, and n is 1.
- R 3 represents phenyl, which phenyl is optionally substituted one or more times with halogen.
- R 3 represents C 1-6 -alkyl.
- R 4 represents halogen.
- R 4 represents hydrogen.
- the Kv7 Channel activator is selected from the group consisting of: N- ⁇ 6-[(6-Chloro-pyridin-3-ylmethyl)-amino]-2-pyrrolidin-1-yl-pyridin-3-yl ⁇ - 2-(3,5-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N- ⁇ 6-[(pyridin-3-ylmethyl)- amino]-2-pyrrolidin-1-yl-pyridin-3-yl ⁇ -acetamide; N- ⁇ 6-[(6-Chloro-pyridin-3-ylmethyl)- amino]-2-pyrrolidin-1yl-pyridin-3-yl ⁇ -3,3-dimethyl-butyramide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N- oxide thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 36.
- Such compounds are described in Patent Cooperation Treaty application No. EP2010/052257 published September 2, 2010, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 36, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to formula 36: Formula 36 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent hydrogen, Ci -6 -alkyl, hydroxy- C- ⁇ - 6 -alkyl or Ci- 6 -alkoxy-Ci- 6 -alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1-yl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen,
- R 1 and R 2 independently of each other, represent Ci- 6 -alkyl. [0479] In further embodiments, R 1 and R 2 together with the nitrogen to which they are attached, is morpholinyl. [0480] In further embodiments, L represents -CH 2 -. [0481] In further embodiments, R 3 represents phenyl, which phenyl is optionally substituted one or more times with halogen. [0482] In further embodiments, R 4 represents methyl.
- the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N- ⁇ 4-methyl-6-morpholin-4-yl-2-[(tetrahydro-pyran- 4- ylmethyl)-amino]-pyrimidin-5-yl ⁇ -acetamide; 2-(3,5-Difluoro-phenyl)-N- ⁇ 4- dimethylamino-6-methyl-2-[(tetrahydro-pyran-4- ylmethyl)-amino]-pyrimidin-5-yl ⁇ - acetamide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically- acceptable addition salt thereof, or an /V-oxide thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 37.
- Such compounds are described in International Publication No. WO2010094644A1, published August 26, 2010, and corresponding to International Application No. PCT/EP2010/051839 filed February 15, 2010; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 37, the reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to formula 37: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent Ci -6 -alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1 -yl, piperidinyl and morpholinyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, C 1-6 -alkyl, trifluoromethyl, Ci- 6 -alkoxy, hydroxy-d- 6 -alkyl and Ci- 6 -alkoxy-Ci- 6 -alkyl; L represents a link
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen.
- R' and R independently of each other, represents hydrogen or methyl.
- R 3 represents phenyl, which phenyl is optionally substituted one or more times with halogen.
- R 3 represents d-e-alkyl.
- R 4 represents methyl.
- the Kv7 Channel activator is selected from the group consisting of: 3,3-Dimethyl-N-(5-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl-pyridin-3-yl)- butyramide; 2-(3,5-Difluoro-phenyl)-N-(5-methyl-6-morpholin-4-yl-2-pyrrolidin-1-yl- pyridin-3-yl)-acetamide; N-[2-((R)-3-Fluoro-pyrrolidin-1-yl)-5-methyl-6-morpholin-4-yl- pyridin-3-yl]-3,3-dimethylbutyramide; (S)-N-[2-((R)-3-Fluoro-pyrrolidin-1-yl)-5-methyl-6- morpholin-4-yl-pyridin-3-yl]-2-phenylpropionamide;[2-((R)-3-Fluor
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 38.
- Such compounds are described in International Publication No. WO2010094645A1, published August 26, 2010, and corresponding to International Application No. PCT/EP2010/051840 filed February 15, 2010; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 38, the reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 38: Formula 38 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent d-e-alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1 H-pyrrol-1-yl, piperidinyl, mor- pholinyl and 1 ,4-oxazepanyl, which pyrrolidinyl and piperidinyl is optionally substituted one or more times with a substituent selected from the group consisting of halogen, hydroxy, amino, d -6 -alkyl, trifluoromethyl, d- 6 -alkoxy, hydroxy-Ci -6 -alkyl and Ci-
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl, which pyrrolidinyl is optionally substituted one or more times with halogen.
- R 1 and R 2 together with the nitrogen to which they are attached is 1 ,4-oxazepanyl.
- L is -CH 2 - and n is 1.
- n is 0.
- R 3 represents phenyl, which phenyl is optionally substituted one or more times with halogen.
- the Kv7 Channel activator is selected from the group consisting of: 2-(3,4-Difluoro-phenyl)-N-[2-((R)-3-fluoro-pyrrolidin-1-yl)-5-methyl-6- [1 ,4]oxazepan-4-yl-pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-/V-(5-methyl-2,6-bis-[1 ,4]oxazepan-4-yl-pyridin-3-yl)- acetamide; 3-Fluoro-/V-(5-methyl-6-[1 ,4]oxazepan-4-yl-2- pyrrolidin-1-yl-pyridin-3-yl)- benzamide; 3-methyl-N-[5-methyl-6-(1 ,4-oxazepan-4-yl)-2- pyrrolidin-1-yl-3-pyri
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 1.
- Such compounds are described in International Publication No. WO2008142140A2, published November 27, 2008, and corresponding to International Application No. PCT/EP2008/056322 filed May 22, 2008; US Patent No.8,178,544 published May 15, 2012 and corresponding to US Application No. 12/601,124 filed May 22, 2008; which are incorporated by reference in their entirety herein.
- the reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 39: , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents hydrogen, alkyl or halo; and R 2 represents hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenyl-alkyl, amino, alkyl-carbonyl-amino, cyano or nitro; or R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkyl (spiro) group; or R 1 represents hydrogen; and R 2 together with one of R 3 , R 4 and R 5 , attached in ortho-position on the aromatic ring, form a —(CH 2 ) n — bridge, wherein n is 1, 2 or 3; R 3 , R 4 and
- R 1 represents hydrogen or alkyl
- R 2 represents hydrogen or alkyl
- R 3 , R 4 and R 5 independently of each other, represent hydrogen, alkyl, halo, haloalkyl, hydroxy, alkoxy, alkyl-sulfanyl, alkyl-sulfonyl, phenyl or phenoxy.
- R 6 and R 7 independently of each other, represent hydrogen, halo, haloalkyl, hydroxy, alkoxy, or amino.
- R′ and R′′ independently of each other, represent alkyl, hydroxy-alkyl, cycloalkyl, or phenyl-alkyl.
- R′ and R′′ together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, thiazolidinyl, piperidinyl, piperazinyl, homopiperazinyl and morpholinyl, which piperazinyl is optionally substituted one or more times with alkyl.
- the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)- acetamide; 2-(3,5-Difluoro-phenyl)-N-(2-dimethylamino-4-oxo-4H-quinazolin-3-yl)- acetamide; 2-(4-Chloro-phenyl)-N-(2-diethylamino-4-oxo-4H-quinazolin-3-yl)-acetamide; 2- (3,5-Difluoro-phenyl)-N-[2-(ethyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-acetamide; 2- (3,5-Difluoro-phenyl)-N-(2-dimethylamino
- the Kv7 Channel activator is selected from the group consisting of: 2-(3-Fluoro-4-trifluoromethyl-phenyl)-N-(4-oxo-2-pyrrolidin-1-yl-4H- quinazolin-3-yl)-acetamide; 2-(3,5-Bis-trifluoromethyl-phenyl)-N- ⁇ 2-[(2-methoxy-ethyl)- methyl-amino]-4-oxo-4H-quinazolin-3-yl ⁇ -acetamide; N-[2-(Benzyl-methyl-amino)-4-oxo- 4H-quinazolin-3-yl]-2-(3,4-difluoro-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-(2- morpholin-4-yl-4-oxo-4H-quinazolin-3-yl)-acetamide; 2-(3,5-Difluor
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 40. Such compounds are described in International Publication No. WO2010060955A1, published June 3, 2010 and corresponding to International Application No. PCT/EP2009/065890 filed November 26, 2009; US Publication No.
- the Kv7 channel activator is a compound according to Formula 40: Formula 40 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein Y represents —(CH 2 ) n —, —(CH 2 ) n —O— or — (CH 2 ) n —S— wherein n is 0 or 1;
- R 1 represents C 1-6 -alkyl, benzo[1,3]dioxolyl, phenyl or pyridyl, which phenyl and pyridyl are optionally substituted one or more times with substituents selected from the group consisting of C 1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C 1-6 -alkoxy and trifluoromethoxy;
- R 2 and R 3 independently of each other, represent hydrogen or C 1-6 -alkyl; and
- R 4 and R 5 independently of each
- Y represents —(CH 2 ) n —, wherein n is 0 or 1;
- R 1 represents C 1-6 -alkyl, benzo[1,3]dioxolyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from the group consisting of C 1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C 1-6 -alkoxy and trifluoromethoxy;
- R 2 and R 3 independently of each other, represent hydrogen or C 1-6 -alkyl;
- R 4 and R 5 independently of each other, represent hydrogen, C 1-6 -alkyl, halogen, trifluoromethyl, hydroxy, C 1-6 -alkoxy or trifluoromethoxy.
- n is 1.
- R 1 represents phenyl optionally substituted one or more times with substituents selected from the group consisting of C 1-6 -alkyl, halogen, trifluoromethyl and C 1-6 -alkoxy.
- R 2 and R 3 represent hydrogen.
- R 2 and R 3 represent C 1-6 -alkyl.
- R 4 and R 5 independently of each other, represent hydrogen or halogen.
- the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluoro-phenyl)-N-[6-(4-fluoro-benzylamino)-2-morpholin-4-yl- pyridin-3-yl]-acetamide; 2-(3,5-Difluoro-phenyl)-N- ⁇ 6-[1-(4-fluoro-phenyl)-1-methyl- ethylamino]-2-morpholin-4-yl-pyridin-3-yl ⁇ -acetamide; N-[6-(4-Fluoro-benzylamino)-2- morpholin-4-yl-pyridin-3-yl]-2-methyl-benzamide; 2-Benzo[1,3]dioxol-5-yl-N-[6-(4-fluoro- benzylamino)-2-morpholin-4-yl-pyridin-3-yl]-acetamide;
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 41.
- Such compounds are described in US Publication No. US20110269783A1, published November 3, 2011, and corresponding to US Application No.13/128,015 filed November 6, 2009; International Publication No. WO2010051819A1, published May 14, 2010, and corresponding to International Application No. PCT/DK2009/050293 filed November 6, 2009; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 41, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 41: Formula 41 , A stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein L represents a linker selected from —(CR′R′′) 2 —, —CR′R′′—S—, —CR′R′′—O— or wherein R′ and R′′, independently of each other, represent hydrogen, C 1-6 -alkyl or halogen; R 1 and R 2 , independently of each other, represent C 1-6 -alkyl, hydroxy-C 1-6 -alkyl-, C 1-6 -alkoxy-C 1-6 -alkyl-, phenyl, phenyl-C 1-6 -alkyl-, which phenyl is optionally substituted with one or two times with a substituent selected from the group consisting of C 1-6 -alkoxy, halogen and cyano; or R 1 and
- R 1 and R 2 independently of each other, represent C 1-6 -alkyl, alkoxy-C 1-6 -alkyl- or phenyl-C 1-6 -alkyl-.
- R 1 and R 2 together with the nitrogen to which they are attached, form a pyrrolidinyl ring.
- R 3 , R 4 and R 5 independently of each other, represent hydrogen, C 1-6 -alkyl or halogen.
- R 6 and R 7 independently of each other, represent hydrogen or halogen.
- the Kv7 Channel activator is selected from the group consisting of: N-(7-Fluoro-4-oxo-2-pyrrolidin-1-yl-4H-quinazolin-3-yl)-3-(3-fluoro-phenyl)- propionamide; 3-(3-Fluoro-phenyl)-N- ⁇ 2-[(2-methoxy-ethyl)-methyl-amino]-4-oxo-4H- quinazolin-3-yl ⁇ -propionamide; N-[2-(Benzyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-3- (3-fluoro-phenyl)-propionamide; N-[2-(Benzyl-methyl-amino)-4-oxo-4H-quinazolin-3-yl]-3- (3,5-difluoro-phenyl)-propionamide; 3-(3-Fluoro
- the compound is of formula: wherein: X represents —CR′R′′—, —S—, or —O—, wherein R′ and R′′, independently of each other, represent hydrogen, C 1-6 -alkyl or halogen, and R′, R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above. [0527] In further embodiments, the compound is of formula: wherein: R 1 , R 2 , R 3 , R 4 , R 5 , R 6 and R 7 are as defined above.
- the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in International Publication No.
- the Kv7 channel activator is a compound according to Formula 42: Formula 42 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5-dihydro-1H-pyrrol- 1-yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo and trifluoromethyl; R 3 represents a heterocyclic ring selected from furanyl and pyrrolyl which furanyl and pyrrolyl is optionally substituted one
- R 1 and R 2 together with the nitrogen to which they are attached is pyrrolidinyl which is optionally substituted one or more times with halo.
- R 3 represents furanyl which is optionally substituted with C 1- 6 -alkyl.
- R 4 represents C 1-6 -alkyl.
- R 5 and R 6 together with the nitrogen to which they are attached, represents morpholinyl.
- the Kv7 Channel activator is selected from the group consisting of: 3-Methyl-furan-2-carboxylic acid [2-((R)-3-fluoro-pyrrolidin-1-yl)-4-methyl-6- [1,4]oxazepan-4-yl-pyridin-3-yl]-amide; 3-Methyl-furan-2-carboxylic acid [2-((R)-3-fluoro- pyrrolidin-1-yl)-4-methyl-6-morpholin-4-yl-pyridin-3-yl]-amide; or a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically acceptable addition salt thereof, or an N- oxide thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 43.
- Such compounds are described in International Publication No. WO2010026104A1, published March 11, 2010, and corresponding to International Application No. PCT/EP2009/061125 filed August 28, 2009; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 43, the reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 43: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent Ci -6 -alkyl, hydroxy-d-e-alkyl or Ci -6 - alkoxy-Ci- 6 -alkyl; or R 1 and R 2 , together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, 2,5- dihydro-1 H-pyrrol-1 -yl, azetidinyl, thiazolidinyl, piperidinyl, piperazinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the
- R 1 and R 2 independently of each other, represent Ci -6 -alkyl.
- R 1 and R 2 together with the nitrogen to which they are attached, form a heterocyclic ring selected from pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl, which pyrrolidinyl, azetidinyl, piperidinyl and morpholinyl is optionally substituted one or more times with a substituent selected from the group consisting of halo, d- e-alkyl and trifluoromethyl.
- R 1 and R 2 together with the nitrogen to which they are attached, form a heterocyclic ring which is pyrrolidinyl optionally substituted one or more times with a substituent selected from the group consisting of halo, d-e-alkyl and trifluoromethyl.
- R 1 and R 2 together with the nitrogen to which they are attached, form a heterocyclic ring which is piperidinyl optionally substituted one or more times with a substituent selected from the group consisting of halo, d-e-alkyl and trifluoromethyl.
- R 3 represents te/t-butyl.
- R 3 represents phenyl, which is optionally substituted one or more times with substituents selected from Ci -6 -alkyl, Ci -6 -alkoxy, halo and trifluoromethyl.
- L represents -CH 2 -.
- the Kv7 Channel activator is selected from the group consisting of: 2-(3,5-Difluorophenyl)-N- ⁇ 2-pyrrolidin-1-yl-6-[(tetrahydro-pyran-4-ylmethyl)- amino]- pyridin-3-yll-acetamide; 3,3-Dimethyl-N- ⁇ 2-pyrrolidin-1-yl-6-[(tetrahydro-pyran-4- ylmethyl)-amino]-pyridin-3-yllbutyramide; 2-(3,5-Difluoro-phenyl)-N- ⁇ 2-morpholin-4-yl-6- [(tetrahydro-pyran-4-ylmethyl)-amino]- pyridin-3-yll-acetamide; 2-(3,5-Difluoro-phenyl)-N- ⁇ 2-dimethylamino-6-[(tetrahydro-pyran-4-ylmethyl)-amino]- pyridin-3-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 44.
- Such compounds are described in International Publication No. WO2010105960A1, published September 23, 2010, and corresponding to International Application No. PCT/EP2010/053072 filed March 11, 2010; US Publication No. US20110003865A1, published January 6, 2011, and corresponding to US Application No.12/747,394 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 44, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 44: Formula 44 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R 2 represents hydrogen; R 3 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R′′—, —CH 2 —CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- R 1 represents alkyl or phenyl, which phenyl is optionally
- R 1 represents alkyl.
- R 1 represents phenyl optionally substituted one or more times with substituents selected from alkyl and halo.
- R 3 represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl.
- R 3 represents alkyl.
- L represents a linker selected from —CR′R′′—, —CH 2 — CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen or alkyl.
- the Kv7 Channel activator is selected from the group consisting of: N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,5-difluoro- phenyl)-acetamide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,4- difluoro-phenyl)-acetamide; N-[2-Diethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3-fluoro-4-trifluoromethyl-phenyl)-acetamide; (S)—N-[2-Diethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-2-phenyl-propionamide; N-[2-Diethylamino-6-(
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 45.
- Such compounds are described in US Publication No. US20110039896A1, published February 17, 2011, and corresponding to US Application No.12/747,346 filed December 10, 2008; International Publication No. WO2009074593A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067164 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 45, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 45: Formula 45 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents alkyl, phenyl, benzo[1,3]dioxolyl or benzo[1,4]dioxinyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, trifluoromethyl, alkoxy, cyano and difluoromethoxy; R 2 represents hydrogen; R 3 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R′′—, —CH 2 —CR′R′′—, —CR′R′′—CH 2 — and cycloal
- R 1 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl
- R 2 represents hydrogen
- R 3 represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl
- L represents a linker selected from —CR′R′′—, —CH 2 —CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- R 1 represents alkyl.
- R 1 represents phenyl, benzo[1,3]dioxolyl or benzo[1,4]dioxinyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, trifluoromethyl, alkoxy, cyano and difluoromethoxy.
- R 3 represents alkyl.
- R 3 represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl.
- L represents a linker selected from —CR′R′′—, —CH 2 — CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen or alkyl.
- the Kv7 Channel activator is selected from the group consisting of: N-[6-(4-Fluoro-benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-2-(3-fluoro-4- trifluoromethyl-phenyl)-acetamide; 2-(3,5-Difluoro-phenyl)-N-[6-(4-fluoro-benzylamino)-2- pyrrolidin-1-yl-pyridin-3-yl]-acetamide; 2-(3,4-Difluoro-phenyl)-N-[6-(4-fluoro- benzylamino)-2-pyrrolidin-1-yl-pyridin-3-yl]-acetamide; (S)-N-[6-(4-Fluoro-benzylamino)- 2-pyrrolidin-1-yl-pyridin-3-yl]-2-phenyl
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 46.
- Such compounds are described in International Publication No. WO2009074591A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067161 filed December 10, 2008; US Publication No. US20110003866A1, published December 10, 2008, and corresponding to US Application No.12/747,414 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 46, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 46: a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R 2 represents hydrogen; R 3 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- R 1 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl,
- R 1 represents alkyl.
- R 1 represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl.
- R 3 represents alkyl.
- R 3 represents phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl.
- L represents a linker selected from —CR′R′′—, —CR′R′′— CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- the Kv7 Channel activator is selected from the group consisting of: N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,4-difluoro- phenyl)-acetamide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,5- difluoro-phenyl)-acetamide; N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2- (3-fluoro-4-trifluoromethyl-phenyl)-acetamide; (S)—N-[2-Dimethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-2-phenyl-propionamide; N-[2-Dimethylamino-6-(2-Dimethylamino-6
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 47.
- Such compounds are described in US Publication No. US20110003867A1, published January 6, 2011, and corresponding to US Application No.12/747,422 filed December 10, 2008; International Publication No. WO2009074594A1, published June 18, 2009, and corresponding to International Application No. PCT/EP2008/067165 filed December 10, 2008; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 47, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 47: Formula 47 , a stereoisomer or a mixture of its stereoisomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl; R 2 represents hydrogen; R 3 represents alkyl or phenyl, which phenyl is optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl; and L represents a linker selected from —CR′R′′—, —CH 2 —CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- R 1 represents alkyl or phenyl, which phenyl is optionally
- R 1 represents alkyl.
- R 1 represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo and trifluoromethyl.
- R 3 represents phenyl, optionally substituted one or more times with substituents selected from alkyl, halo, alkoxy and trifluoromethyl.
- R 3 represents alkyl.
- L represents a linker selected from —CR′R′′—, —CH 2 — CR′R′′—, —CR′R′′—CH 2 — and cycloalkyl, wherein R′ and R′′, independently of each other, represent hydrogen, alkyl or halo.
- the Kv7 Channel activator is selected from the group consisting of: N-[2-Dimethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,5-difluoro- phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3-yl]-2-(3,4- difluoro-phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro-benzylamino)-pyridin-3- yl]-2-(3-fluoro-4-trifluoromethyl-phenyl)-acetamide; N-[2-Ethylmethylamino-6-(4-fluoro- benzylamino)-pyridin-3-yl]-3-(3-fluoro-phenyl)-propionamide; (
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 48.
- Such compounds are described in International Publication No. WO2007104717A1, published September 20, 2007, and corresponding to International Application No. PCT/EP2007/052239 filed March 9, 2007; US Publication No. US20090036473A1, published February 5, 2009, and corresponding to US Application No.12/278,091 filed March 9, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 48, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 48:
- Formula 48 including any of its stereoisomers, or any mixture of its stereoisomers, or a pharmaceutically- acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 and R 2 , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, baloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfonyl, cyano or nitro; R 3 represents alkyl, cycloalkyl or alkoxy; and R 4 and R 5 , independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, nitro or cyano.
- R 1 and R 2 independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfonyl, cyano or nitro.
- R 3 represents alkyl, cycloalkyl or alkoxy.
- R 4 and R 5 independently of each other, represent hydrogen, alkyd, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl- amino, nitro or cyano.
- the Kv7 Channel activator is selected from the group consisting of: 2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H- quinazolin-3-yl)-amide; 2-(4-Fluoro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4- oxo-4H-quinazolin-3-yl)-amide; 2-(3-Fluoro-4-methyl-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-oxo-4H-quinazolin-3-yl)- amide; 2-Phenyl-cyclopropanecarboxylic acid (2- isopropyl-4-oxo-4H-quinazolin-3-yl)-amide; 2-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (2-isopropyl-4-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 49.
- Such compounds are described in International Publication No. WO2007057447A1, published May 24, 2007, and corresponding to International Application No. PCT/EP2006/068627 filed November 17, 2006; US Publication No. US20090291973A1, published November 26, 2009, and corresponding to US Application No.12/085,188 filed November 17, 2006; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 49, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 49: Formula 49 , including any of its stereoenantiomers or any mixture of its stereoenantiomers, or a pharmaceutically-acceptable addition salt thereof, or an N-oxide thereof, wherein R 1 represents hydrogen or alkyl; and R 2 represents alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenylalkyl, amino, alkyl-carbonyl-amino, cyano or nitro; or R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkyl group; or R 1 represents hydrogen; and R 2 together with R 3 attached in ortho-position on the aromatic ring form a —(CH 2 ) n — bridge, wherein n is 1, 2 or 3; R 3 and R 4 , independently of each other, represent hydrogen, alkyl, cycloalkyl,
- R 1 represents hydrogen or alkyl.
- R 2 represents alkyl, cycloalkyl, halo, haloalkyl, hydroxyalkyl, hydroxy, alkoxy, phenyl, phenylalkyl, amino, alkyl-carbonyl-amino, cyano or nitro.
- R 1 represents hydrogen or methyl; and R 2 represents methyl, ethyl, isopropyl, cyclohexyl, fluoro or benzyl.
- R 1 and R 2 together with the carbon atom to which they are attached form a cycloalkyl group.
- R 1 represents hydrogen; and R 2 together with R 3 attached in ortho-position on the aromatic ring form a —(CH 2 ) n — bridge, wherein n is 1, 2 or 3.
- R 3 and R 4 independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl-amino, alkyl-sulfonyl, phenyl, benzoyl, cyano or nitro; or R 3 and R 4 together form a methylenedioxy group.
- R 3 attached in ortho-position on the aromatic ring and together with R 2 form a —(CH 2 )n— bridge, wherein n is 1, 2 or 3; and R 4 is as defined in claim 7.
- R 5 represents alkyl, cycloalkyl, alkoxy, alkylthio or phenyl.
- R 6 and R 7 independently of each other, represent hydrogen, alkyl, cycloalkyl, halo, haloalkyl, hydroxy, alkoxy, haloalkoxy, amino, alkyl-carbonyl- amino(acetamido), nitro, cyano or phenyl.
- the Kv7 Channel activator is selected from the group consisting of: N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-3-methyl-2-phenyl-butyramide; 2- (4-Chloro-phenyl)-N-(2-isopropylsulfanyl-4-oxo-4H-quinazolin-3-yl)-butyramide; 2-(3,5- Difluoro-phenyl)-N-(2-isopropylsulfanyl-4-oxo-7-trifluoromethyl-4H-quinazolin-3-yl)- propionamide; N-(2-Ethyl-7-fluoro-4-oxo-4H-quinazolin-3-yl)-2-phenyl-propionamide; (S)- N-(2-Isopropyl-4-oxo-4H-quinazolin-3-yl)-2-phenyl-propionamide; (S)-
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 50.
- Such compounds are described in US Patent No.7,741,352, issued June 22, 2010, and corresponding to US Application No.10/546,533 filed March 11, 2004; International Publication No. WO2004080377A2, published September 23, 2004, and corresponding to International Application No. PCT/EP2004/050290 filed March 11, 2004; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 50, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 50: Formula 50 , any of its enantiomers or any mixture of its enantiomers, or a prodrug, or a pharmaceutically- acceptable addition salt thereof, wherein R 1 represents —CN; R 2 represents halo, haloalkyl, hydroxyl or alkoxy; X represents, NR′′ or NR′′CH 2 (read in the stated direction); wherein R′′ represents hydrogen; R 4 represents aryl-alkyl, which is substituted one or more times with substituents selected from the group consisting of halo, or methylenedioxy; or R 4 represents a group of formula -Z′-L′′-Z′′; wherein Z′ and Z′′, independently of one another, represent an aryl group, which aryl may be optionally substituted one or more times with halo; and L′′ represents a single (covalent) bond, or a linker selected from O or OCH 2 , with the proviso
- R 4 represents benzyl which is substituted one or two times with halo or one time with methylenedioxy. [0599] In further embodiments, R 4 represents 4-fluoro-benzyl, 3,4-dichloro-benzyl or benzo[1,3]dioxol-5-ylmethyl.
- the Kv7 Channel activator is selected from the group consisting of: 4-(4-Fluoro-benzylamino)-2-hydroxy-benzonitrile 4-(3,4-Dichloro- benzylamino)-2-hydroxy-benzonitrile or 4-[(Benzo[1,3]dioxol-5-ylmethyl)-amino]-2- hydroxy-benzonitrile; or a pharmaceutically-acceptable addition salt thereof.
- R 4 represents a group of formula -Z′-L′′-Z′′; wherein Z′ represents phenyl, or phen-4-yl; which phenyl may optionally be substituted one or two times with halo; and Z′′ represent phenyl; which may optionally be substituted one or two times with halo; and L′′ represents a single (covalent) bond, or a linker selected from alkyl, O, or OCH 2 .
- R 4 represents 3-phenoxy-phenyl, 3-benzyloxy-phenyl, or biphenyl-4-yl.
- the Kv7 Channel activator is selected from the group consisting of: 2-Hydroxy-4-(3-phenoxy-benzylamino)-benzonitrile; 4-(3-Benzyloxy- benzylamino)-2-hydroxy-benzonitrile; or 4-[(Biphenyl-4-ylmethyl)-amino]-2-hydroxy- benzonitrile; or a pharmaceutically-acceptable addition salt thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 51. Such compounds are described in US Patent No.7,741,352, issued June 22, 2010, and corresponding to US Application No.10/546,533 filed March 11, 2004; International Publication No.
- the Kv7 channel activator is a compound according to Formula 51: Formula 51 , wherein, R represents hydrogen, halogen or hydroxy.
- R 1 , R 2 , R 3 and R 4 independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl-phenyl or p- trihalogenmethyl-phenyl, or R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are joined together to form a benzo fused ring, R 5 represents hydrogen or alkyl, and R 6 represents halogen or trihalogenmethyl, or a pharmaceutically-acceptable addition salt thereof.
- R represents hydrogen, halogen or hydroxy
- R 1 , R 2 , R 3 and R 4 independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl-phenyl or p-trihalogenmethyl-phenyl, and when R 1 and R 4 are hydrogen, then R 2 or R 3 is phenyl, p-methyl-phenyl or p-trihalogenmethyl-phenyl; or R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are joined together to form a benzo fused ring, R 5 represents hydrogen or alkyl, and R 6 represents halogen or trihalogenmethyl.
- R 1 , R 3 and R 4 represent hydrogen, and R 2 represents halogen, trihalogenmethyl or phenyl.
- R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are joined together to form a benzo fused ring.
- R 5 is hydrogen or methyl.
- R 6 is chlorine.
- the Kv7 Channel activator is selected from the group consisting of: (+)-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2- one; ( ⁇ )-3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6-(trifluoromethyl)-2H-indol-2-one; ( ⁇ )- 3-(5-chloro-2-methoxyphenyl)-1,3-dihydro-6(4-methylphenyl)-2H-indol-2-one; ( ⁇ )-3-(5- chloro-2-hydroxyphenyl)-1,3-dihydro-2H-indol-one; ( ⁇ )-3-(5-chloro-2-hydroxyphenyl)-4,6- dichloro-1,3-dihydro-2H-indol-one; ( ⁇ )-3-(5-chloro-2-methoxyphen
- R represents hydrogen, halogen or hydroxy
- R 1 , R 2 , R 3 and R 4 independently of each another represent hydrogen, halogen, alkyl, trihalogenmethyl, phenyl, p-methyl-phenyl or p-trihalogenmethyl-phenyl, or R 1 and R 2 , R 2 and R 3 , or R 3 and R 4 are joined together to form a bezo fused ring
- R 5 represents hydrogen or alkyl
- R 6 represents halogen or trihalogenmethyl, or a pharmaceutically-acceptable addition salt thereof, together with at least one pharmaceutically-acceptable carrier or diluent.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 52.
- Such compounds are described in International Publication No. CN114380731A, published April 22, 2022, and corresponding to International Application No. CN202210226122.7A filed March 9, 2022; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 52, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 52: Formula 52 , wherein, R 1 is selected from H, halogen, substituted or unsubstituted phenyl, or a substituted or unsubstituted phenylalkyl group, the substituents of said phenyl and phenylalkyl groups each being independently selected from halogen or haloalkyl; X is selected from S or C; R 2 is optionally selected from H, alkyl, alkenyl or alkynyl; R3 and R4 each independently selected from H or alkyl; y is selected from O or S; R 5 is selected from substituted or unsubstituted alkyl, substituted or unsubstituted cycloalkyl, alkoxy or furyl, the substituent of the alkyl is selected from alkoxy, dialkylamino or alkoxycarbonyl, and the substituent of the cycloalkyl is selected from hal
- R 2 is selected from H, C 1 -C 3 Alkyl radical, C 1 -C 3 Alkenyl or C 1 -C 3 Alkynyl.
- R 3 and R 4 are each independently selected from H or C 1 - C 6 An alkyl group.
- R 5 is selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy or furyl, the substituents of the alkyl or the alkoxy being selected from C 1 -C 6 Alkoxy, di (C) 1 -C 4 Alkyl) amino or C 1 - C 6 Alkoxycarbonyl, the substituents of cycloalkyl being selected from halogen.
- the formula is one of formulas II – IV: wherein, n is more than or equal to 0;R 11 and R 12 each independently selected from H, halogen or halomethyl; R 2 is selected from H, C 1 -C 3 Alkyl radical, C 2 -C 3 Alkenyl or C 2 -C 3 An alkynyl group; R 3 and R 4 are independently selected from H or C 1 -C 6 alkyl group; y is selected from O or S; R 5 is selected from substituted or unsubstituted C 1 -C 6 Alkyl, substituted or unsubstituted C 3 -C 6 Cycloalkyl radical, C 1 -C 6 Alkoxy or furyl, the substituents of the alkyl being selected from C 1 -C 6 Alkoxy, di (C) 1 -C 4 Alkyl) amino or C 1 -C 6 Alkoxycarbonyl, the substituents of cycloalkyl being selected from halogen
- n is 0 to 3
- R 11 is selected from H, F or trifluoromethyl
- R 12 is selected from H, F, Cl or methyl.
- R 3 is one of H or methyl
- R 4 is other of H or methyl.
- R 5 is selected from methyl, ethyl, isopropyl, isobutyl, neopentyl, cyclobutyl, ethoxy, isopropoxy, tert-butoxy or tetrahydrofuranyl.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 53.
- the Kv7 channel activator is a compound according to Formula 53: Formula 53 , wherein, X 1 represents nitrogen or CR X1 ; wherein R X1 represents hydrogen, halogen, (C 1- 4 )alkyl, or (C 1-4 )alkoxy; X 2 represents nitrogen or CR X2 ; wherein R X2 represents hydrogen, halogen, (C 1-4 )alkyl, or (C 1-4 )alkoxy; X 3 represents nitrogen or CR X3 ; wherein R X3 represents hydrogen, halogen, (C 1-4 )alkyl, (C1- 4)alkoxy, or hydroxy; R 1 represents hydrogen or methyl; R X4 represents hydrogen, halogen, or (C 1-4 )alkyl; • R 2A represents hydrogen; (C 1-4 )alkyl; (C 2- 4 )alkenyl; (C 2-4 )alkynyl; (C 3-6 )cycloalky
- X 1 represents CR X1 ; wherein R X1 represents hydrogen or halogen; X 2 represents nitrogen or CH; X 3 represents nitrogen or CH; R 1 represents hydrogen; R X4 represents hydrogen, halogen, or (C 1-4 )alkyl; R 2A represents hydrogen; (C 1- 4 )alkyl; (C 1-4 )fluoroalkyl; (C 1-4 )hydroxyalkyl; or (C 1-4 )alkoxy-(C 1- 2 )alkyl; R 2B represents hydrogen; L represents a direct bond, -CH 2 -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; R 3 represents hydrogen or fluoro; • R 4 represents hydrogen or (C 1-4 )alkyl; R 5 represents hydrogen, fluoro, or hydroxy; and R 6 represents fluoro or (C 1 )fluoroalkyl; or • R 4 and R 5 together represent a bridge selected
- R 2A represents hydrogen, (C 1-4 )alkyl, (C 1-4 )fluoroalkyl, (C 1- 4 )hydroxyalkyl, or methoxymethyl; and R 2B represents hydrogen; or a salt thereof.
- L represents a direct bond; or a salt thereof.
- R 3 represents fluoro; or a salt thereof.
- R X4 represents hydrogen; or a salt thereof.
- each of X 1 , X 2 , and X 3 represents CH; or a salt thereof.
- the fragment represents: wherein R X4 represents hydrogen or halogen; R 3 represents hydrogen or fluoro; and L represents a direct bond, -CH 2 -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; or • ; wherein X 3 represents nitrogen or CH; R X4 represents hydrogen or (C 1-4 )alkyl; R 3 represents hydrogen or fluoro; and L represents - CH 2 -O-*, or-O-; wherein the asterisk indicates the bond which is linked to the aromatic carbon atom; or a salt thereof.
- R 4 represents hydrogen; R 5 represents hydrogen or fluoro; and R 6 represents fluoro, difluoromethyl or trifluoromethyl; or a salt thereof.
- R 4 and R 5 together represent a -CH 2 - bridge; and R 6 represents hydrogen, fluoro, difluoromethyl, or trifluoromethyl; or a salt thereof.
- the Kv7 Channel activator is selected from the group consisting of: 1-(3,3-Difluoro-cyclobutyl)-3-(3-trifluoromethyl-benzyl)-urea; 1- Bicyclo[1.1.1]pent-1-yl-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl- cyclobutyl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Fluoro-bicyclo[1.1.1]pent-1- yl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Difluoromethyl-bicyclo[1.1.1]pent-1- yl)-3-[1-(3-trifluoromethyl-phenyl)-ethyl]-urea; 1-(3-Diflu
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 54.
- Such compounds are described in International Publication No. WO2021219594A1, published November 4, 2021 and corresponding to International Application No. PCT/EP2021/060918 filed April 27, 2021; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 54, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 54: Formula 54 , wherein, X 1 represents nitrogen or CR x1 ; wherein R X1 represents hydrogen, halogen, (C 1- 4 )alkyl, or (C 1- 4 )alkoxy;X 2 represents nitrogen or CR X2 ; wherein R X2 represents hydrogen, halogen, (C 1-4 )alkyl, or (C 1- 4 )alkoxy; X 3 represents nitrogen or CR X3 ; wherein R X3 represents hydrogen, halogen, (C 1-4 )alkyl, (C 1- 4 )alkoxy, or hydroxy;• R 1 represents hydrogen, or methyl; or• R 1 and R X1 together represent a -CH 2 CH 2 - bridge; Y represents -C(R Y1 )(R Y2 )-, or *-CH 2 -C(R Y3 )(R Y4 )-, wherein
- R 1 represents hydrogen; or a salt thereof (meaning a salt of compound of Formula 54).
- R Y1 , R Y2 , R Y3 and R Y4 all represent hydrogen; or a salt thereof.
- R 2A represents hydrogen, (C 1-4 )alkyl, (C 3-6 )cycloalkyl, (C1- 4 )fluoroalkyl, (C 1-4 )hydroxyalkyl, (C 1-4 )alkoxy-(C 1-2 )alkyl, (C 1-2 )alkyl-S-(C 1-2 )alkyl, (C 1- 2 )alkyl-(SO 2 )-(C 1-2 )alkyl, cyano, (C 1- 2 )cyanoalkyl, H 2 N-C(O)-(C 1-2 )alkyl, (R N1 ) 2 N-(C 1- 2 )alkyl, or (R N1 ) 2 N-C(O)-, wherein R N1 independently represents hydrogen or (C 1-2 )alkyl; and R 2B represents hydrogen; or R 2A and R 2B form, together with the carbon atom to which they are attached, a ring of 3- to
- R 2A represents hydrogen, methyl, or hydroxymethyl; and R 2B represents hydrogen; or a salt thereof.
- R 3 represents a fragment , where 31 inR represents hydrogen, or fluoro; and L represents a direct bond, -CHR L -O- * , -O-CH 2 - * , -CH 2 -NH- * , -CH 2 - N(CH 3 )- * , or -O-; wherein R L represents hydrogen, methyl, CH 3 -O-CH 2 -, or (CH 3 ) 2 NCH 2 -; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; or a salt thereof.
- R 4 represents hydrogen; or a salt thereof.
- the fragment represents: wherein X 3 represents nitrogen and X 1 represents CR X1 ; X 1 represents nitrogen and X 3 represents CR X3 ; or X 1 represents CR X1 and X 3 represents CR X3 ; or a salt thereof.
- the fragment represents wherein R X1 represents hydrogen, fluoro, chloro, methyl, or methoxy; R X2 represents hydrogen; R X3 represents hydrogen, fluoro, or chloro; R 4 represents hydrogen, fluoro, chloro, or methyl; R 31 represents hydrogen, or fluoro; and L represents a direct bond, -CHR L -O- * , - CH 2 -NH- * , -CH 2 -N(CH 3 )- * , -O-, or ; wherein R L represents hydrogen, or methyl; wherein the asterisks indicate the bond which is linked to the aromatic carbon atom; or wherein X 3 represents nitrogen and X 1 represents CR X1 ; X 1 represents nitrogen and X 3 represents CR X3 ; or X 1 represents CR X1 and X 3 represents CR X3 ; wherein R X1 represents hydrogen, or methoxy; R X3 represents hydrogen; R 4 represents hydrogen,
- X 1 represents CR X1 ; wherein R X1 represents hydrogen; X 2 represents nitrogen or CR X2 ; wherein R X2 represents hydrogen; X 3 represents nitrogen or CR X3 ; wherein R X3 represents hydrogen; R 1 represents hydrogen; Y represents -CH 2 -, or - CH 2 -CH 2 -; R 2A represents hydrogen, or hydroxymethyl;R 2B represents hydrogen; R 3 represents trifluoromethyl or 2,2,2-trifluoroethoxy; and R 4 represents hydrogen; or a salt thereof.
- the Kv7 Channel activator is selected from the group consisting of: 1-Spiro[3.3]hept-2-yl-3-(3-trifluoromethyl-benzyl)-urea;1-Spiro[2.3]hex-5-yl- 3-(3-trifluoromethyl-benzyl)-urea;1 -(1 , 1 -Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-((3r,5r)-1,1-Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-((3s,5s)-1 , 1 -Difluoro-spiro[2.3]hex-5-yl)-3-(3- trifluoromethyl-benzyl)-urea; 1-(6,6-Difluoro-spir
- the Kv7 channel activator may be selected from one of the following compounds of Formula 55.
- Such compounds are described in International Publication No. WO2020157126A1, published August 6, 2020, and corresponding to International Application No. PCT/EP2020/052156 filed January 29, 2020; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 55, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 55: Formula 55 , or a tautomer, salt, solvate, stereoisomer or isotope thereof, wherein: Y is selected from: C1- C10 alkylamino, C1-C10 alkyl, C1-C10 alkoxy, C3-C8 cycloalkyl, Cl- C10 alkylcarbonyl, Cl -CIO alkylaminocarbonyl, Cl -CIO alkylthio, aryl, heterocycle, Cl -CIO carbonyl, C1-C10 amide and C1-C10 carboxyl and it is optionally mono-substituted or bi- substituted with a first substituent independently selected from: hydroxyl, amino, thiol, carboxylic acid, amide, carbonyl, halogen, C1-C6 alkyl, C3-C6 cycloalkyl, C1-C6 alkylcarbon
- b is 1.
- Y is Cl -CIO alkylamino, Cl -CIO alkyl or Cl -CIO alkoxy.
- R2 is an aromatic ring optionally substituted with one or more substituents independently selected from the group consisting of: OH, NO2, halogen, NH2, C1-C3 haloalkyl, acetamidyl, C1-C6 alkyloxy, C1-C3 haloalkoxy, and C1-C6 alkylcarbonyl.
- Ri, R3, R4 and R5 are each independently: H, C1-C6 alkyl, C3- C6 cycloalkyl, NH 2 , NH(C1-C6 alkyl), N(C1-C6 alkyl)2 , azepane, pirrolidine, piperidine, aziridine or halogen.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 56.
- Such compounds are described in International Publication No. WO2020016297A1, published January 23, 2020, and corresponding to International Application No. PCT/EP2019/069240 filed July 17, 2019; Patent Cooperation Treaty application No. PCT/EP2019/069240 published January 23, 2020, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of Formula 56, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 56: Formula 56 , wherein, R 1 is selected from a branched or unbranched C1 to C5 alkyl group and – NR 1a R 1b group, where R 1a and R 1b are selected independently of one another from hydrogen atom and branched or unbranched C1 to C5 alkyl group or with one another and with the nitrogen atom the NR 1a R 1b group form a C3 to C9 heterocycloalkyl group, the C3 to C9 heterocycloalkyl group each having at least one substituent selected from the hydrogen atom and C1 to C3 alkyl group and optionally in addition to the nitrogen atom of the NR 1a R 1b - Group has at least one further heteroatom in the cycle; R 2 is selected from the group consisting of branched or unbranched C1 to C10 alkyl group, C3 to C10 cycloalkyl group, C3 to C10 heterocycloalky
- R 1 is selected from the group consisting of branched or unbranched C1- to C3-alkyl group and - NR 1a R 1b group, wherein R 1a and R 1b are independently selected from hydrogen atom and branched or unbranched C1- to C3-alkyl group or with one another and form a C4 to C6 heterocycloalkyl group with the nitrogen atom of the NR 1a R 1b group, the C4 to C6 heterocycloalkyl group each having at least one substituent selected from the hydrogen atom and C1 to C3 alkyl group and optionally in addition to the nitrogen atom of the NR 1a R 1b group has at least one further oxygen atom in the cycle; and or R 2 is selected from the group consisting of mono- or difluorophenyl group; CF 3 phenyl group;
- the Kv7 channel activator is selected from the group consisting of: Formulas 57 – 139
- the Kv7 channel activator may be selected from one of the following compounds of formulas 57 - 139. Such compounds are described in International Publication No. WO2018204765A1, published November 8, 2018, and corresponding to International Application No. PCT/US2018/031057 filed May 4, 2018; which is incorporated by reference in its entirety herein. In the case of any conflict of terminology in the context of any of Formulas 57 - 139, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to any one of formulas 57 – 139:
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 140.
- Such compounds are described in International Publication No. WO2016077724A1, published May 19, 2016, and corresponding to International Application No. PCT/US2015/060627 filed November 13, 2015; US Patent No.10,526,280, issued January 7, 2020 and corresponding to US Application No. US10526280B2 filed November 11, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 140, this reference incorporated by reference herein controls.
- the Kv7 channel activator is a compound according to Formula 140: Formula 140 , wherein, R 1 is H or optionally-substituted alkyl;R 2 is optionally-substituted alkyl;R 3 and R 4 are each independently H or optionally-substituted alkyl;R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;R 6 and R 7 are each independently H, deuterium, optionally- substituted alkyl, or R 6 and R 7 together form a carbocycle;R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R 8 is 4- halophenyl, then R 2 is substituted alkyl or branched alkyl or at least one of R 6 or R 7 is not H; andR 30 , R 31 and R 32 are each independently H, deuterium,
- R 1 is H.
- R 2 is C 1 -C 6 alkyl.
- R 2 is carbocyclic-substituted alkyl or heterocyclic-substituted alkyl.
- R 3 and R 4 are each H.
- R 5 is H.
- R 6 and R 7 are both H; R 6 and R 7 are both deuterium; R 6 and R 7 together form a cycloalkyl; or at least one of R 6 or R 7 is a substituted alkyl.
- R 8 is selected from: wherein R 9 25 -R are each independently H, halogen, optionally-substituted sulfanyl, or optionally-substituted alkyl. [0671] In further embodiments, R 8 is: wherein at least one of R 9 or R 10 is halogen. [0672] In further embodiments, R 8 is: wherein at least one of R 19 or R 20 is halogen. [0673] In further embodiments, R 8 is: wherein at least one of R 14 -R 18 is substituted sulfanyl or haloalkyl; or wherein R 16 is F.
- R 14 -R 18 is —SF 5 or CF 3 .
- R 8 is wherein at least one of R 11 -R 13 or R 23 -R 25 is substituted sulfanyl.
- R 8 is: wherein at least one of R 14 -R 18 is halo- substituted sulfanyl, haloalkyl or halogen.
- at least one of R 14 -R 18 is —SF 5 or —CF 3 .
- R 15 , R 16 , or R 17 is —SF 5 or —CF 3 .
- R 32 is —F
- R 30 and R 31 are each H.
- the Kv7 Channel activator is selected from the group consisting of: [0681]
- the compound is according to formula 141 wherein: R 1 is H or optionally-substituted alkyl; R 2 is substituted alkyl having one or more hydrogen atoms substituted with a substituent selected from halogen, cycloalkyl, alkoxy, amino, hydroxyl, aryl, alkenyl, or carboxyl; R 3 and R 4 are each independently H or optionally-substituted alkyl; R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle; R 8 is optionally-substituted thiazolyl
- the compound is according to formula 141 wherein: R 1 is H or optionally-substituted alkyl; R 2 is optionally-substituted alkyl; R 3 and R 4 are each independently H or optionally-substituted alkyl; R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle, provided at least one R 6 or R 7 is not H; R 8 is optionally-substituted thiazolyl, optionally-substituted thiophenyl, or substituted phenyl, provided that if R 8 is 4-halophenyl, then R 2 is substituted alkyl or branched alkyl or at least one of R 6 or R 7 is not H; andR 30 , R 31 and R 32 are each independently H,
- the compound is according to formula 141 wherein: R 1 is H or optionally-substituted alkyl;R 2 is optionally-substituted alkyl;R 3 and R 4 are each independently H or optionally-substituted alkyl;R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl;R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle;R 8 is 14 wherein at least one of R - R 18 is substituted sulfanyl or haloalkyl; andR 3 and R 31 are each independently H, deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy; andR 32 is deuterium, halogen, substituted sulfanyl, or optionally-substituted alkoxy.
- R 32 is halogen. [0685] In further embodiments, R 32 is —F. [0686] In further embodiments, at least one of R 14 -R 18 is halo-substituted sulfanyl. [0687] In further embodiments, at least one of R 14 -R 18 is haloalkyl. [0688] In further embodiments, at least one of R 14 -R 18 is —SF 5 . [0689] In further embodiments, at least one of R 14 -R 18 is —CF 3 . [0690] In further embodiments, R 16 is —SF 5 . [0691] In further embodiments, R 16 is —CF 3 .
- R 2 is alkyl.
- R 2 is C 1 -C 6 alkyl.
- R 2 is ethyl.
- R 3 , R 4 , R 5 , R 6 , and R 7 are each H.
- R 32 is —F and R 16 is —CF 3 .
- R 2 is alkyl.
- R 3 and R 31 are each H.
- R 15 , R 16 , or R 17 is —SF 5 or —CF 3 .
- R 1 , R 1 , R 3 , R 4 , R 5 , R 6 , and R 7 are each H; R 2 is alkyl; and R 32 is —F.
- Formula 141 the Kv7 channel activator may be selected from one of the following compounds according to Formula 141. Such compounds are described in International Publication No. WO2016077724A1, published May 19, 2016, and corresponding to International Application No. PCT/US2015/060627 filed November 13, 2015; US Patent No.10,526,280, issued January 7, 2020, and corresponding to US Application No. US10526280B2 filed November 11, 2015; which are incorporated by reference in their entirety herein.
- the Kv7 channel activator is a compound according to Formula 141: wherein, R 1 is H or optionally-substituted alkyl; R 2 is optionally-substituted alkyl; R 3 and R 4 are each independently H or optionally-substituted alkyl; R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R 6 and R 7 are each independently H, deuterium, optionally- substituted alkyl, or R 6 and R 7 together form a carbocycle; andR 8 is optionally-substituted thiazolyl.
- the compound is according to formula 142 wherein: R 1 is H or optionally-substituted alkyl; R 2 is optionally-substituted alkyl; R 3 and R 4 are each independently H or optionally-substituted alkyl; R 5 is H, optionally-substituted alkyl, acyl, or alkoxycarbonyl; R 6 and R 7 are each independently H, deuterium, optionally-substituted alkyl, or R 6 and R 7 together form a carbocycle; and R 8 is substituted thiophenyl, wherein at least one substituent on the thiophenyl is halo-substituted sulfanyl.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 142.
- Such compounds are described in US Patent No.10,077,245, issued September 18, 2018, and corresponding to US Application No. 15/306,971 filed April 22, 2015; US Patent No.10,316,008, issued June 11, 2019 and corresponding to US Application No.15/870,276 filed January 12, 2018; international Publication No. WO2015165352A1, published November 5, 2015 and corresponding to International Application No. PCT/CN2015/077216 filed April 22, 2015; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 142, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 142: wherein, X is selected from a group consisting of oxygen and sulfur; n is 1, 2 or 3;R 1 is H or halogen;R 2 and R 3 are each independently selected from a group consisting of H, D and C 1 - C 3 alkyl; or R 2 and R 3 together with the carbon atom to which they attached form C 3 - C 6 saturated ring;R 4 and R 5 are each independently selected from a group consisting of H; halogen; C 1 -C 6 alkyl; C 3 -C 6 cycloalkyl; cyano; alkoxyl; C 1 -C 6 alkyl substituted by hydroxy, amino, C 1 -C 4 alkoxy, C 1 -C 4 alkylcarbonyl, or halogen; C 1 -C 4 alkoxy substituted by halogen; C 1 -C 6 alkylcarbonyl; C 1 -C 6 alkoxycarbon
- R 1 is H or fluorine
- R 2 and R 3 are each independently selected from a group consisting of H and D, or R 2 and R 3 together with the carbon atom to which they attached form cyclopropyl
- one of R 4 and R 5 is C 1 -C 4 alkyl, and the other is H or C 1 -C 4 alkyl.
- one of R4 and R5 is methyl, and the other is H or methyl.
- Formula 143 [0708]
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 143. Such compounds are described in US Patent No.10,077,245, issued September 18, 2018, and corresponding to US Application No.
- the Kv7 channel activator is a compound according to Formula 143: Formula 143 , wherein, X: is selected from a group consisting of oxygen and sulfur;R 1 is H or halogen;R 2 and R 3 are each independently selected from a group consisting of H, D and C 1 - C3 alkyl; or R2 and R3 together with the carbon atom to which they attached form C3- C 6 saturated ring;R 4 and R 5 are each independently selected from a group consisting of H; halogen; C 1 -C 6 alkyl; C 3 -C 6 cycloalkyl; cyano; C 1 -C 4 alkoxyl; C 1 -C 6 alkyl substituted by hydroxy, amino, C 1 -C 4 alkoxy, C 1 -C 4 alkylcarbonyl, or halogen; C 1 -C 4 alkoxy substituted by halogen; C 1 -C 6 alkylcarbonyl; C 1 -C 6 alkylcarbonyl; C
- R 1 is H or fluorine
- R 2 and R 3 are each independently selected from a group consisting of H and D, or R 2 and R 3 together with the carbon atom to which they attached form cyclopropyl
- one of R 4 and R 5 is C 1 -C 4 alkyl, and the other is H or C 1 -C 4 alkyl.
- Formula 144 - 146 [0711]
- the Kv7 channel activator may be selected from one of the following compounds according to any one of Formulas 144 - 146.
- the Kv7 channel activator is a compound according to a formula from the group consisting of 144, 145, and 146:
- R 2 and R 3 are each independently selected from a group consisting of H, D and C 1 - C3 alkyl; or R2 and R3 together with the carbon atom to which they attached form C3- C 6 saturated ring;
- R 4 and R 5 are each independently selected from a group consisting of H; C 1 - C 6 alkyl; C 1 -C 4 alkoxyl; C 1 -C 6 alkyl substituted by halogen; C 1 -C 4 alkoxy substituted by halogen; provided that R 4 and R 5 are not simultaneously hydrogen;
- R 9 is selected from a group consisting of C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl;
- R 10 is selected from a group consisting of C 1 - C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, cyano, hydroxy, C 1 -C 6 alkoxyl, di(C 1 - C 4 alkyl)amino, C 1 -
- R 2 and R 3 are each independently selected from a group consisting of H and D, or R 2 and R 3 together with the carbon atom to which they attached form cyclopropyl; one of R 4 and R 5 is C 1 -C 1 alkyl, and the other is H or C 1 -C 4 alkyl;R 9 is selected from a group consisting of C 1 -C 6 alkyl and C 3 -C 6 cycloalkyl;R 10 is selected from a group consisting of C 1 -C 6 alkyl; C 1 -C 6 alkyl substituted by halogen, cyano, hydroxy, C1- C 6 alkoxyl, di(C 1 -C 4 alkyl)amino, C 1 -C 6 alkylcarbonyl, C 1 -C 6 alkylamido, or C 1 - C 6 alkoxycarbonyl; C 3 -C 6 cycloalkyl; C 3 -C 6 cycloalkyl; C 3 -C 6
- R 9 is selected from a group consisting of methyl, ethyl and propyl
- R 10 is selected from a group consisting of C 1 -C 3 alkyl; C 1 -C 3 alkyl substituted by halogen, cyano, hydroxy, C 1 -C 3 alkoxyl, di(C 1 -C 3 alkyl)amino, C 1 -C 3 alkylcarbonyl, C 1 - C 3 alkylamido, or C 1 -C 3 alkoxycarbonyl; C 3 -C 6 cycloakyl; C 3 -C 6 cycloakyl substituted by halogen; tetrahydrofuranyl; and wherein, R 7 and R 8 are each independently selected from a group consisting of C 1 -C 3 alkyl.
- the Kv7 Channel activator is selected from the group consisting of: Formula 147
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 147. Such compounds are described in International Publication No. WO2013165575A1, published November 7, 2013, and corresponding to International Application No. PCT/US2013/030984 filed March 13, 2013; US Patent No.9,556,114 issued January 31, 2017, and corresponding to US Application No. 14/566,167 filed December 10, 2014; US Publication No. US20170096390A1, published April 6, 2017, and corresponding to US Application No.15/380,216 filed December 15, 2016; which are incorporated by reference in their entirety herein.
- the Kv7 channel activator is a compound according to Formula 147: Formula 147 or a pharmaceutically acceptable salt or solvate thereof, wherein: X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are each independently selected from hydrogen, deuterium, and F; X 9 and X 10 are each independently selected from hydrogen and deuterium; and n is 1, 2, or 3, wherein at least one of X 1 , X 2 , and X 3 is F.
- the Kv7 channel activator is: wherein, A is N or C—X 3 ; X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 are each independently selected from hydrogen, 19F and 18F; and n is 2 or 3, provided that one of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , and X 8 is 18F. [0719] In further embodiments, two of X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 and X 8 are F.
- the Kv7 channel activator is: wherein, X 1 , X 2 , X 3 , and X 6 are each independently selected from hydrogen, 18F, and 19F, provided that one of X 1 , X 2 , X 3 , and X 6 is 18F.
- X 6 is fluorine and one of X 1 , X 2 , and X 3 is fluorine.
- one of X1, X2, X3, and X6 is 18F.
- at least one of X 1 , X 2 , and X 3 is 19F.
- X 6 is 19F or 18F.
- the compound is selected from the group consisting of: Formula 148
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 148. Such compounds are described in US Publication No. US20130184294A1, published July 18, 2013, and corresponding to US Application No.13/822,669 filed September 7, 2011; International Publication No.
- the Kv7 channel activator is a compound according to Formula 148: Formula 148 , wherein, R 1 is alkyl, cycloalkyl, wherein alkyl or cycloalkyl may be substituted with one or more halogen, alkoxy, aryl, or aryloxy; R 2 is cycloalkyl or NR 4 R 5 ; R 3 is H, halogen, alkyl, or alkoxy, wherein any alkyl may be substituted with one or more halogen atoms; R 4 and R 5 are independently selected from H, C 1-6 alkyl, C 3-6 cycloalkyl, or —C 1-6 alkyl-C 3-6 cycloalkyl, wherein each alkyl or each cycloalkyl may be substituted with one or more halogen, provided that both R 4 and R 5 are not H simultaneously; or R 4 and R 5 , together with the N atom to which they are attached, form a heterocycloal
- R 1 is C 5-6 alkyl
- R 2 is NR 4 R 5 , wherein one of R 4 or R 5 is H and the other is C 3-6 alkyl, C 3-6 cycloalkyl, or —C 1-3 alkyl-C 3-6 cycloalkyl
- R 3 is halogen, alkyl, or alkoxy, wherein any alkyl may be substituted with one or more halogen atoms
- —X—Y— is ⁇ CH—CH ⁇ or —CH 2 —CH 2 —; or a pharmaceutically acceptable salt thereof.
- R 1 is —CH 2 C(CH 3 ) 3 ;
- R 3 is chloro, methyl, trifluoromethyl or 1,1-difluoroethoxy;
- R 4 is H and
- R 5 is isopropyl, isobutyl, 1-cyclopropylethyl, cyclobutyl or cyclopentyl;
- —X—Y— is ⁇ CH—CH ⁇ or —CH 2 —CH 2 —; or a pharmaceutically acceptable salt thereof.
- R 1 is C 5-6 alkyl
- R 2 is C 3-6 cycloalkyl
- R 3 is halogen, or alkyl, wherein alkyl may be substituted with one or more halogen atoms
- —X—Y— is ⁇ CH— CH ⁇ or —CH 2 —CH 2 —; or a pharmaceutically acceptable salt thereof.
- R 1 is —CH 2 C(CH 3 ) 3 ;
- R 2 is cyclopropyl;
- R 3 is chloro, methyl, trifluoromethyl or 1,1-difluoroethoxy;
- —X—Y— is ⁇ CH—CH ⁇ or —CH 2 —CH 2 —; or a pharmaceutically acceptable salt thereof.
- Formula 149 [0733]
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 149. Such compounds are described in US Patent No.8,466,201, issued June 18, 2013, and corresponding to US Application No.
- the Kv7 channel activator is a compound according to Formula 149: Formula 149 , wherein, Ar 1 and Ar 2 are each phenyl; are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5;R 1 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substitu
- R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different.
- b is an integer of from 0 to 4.
- R 2 is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups.
- R 4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups.
- V is selected from the group consisting of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of from 0 to 2, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR (CR 6a R 6b ) c1 — O—(CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the
- V is a group of formula of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of 0 or 1, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO—[(CR 6a R 6b ) c1 —O— (CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R 6a , R 6b , R 6c , R 6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atom
- V is a group of formula of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of 0 or 1, each of R 3a and R 3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—- [CR 6a R 6b ) c1 —O—(CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R 6a , R 6b , R 6c and R 6d is a hydrogen atom.
- Ar 1 and Ar 2 are each phenyl; a is an integer of from 0 to 3;R 1 is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphony
- Ar 1 and Ar 2 are each phenyl; a is 0 or 1;R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is an integer of from 0 to 3;R 2 is
- Ar 1 and Ar 2 are each phenyl; a is 0 or 1;R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is 0 to 3;R 2 is selected from the group
- Ar 1 and Ar 2 are each phenyl; a is an integer of from 0 to 3;R 1 is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon atoms, alkylsulphony
- the Kv7 Channel activator is selected from the group consisting of: 1-[2-(2,6-Dichlorophenylamino)phenyl]-N-[2-(2-hydroxyethoxy)ethyl]- methanesulfonamide,N-[2-(2-hydroxyethoxy)ethyl]-C-[2-(2,4,6- trichlorophenylamino)phenyl]-methanesulfonamide,1-[2-(2,6-dichloro-4- trifluoromethylphenylamino)phenyl]-N- ⁇ 2-(2-hydroxyethoxy)ethyl]methanesulfonamide,1- [2-(2,6-dichloro-3-methylphenylamino)phenyl]-N- ⁇ 2-(2-hydroxyethoxy)- ethyl]methanesulfonamide,N-(2-hydroxyethyl)-1-[3-(2,4,6- trich
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R 1 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, haloalkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is an integer of from 0 to 5;R 2 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, haloalkoxy groups,
- Ar 1 and Ar 2 are the same or different and each is an aryl group having from 5 to 14 carbon atoms or a 5- to 7-membered aromatic heterocyclic group containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms.
- Ar 1 and Ar 2 are the same or different and each is an aryl group having from 6 to 10 carbon atoms or a 5- or 6-membered aromatic heterocyclic group containing 1 or 2 sulfur atoms, oxygen atoms and/or nitrogen atoms.
- Ar 1 and Ar 2 are each phenyl.
- R 2 is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, haloalkoxy groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups.
- W is a group of formula NR 4a , wherein R 4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups.
- Y and Z are each a group of formula (CR 5a R 5b ) n1 wherein each n1 is 0.
- V is selected from the group consisting of (CR 3a R 3b ) p CON(R 3b )X and (CR 3a R 3b ) p N(R 3b CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of from 0 to 2, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7- membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the
- V is selected from the group consisting of (CR 3a R 3b ) p CON(R 3b )X and (CR 3a R 3b ) p N(R 3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms, polyalkylene glycol residues of general formula HO—[(CR 6a R 6b ) c1 —O—(CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10
- V is selected from the group consisting of (CR 3a R 3b ) p CON(R 3b )X and (CR 3a R 3b ) p N(R 3b )CO(X), wherein said groups are in the 3- (meta) or 4- (para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R 3a and R 3b is a hydrogen atom, and X is selected from the group consisting of alkyl groups having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups.
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is 0 or 1;R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, haloalkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, nitro groups, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, wherein: Ar 1 and Ar 2 are each
- the Kv7 Channel activator is selected from the group consisting of: N-(2-hydroxyethyl)-2-[3-(2,4,6-trichlorophenylamino)phenyl]acetamide; ⁇ 2-[5- (3,5-dichlorophenylamino)-2-fluorophenyl]-acetylamino ⁇ acetic acid; 2-[4-(2,6-dichloro-4- trifluoromethyl-phenylamino)-phenyl]-N-(2-hydroxyethyl)-acetamide; ⁇ 2-[4-(3,5- dichlorophenylamino)-phenyl]-acetylamino ⁇ acetic acid;N-(2-hydroxy-ethyl)-2-[4-(2,4,6- trichloro-phenylamino)-phenyl]acetamide; 3-(2,6-dichloro-4-trifluoromethyl-phenylamino)- N-(
- the compound is according to formula 150 wherein: Ar 1 and Ar 2 are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R 1 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, haloalkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monoalkylamino groups, dialkylamino groups, nitro groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is an integer of from 0 to 5; R 2 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, haloalkoxy groups, alkoxycarbonyl groups, carb
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is 1; R 1 is halogen; b is an integer of from 0 to 3; R 2 is selected from the group consisting of alkyl having from 1 to 3 carbon atoms, halogen, haloalkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, haloalkoxy having from 1 to 3 carbon atoms, carboxyl, amino, hydroxyl and cyano, and where b is greater than 1, each substituent R 2 may be the same or different; V is (CR 3a R 3b ) p CON(R 3b )X, wherein said group is in the 3-(meta) or 4-(para) position with respect to the substituent Z;W is NR 4a , wherein R 4a is selected from the group consisting of hydrogen, alkyl having from 1 to 3 carbon atoms and phenyl; X is
- V is (CR 3a R 3b ) p CON(R 3b )X, wherein said groups is in the 3- (meta) or 4-(para) position with respect to the substituent Z, wherein p is an integer of 0 or 1, each of R 3a and R 3b is hydrogen, and X is selected from the group consisting of alkyl having 1 or 2 carbon atoms which are substituted with a group selected from hydroxyl groups, methoxy groups, ethoxy groups, carboxy groups, methoxycarbonyl groups and ethoxycarbonyl groups.
- the Kv7 Channel activator is selected from the group consisting of: ⁇ 2-[5-(3,5-dichlorophenylamino)-2-fluorophenyl]-acetylamino ⁇ acetic acid; 2- [5-(2,6-dichloro-4-trifluoromethoxy-phenylamino)-2-fluoro-phenyl]-N-(2-hydroxy- ethyl)acetamide; 5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-N-(2-hydroxy- ethyl)-benzamide; 2-[5-(2,6-dichloro-4-trifluoromethyl-phenylamino)-2-fluoro-phenyl]-N-(2- hydroxy-2-methyl-propyl)acetamide; and 2-[4-(2,6-dichloro-4-trifluoromethoxy- phenylamino)-2-fluoro-
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; are the same or different and each is an aryl group or a heteroaryl group; a is an integer of from 0 to 5; R 1 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups, dialkylamino groups, acylamino groups, alkoxycarbonylamino groups, alkylsulphonyl groups, alkylsulphonylamino groups and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is an integer of from 0 to 5; R 2 is selected from the group consisting of alkyl groups, halogen atoms, haloalkyl groups, alkoxy groups, alkoxycarbonyl groups,
- R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different.
- b is an integer of from 0 to 4.
- R 2 is selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 3 carbon atoms, alkoxy groups having from 1 to 3 carbon atoms, carboxyl groups, amino groups, hydroxyl groups and cyano groups.
- R 4a is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 3 carbon atoms and phenyl groups.
- V is selected from the group consisting of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of from 0 to 2, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms, alkyl groups having from 1 to 6 carbon atoms, cycloalkyl groups having from 3 to 7 carbon atoms, aryl groups having from 5 to 14 carbon atoms and 5- to 7-membered aromatic heterocyclic groups containing from 1 to 3 sulfur atoms, oxygen atoms and/or nitrogen atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 6 carbon atoms, and polyalkylene glycol residues of general formula HO—[(CR (CR 6a R 6b ) c1 — O—(CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the
- V is a group of formula of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of 0 or 1, R 3a and R 3b are the same or different and each is selected from the group consisting of hydrogen atoms and alkyl groups having from 1 to 4 carbon atoms, and X is a substituent selected from the group consisting of hydroxyalkyl groups having from 1 to 4 carbon atoms and polyalkylene glycol residues of general formula HO—[(CR 6a R 6b ) c1 —O— (CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the same or different and each is an integer of from 1 to 3, c3 is an integer of from 1 to 10 and R 6a , R 6b , R 6c , R 6d may be the same or different and each is a hydrogen atom or an alkyl group having from 1 to 4 carbon atom
- V is a group of formula of (CR 3a R 3b ) p SO 2 N(R 3b )X, wherein p is an integer of 0 or 1, each of R 3a and R 3b is a hydrogen atom, and X is a hydroxylalkyl group having from 1 to 4 carbon atoms or a polyalkylene glycol residue of general formula HO—- [CR 6a R 6b ) c1 —O—(CR 6c R 6d ) c2 ] c3 — wherein c1 and c2 are the same or different and each is 1 or 2, c3 is an integer of from 1 to 6 and each of R 6a , R 6b , R 6c and R 6d is a hydrogen atom.
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is an integer of from 0 to 3;R 1 is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is 0 or 1;R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is an
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is 0 or 1; R 1 is selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 4 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 4 carbon atoms, acylamino groups having from 1 to 4 carbon atoms, alkylsulphonyl groups having from 1 to 4 carbon atoms, alkylsulphonylamino groups having from 1 to 4 carbon atoms and cyano groups and, where a is greater than 1, each substituent R 1 may be the same or different; b is
- the compound is according to Formula 149 wherein: Ar 1 and Ar 2 are each phenyl; a is an integer of from 0 to 3; R 1 is selected from the group consisting of alkyl groups having from 1 to 6 carbon atoms, halogen atoms, haloalkyl groups having from 1 to 6 carbon atoms, alkoxy groups having from 1 to 6 carbon atoms, alkoxycarbonyl groups wherein the alkoxy group has from 1 to 6 carbon atoms, carboxyl groups, hydroxyl groups, amino groups, monalkylamino groups wherein the alkyl group has from 1 to 6 carbon atoms, dialkylamino groups wherein the alkyl groups may be the same or different and each has from 1 to 6 carbon atoms, acylamino groups having from 1 to 6 carbon atoms, alkoxycarbonylamino groups wherein the alkoxy group has from 1 to 6 carbon atoms, alkylsulphonyl groups having from 1 to 6 carbon
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 150.
- Such compounds are described in International Publication No. WO2012004698A1, published January 12, 2012, and corresponding to International Application No. PCT/IB2011/052686 filed June 20, 2011; US Patent No.8,883,812, issued November 11, 2014 and corresponding to US Application No. 13/808,355 filed June 20, 2011; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 150, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 150: Formula 150 , wherein, n is an integer of 1 or 2; t is 0 or 1; each R 1 is independently selected from C 1- 3 alkoxy, C 1-3 alkyl, C 1-3 alkyl-O—C 1-3 alkyl; R 2 and R 3 are independently C 1-3 alkyl, C 1- 3 alkoxy, or C 3-6 cyloalkyl provided that at least one is C 1-3 alkoxy; R 4 is C 1-6 alkyl, C 1-3 alkyl- C 3-6 cyloalkyl, C 3-6 heterocycloalkyl; or a pharmaceutically acceptable salt thereof.
- R 1 , R 2 , and R 3 are each C 1-3 alkoxy; wherein R 4 is C 4-6 alkyl, and wherein n and t are each 1, or a pharmaceutically acceptable salt thereof.
- R 1 , R 2 , and R 3 are each methoxy; R 4 is —CH 2 -t-butyl, and n and t are each 1, or a pharmaceutically acceptable salt thereof.
- the compound is N-(4,6-dimethoxy-2-(4-methoxypiperidin- 1-yl)pyrimidin-5-yl)-3,3-dimethylbutanamide, or a pharmaceutically acceptable salt thereof.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 151.
- Such compounds are described in US Patent No.9,353,048 issued May 31, 2016, and corresponding to US Application No.14/353,842 filed October 23, 2012; International Publication No. WO2013060097A1, published May 2, 2013, and corresponding to International Application No. PCT/CN2012/001423 filed October 23, 2012; which are incorporated by reference in their entirety herein.
- these references incorporated by reference herein control are described in US Patent No.9,353,048 issued May 31, 2016, and corresponding to US Application No.14/353,842 filed October 23, 2012; International Publication No. WO2013060097A1, published May 2, 2013, and corresponding to International Application No. PCT/CN2012/001423 filed October 23, 2012; which are incorporated by reference in their entirety herein.
- these references incorporated by reference herein control are described in US Patent No.9,353,048 issued May 31, 2016, and corresponding to US Application No.14/353,842 filed
- the Kv7 channel activator is a compound according to Formula 151: Formula 151 , wherein, R 1 is a radical selected from the group consisting of C 2 -C 8 alkenyl, C 5 - C 7 cycloalkenyl and C 2 -C 8 alkynyl; wherein, the C 2 -C 8 alkenyl is unsubstituted or optionally substituted by hydroxyl, amino, halogen atom, phenyl or halogenated phenyl; the C 2 - C 8 alkynyl is unsubstituted or optionally substituted by hydroxyl, amino, halogen atom, phenyl or halogenated phenyl; R 2 is a radical selected from the group consisting of F, Cl and methoxyl;R 3 is a radical selected from the group consisting of H, halogen atom and trifluoromethyl; Y is not present or Y is O;R 4 is a radical selected from
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 152.
- the Kv7 channel activator may be selected from one of the following compounds.
- Such compounds are described in International Publication No. US20100057224A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; US Patent No.8,629,143 published January 14, 2014, and corresponding to US Application No.12/949,435 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 152, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 152: Formula 152 , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein Z is a ring fused with the pyridazine ring, selected from the group consisting of benzo, cycloalkyl, cycloalkenyl, heterocycle, and heteroaryl;R 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO 2 , -OR a , -OC(O)R a , -OC(O)NR a R b , -NR a R b , -SR a , -S(O)R a , - S(O) 2 R a , -S(O)
- Z 1 is benzo, heteroaryl, or cycloalkyl.
- R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a .
- R 4 is unsubstituted alkyl, haloalkyl, -C(R 4a R 4b ) n -G 4a , or alkyl substituted with a -S(R la ) group.
- Z 1 is benzo, cycloalkyl, or heteroaryl; and R 4 is unsubstituted alkyl, haloalkyl, -C(R 4a R 4b ) n -G 4a , or alkyl substituted with a -S(R la ) group.
- Z 1 is benzo, cycloalkyl, or heteroaryl; and R 4 is -C(R 4a R 4b ) n -G 4a .
- Z 1 is benzo, cycloalkyl, or heteroaryl;
- R 4 is -C(R 4a R 4b ) n -G 4a ; and
- R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a .
- Z 1 is benzo, cycloalkyl, or heteroaryl;
- R 4 is -C(R 4a R 4b ) n - G 4a ;
- R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a ; and
- G 3a is aryl or cycloalkyl.
- Z 1 is benzo, cycloalkyl, or heteroaryl; andR 4 is unsubstituted alkyl or haloalkyl.
- Z 1 is benzo, cycloalkyl, or heteroaryl; R 4 is unsubstituted alkyl or haloalkyl; and R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a .
- Z 1 is benzo, cycloalkyl, or heteroaryl; R 4 is unsubstituted alkyl or haloalkyl; R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a ; and G 3a is aryl or cycloalkyl.
- Z 1 is benzo, cycloalkyl, or heteroaryl; and R 4 is alkyl substituted with a -S(R la ) group.
- Z 1 is benzo, cycloalkyl, or heteroaryl;
- R 4 is alkyl substituted with a -S(R la ) group; and
- R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a .
- Z 1 is benzo, cycloalkyl, or heteroaryl;
- R 4 is alkyl substituted with a -S(R la ) group;
- R 3 is alkyl, halogen, haloalkyl, G 3a , or -(CR 3a R 3b ) m -G 3a ; and
- G 3a is aryl or cycloalkyl.
- the Kv7 Channel activator is selected from the group consisting of: 2-(4-chlorophenyl)-N-(4-isopropyl-l-oxophthalazin-2(lH)-yl)acetamide; 2-( 1 - adamantyl)-N- [4-(4-bromophenyl)- 1 -oxophthalazin-2( 1 H)-yl]acetamide; N-[4-(4- bromophenyl)-l-oxophthalazin-2(lH)-yl]-2-(4-chlorophenyl)acetamide; 2-(4-chlorophenyl)- N-( 1 -oxo-4-phenylphthalazin-2( 1 H)-yl)acetamide; 2-(3,5-difluorophenyl)-N-(4-isopropyl- l-oxophthalazin-2(lH)-yl)acetamide;
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 153.
- Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 153, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 153: Formula 153 , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein, R 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO 2 , -OR a , -OC(O)R a , -OC(O)NR a R b , -NR a R b , -SR a , -S(O)R a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)R a , -C(O)OR a , -C(O)NR a R b ,- N(R
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 154.
- Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 154, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 154: Formula 154 , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, whereinR 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO 2 , -OR a , -OC(O)R a , -OC(O)NR a R b , -NR a R b , -SR a , -S(O)R a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)R a , -C(O)OR a , -C(O)NR a R b ,- N(R a
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 155.
- Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 155, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 155: Formula 155 , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein R 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO 2 , -OR a , -OC(O)R a , -OC(O)NR a R b , -NR a R b , -SR a , -S(O)R a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)R a , -C(O)OR a , -C(O)NR a R b ,- N(R a
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 156.
- Such compounds are described in US Patent No.8,629,143, issued January 14, 2014, and corresponding to US Application No. US8629143B2 filed November 18, 2010; International Publication No. WO2011066168A1, published June 3, 2011, and corresponding to International Application No. PCT/US2010/057224 filed November 18, 2010; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 156, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 156: Formula 156 , or a pharmaceutically acceptable salt, solvate, prodrug, or salt of a prodrug or solvate thereof, wherein R 1 is an optional substituent wherein each occurrence of R 1 is independently G a , alkyl, alkenyl, alkynyl, halogen, haloalkyl, oxo, -CN, -NO 2 , -OR a , -OC(O)R a , -OC(O)NR a R b , -NR a R b , -SR a , -S(O)R a , -S(O) 2 R a , -S(O) 2 NR a R b , -C(O)R a , -C(O)OR a , -C(O)NR a R b ,- N(R a
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 157.
- Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 157, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 157: [0810] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-5,7-Diiodo-8-hydroxyquinoline and zinc-8-Hydroxyquinoline. [0811] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-pyrrolidine dithiocarbamate, zinc-diethyldithiocarbamate, zinc-disulfiram and zinc-dimethyldithiocarbamate. [0812] In further embodiments, the Kv7 Channel activator is selected from the group consisting of: zinc-vitamin E and zinc-vitamin A.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 158.
- Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 158, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 158: Formula 158 wherein, A is a bond, CH 2 , CHR b , CH 2 S, CHR b S, CH 2 O, CH 2 NR c , or NH; Rb is alkyl; R c is H or S(O) m -aryl; R 1 is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cycloalkyl, or an optionally substituted heteroaryl; R 2 is an optionally substituted alkyl, an optionally substituted alkenyl, an optionally substituted aryl, an optionally substituted cycloalkyl, an optionally substituted heteroaryl, an optionally substituted heterocyclic, an optionally substituted aralkyl, H or alkyl; each R d and R e is independently an optionally substituted alkyl, an optionally substituted aryl, or R d and R e together
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 159.
- Such compounds are described in US Publication No. US20110257146A1, published October 20, 2011, and corresponding to US Application No.12/223,136 filed January 25, 2007; International Publication No. WO2007087424A2, published August 2, 2007, and corresponding to International Application No. PCT/US2007/002116 filed January 26, 2007; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 159, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 159: Formula 159 wherein, R 4 is H, an optionally substituted alkyl, an optionally substituted alkenyl, alkynyl, allyl, or an optionally substituted aryl; R 5 is H, hal, or hydroxyl; R 6 is H, hal, hydroxyl, NH 2 , a mono- or di-substituted amine, or an optionally substituted alkoxy; R 7 is H, hal, hydroxyl, an optionally substituted alkoxy, or nitro; X is S or NR a ; Y is O, S, or NR a ; and each R a is independently H or an optionally substituted aryl.
- the Kv7 Channel activator is selected from the group consisting of: N-Benzo[g]quinolin-4-yl-N′-(2-diethylamino-ethyl)-benzene-1,4-diamine; 2- [2-(3,4-Dihydroxy-phenyl)-2-oxo-ethylsulfanyl]-4,6-dimethyl-nicotinonitrile; 2-[2-(4- Methoxy-phenyl)-2-oxo-ethylsulfanyl]-4-(5-methyl-furan-2-yl)-5,6,7,8-tetrahydro-quinoline- 3-carbonitrile; 6-Methyl-4-(5-methyl-furan-2-yl)-2-(2-oxo-2-phenyl-ethylsulfanyl)- nicotinonitrile; 2-(2-Oxo-2-thiophen-2-yl-ethylsulfanyl)- nico
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 160.
- Such compounds are described in International Publication No. WO2004060880A1, published July 22, 2004, and corresponding to International Application No. PCT/US2003/039352 filed December 11, 2003; US Patent No.6,933,308, issued August 23, 2005, and corresponding to US Application No.10/730,781 filed December 9, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 160, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 160: Formula 160 , wherein, R 1 is C 1-6 alkyl, C 3-7 cycloalkyl, —(CH 2 ) 1-4 C 3-7 cycloalkyl, —(CH 2 ) 2-4 N(C 1-6 alkyl) 2 , —(CH 2 ) 2-4 OC 1-6 alkyl, R 2 is hydrogen, C 1-6 alkyl, or — (CH 2 ) 2-4 OC 1-6 alkyl; or where R 1 and R 2 taken together are —CH 2 CH 2 XCH 2 CH 2 —, where X is a chemical bond, CH 2 , CHOH, NH, NCH 3 , NCOCH 3 , O, or S; R 3 is hydrogen or hydroxy, provided that where R 3 is hydroxy, m is not 0; R 4 is hydrogen, C 1-6 alkyl, hydroxymethyl, or trifluoromethyl; R 5 is halogen, C 1-6 alkyl, C 3-7
- R 3 is hydrogen and m is 1.
- R 4 is methyl.
- the Kv7 Channel activator is selected from the group consisting of: 2-[2-(4-morpholinyl)ethyl]-N-[1-[3-(3-pyridinyl)phenyl]ethyl]-4- (trifluoromethyl)-5-thiazolecarboxamide; N-[1-[3-(dimethylamino)phenyl]ethyl]-2-[2-(1- pyrrolidinyl)ethyl]-4-(trifluoromethyl)-5-thiazolecarboxamide; 2-[2-(1-pyrrolidinyl)ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[2-[(2- furanylmethyl)methyl
- the Kv7 Channel activator is selected from the group consisting of: 2-[1-hydroxy-2-(1-piperidinyl)ethyl]-N-[1-[3-(trifluoromethoxy)phenyl]ethyl]- 4-(trifluoromethyl)-5-thiazolecarboxamide; 2-[1-hydroxy-2-(1-pyrrolidinyl)ethyl]-4- (trifluoromethyl)-N-[1-[3-(trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide; 2-[2-[(2- furanylmethyl)methylamino]-1-hydroxyethyl]-4-(trifluoromethyl)-N-[1-[3- (trifluoromethyl)phenyl]ethyl]-5-thiazolecarboxamide
- the compound has a stereochemical configuration according to the formula: [0827] In further embodiments, the compound is according to the formula: [0828] Wherein, R 1 is C 1-6 alkyl, C 3-7 cycloalkyl, —(CH 2 ) 1-4 C 3-7 cycloalkyl, —(CH 2 ) 2-4 N(C 1- 6 alkyl) 2 , —(CH 2 ) 2-4 OC 1-6 alkyl, R 2 is hydrogen C 1-6 alkyl, or —(CH 2 ) 2-4 OC 1-6 alkyl; or where R 1 and R 2 taken together are —CH 2 CH 2 XCH 2 CH 2 —, where X is a chemical bond, CH 2 , CHOH, NH, NCH 3 , NCOCH 3 , O, or S; R 3 is hydrogen or hydroxy, provided that where R 3 is hydroxy, m is not 0; R 4 is hydrogen, C 1-6 alkyl, hydroxymethyl, or trifluoride
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 161.
- Such compounds are described in US Patent No.7,144,881 issued December 5, 2006, and corresponding to US Application No. 10/919,184 filed November 21, 2003; International Publication No. WO2004047738A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037305 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 161, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 161: wherein, R is C 1-4 alkyl, CF 3 or hydroxymethyl; R 1 and R 2 are each independently hydrogen, C 1-4 alkyl, halogen or morpholin-4-yl; R 4 is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C 1-4 alkyl, dimethylamino, hydroxymethyl, chloro and fluoro; R 5 is hydrogen or fluoro; or R 4 and R 5 taken together are —CH ⁇ CH—CH ⁇ CH— or —CH 2 CH 2 O—; and R 3 , R 6 and R 7 are each independently selected from hydrogen or fluoro.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 162.
- Such compounds are described in US Patent No.7,144,881 issued December 5, 2006, and corresponding to US Application No. 10/919,184 filed November 21, 2003; International Publication No. WO2004047738A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037305 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 162, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 162: Formula 162 , wherein, R is methyl or hydroxymethyl; R 1 and R 2 are each independently hydrogen, C 1- 4 alkyl, halogen or morpholin-4-yl; R 4 is selected from the group consisting of optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl, in which said substituent is independently selected from the group consisting of C 1-4 alkyl, dimethylamino, hydroxymethyl, chloro and fluoro; R 5 is hydrogen or fluoro; or R 4 and R 5 taken together are —CH ⁇ CH—CH ⁇ CH— or —CH 2 CH 2 O—; and R 3 , R 6 and R 7 are each independently selected from hydrogen or fluoro.
- R is methyl or hydroxymethyl
- R 1 and R 2 are each independently hydrogen, C 1- 4 alkyl, halogen or morpholin-4-yl
- R 4
- the Kv7 Channel activator is selected from the group consisting of: 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5- yl)-ethyl]-amide; 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro- benzofuran-5-yl)-ethyl]-amide; 2-(4-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3- dihydro-benzofuran-5-yl)-ethyl]-amide; 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid(2- hydroxy-1-naphthalen-2-yl-ethyl)-amide; 2-(3-fluoro-phenyl)-cyclopropanecarboxylic acid(2-hydroxy-1-naphthalen-2-y
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 163.
- Such compounds are described in International Publication No. WO2004047743A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037348 filed November 21, 2003; US Patent No.7,045,551 issued May 16, 2006, and corresponding to US Application No.10/719,465 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 163, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 163: Formula 163 , wherein, R 1 is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, furanyl, C 3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; A is —CH ⁇ CH— or —(CH 2 ) n —; R 2 is hydrogen or hydroxymethyl; n is an integer of 0, 1 or 2; R 4 is selected from the group consisting of di(C 1- 4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, morpholin-4- ylmethyl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substitu
- R 1 is selected from
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 164.
- Such compounds are described in International Publication No. WO2004047743A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037348 filed November 21, 2003; US Patent No.7,045,551 issued May 16, 2006, and corresponding to US Application No.10/719,465 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 164, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 164: Formula 164 , wherein, R 1 is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, furanyl, C 3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; A is —CH ⁇ CH— or —(CH 2 ) n —; R 2 is hydrogen; n is an integer of 0, 1 or 2; R 4 is selected from the group consisting of di(C 1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, morpholin-4-ylmethyl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one or two substituents in which said
- the Kv7 Channel activator is selected from the group consisting of: (R)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-3-phenyl-propionamide; (R)-3-(2-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)- 3-(3-fluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)-3- (2,4-difluoro-phenyl)-N-[2-hydroxy-1-(3-morpholin-4-yl-phenyl)-ethyl]-acrylamide; (R)-N- [1-(4-fluoro-3-morpholin-4-yl-phenyl)-2-hydroxy-ethyl]-3-(2-fluor
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 165.
- Such compounds are described in US Patent No.7,135,472 issued November 14, 2006, and corresponding to US Application No. 10/719,187 filed November 21, 2003; International Publication No. WO2004047744A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037349 filed November 21, 2003; US Patent No.7,135,472 issued November 14, 2006, and Patent Cooperation Treaty application No. US2003/037349 published June 10, 2004, which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 165, these references incorporated by reference herein control.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 166.
- Such compounds are described in US Patent No.7,135,472, issued November 14, 2006, and corresponding to US Application No. 10/719,187 filed November 21, 2003; International Publication No. WO2004047744A2, published June 10, 2004, and corresponding to International Application No. PCT/US2003/037349 filed November 21, 2003; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 166, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 166: Formula 166 , wherein, R 1 is selected from the group consisting of straight or branched chain C 1-6 alkyl optionally substituted with amino, C 1-4 alkylamino or di(C 1-4 alkyl) amino, pyridinyl, pyrrodidinyl, piperidinyl, 2-thienyl, furanyl, imidazolyl, indenyl, benzofuran, C 3-6 cycloalkyl and phenyl optionally substituted with substituent independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, and trifluoromethoxy; A is — CH ⁇ CH—, 1,1-cyclopropyl, or —(CH 2 ) n —; R 2 is methyl or hydroxymethyl; R 3 , R 4 , R 5 and R 6 each are independently hydrogen or fluoro; n
- the Kv7 Channel activator is selected from the group consisting of: (S)-3-(2-fluoro-phenyl)-N-[1-(3-[1,2,4]triazol-1-yl-phenyl)-ethyl]-acrylamide; (S)-3-(2-fluoro-phenyl)-N-[1-(3-thiazol-2-yl-phenyl)-ethyl]-acrylamide; (S)-3-(2-fluoro- phenyl)-N-[1-(3-pyrazol-1-yl-phenyl)-ethyl]-acrylamide; (S)-3-(2-fluoro-phenyl)-N-[1-(3- imidazol-1-yl-phenyl)-ethyl]-acrylamide; (S)-4-phenyl-N-[1-(3-pyridin-3-yl-phenyl)-ethyl]-butyr
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 167.
- Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080, issued December 14, 2004, and corresponding to US Application No. 10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 167, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 167: Formula 167 , wherein, R is C 1-4 alkyl or trifluoromethyl; R 1 is selected from the group consisting of pyridinyl, quinolinyl, thienyl, furanyl, 1,4-benzodioxanyl, 1,3-benzodioxolyl, chromanyl, indanyl, biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C 1- 4 alkyl, C 1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R 2 and R 3 are each independently selected from the group consisting of hydrogen, C 1-4 alkyl and halogen; R 4 is selected from the group consisting of di(C 1-4 alkyl)amino, trifluoromethoxy and optionally substituted
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 168.
- Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080 issued December 14, 2004, and corresponding to US Application No. 10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 168, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 168: Formula 168 , wherein, R 1 is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, benzodioxanyl, 1,3-benzodioxol-5-yl, chroman-5-yl, indan-5-yl, 4-biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C 1-4 alkyl, C -4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R 4 is selected from the group consisting of optionally substituted di(C 1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one
- R 1 is substituted phenyl or 1,3-benzodioxol-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, and C 1-4 alkoxy; and R 4 and R 5 taken together are —X(CH 2 ) m Y— in which X and Y are each O, and m is 1.
- R 1 is selected from the group consisting of substituted phenyl, 1,3-benzodioxol-5-yl, and indan-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy and trifluoromethyl; and R 4 and R 5 taken together are —X(CH 2 ) m Y— in which X is CH 2 , Y is O, and m is 1.
- R 1 is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, trifluoromethyl and nitro;
- R 4 is optionally substituted morpholin-4-yl with one or two substituents each independently selected from the group consisting of C 1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; and
- R 5 is hydrogen or fluoro.
- R 1 is phenyl, fluorophenyl or difluorophenyl.
- R 1 is substituted phenyl or 1,3-benzodioxol-5-yl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen or C 1-4 alkyl; and R 4 and R 5 taken together are —X(CH 2 ) m Y— in which X and Y are O, and m is 2.
- R 1 is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen or C 1-4 alkyl;
- R 4 and R 5 taken together are —X(CH 2 ) m Y— in which X is (CH 2 ) n N(R 9 )—; Y is CH 2 , and m and n are 1; and
- R 9 is CO 2 (C 1-4 alkyl).
- R 1 is substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from halogen; R 4 and R 5 taken together are —X(CH 2 ) m Y— in which X is (CH 2 ) n N(R 9 )— and Y is O wherein m is 2 and n is 0; and R 9 is hydrogen, cyclopropylmethyl or C 1-4 alkyl.
- R 1 is 3-quinolinyl or pyridinyl; R 4 is trifluoromethoxy; and R 5 is hydrogen.
- R 1 is substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen or C 1-4 alkyl;
- R 4 and R 5 taken together are —X(CH 2 ) m Y—, in which X is CH 2 and Y is (CH 2 ) n N(R 9 )— wherein m is 1 and n is 0; and R 9 is CO 2 (C 1-4 alkyl).
- R 1 is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen;
- R 4 and R 5 taken together are —X(CH 2 ) m Y—, in which X is (CH 2 ) n N(R 9 )— and Y is CH 2 wherein m is 2 and n is 0; and
- R 9 is hydrogen, C 1-4 alkyl, acetyl, hydroxyethyl or methoxyethyl.
- R 1 is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen;
- R 4 and R 5 taken together are —X(CH 2 ) n Y—, in which X is CH 2 and Y is (CH 2 ) n N(R 9 )— wherein m is 2 and n is 0; and
- R 9 is hydrogen, C 1-4 alkyl, acetyl, hydroxyethyl or methoxyethyl.
- R 1 is pyridinyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R 4 is optionally substituted pyridinyl with one or two substituents each independently selected from C 1-4 alkyl and halogen; and R 5 is hydrogen or fluoro.
- R 1 is 1,3-benzodioxol-5-yl; R 4 is di(C 1-4 alkyl)amino; and R 5 is hydrogen or fluoro.
- R 1 is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R 4 is pyrimidinyl; and R 5 is hydrogen or fluoro.
- R 1 is phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R 4 is pyrazinyl; and R 5 is hydrogen or fluoro.
- R 1 is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from C 1-4 alkyl and halogen;
- R 4 is piperazinyl or 4-methylpiperazinyl; and
- R 5 is hydrogen or fluoro.
- the Kv7 Channel activator is selected from the group consisting of: 2-Methyl-3-phenyl-but-2-enoic acid (1-naphthalen-2-ylethyl)-amide; N-(1- Benzo[1,3]dioxol-5-yl-ethyl)-3-(3-methoxy-phenyl)-acrylamide; N-[1-(2,3- Dihydrobenzofuran-5-yl)ethyl]-3-(3-methoxyphenyl)-acrylamide; (S)-3-Phenyl-N-[1-(3- morpholin-4-yl-phenyl)ethyl]acrylamide; 3-(3-Fluorophenyl)-N-[1-(2,3- dihydrobenzo[1,4]dioxin-6-yl)-ethyl]acrylamide; ( ⁇ )-7- ⁇ 1-[3-(4- Fluorophenyl
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 169.
- Such compounds are described in International Publication No. WO2002096858A1, published December 5, 2002, and corresponding to International Application No. PCT/US2002/017049 filed May 31, 2002; US Patent No.6,831,080, issued December 14, 2004, and corresponding to US Application No. 10/160,582 filed May 31, 2002; which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 169, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 169: Formula 169 , wherein, R 1 is selected from the group consisting of pyridinyl, 3-quinolinyl, 2-thienyl, benzodioxanyl, 1,3-benzodioxol-5-yl, chroman-5-yl, indan-5-yl, 4-biphenylyl, phenyl and substituted phenyl, in which said substituted phenyl is substituted with substituent independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl, trifluoromethoxy and nitro; R 4 is selected from the group consisting of optionally substituted di(C 1-4 alkyl)amino, trifluoromethoxy and optionally substituted morpholin-4-yl, pyridinyl, pyrimidinyl, piperazinyl, and pyrazinyl with one
- R 1 is selected from the group consisting of 2-thienyl, chroman-5-yl, 4-biphenylyl, phenyl and substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy and nitro; and R 4 and R 5 taken together are —CH ⁇ CH—CH ⁇ CH—.
- R 1 is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents each independently selected from the group consisting of halogen, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethoxy, trifluoromethyl and nitro;
- R 4 is optionally substituted morpholin-4-yl with one or two substituents each independently selected from the group consisting of C 1-4 alkyl, aminomethyl, hydroxymethyl, chloro or fluoro; and
- R 5 is hydrogen or fluoro.
- R 1 is phenyl, fluorophenyl or difluorophenyl.
- R 1 is pyridinyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from halogen; R 4 is optionally substituted pyridinyl with one or two substituents each independently selected from C 1-4 alkyl and halogen; and R 5 is hydrogen or fluoro.
- R 1 is thienyl, phenyl or substituted phenyl in which said substituted phenyl is substituted with one or two substituents selected from C 1-4 alkyl and halogen; R 4 is piperazinyl or 4-methylpiperazinyl; and R 5 is hydrogen or fluoro.
- the Kv7 channel activator may be selected from one of the following compounds according to Formula 170.
- Such compounds are described in US Patent No.6,326,385, issued December 4, 2001, and corresponding to US Application No. 09/361,747 filed August 4, 2000; International Publication No. WO2001010381A2, published February 15, 2001, and corresponding to International Application No. PCT/US2000/021309 filed August 4, 2000; US Patent No.6,326,385 issued December 4, 2001, and Patent Cooperation Treaty application No. US2000/021309 published February 15, 2001, which are incorporated by reference in their entirety herein. In the case of any conflict of terminology in the context of Formula 170, these references incorporated by reference herein control.
- the Kv7 channel activator is a compound according to Formula 170: Formula 170 , wherein, Ar 1 and Ar 2 are each members independently selected from the group consisting of aryl, substituted aryl, heteroaryl and substituted heteroaryl; and X is a member selected from the group consisting of O, S and N—R 1 , wherein R 1 is a member selected from the group consisting of H, (C 1 -C 8 )alkyl, substituted (C 1 -C 8 )alkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C 1 -C 4 )alkyl, substituted aryl(C 1 -C 4 )alkyl, CN, —C(O)R 2 , —OR 3 , —C(O)NR 3 R 4 , and —S(O) 2 NR 3 R 4 ; wherein R 2 is a member selected from the group consisting of (C 1 -C 8 )
- Ar 1 is a member selected from the group consisting of phenyl, substituted phenyl, indolyl, substituted indolyl, benzofuranyl, substituted benzofuranyl, furanyl, substituted furanyl, thienyl, substituted thienyl, isothiazolyl, substituted isothiazolyl, pyrazolyl and substituted pyrazolyl.
- Ar 1 is substituted phenyl, substituted or unsubstituted 2- indolyl and substituted or unsubstituted 2-thienyl.
- X is O.
- the Ar 1 substituents are selected from the group consisting of halogen, alkyl, halo(C 1 -C 4 )alkyl, (C 1 -C 4 )alkoxy, halo(C 1 -C 4 )alkoxy, nitro, cyano, — NHC(O)R 7 , —NHR 7 , phenyl and substituted phenyl, wherein R 7 is a member selected from hydrogen, (C 1 -C 8 )alkyl, substituted (C 1 -C 8 )alkyl, cycloalkyl, substituted cycloalkyl, heteroalkyl, substituted heteroalkyl, heterocyclyl, substituted hcterocyclyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, aryl(C 1 -C 4 )alkyl and substituted aryl(C 1 -C 4 )alkyl, or R 7 can
- Ar 2 is selected from the group consisting of heteroaryl and substituted heteroaryl.
- Ar 1 is substituted aryl;
- Ar 2 is heteroaryl or substituted heteroaryl; and
- X is O.
- Ar 2 is pyridyl or substituted pyridyl.
- Ar 2 is selected from the group consisting of 6-methyl-3- pyridyl and 2-chloro-5-pyridyl.
- Ar 1 is substituted phenyl.
- the compound is according to the formula: , [0884] wherein, Y is a member selected from the group consisting of halogen, C 1 -C 4 alkyl, C 1 -C 4 substituted alkyl, —OCH 3 and —OCF 3 , and R 5 and R 6 are members independently selected from the group consisting of H, halogen, alkyl, halo(C 1 -C 4 )alkyl, nitro, cyano and phenyl, with the proviso that both R 5 and R 6 are not H.
- R 5 and R 6 are members independently selected from the group consisting of H, F, and Cl, with the optional proviso that both R 5 and R 6 are not H.
- Further embodiments (Collectively referred to as “Formula 171” for ease of reference in the appended claims. “Formula 171”, as recited in the claims, captures any of the below compounds preceding the NMDA receptor antanogists section.)
- the Kv7 channel activator may be selected from one of the following compounds. Such compounds are described in International Publication No. WO2021055538A1, published March 25, 2021, and corresponding to International Application No. PCT/US2020/051171 filed September 17, 2020; International Publication No.
- the compound is selected from the group consisting of N-(l- cyclobutyl-4-fluoro-6-(l- hydroxycyclobutyl)-lH-benzo[d]imidazol-2-yl)-4,4,4-trifluoro-3,3- dimethylbutanamide; N-(l -(tert-butyl)-6-(difluoromethoxy)- 1H- benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N-(6-cyano-l-(l,l,l- trifluoro-2-methylpropan-2-yl)-lH- benzo[d]imidazol-2-yl)-3,3- dimethylbutanamide; N-(l -cyclobutyl -4-fluoro-6-(2- hydroxypropan-2-yl)- 1H- benzo[d]imidazol-2-yl)-2-(l -methyl cyclo
- the Kv7 channel activator is selected from the group consisting of N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide in a crystalline form with XRPD reflections at 10.36, 12.67, 28.64 and 29.98 (°2 ⁇ ) using CuK ⁇ 1 radiation.; N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide in a crystalline form with XRPD reflections at 8.68, 18.09, 22.60 and 30.62 (°2 ⁇ ) using CuK ⁇ 1 radiation.; N-(2,6-dimethyl-4-morpholin-4-yl-phenyl)-3,3-dimethyl-butyramide in a crystalline form with XRPD reflections at 8.63, 22.26, 23.40 and 30.49 (°2 ⁇ ) using CuK ⁇ 1 radiation.
- the Kv7 Channel activator is selected from the group consisting of: Chromanol 293B, MIR-1556, UCL2077, JNJ303, L-735821 (L-7), fenofibrate; and a salt or hydrate thereof.
- the Kv7 Channel activator is selected from the group consisting of: a Triaminopyridine or one of its derivatives, an Acrylamide, a Benzamide, a Fenamate, a Dimethoxypyrimidine or one of its derivatives, Oxindole, Celecoxib, zinc pyrithione, ML213, QO58, QO58 lysine, NS1643, Benzbromarone, ZG1732 and ZG2083.
- the Kv7 Channel activator is selected from the group consisting of: NS15370, P-Retigabine, SF0034 or RL648_81 or any combination thereof.
- the Kv7 channel activator is selected from the group consisting of: linopirdine, (1,3-Dihydro-1-phenyl-3,3-bis(4-pyridinylmethyl)-2H-indol-2-one)
- XE991 (10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone (XE991)
- DMP-543 (10,10- bis(2-fluoro-4-pyridinylmethyl)-9(10H)-anthracenone (DMP-543)
- ML252 ((S)-2-phenyl-N- (2-(pyrrolidin-1-yl)phenyl)butanamide (ML252)) and UCL2077.
- the Kv7 channel activator is an analog of flupirtine.
- the Kv7 channel activator is selected from the group consisting of: N-(2,4,6-trimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide; N- (2,6- dimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide; N-(2,5- dimethylphenyl)bicyclo[2.2.1]heptane-3-carboxamide; N-(2-chloro-4,6- dimethylphenyl)pentanamide; N-(2-chloro-4,6-dimethylphenyl)-3,3-dimethylbutanamide; 2- (l -adamantyl)-N-(2,6-difluorophenyl)acetamide; N-(2-bromo-4-methylphenyl)-2- cyclopentylacetamide; N-(2,3-dimethylpheny
- the metal channel activator is QRA-244 as described in Dan Elbaum et al. “TST-20: QRA-244 a Potent, Selective KCNQ2/3 Opener and a Potential Therapy for Motor System Hyperexcitability induced Disease Progression in ALS patients”; 31 st International symposium on ALS/MND; Live Poster Session C, December 11, 2020.
- NMDA RECEPTOR ANTAGONISTS [0896] NMDA receptor antagonists are a class of pharmaceutically active molecules that work to antagonize, or inhibit the action of, the N-Methyl-D-aspartate receptor (NMDA R ).
- NMDA receptor antagonists include ketamine, lanicemine, dextromethorphan (DXM), phencyclidine (PCP), methoxetamine (MXE), and nitrous oxide (N 2 O).
- DXM dextromethorphan
- PCP phencyclidine
- MXE methoxetamine
- N 2 O nitrous oxide
- NMDA R -antagonists such as pethidine, levorphanol, methadone, dextropropoxyphene, tramadol and ketobemidone.
- NMDA receptor is an ionotropic receptor that allows for the transfer of electrical signals between neurons in the brain and in the spinal column. For electrical signals to pass, the NMDA receptor must be open.
- NMDA receptor antagonists Chemicals that deactivate the NMDA receptor are known as NMDA receptor antagonists (NMDA R ).
- NMDA R antagonists fall into four categories: competitive antagonists, which bind to and block the binding site of the neurotransmitter glutamate; glycine antagonists, which bind to and block the glycine site; noncompetitive antagonists, which inhibit NMDA R by binding to allosteric sites; and uncompetitive antagonists, which block the ion channel by binding to a site within it.
- the NMDA receptor antagonist is ketamine or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist is (S)-1- phenyl-2-(pyridin-2-yl)ethanamine (lanicemine) or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist may be a prodrug of ketamine or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist may be EVT-101 pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist is rapastinel: , (S)—N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2- yl)-1-((S)-1-((S)-2-amino-3-hydroxypropanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2- carboxamide, (S)—N—((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((2S,3R)-2- amino-3-hydroxybutanoyl) pyrrolidine-2-carbonyl) pyrrolidine-2-carboxamide, (S)—N— ((S)-1-amino-3-hydroxy-1-oxopropan-2-yl)-1-((S)-1-((S)-2-amino-3-hydroxy-propanoyl)- pyrrolidine-2-carbonyl)-pyrrolidine-2-carboxamide, (S)
- the NMDA receptor antagonist may be lanicemine.
- the NMDA receptor antagonist may be a prodrug of lanicemine.
- the prodrug of lanicemine may have the following chemical structure:
- the prodrug of lanicemine may have the following structure: , or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist may be selected from ketamine, lanicemine, dextromethorphan (DXM), phencyclidine (PCP), methoxetamine (MXE), and nitrous oxide (N2O).
- a pharmaceutical composition including the following compound (ezogabine) or a pharmaceutically acceptable salt thereof and an NMDA receptor antagonist or a pharmaceutically acceptable salt thereof:
- the NMDA receptor antagonist is flupirtine: acceptable salt thereof.
- the NMDA receptor antagonist may be selected from ketamine, lanicemine, dextromethorphan (DXM), phencyclidine (PCP), methoxetamine (MXE), and pharmaceutically acceptable salts and prodrugs thereof, or nitrous oxide (N2O).
- the NMDA receptor antagonist is one or more of a compound according to Formulas 200 – 260.
- compositions may include one or more metal channel activators according to Formulas 1 – 171 and one or more NMDA receptor antagonist compounds according to Formulas 200-260 described below.
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 200.
- Such compounds are described in International Publication No. WO2015/067923, published May 14, 2015, and corresponding to International Application No. PCT/GB2014/053236 filed October 30, 2014, as well as U.S. Patent No.9,822,075 issued on November 21, 2017; U.S. Patent No.10,207,994 issued on February 19, 2019; U.S. Patent No.10,815,199 issued on October 27, 2020, and U.S.
- the NMDA receptor antagonist is lanicemine, or a prodrug of lanicemine or a pharmaceutically acceptable salt thereof.
- the prodrug of lanicemine may have the following chemical structure: Formula 200
- the prodrug of lanicemine may have the following chemical structure: , or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist is one or more of: (S)-(l-Phenyl-2-(pyridin-2-yl)ethylcarbamoyloxy)methyl isobutyrate; 2-Methyl- 1 -((S)- 1 -phenyl-2-(pyridin-2-yl)ethylcarbamoyloxy)propyl isobutyrate; 2-Methyl- 1 -((S)- 1 -phenyl-2-(pyridin-2-yl)ethylcarbamoyloxy)propyl isobutyrate diastereomer 1 ; 2-Methyl- 1 -((S)- 1 -phenyl-2-(pyridin-2-yl)ethylcarbamoyloxy)propyl isobutyrate diastereomer 2; 1 -((S)- 1 -phenyl-2-(pyridin-2-yl)ethylcarbam
- the NMDA receptor antagonist is (S)- 1 -((S)-2-amino-3 - methylbutanoyl)-N-((S)- 1 -phenyl-2-(pyridin-2- yl)ethyl)pyrrolidine-2-carboxamide or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist is:
- the NMDA receptor antagonist is: .
- the NMDA receptor antagonist is a compound according to: , wherein R1 is C1-6 alkylC(O)O(C1-6 alkoxy), or wherein AA is a peptide bond-lined natural amino acid; or a pharmaceutically acceptable salt thereof.
- the NMDA receptor antagonist is (S)-1-((S)-2-amino-3- methylbutanoyl)-N—((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide dihydrochloride salt: [0919] In further embodiments, the NMDA receptor antagonist is (S)-1-((S)-2-amino-3- methylbutanoyl)-N—((S)-1-phenyl-2-(pyridin-2-yl)ethyl)pyrrolidine-2-carboxamide fumarate salt: .
- the NMDA receptor modulator may be selected from one of the following compounds according to Formula 201.
- Such compounds are described in International Publication No. WO 2021/228123, published November 18, 2021 and corresponding to PCT/CN2021/093264, filed May 12, 2021, is incorporated by reference in its entirety herein. In the case of any conflict of terminology of Formula 201, these references incorporated by reference herein control.
- the NMDA receptor modulator is a compound according to Formula 201: [0922] or a pharmaceutically acceptable salt or ester, stereoisomer, or solvate thereof, wherein, Ring A is 3- to 8-membered aliphatic heterocycle; R 1 is selected from H, C1- C6 alkyl, aryl-C1-C4 alkyl, C2-C6 acyl, -CONRR' and natural amino acid fragments; R2 is selected from H, C1-C6 alkyl, C1-C6 alkoxycarbonyl, C2-C6 acyl, -CONRR' and natural amino acid fragments; R3 is selected from H, cyano, 3- to 8-membered nitrogen-containing aliphatic heterocycle- C1-C4 acyl, C1-C6 alkoxycarbonyl and - CONHR4; R and R' are each independently selected from H and C1-C6 alkyl; R4 is selected from H, C1-C6 alkyl; R4 is
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 202.
- Such compounds are described in International Publication No. WO 2021/080880, published April 29, 2021 and corresponding to PCT/US2020/056171, filed October 16, 2020, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology of Formula 202, these references incorporated by reference herein control.
- the compound according to Formula 202 is: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, and X are as defined above.
- the compound according to Formula 202 is: or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, R7, and X are as defined above.
- the compound according to Formula 202 is selected from: pharmaceutically acceptable salts thereof.
- Formula 203 [0929]
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 203.
- the compound according to Formula 203 is: Formula 203 , and/or wherein ring A is a 6-membered aromatic ring further substituted by 1 to 4 substituents selected from (1) a C1-3 alkyl group, (2) a C1-3 haloalkyl group, (3) an optionally substituted cyclic group, (4) an optionally substituted C1-6 alkoxy group, and (5) a halogen atom; R1 and R2 are each independently a hydrogen atom or a C1-3 alkyl group optionally substituted by fluorine atom(s); R3 is (1) a group represented by wherein R4 is a substituent selected from (1) a C1-3 haloalkyl group, (2) an optionally substituted C3-7 cycloalkyl group, and (3) an optionally substituted C1-6 alkoxy group, Y is a nitrogen atom or CR6, R6 is a hydrogen atom or a halogen atom, and Z is a hydrogen atom or a halogen atom,
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 204.
- Such compounds are described in WO2019/210130, published October 31, 2019, corresponding to PCT/US2019/029285, filed April 26, 2019, and US2021/0094920, published April 1, 2021, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 204, these references incorporated by reference herein control.
- the NMDA receptor antagonist is: Formula 204 , wherein X is O or S, specifically O;R1 is H, C1-C6 alkyl, C1-C6 haloalkyl, specifically C1-C3 alkyl, and more specifically methyl; R2 is H, C1-C6 alkyl, C1-C6 haloalkyl, specifically H or C1-C3 alkyl, and more specifically H; R3 is H, C1-C6 alkyl, C1-C6 alkoxy, C1-C6 haloalkyl, C1-C6 haloalkoxy, —OH, halo, —COOH, —CN, —NO2, amino, mono- or di-alkylamino, C2-C6 alkanoyl, C2-C8 cycloalkyl, or heterocycloalkyl, specifically H, C1-C3 alkyl, or C1-C3 haloalkyl, and more
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 205. Such compounds are described in WO2019/152688, published August 8, 2019 and corresponding to PCT/US2019/016114, filed January 31, 2019, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology of Formula 205, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 205: Formula 205
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 206. Such compounds are described in, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 206, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is selected from:
- the NMDA receptor antagonist is selected from: pharmaceutically acceptable salts thereof.
- Formula 207 [0943] In an embodiment, the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 207. Such compounds are described in WO2018/075699, published April 26, 2018 and corresponding to PCT/US2017/057277, filed October 18, 2017, and US 11,149,054, issued October 19, 2021, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 207, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 207: Formula 207 , or a pharmaceutically acceptable salt thereof, wherein: each of R2 and R3 is independently hydrogen, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted carbocyclyl, or substituted or unsubstituted heterocyclyl, or R2 and R3, together with the carbon atom to which they are attached form a substituted or unsubstituted 3-8 membered ring; each of R4 and R5 is independently hydrogen, halo, or -ORc, wherein Rc is hydrogen or substituted or unsubstituted C1-C6 alkyl, or R4 and R5, together with the carbon atom to which they are attached form an oxo group; R6 is absent or hydrogen; and represents a single or double bond, wherein when one of is a double bond, the other is a single bond; when both of are single bonds, then R is hydrogen;
- the NMDA receptor antagonist is a compound selected from: . [0946] In further embodiments, the NMDA receptor antagonist is a compound selected from: [0947] In further embodiments, the NMDA receptor antagonist is a compound selected from: ⁇
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 208.
- Such compounds are described in WO 2016/196513, published December 8, 2016, corresponding to PCT/US2016/035098, filed May 31, 2016, and US 10,584,127 issued March 10, 2020, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 208, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 208: Formula 208 , wherein R1 is alkyl, cycloalkyi, (cycloalkyl)alkyl, heterocyclyl, (heterocyclyl)alkyl, aryl, (aryl)alkyl, heteroaryl or (heteroaryl)alkyl, wherein each of cycloalkyi, (cycloalkyl)alkyl, heterocyclyl, (heterocyclyl)alkyl, aryl, (aryl)alkyl, heteroaryl and (heteroaryl)alkyl is independently optionally substituted with 1 to 3 groups independently selected from -F, -CI, C1-C4 alkyl, cyclopropyl, -C ⁇ CH, -CFH2, -CF2H, - CF3, -CF2CH3, -CH2CF3, C1-C4 alkoxy, -OCFH2, -OC
- the NMDA receptor antagonist is a compound selected from: , wherein R5, R6 and R7 independently are -H, -F, -CI, C C alkyl, cyclopropyl, -C ⁇ CH, -CFH2, -CF2H, -CF3, -CF2CH3, -CH2CF3, C1-C4 alkoxy, - OCFH2, -OCF2H, -OCF3, -CN, -N(R2)(R3), -NO2, C C4 alkylthio, C1-C4 alkylsulfonyl or - S(O)2CF3; wherein each instance of R2 and R3 independently is -H or C1-C4 alkyl, or C1- C4 alkyl, or , including pharmaceutically acceptable salts thereof.
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist is selected from:
- the NMDA receptor antagonist is selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 209.
- Such compounds are described in International application publication no. WO2010/088414, published August 5, 2010, corresponding to PCT/US2010/022439, filed January 28, 2010, International application publication no. WO 2010/088408, published August 5, 2010, corresponding to PCT/US2010/022432, filed January 28, 2010, and US 8,822,462, issued September 2, 2014, which are each incorporated by reference in their entirety herein.
- these references incorporated by reference herein control are described in International application publication no. WO2010/088414, published August 5, 2010, corresponding to PCT/US2010/022439, filed January 28, 2010, International application publication no. WO 2010/088408, published August 5, 2010, corresponding to PCT/US2010/022432, filed January 28, 2010, and US 8,822,462, issued September 2, 2014, which are each incorporated by reference in their entirety herein.
- these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 209a – 209b:
- Formula 209a , Formula 209b X is, independently, N or C bonded to H or a substituent, J, with the proviso that no more than three of X are N;
- Y is independently selected from O, S, NR1, CH2, and CR2;
- R1 and R2 are, independently, selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and hydroxy, and, when R1 is attached to a carbon atom, it can be halo or cyano
- T is, independently, CHR1, CR2, O, S, or NR1
- V is, independently, N, or C bonded to H or a substituent J
- J is a non-hydrogen substituent selected from the group consisting of halo (-F, -Cl, -B
- the NMDA receptor antagonist is a compound according to Formula 209c: wherein A-B i s a linker moiety selected from: X is, independently, N, or C bonded to H or a substituent, J, with the proviso that no more than three of X are N; Y1 and Y2 are, independently, selected from O, S, NR1, CH2, and CRX 1 2 ; R1 and R2 are independently selected from H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, and hydroxy, R1 and R2 can optionally join to form a C3-10 heterocyclic moiety, which heterocyclic moiety can optionally include a second heteroatom selected from O, S, and N, R2 is absent when Q is O or S, Z is, independently, (CH2) n , CHR, CR2, O, S, or NR1, T is,
- the NMDA receptor antagonist has a structure according to Formula I or J:
- R7 is selected from the group consisting of H, -Ci_6 alkyl, -Ci_6 substituted alkyl, - C6-io aryl, - Ce io substituted aryl, -Ce io heteroaryl, -Ce io substituted heteroaryl, - C(O)-alkyl, -C(O)-substituted alkyl, -C(O)-aryl, -C(O)-substituted aryl, -C(O)- arylalkyl, C(O)-substituted arylalkyl, -C(O)-alkylaryl, -C(O)-substituted alkylaryl- CN, N3, NO2, -OH, -NH2, -SH, -OR1, -NHR1, -N(R1K -SR1, -OC(O)R1,
- the NMDA receptor antagonist is a compound according to: , and pharmaceutically acceptable salts, esters, prodrugs, or derivatives therof.
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 210.
- Such compounds are described in WO 2011/100585, published August 18, 2011, corresponding to PCT/US2011/024583, filed February 11, 2011, and US 9,101,612, issued August 11, 2015, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 210, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 210: Formula 210 and pharmaceutically acceptable salts, stereoisomers, and N-oxides thereof; wherein T is, independently for each occurrence, CR4R4 , and n is 0, 1, 2 or 3; A is optionally present and is selected from phenyl or pyridine, wherein A is optionally substituted by one or more substituents selected from Ra; Ri is selected from the group consisting of H, hydroxyl, -S(O)2-C1-4alkyl; -SO2, C1- 4alkyl, C2-C4alkenyl, phenyl, R7, or , wherein C1-4 alkyl, C2-4alkenyl, or phenyl is optionally substituted by one or more substituents selected from Ra; X is CH or N; R3 and R3 are independently selected from the group consisting of H, halogen, hydroxyl, phenyl, C1-4alkyl, amido, amine
- the NMDA receptor antagonist is a compound according to: , wherein R4 is H, R1 is benzyl, R5 is R2 is H or CH3, R3 is H or CH3, and stereoisomers, N-oxides or pharmaceutically acceptable salts thereof.
- the NMDA receptor antagonist is a compound according to: .
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 211. Such compounds are described in WO 2012/019106, published February 9, 2012, correcponding to PCT/US2011/046756, filed August 5, 2011, which is incorporated by reference in its entirety herein. In the case of any conflict of terminology of Formula 211, this references incorporated by reference herein controls.
- the NMDA receptor antagonist is a compound according to formulas 211 a – c: Formula 211a - c , wherein R1b is iodo, alkyl, alkenyl, alkynyl, alkoxy, amino, cycloalkyl, aryl, heteroaryl, alkyleneamino, alkylene-CO2H, alkenylene-CO2alkyl, alkylene-OH, alkylene-cycloalkyl, alkylenearyl, alkenylenearyl, CHO, or thioalkyl; R2b and R5a are each independently R A , alkylene-R A , NH 2 , C(O)NH-alkylenearyl, C(O)NH-alkyleneheteroaryl, C(O)NH-alkylene-R A , alkylene-OH, C(O)alkyl, or NO2; Rla is halo; R2a is C(Odo, alkyl,
- the NMDA receptor antagonist is a compound selected from: [0979]
- the NMDA receptor antagonist is a compound according to Formula 212d-e: Formula 212d and 212e , wherein R6b is RA or alkylene-RA; R7b is OH, alkoxy, or CO2H; R8b is H, halo, or C4-C20alkyl; R9b is halo, alkenyl, aryl, or alkyl; R13b is H, C4-C2oalkyl, alkenyl, aryl, heteroaryl, alkeylenearyl, or alkenylenearyl; R13a is C4-C20alkyl, alkenyl, alkenylene-CO2H, alkenylene-CO2alkyl, O-alkylene- CO2alkyl, or alkylenearyl; R6a is RA, alkylene-RA, or alkylene-OH;
- the NMDA receptor antagonist is a compound according to: Formula 212
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 212. Such compounds are described in US 2011/0206780 published August 25, 2011 corresponding to US 12/984,989 filed January 5, 2011 which is incorporated by reference in its entirety herein. In the case of any conflict of terminology of Formula 212, this reference incorporated by reference herein controls.
- the NMDA receptor antagonist is dextromethorphan: [0984] In further embodiments, the NMDA receptor antagonist is dextromethorphan or a dextromethorphan analogue having one or more H replaced with deuterium (D).
- the NMDA receptor antagonist is a compound according to Formula 212: or a salt thereof, wherein: R1 and R2 are independently selected from the group consisting of —CH3, —CH2D, —CD2H, and —CD3; R3-R25 are independently selected from the group consisting of hydrogen and deuterium; at least one of R3-R25 is deuterium; and if R6-R8 and R20-R21 are deuterium and R2 is —CD3, then at least one of R1-R5, R9-R19, and R22-R25 is deuterium or contains deuterium. [0986] In further embodiments, the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 213. Such compounds are described in, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 213, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a derivative of quinazoline, i.e. the following molecule portion, substituted in any manner: .
- the NMDA receptor antagonist is: , or a pharmaceutically acceptable salt or derivative thereof.
- the NMDA receptor antagonist is a compound according to: , or a pharmaceutically acceptable salt or derivative thereof.
- the NMDA receptor antagonist is a compound according to: , wherein Z is N; a is 1 or 2; b is 1, 2or 3; c is 1, 2 or 3; each R1 is independently selected from groups of the formula ⁇ (X)d ⁇ (CH2)e ⁇ R5 wherein d is 0 or 1; e is 0 to 6; X is O, NR or S(O)f where f is 0, 1 or 2; R is hydrogen, halogen, Ci_6 alkyl, C2-6 alkyl, C2-6 alkenyl, C3-12 cycloalkyl, heterocyclyl, aryl, heteroaryl, hydroxyl, cyano, nitro, trihalomethyl, NR7R8, C5H4NR7R8, C5H4(CH2)NR7R8, C(O)R7, C(O)R7, C(O
- the compound is l-oxa-8-thia-3-aza- dibenzo[e,h]azulene; l,8-dioxa-3-aza-dibenzo[e,h]azulene; 3-(l-oxa-8-thia-3-aza- dibenzo[e,h]azulen-2-yl)- propionic acid ethyl ester; 3-(l,8-dioxa-3-aza- dibenzo[e,h]azulen-2-yl)-propionic acid ethyl ester; 2-methyl-l-oxa-8-thia-3-aza- dibenzo[e,h]azulene; 2-methyl-l,8-dioxa-3-aza- dibenzo[e,h]azulene; 1 l-chloro-2- methyl-l-oxa-8-thia-3-aza-dibenzo[e,h]azulene; 5-chloro- 2-methyl
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 214.
- Such compounds are described in US 2010/0130617, published May 27, 2010 and corresponding to US application No. 12/623,948, filed November 23, 2009, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 214, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 214: Formula 214 , or a salt thereof, wherein: R1-R23 are independently selected from the group consisting of hydrogen and deuterium; at least one of R1-R23 is deuterium; and if each of R1-R3 are deuterium, then at least one of R4-R23 is deuterium.
- R1-R23 are independently selected from the group consisting of hydrogen and deuterium; at least one of R1-R23 is deuterium; and if each of R1-R3 are deuterium, then at least one of R4-R23 is deuterium.
- the NMDA receptor antagonist is a compound according to:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 215.
- Such compounds are described in WO 2010/0033757, published March 25, 2010 and corresponding to PCT/US2009/057401, filed September 18, 2009, US 9,512,133, issued December 6, 2016, US 9,802,946, issued October 31, 2017, and US 10,906,913, issued February 2, 2021, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 215, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to: Formula 215 , and pharmaceutically acceptable salts, stereoisomers, and N-oxides thereof; wherein T is, independently for each occurrence, CR4R4 , and n is 0, 1, 2 or 3; A is optionally present and is selected from phenyl or pyridine, wherein A is optionally substituted by one or more substituents selected from Ra; R1 is selected from the group consisting of H, hydroxyl, -S(O)2-C1-C4alkyl; -SO2, C1- C4alkyl, C2-C4alkenyl, phenyl, R7, or wherein C1-C4alkyl, C2-C4alkenyl, or phenyl is optionally substituted by one or more substituents selected from Ra; X is CH or N; R3 and R3 are independently selected from the group consisting of H, halogen, hydroxyl, phenyl, C1-C
- the NMDA receptor antagonist is a compound according to: , wherein R1 is C(O)-C2-C4alkyl, wherein C2-C4alkyl is substituted at one carbon with NH2 or -N- carbobenzyloxy and at a different carbon by hydroxyl.
- the NMDA receptor antagonist is represented by: [1007]
- the NMDA receptor antagonist is a compound according to: and pharmaceutically acceptable salts, stereoisomers and N-oxides thereof; wherein R1 is selected from the group consisting of H, hydroxyl, -S(O)2-C1-C4alkyl; -SO2, C1- C 4alkyl; R7, or X is CH or N; R3 and R3' are each independently selected from the group consisting of H, halogen, hydroxyl, phenyl, C1-C4alkyl, amido, amine, or C2-C4alkenyl, wherein C1-C4alkyl, C2- C4alkenyl and phenyl are optionally substituted by one or more substituents selected from Ra; R2 is selected from the group consisting of H, R7, -S(O)2, S(O)2-C1-C4alkyl, C1-C4
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 216.
- Such compounds are described in US 2009/0004112, published January 1, 2009 and corresponding to application no 12/049,782, filed March 17, 2008, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 216, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 216: or a pharmaceutically acceptable base or acid addition salt, hydrate, stereoisomer, or mixture thereof, wherein X is one or more halogen radicals; Q is NH or N; W is CR2, CHR2, NR3, or CH ⁇ COH; Y is C or CH; Z is C ⁇ O, SO2, COH, CHOH, or NHR4; R1 is CO2H or oxo ( ⁇ O); R2 is H, C( ⁇ O)—C1-C6 alkyl, C( ⁇ O)O—C1-C6 alkyl, or C( ⁇ O)—C3-C8 cycloalkyl; R3 is optionally substituted C3-C10 aryl; and R4 is R2 and R1 combine with the carbons to which they are attached to form a 6 membered heterocycle that is optionally substituted at one or more of the heteroatoms with C3-C10 aryl, wherein the
- the NMDA receptor antagonist is a compound according to: or a pharmaceutically acceptable base or acid addition salt, hydrate, stereoisomer, or mixture thereof, wherein X is one or more halogen radicals; R1 is (CH2)n—CO2H, or CH ⁇ CHC( ⁇ O)NHR2; and R2 is C3-C10 aryl optionally substituted with one or more of C1-C6 alkyl, —O—C1- C6 alkyl, or halogen; and n is 0, 1, 2, 3, 4, 5, or 6. [1012] In an embodiment, the NMDA receptor antagonist is an NMDA receptor glycine site antagonist.
- the NMDA receptor antagonist is ACEA 1021 (liconstinel), GV150526 (Gavestinal), GV196771, MDL 105,519, L-701324, L-687414, RPR 104632, ACPC (SYM2030), ZD9379, AR-R15896AR, or RPR118723.
- the NMDA receptor antagonist is selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 217. Such compounds are described in WO2008/134525, published November 6, 2008 and corresponding to PCT/US2008/061598, filed April 25, 2008, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 217, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a deuterium-labeled ketamine analogue.
- the NMDA receptor antagonist is a compound according to Formula 217: Formula 217 , or a pharmaceutically acceptable salt, solvate, or prodrug thereof; wherein: R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16 are independently selected from the group consisting of hydrogen and deuterium; and at least one of R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, and R16 is deuterium.
- the NMDA receptor antagonist is a compound selected from:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 218. Such compounds are described in WO 2008/022285, published February 2008, corresponding to PCT/US2007/076146, filed August 16, 2007 which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 218, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 218: Formula 218
- any bond represented by a dashed line and a solid line represents a bond selected from the group consisting of a single bond and a double bond, and any carbon-carbon double bond has a configuration selected from the group consisting of cis and trans;
- R2, R3, R4, R5, R6, R8, R9, R10, R11 and R12 are independently selected from the group consisting of hydrogen, and deuterium;
- R1 and R7 are independently selected from the group consisting of hydrogen, and deuterium;
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 219. Such compounds are described in WO 2006/017409, published February 16, 2006 and corresponding to PCT/US2005/027160, filed July 29, 2005, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 219, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 219: Formula 219 , wherein W is aryl or heteroaryl, unsubstituted or substituted with 1-5 substituents independently selected from halogen and C1-6 alkyl optionally substituted with one or more substituents selected from halogen, hydroxy, and C1-4 alkoxy, C1 -4 alkoxy, C3-6 cycloalkyl, cyano and N(R4)2; Y is absent or is selected from C 1-3 alkyl optionally substituted with one or more substituents selected from halogen, hydroxyl and C 1-4 alkoxy, cyclopropyl and C(O); Z is N and P and Q are C(R4)2, or Z is CR5 and P and Q are C(R5)2; A, B and D are each independently selected from O, CR6, S and NR6; Rl , R4 and R6 are each independently selected from hydrogen or C 1-4 alkyl optionally substituted with one or
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 220. Such compounds are described in WO 2003/097637, published November 27, 2003 and corresponding to PCT/EP2003/005151, filed May 16, 2003, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 220, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 220a or 220b: , wherein A is an unsubstituted or substituted cyclic group; and R is a hydrogen or lower alkyl; and pharmaceutically acceptable salts thereof.
- A is the group: , and wherein R1, R2, R3, and R4 are independently hydrogen, halogen, CF3, CHF2, C(CH3)F2, C3-C6 cycloalkyl, lower alkoxy, lower alkyl, OCF3, or phenyl; or A is , and R5, R6, R7, R8, R9, R10 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or CHF2; or A , and R11, R12, R13, R14, R15, and R16 are independently hydrogen, halogen, lower alkoxy, or lower alkyl.
- A is , wherein R17 is hydrogen or CHF2; or A is , or , wherein R18, R19, and R20 are independently hydrogen, lower alkyl or lower alkoxy.
- the compound is:
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 221.
- Such compounds are described in US 2002/0072485, published June 13, 2002, corresponding to Application No.09/969,354, filed October 2, 2001, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 221, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a compound according to Formula 221: Formula 221 , or a pharmaceutically acceptable acid addition salt thereof, wherein: (a) R2 and R5 are taken separately and R1, R2, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7 and R5 is methyl or ethyl; or (b) R2 and R5 are, taken together, thereby forming a chroman-4-ol ring, and R1, R3 and R4 are each independently hydrogen, (C1-C6) alkyl, halo, CF3, OH or OR7; R6 is R7 is methyl, ethyl, isopropyl or n-propyl; R8 is phenyl optionally substituted with up to three substituents independently selected from the group consisting of (C1-C6) alkyl, halo and CF3; X is O, S or (CH2)n; and
- the NMDA receptor antagonis is selected from: (+)-(1S, 2S)-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; a pharmaceutically acceptable acid addition salt thereof; (1S, 2S)-1-(4-hydroxy-3-methoxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol; a pharmaceutically acceptable acid addition salt thereof; (3R,4S)-3-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)-chroman4,7-diol; a pharmaceutically acceptable acid addition salt thereof; and (1R*, 2R*)-1-(4-hydroxy-3-methylphenyl)-2-(4-(4-fluorophenyl)-4-hydroxypiperidin-1-yl)- propan-1 -ol-mesylate.
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 222. Such compounds are described in US 2002/0077352, published June 20, 2002, corresponding to US application No.09/922,535, filed August 3, 2001, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 222, these references incorporated by reference herein control. [1034] In an embodiment, the NMDA receptor antagonist is selected from: . [1035] In further embodiments, the NMDA receptor antagonist is: , or . Formula 223 [1036] In an embodiment, the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 223.
- the NMDA receptor antagonist is a bicycle-substituted cyclohexylamine.
- the NMDA receptor antagonist is a compound of Formula 223: Formula 223 wherein: Ar is substituted 1 to 3 times or unsubstituted aryl or substituted 1 to 3 times or unsubstituted heteroaryl, which heteroaryl is from 5 to 14 atoms having from 1 to 2 heteroatoms selected from N, O, and S wherein the substituents are selected from the groups F, Cl, Br, I, OH, NH2, SH, CN, NO2, OCH3, OC(O)CH3, CF3, OCH2CH2OH, NHC(O)CH3, NHCH3, or N(CH3)2;
- V is –(CH 2 ) n -, -S(O)-, or -S(O) 2 -;
- W is –(CH 2 ) n -, —S(SO)—, —S(O)2—, — O—, —S—, —C ⁇ C—, or
- d is an integer from 0 to 2;
- n is an integer from 1 to 6;
- q is an integer from 0 to 6;
- R1 and R2 are independently selected from the group consisting of hydrogen, alkyl, OH, hydroxyalkyl, aminoalkyl, aralkyl, or N(R4)(R5) wherein R4 and R5 are independently selected from hydrogen, alkyl, aralkyl, heteroaryl, heteroaralkyl, aminoalkyl, hydroxyalkyl, and thioalkyl;
- R is hydrogen, alkyl, C(O)R6, C(O)OR6, C
- the NMDA receptor antagonist is a compound selected from: 6-[trans-4-(3-Phenylpropylamino)cyclohexyl]-3H-benzoxazol-2-one; 6- ⁇ trans-4-[2-(4-Fluorophenoxy)ethylamino]cyclohexyl ⁇ -3H-benzoxazol-2-one; 6-[trans-4-(2-Phenoxyethylamino)cyclohexyl]-3H-benzoxazol-2-one; 6- ⁇ trans-4-[3-(4-Fluorophenyl)propylamino]cyclohexyl ⁇ -3H-benzoxazol-2-one; 6- ⁇ cis-4-[3-(4-Fluorophenyl)propylamino]cyclohexyl ⁇ -3H-benzoxazol-2-one; 6-[trans-4-(2-Phenylsulfanylethylamino)cyclohexyl]-3H-benz
- the NMDA receptor antagonist may be selected from one of the following compounds according to Formula 224. Such compounds are described in, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 224, these references incorporated by reference herein control. [1041] In an embodiment, the NMDA receptor antagonist is a compound according to Formula 224: Formula 224:
- B is CH or N
- R1, R2, and R5 are independently H, A, or halogen
- R3 and R4 are independently H, A, OH, OA, halogen, CF3, NO2, NH2, NHA, N(A)2 or NHAc
- R6 is H or halogen
- X is -CH2-, -CO-, -O-, -NH-, -NA- or -S-
- A is alkyl having 1-4 carbon atoms
- Ac is an alkanoyl having 1-6 carbon atoms
- benzoyl and halogen is F, Cl, Br, or I, and pharmaceutically acceptable salts thereof.
- the NMDA receptor antagonist is 2-Chloro-3-methyl-4-hydroxy-5- phenyl-6,7-dihydrothieno-2,3-bipyridin-6-one Peptide NMDA Receptor Antagonists
- the NMDA receptor antagonist is a peptide agent.
- the peptide NMDA receptor antagonists are classified under Formula numbers, each of which may refer to one or more different peptide sequences. Where a sequence homology percentage is recited, e.g. at least 80% sequence homology, it is contemplated that higher percentages are also contemplated.
- the peptides may be useful as therapeutic agents.
- the peptides may be produced in vivo from a therapeutic agent containing a polynucleotide sequence encoding the peptide.
- a polynucleotide sequence may be a DNA sequence or an RNA sequence.
- the sequence may be delivered or introduced to the patient by a plasmid or vector. It should be appreciated that any known delivery technique or construct is contemplated.
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 250. Such peptides are described in US 10,689,418, issued June 23, 2020 and corresponding to Application No.16/065,078, filed June 21, 2018, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 250, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a peptide comprising the amino acid sequence GEDDLQDNQDLIRDKSN, or a sequence having at least 80% sequence homology thereto.
- the NMDA receptor antagonist is a peptide comprising the amino acid sequence GEDDYQDAQDLIRDKSN, or a sequence having at least 80% sequence homology thereto.
- the NMDA receptor antagonist is a peptide comprising the amino acid sequence KLGMRSELQIDNDQDAD, or a sequence having at least 80% sequence homology thereto.
- Formula 251 [1049] In an embodiment, the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 251.
- the NMDA receptor antagonist is a natural or modified conantokin-P peptide.
- the NDMA receptor antagonist is a peptide comprises one or more amino acid sequences according to: or one or more amino acid sequences having at least 80% sequence homology thereto.
- the NMDA receptor antagonist comprises one or more amino acid sequences according to: sequences having at least 80% sequence homology thereto.
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 252. Such peptides are described in WO 2019/074858, published April 18, 2019, corresponding to PCT/US2018/054889, filed October 8, 2018, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 252, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a peptide comprising one or more amino acid sequences according to:
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 253. Such peptides are described in CN 109553685, filed September 25, 2017 which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 253, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a polypeptide comprising one or more of an NR2B (NMDA receptor subunit NR2B) sequence, a CTM (chaperone-mediated autophagy targeting motif) sequence, and a cell-penetrating peptide (such as a TAT cell- penetrating peptide or others).
- NR2B NMDA receptor subunit NR2B
- CTM chaperone-mediated autophagy targeting motif
- cell-penetrating peptide such as a TAT cell- penetrating peptide or others.
- the NMDA receptor antagonist comprises one or more of an TAT cell-penetrating peptide sequence having a polypeptide sequence having at least 80% homology to YGRKKRRQRRR; an NR2B peptide sequence having a polypeptide sequence having at least 80% homology to RRPPRSPDHKRYFRDKE; and a CTM sequence having at least 80% homology to KFERQKILDQRFFE.
- the NMDA receptor antagonist comprises the sequence YGRKKRRQRRRRRPPRSPDHKRYFRDKEKFERQKILDQRFFE, or a sequence having at least 80% homology thereto.
- the NMDA expression may be selectively reduced by administration or dosing with a peptide according to Formula 254.
- a peptide according to Formula 254 Such peptides are described in WO2019/036511, published February 21, 2019 and corresponding to PCT/US2018/046770, filed August 14, 2018, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 254, these references incorporated by reference herein control.
- the peptide comprises the polypeptide sequence VSGLNPSLWSIFGLQFILLWLVSGSRHYLW or YGRKKRRQRRRVSGLNPSLWSIFGLQFILLWLVSGSRHYLW, or a sequence having at least 80% sequence homology with either of these sequences.
- the peptide may be a polypeptide having portions (for example, three or more consecutive amino acids) of either of these sequences and having an overall length of 10 – 50 residues.
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 255. Such peptides are described in WO 2010/004003, published January 14, 2010, corresponding to PCT/EP2009/058752, filed July 9, 2009, and US 9,241,967, issued January 26, 2016, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 255, these references incorporated by reference herein control.
- a compound comprising a first peptide or peptide analogue linked to a second peptide or peptide analogue by a linker, optionally a PEG linker, wherein said linker is associated with a N-terminus of said first and second peptide or peptide analogue, and wherein said first and said second peptide or peptide analogue comprise at least four amide-bonded residues having a sequence Xaa1-Thr-Xaa3-Val or Xaa1-Ser-Xaa3-Val, wherein: a. Xaa1 is selected from among E, Q, and A, or an analogue thereof, and b.
- Xaa3 is selected from among A, Q, D, N, N-Me-A, N-Me-Q, N-Me-D, and N-Me-N or an analogue thereof. [1063] In further embodiments, the compound is selected from:
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 256. Such peptides are described in WO 2014/096402, published June 26, 2014 corresponding to PCT/EP2013/077780, filed December 20, 2013 and US 2015/0337276, published November 26, 2015, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 256, these references incorporated by reference herein control.
- the NMDA receptor antagonist is an enzyme, optionally a metalloenzyme comprising at least one divalent cation.
- the divalent cation is Zn2+, Mg2+, Ni2+, Cd2+, Mn2+, Co2+, Fe2+, and Ag2+, preferably is Zn2+.
- the enzyme is a phosphotriesterase or phosphotriesterase derivative.
- the enzyme comprises a sequence, or functional portion thereof, having a sequence according to: MQTRRVVLKSAAAAGTLLGGLAGCASVAGSIGTGDRINTVRGPITISEAGFTL THEHICGSSAGFLRAWPEFFGSRKALAEKAVRGLRRARAAGVRTIVDVSTFDI GRDVSLLAEVSRAADVHIVAATGLWFDPPLSMRLRSVEELTQFFLREIQYGIE DTGIRAGIIKVATTGKATPFQELVLKAAARASLATGVPVTTHTAASQRDGEQ QAAIFESEGLSPSRVCIGHSDDTDDLSYLTALAARGYLIGLDHIPHSAIGLEDN ASASALLGIRSWQTRALLIKALIDQGYMKQILVSNDWLFGFSSYVTNIMDVM DRVNPDGMAFIPLRVIPFLREKGVPQETLAGITVTNPARFLSPTLRAS; or SIGTGDRINTVRGPITISEAGFTLTHEHICGSSAGFLRAWPEFFG
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 257.
- Such peptides are described in WO 2013/185572, published December 19, 2013 and corresponding to PCT/CN2013/076967, filed June 8, 2013, and US 9,718,864, issued August 1, 2017. which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 257, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a polypeptide comprising one or more sequences according to: MKLTCVLIITVLFLTACQLTTAVTYSRGEHKHRALMSTGTNYRLPKTCRSSGR YCRSPYDCRRRYCRRITDACV; or MKLTCVVIITVLFLTACQLTTAVTYSRGEHKHRALMSTGTNYRLPKTCRSSG RYCRSPYDCRRRYCRRITDACV; or TCRSSGRYCRSPYDCRRRYCRRITDACV; or MKLTCVLIITVLFLTACQLTTAVTYSRGEHKHRALMSTGTNYRLPKTCRSSGR YCRSPYDRRRRYCRRITDACV; or MKLTCVVIITVLFLTACQLTTAVTYSRGEHKHRALMSTGTNYRLPKTCRSSG RYCRSPYDRRRRYCRRITDACV; or TCRSSGRYCRSPYDRRRRYCRRITDACV, or a sequence comprising a portion having at least 80% homology with any
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 258. Such peptides are described in WO2008/014917, published February 7, 2008, corresponding to PCT/EP2007/006619, filed July 25, 2007, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 258, these references incorporated by reference herein control.
- the NMDA receptor antagonist is a polypeptide comprising entirely D-enantiomeric amino acids.
- the NMDA receptor antagonist is a fusion peptide comprising at least a component (I), wherein component (I) comprises a transporter peptide, and a component (II), selected from a peptide inhibiting interaction of neuronal N-methyl-D-aspartate receptor (NMDAR) with NMDAR interacting proteins, wherein component (II) entirely consists of D- enantiomeric amino acids.
- component (I) comprises a transporter peptide
- component (II) selected from a peptide inhibiting interaction of neuronal N-methyl-D-aspartate receptor (NMDAR) with NMDAR interacting proteins, wherein component (II) entirely consists of D- enantiomeric amino acids.
- component (I) is selected from cell penetrating peptides including: (a) protein transduction domains (PTD) and protein derived CPPs, including sequences derived from Antennapedia, pAntp (43-58), comprising the sequences RQI KIVVFQN RRMKWKK or RQIKIWFQNRRMKWKK-amide, including sequences derived from human immunodeficiency virus 1 (HIV-1 ), TAT, region 37 to 72, region 37 to 60, region 48 to 60 or region 49 to 57 from TAT, sequences GRKKRRQRRR, YGRKKRRQRRR, CGRKKRRQRRRPPQC or CGRKKRRQRRRPPQCC, including hCT(9-32) having the sequence LGTYTQDFNKFHTFPQTAIGVGAP-NH2, pVEC comprising the sequence LLIILRRRIRKQAHAHSK-NH2, plSL comprising the sequence RVIRVWFQNKRCKDKK-
- (Arg)9-NH2 or (c) designed CPPs including MPG comprising the sequence GALFLGFLGAAGSTMGAWSQPKSKRKV or GALFLGFLGAAGSTMGAWSQPKSKRKV-cysteamide; Transportan comprising the sequence GWTLNSAGYLLGKINLKALAALAKKIL- NH2 (SEQ , Transportan 10 comprising the sequence AGYLLGKINLKALAALAKKIL-NH2, Pep-1 comprising the sequence KETWWETWWTEWSQPKKKRKV or KETWWETWWTEWSQPKKKRKV- cysteamide, or may be selected from the KALA peptide comprising the sequence WEAKLAKALAKALAKHLAKALAKALKACEA or from Bulforin 2 comprising the sequence TRSSRAGLQFPVGRVHRLLRK, or an retro-inverso isomer of any of these sequences composed of D amino acids, or any sequences having at least 80% homology with any of these sequences.
- Transportan compris
- component (II) comprises the polypeptide sequence vdseisslk, or a sequence having at least 80% homology thereto. In an embodiment, the component (II) sequence comprises a length of 5 to 40 amino acids.
- the NMDA receptor antagonist may be selected from one of the following peptides according to Formula 259 Such peptides are described in US 5,854,217, issued December 29, 1998, and US 6,284,731, issued September 4, 2001, which are each incorporated by reference in their entirety herein. In the case of any conflict of terminology of Formula 259, these references incorporated by reference herein control.
- the NMDA receptor antagonist comprises one or more sequences according to: Asn Gly Glu Gla Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn-NH2; Phe Gly Glu Gla Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn-NH2; t-BuTyr Gly Glu Gla Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn- NH2; Ser Gly Glu Gla Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn-NH2; Gly Glu Ser Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn-NH2, wherein the serine at position 3 is phosphorylated; Gly Glu Ala Gla Leu Gln Gla Asn Gln Gla Leu Ile Arg Gla Lys Ser Asn-NH2; Gly Glu Ala Gla Le
- the NMDA receptor antagonist has the structure: A1-A2-A3-A4-A5-A6-(A7)x c-[A8-(A9-A10)x d—NH2]n wherein A1 is glycine, alanine, valine, leucine or isoleucine; A2 is glutamic acid, aspartic acid, ⁇ -carboxyglutamate (Gla), 3-carboxyaspartic acid, D-glutamic acid, phosphoserine or phosphothreonine; A3 is glutamic acid, aspartic acid, ⁇ -carboxyglutamate (Gla), 3-carboxyaspartic acid, D-glutamic acid, phosphoserine or phosphothreonine; A4 is Gla; A5 is glycine, alanine, valinc, leucine or isoleucine; A6 is a peptide of 7-9 amino acids; A7 is an amino acid selected
- the NMDA receptor antagonist is a histogranin or analog thereof, as described in CA 2097533, published December 4, 1993.
- PHARMACEUTICAL COMPOSITIONS [1079]
- a pharmaceutical composition comprising a metal channel activator and a NMDA receptor antagonist.
- the metal channel activator in said pharmaceutical composition is a potassium channel activator.
- the potassium channel activator in said pharmaceutical composition is a Kv7 channel activator.
- the Kv7 channel activator in said pharmaceutical composition is selected from the group consisting of a Kv7.1 channel activator, a Kv7.2 channel activator, a Kv7.3 channel activator, a Kv7.4 channel activator, a Kv7.5 channel activator, or any combination thereof.
- the Kv7 channel activator in said pharmaceutical composition is a Kv7.2/7.3 channel activator.
- the metal channel activator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 1 to 171 and the compounds disclosed in the “further embodiments” under the “METAL CHANNEL ACTIVATORS” subheading.
- the NMDA receptor antagonist in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 200 to 260.
- the NMDA receptor antagonist in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 200 to 260, and the metal channel activator in said pharmaceutical composition is selected from one or more of the disclosed compounds according to any one or more of formulas 1 to 171 and the compounds disclosed in the “further embodiments” under the “METAL CHANNEL ACTIVATORS” subheading.
- the NMDA receptor antagonist or a pharmaceutically acceptable salt thereof in said pharmaceutical composition is in a form of a prodrug.
- the combination therapies (comprising at least one of any metal channel activator described herein and at least one NMDA receptor antagonist described herein) disclosed herein are useful for treating various depressive disorders.
- the depressive disorder include major depressive disorder (MDD), disruptive mood dysregulation disorder, persistent depressive disorder, bipolar spectrum disorder, postpartum depression, premenstrual dysphoric disorder (PMDD), seasonal affective disorder (SAD), atypical depression, treatment-resistant depression (TRD), depression associated with agitation or anxiety, adjustment disorder with depressed mood, prolonged depressive reaction, or a combination thereof.
- disorders include amyotrophic lateral sclerosis, bipolar disorder, treatment resistant and major depression, general anxiety disorder, panic disorder, social anxiety, mood disorders, cognitive disorders, dementia, agitation, apathy, psychoses, post-traumatic stress disorders, irritability, disinhibition, learning disorders, memory loss, personality disorders, bipolar disorders, Rett syndrome, eating disorders, conduct disorder, neurodegenerative disorders, pain disorders, supranuclear palsy, frontotemporal dementia, frontotemporal lobar degeneration, delirium, Alzheimer's disease, mild cognitive impairment, mild cognitive impairment due to Alzheimer’s disease, drug addiction, tinnitus, mental retardation, obsessive-compulsive disorder, spinal muscular atrophy, radiation therapy, multiple sclerosis, chronic cerebellar ataxia, cervical spondylotic myelopathy, spinal cord injury, hereditary cerebellar ataxia, Tourette syndrome, autism spectrum disorder, schizophrenia, fragile X syndrome, Parkinson's Disease, Huntington’s disease, or any combination thereof.
- the combination therapies disclosed herein are useful for treating various pain disorders.
- the pain disorders include acute pain, chronic pain, neuropathic pain, nociceptive pain, radicular pain.
- the pain disorders may also include migraine, inflammatory pain, persistent pain, cancer pain, and postoperative pain.
- the metal channel activator and the NMDA receptor antagonist may be given orally, sublingually, subcutaneously or in any other means of delivery.
- the agents may be delivered simultaneously or sequentially. If the agents are delivered sequentially, either agent may be dosed first, and the separation of time may include finishing the dosing of one agent completely before commencing the dosage of the other or they may be intermingled in time.
- kits for treating a patient afflicted with at least one of the aforementioned disorders said kit including: (a) a metal channel activator; and (b) instructions for administering said metal channel activator in combination with an NMDA receptor antagonist by one of the aforementioned methods.
- a kit for treating a patient afflicted with at least one of the aforementioned disorders said kit including: (a) an NMDA receptor antagonist; and (b) instructions for administering said NMDA receptor antagonist with a metal channel activator by one of the aforementioned methods.
- the term “metal channel activator” is construed to include both metal channel activator and pharmaceutically acceptable salt thereof.
- NMDA receptor antagonist is construed to include both NMDA receptor antagonist and pharmaceutically acceptable salt thereof.
- various publications are referenced by author name and date, or by patent number or patent publication number. The disclosures of these publications are hereby incorporated in their entireties by reference into this application in order to more fully describe the state of the art as known to those skilled therein as of the date of the invention described and claimed herein. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention.
- Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein.
- Compounds are generally given as pharmaceutical compositions comprised of a therapeutically effective amount of one or more of a compound of any one of Formulas 1 – 180, Formulas 200 – 260, those listed in “Further Embodiments” under the “METAL CHANNEL ACTIVATORS” subsection, or pharmaceutically acceptable salt(s) thereof, and a pharmaceutically acceptable carrier, further optionally containing conventional excipients.
- a therapeutically effective amount is the amount needed to provide a meaningful patient benefit as determined by practitioners in that art.
- Pharmaceutically acceptable carriers are those having acceptable safety profiles which are conventionally known.
- compositions encompass common solid and liquid forms including but not limited to capsules, tablets, lozenges, liquid suspensions, syrups, elixirs, and solutions. Solid compositions may by formulated to timed or sustained release. Compositions are made using common formulation techniques, such as the aforementioned solid and liquid forms, conventional excipients, such as binding and wetting agents, and vehicles, such as water and alcohols. [1099] The NMDA receptor antagonists of the present invention may be given orally, sublingually, intranasally, buccally, subcutaneously or in any other suitable means of delivery in table 1.
- the NMDA receptor antagonists may be in the form of a prodrug, which releases the agent in the body, a sustained release vehicle, a delayed release vehicle, or any other suitable delivery form.
- the NMDA receptor antagonists and the metal channel activator may be delivered simultaneously or sequentially. If the agents are delivered sequentially, either agent may be dosed first, and the separation of time may include finishing the dosing of one agent completely before commencing the dosage of the other or they may be intermingled in time.
- the NMDA receptor antagonist is administered at a time proximate to the administration of the metal channel activator, e.g., within 1 week, 1 day, 1 hour, 1 minute before or after the metal channel activator or simultaneously with the metal channel activator.
- the metal channel activators of the present invention may be given orally, sublingually, intranasally, buccally, subcutaneously or in any other suitable means of delivery in table 1.
- Metal channel activators may be given in the form of a prodrug, which will release the active compound in the body, a delayed release formulation, which will release the active compound after a time delay, a sustained release formulation, which will release the active compound slowly over time, or any other suitable formulation to deliver the active ingredient.
- the metal channel activator may be delivered simultaneously or sequentially with the NMDA receptor antagonist. If the agents are delivered sequentially, either agent may be dosed first, and the separation of time may include finishing the dosing of one agent completely before commencing the dosage of the other or they may be intermingled in time.
- the metal channel activator will be administered at a time nearing the administration of the NMDA receptor antagonist e.g., within 1 week, 1 day, 1 hour, 1 minute before or after the NMDA receptor antagonist or simultaneously with the metal channel activator.
- the dose of the NMDA receptor antagonist and metal channel activator for use together may depend on the subject to be treated inclusive of the age, sex, weight, and general health condition thereof. In this regard, precise amounts of the agent(s) for administration will depend on the judgment of the practitioner. In determining the effective amount of the NMDA receptor antagonist and metal channel activator to be administered in the treatment or reducing of the conditions associated with the symptoms and disorders, the physician may evaluate clinical factors including symptoms severity or progression of the disorder.
- a rapid absorption of the NMDA receptor antagonist or metal channel activator may be desirable.
- the effective amount of the treatment will vary depending on the subject and disease state being treated, the severity of the affliction and the manner of administration, and may be determined routinely by one of ordinary skill in the art.
- Some of the NMDA receptor antagonists and metal channel activators can be administered sublingually.
- the sublingual formulation may be administered in an effective amount to a subject in need thereof.
- the subject may be an animal or human.
- the NMDA receptor antagonist or metal channel activator is prepared as a sublingual formulation, the sublingually administered chemical agent or the drug can diffuse into capillaries through mucous membrane under the tongue, and then enter venous circulation of the subject.
- a sublingual formulation useful in the present invention comprises an effective amount of an NMDA receptor antagonist, metal channel activator, or pharmaceutically acceptable salts, solvates, anomers, enantiomers, hydrates, or prodrugs thereof.
- the formulation provides sufficient solubility for a NMDA receptor antagonist and/or metal channel activator to be incorporated into the sublingual formulation at relatively large doses and sublingually delivered.
- the formulation is preferably a modified oral disintegrating formulation of a NMDA receptor antagonist and/or metal channel activator.
- the excipients including mannitol and gelatin, are blended, solubilized with water and deaerated before being mixed with the active pharmaceutical ingredient (or “API”), a NMDA receptor antagonist and/or a metal channel activator, which have been milled separately.
- Particle size of the API (D50) may be less than about 2 microns.
- the mixture is lyophilized by flash freezing and then freeze-dried.
- the formulation has good oral palatability.
- the effective amount of a NMDA receptor antagonist and/or metal channel activator for the sublingual formulation useful in the present invention to achieve a lower therapeutic dose may be less than that of orally administered agent.
- the NMDA receptor antagonist and/or metal channel activator is provided in a sublingual formulation in a form of an orally dissolving or disintegrating tablet (ODT).
- ODT as used herein may be prepared by mixing the NMDA receptor antagonist and/or the metal channel activator with water-soluble diluents and compressed in a tablet.
- a suspension comprising the active product may be prepared with appropriate excipients and the suspension may be dispensed into blister packs and freeze- dried.
- An exemplary freeze-dried preparation platform that could be used for the ODT is the ZYDIS® (Catalent, Somerset, NJ, USA) formulation.
- the excipients including water
- the NMDA receptor antagonist and/or metal channel activator are separately milled to size and mixed with the excipients.
- the suspension then undergoes lyophilization by flash freezing and freeze drying.
- the clinical or therapeutic effect of the sublingually formulated NMDA receptor antagonist may have an improved pharmacokinetic profile for the pharmaceutical agent as measured by standard testing parameters.
- the T max , C max and AUC of the drug may be improved compared to the same dose of the orally administered version of the same compound.
- the sublingual formulation of the NMDA receptor antagonist may have a greater C max than the orally administered NMDA receptor antagonist to provide a therapeutically beneficial effect.
- the sublingual formulation of the NMDA receptor antagonist may have an earlier or lesser T max than the orally administered NMDA receptor antagonist to provide a therapeutically beneficial effect and in some instances, a more rapid therapeutic effect.
- the sublingual formulation of the NMDA receptor antagonist may have a greater AUC per milligram of the agent than the orally administered NMDA receptor antagonist.
- the NMDA receptor antagonist may make the metal channel activator more effective, lesser amounts of the metal channel activator may be needed to achieve the same results, lessening the inherent side effects.
- the clinical or therapeutic effect of the sublingually formulated metal channel activator may have an improved pharmacokinetic profile for the pharmaceutical agent as measured by standard testing parameters. When the metal channel activator is administered sublingually, the T max , C max and AUC of the drug may be improved compared to the same dose of the orally administered version of the same compound.
- the sublingual formulation of the metal channel activator may have a greater C max than the orally administered metal channel activator to provide a therapeutically beneficial effect.
- the sublingual formulation of the metal modulator may have an earlier or lesser T max than the orally administered metal channel activator to provide a therapeutically beneficial effect and in some instances, a more rapid therapeutic effect.
- the sublingual formulation of the metal channel activator may have a greater AUC per milligram of the agent than the orally administered metal channel activator.
- the metal channel activator may make the NMDA receptor antagonist more effective, lesser amounts of the NMDA receptor antagonist may be needed to achieve the same results, lessening the inherent side effects.
- the disclosure and methods encompass all conventional modes of administration including oral, parenteral, intranasal, sublingual, topical, and transdermal methods.
- routes of administration the standard routes of administration described by the FDA are contemplated herein as shown in Table 1 below (FDA Routes of Administration; retrieved from www.fda.gov; content current as of 11/1/2022).
- Table 1 FDA Routes of Administration
- the route of administration may be oral, intranasal, inhalation, intravenous, sublingual, topical, injectable and/or transdermal.
- compositions of the present invention comprising the NMDA receptor antagonist and/or metal channel activator may also include other pharmaceutically acceptable carriers and/or excipients such as binders, lubricants, diluents, coatings, disintegrants, barrier layer components, glidants, coloring agents, solubility enhancers, gelling agents, fillers, proteins, co-factors, emulsifiers, solubilizing agents, suspending agents and mixtures thereof.
- binders such as binders, lubricants, diluents, coatings, disintegrants, barrier layer components, glidants, coloring agents, solubility enhancers, gelling agents, fillers, proteins, co-factors, emulsifiers, solubilizing agents, suspending agents and mixtures thereof.
- binders such as binders, lubricants, diluents, coatings, disintegrants, barrier layer components, glidants, coloring agents, solubility enhancers, gelling agents, fillers
- excipients are used primarily to serve in delivering a safe, stable, and functional pharmaceutical. Excipients may also serve as part of the overall vehicle for delivery. Excipients may also be used to achieve effective absorption by the recipient of the active ingredient. An excipient may fill a role as simple and direct as being an inert filler, or an excipient as used herein may be part of a pH stabilizing system or coating. Excipients herein may also serve an antimicrobial function or improve pharmaceutical composition characteristics such as lubricity, flowability, disintegration and taste. [1111] Pharmaceutical compositions may comprise one or more pharmaceutically acceptable carriers, excipients, or diluents.
- pharmaceutically acceptable refers to a substance that is acceptable for use in pharmaceutical applications from a toxicological perspective and does not adversely interact with the active ingredient.
- Pharmaceutically acceptable carriers are biologically acceptable and compatible with the other ingredients in the formulation.
- compositions herein are not limited to a single active ingredient, and supplementary active ingredients can also be incorporated.
- Examples of pharmaceutically acceptable carriers may include, but are not limited to, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methyl-cellulose, sodium carboxymethylcellulose; other carriers such as, polyvinylpyrrolidone (PVP), talc, calcium sulphate, vegetable oils, synthetic oils, polyols, alginic acid, phosphate buffered solutions, emulsifiers, isotonic saline, pyrogen-free water and combinations thereof.
- fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol
- cellulose preparations such as maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropyl methyl
- disintegrating agents may be combined as well, and exemplary disintegrating agents may be, but not limited to, cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- the compositions may be prepared by any of the methods of pharmacy but all methods include the step of bringing into association one or more chemical agents as described above with the carrier which constitutes one or more necessary ingredients.
- the pharmaceutical compositions of the present invention may be manufactured in conventional methods known in the art, for example, by means of conventional mixing, dissolving, granulating, dragee- making, levigating, emulsifying, encapsulating, entrapping, lyophilizing processes, and the like.
- NMDA receptor antagonists, metal channel activator, and/or the pharmaceutically acceptable salts thereof can be formulated using pharmaceutically acceptable carriers well known in the art into dosages suitable for sublingual, intranasal or buccal administration.
- Such carriers enable the NMDA receptor antagonists and/or metal channel activator to be formulated in dosage forms such as tablets, powders, pills, capsules, liquids, gels, films, syrups, slurries, suspensions, and the like.
- the NMDA receptor antagonist and/or metal channel activator compounds disclosed can be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
- Applicable solid carriers can include one or more substances which can also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents, or encapsulating materials.
- Oral formulations containing a compound disclosed can be any conventionally used oral form, including but not limited to tablets, capsules, buccal forms, troches, lozenges and oral liquids, suspensions, or solutions.
- the carrier in powders, can be a finely divided solid, which is an admixture with a finely divided compound.
- a compound disclosed herein can be mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
- Capsules can contain mixtures of one or more compound(s) disclosed herein with inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato, or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
- inert filler(s) and/or diluent(s) such as pharmaceutically acceptable starches (e.g., corn, potato, or tapioca starch), sugars, artificial sweetening agents, powdered celluloses (e.g., crystalline and microcrystalline celluloses), flours, gelatins, gums, and the like.
- Useful tablet formulations can be made by conventional compression, wet granulation or dry granulation methods and utilize pharmaceutically acceptable diluents, binding agents, lubricants, disintegrants, surface modifying agents (including surfactants), suspending or stabilizing agents, including, but not limited to, magnesium stearate, stearic acid, sodium lauryl sulfate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, microcrystalline cellulose, sodium carboxymethyl cellulose, carboxymethylcellulose calcium, polyvinylpyrrolidone, alginic acid, acacia gum, xanthan gum, sodium citrate, complex silicates, calcium carbonate, glycine, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, low melting waxes, ion exchange resins, benzyl alcohol, e
- Surface modifying agents include nonionic and anionic surface modifying agents.
- Representative examples of surface modifying agents include, but are not limited to, poloxamer 188, benzalkonium chloride, calcium stearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, colloidal silicon dioxide, phosphates, sodium dodecyl sulfate, magnesium aluminum silicate, and triethanolamine.
- Oral formulations herein can utilize standard delay or time-release formulations to alter the absorption of the compound(s).
- the oral formulation can also consist of administering a compound disclosed herein in water or fruit juice, containing appropriate solubilizers or emulsifiers as needed.
- Liquid carriers can be used in preparing solutions for oral, parenteral (such as intravenous, intramuscular, or other injections), or inhalation administration including but not limited to suspensions, emulsions, syrups, and elixirs.
- An NMDA receptor antagonist and/or metal channel activator compound of the present teachings can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, or a mixture of both, or pharmaceutically acceptable oils or fats.
- the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators.
- suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators.
- suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, and osmo-regulators.
- suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents
- the carrier can be an oily ester such as ethyl oleate and isopropyl myristate.
- Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
- the liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellants.
- Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be utilized by, for example, intramuscular, intraperitoneal, or subcutaneous injection. Sterile injectable solutions can also be administered intravenously.
- Compositions for oral administration can be in either liquid or solid form.
- the pharmaceutical composition is in unit dosage form, for example, as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories.
- the pharmaceutical composition can be further sub-divided to contain appropriate quantities of the compound.
- the unit dosage forms can be packaged compositions, for example, packeted powders, vials, ampoules, prefilled syringes, or sachets containing liquids.
- the unit dosage form can be a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
- Such doses can be administered in any manner useful in directing the compound(s) to the recipient's bloodstream, including orally, via implants, parenterally (including intravenous, intraperitoneal, and subcutaneous injections), rectally, vaginally, and transdermally.
- parenterally including intravenous, intraperitoneal, and subcutaneous injections
- rectally vaginally
- transdermally transdermally.
- an effective dosage can vary depending upon the particular compound utilized, the pharmaceutical composition formulated, the mode of administration, physical factors related to the individual being treated, and severity of the condition being treated.
- a compound of the present teachings can be provided to a patient already suffering from a disease in an amount sufficient to cure or at least partially ameliorate the symptoms of the disease and its complications.
- the dosage to be used in the treatment of a specific individual typically must be subjectively determined by the attending physician.
- the variables involved include the specific condition, stage of said condition, and the characteristics of the patient including their size, age and response pattern to the compound utilized.
- the compounds of the present teachings can be formulated into a liquid composition, a solid composition, or an aerosol composition.
- the liquid composition can include, by way of illustration, one or more compounds of the present teachings dissolved, partially dissolved, or suspended in one or more pharmaceutically acceptable solvents and can be administered by, for example, a pump or a squeeze-actuated nebulized spray dispenser.
- the solvents can be, for example, isotonic saline or bacteriostatic water.
- the solid composition can be, by way of illustration, a powder preparation including one or more compounds of the present teachings intermixed with lactose or other inert powders that are acceptable for intrabronchial use, and can be administered by, for example, an aerosol dispenser or a device that breaks or punctures a capsule encasing the solid composition and delivers the solid composition for inhalation.
- the aerosol composition can include, by way of illustration, one or more compounds of the present teachings, propellants, surfactants, and co-solvents, and can be administered by, for example, a metered device.
- the propellants can be a chlorofluorocarbon (CFC), a hydrofluoroalkane (HFA), or other propellants that are physiologically and environmentally acceptable.
- compositions described herein can be administered parenterally or intraperitoneally. Solutions or suspensions of these compounds or a pharmaceutically acceptable salts, hydrates, or esters thereof can be prepared in water suitably mixed with a surfactant such as hydroxyl- propylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations typically contain a preservative to inhibit the growth of microorganisms.
- the pharmaceutical forms suitable for injection can include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
- the form can be sterile and its viscosity permits it to flow through a syringe.
- the form preferably is stable under the conditions of manufacture and storage and can be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.
- Compounds described herein can be administered transdermally, i.e., administered across the surface of the body and the inner linings of bodily passages including epithelial and mucosal tissues.
- Transdermal administration can be accomplished through the use of a transdermal patch containing a compound, such as a compound disclosed herein, and a carrier that can be inert to the compound, can be non-toxic to the skin, and can allow delivery of the compound for systemic absorption into the blood stream via the skin.
- the carrier can take any number of forms such as creams and ointments, pastes, gels, and occlusive devices.
- the creams and ointments can be viscous liquid or semisolid emulsions of either the oil-in-water or water-in- oil type.
- Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the compound can also be suitable.
- a variety of occlusive devices can be used to release the compound into the blood stream, such as a semi-permeable membrane covering a reservoir containing the compound with or without a carrier, or a matrix containing the compound. Other occlusive devices are known in the literature. [1125]
- Compounds described herein can be administered rectally or vaginally in the form of a conventional suppository.
- Suppository formulations can be made from traditional materials, including cocoa butter, with or without the addition of waxes to alter the suppository's melting point, and glycerin.
- Water-soluble suppository bases such as polyethylene glycols of various molecular weights, can also be used.
- Lipid formulations or nanocapsules can be used to introduce compounds of the present teachings into host cells either in vitro or in vivo. Lipid formulations and nanocapsules can be prepared by methods known in the art.
- a method of treating a neurological disease may be characterized by one or more pharmacokinetic parameters such as AUC, C max , T max , and others known and understood to persons of skill in the art.
- pharmacokinetic as used herein is used in its ordinary sense to mean the pharmacokinetic aspects of drug delivery.
- pharmacokinetics is the study of how an organism affect a drug, e.g., how, and how fast it metabolizes the drug.
- the pharmacokinetics typically vary based upon the dosage amount of one or more of the disclosed NMDA receptor antagonists and/or metal channel activators.
- a method of treating a neurological disease may be characterized by an AUC for a NMDA receptor antagonist and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 260, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof.
- the AUC 0-t and/or AUC 0-inf may be from about 80 – 125% of a given AUC value.
- the AUC may be within 80 – 125 % of about 25, 50, 100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, and/or 100,000 hr*ng/mL.
- a systemic treatment may have a larger AUC than a localized (such as topical or subdermal) treatment.
- a method of treating a neurological disease may be characterized by a C max for a NMDA receptor antagonist and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 260, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof.
- the C max may be from about 80 – 125% of a given C max value.
- the C max may be within 80 – 125 % of about 1, 2, 3, 4, 5, 8, 10, 20, 35, 50, 80,100, 150, 200, 250, 300, 400, 500, 600, 700, 800, 900, 1000, 1300, 1600, 1900, 2500, 3500, 5000, 7500, 10,000, 15,000, 20,000, 30,000, 50,000, and/or 100,000 ng/mL.
- a systemic treatment may have a larger C max than a localized (such as topical or subdermal) treatment.
- a ratio C max /AUC may be used to characterize a method of treating a neurological disease wherein one or more of a NMDA receptor antagonist and/or metal channel activator compound according to Formulas 1 – 180, Formulas 200 – 260, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof are administered to a subject.
- the C max /AUC ratio may be from about 80 – 125 % of a given C max /AUC ratio.
- the C max /AUC ratio may be from about 80 – 125 % of about 0.01, 0.03, 0.05, 0.08, 0.1, 0.13, 0.17, 0.2, 0.25, 0.3, 0.35, 0.4, 0.45, 0.5, 0.6, 0.7, 0.8, and 0.9.
- the T max may range from about 0.1 – 16 hours, or from about 0.3 – 8 hours, or from about 0.5 – 4 hours, or from 0.5 – 2 hours, or from about 1 – 2 hours.
- the route of administration which may be any route described herein or known to a person of skill in the art, may affect the T max of a compound according to Formulas 1 – 180, Formulas 200 – 260, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof.
- Excipients or other pharmaceutically acceptable carriers in pharmaceutical compositions of one or more compounds according to Formulas 1 – 180, Formulas 200 – 238, compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof may alter the T max value by making it larger or smaller than a pharmaceutical composition having the excipient or carrier excluded.
- Solid compositions are normally formulated in dosage units providing from about 0.1 to about 1000 mg of the active ingredient per dose. Some examples of solid dosage units are 0.1 mg, 1 mg, 10 mg, 100 mg, 500 mg, and 1000 mg. Liquid compositions are generally in a unit dosage range of 0.1-100 mg/mL.
- liquid dosage units are 0.1 mg/mL, 1 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL.
- a dose is daily.
- a dose is twice daily.
- a does is one, two, three, four, or five times daily.
- a dose is once every other day, once every second day, once every third day, once every fourth day, once every fifth day, once every sixth day, weekly, bi-weekly, or monthly.
- a dose may be from 0.01-100 mg/kg body weight, or from .05 – 50 mg/kg body weight, or from 0.1 – 10 mg/kg body weight, or from 0.15 – 5 mg/kg body weight, or from 0.2 – 2 mg/kg body weight, or from 0.5 – 1.5 mg/kg body weight, or from 1 – 1.5 mg/kg body weight.
- the dosing regimen may comprise one or more optional loading doses and a subsequent maintenance dose regimen.
- a loading dose may be larger than the doses given in a subsequent maintenance dose regimen.
- the dosage is adjusted based upon neurological disease symptoms observed in the patient.
- a symptom-dependent regimen may have a larger treatment dose while symptoms are present and a smaller preventative dose while symptoms are lessened, in remission, controlled, etc.
- a treatment dose may comprise a unit dosage of about 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 100 mg, 120 mg, 140 mg, 160 mg, 180 mg, or 200 mg of an NMDA receptor antagonist according to any one of Formulas 1 – 180, and/or a metal channel activator according to any one of Formulas 200 – 260, or a compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof .
- a preventative dose may comprise a unit dosage of about 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 75 mg, 80 mg, 100 mg, 120 mg, or 140 mg of a NMDA receptor antagonist according to any one of Formulas 200 – 260, and/or a metal channel activator according to any one of Formulas 1 – 180, or a compounds disclosed in the “further embodiments section” under the “METAL CHANNEL ACTIVATOR” subheading, and/or pharmaceutically acceptable salts thereof .
- the preventative dose is an amount that is about 7/8, 3/4, 5/8, 1/2, 3/8, 1/4, or about 1/8 of the amount of the treatment dose.
- a treatment dosing regimen may replace the preventative dosing regimen until symptoms have lessened or subsided.
- Each of the treatment and/or preventative doses may be adjusted during the regimen based upon the severity of neurological disorder symptoms.
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Engineering & Computer Science (AREA)
Abstract
L'invention concerne une composition pharmaceutique comprenant un activateur des canaux métalliques et un antagoniste des récepteur NMDA. L'invention concerne également une méthode de traitement d'un trouble dépressif, comprenant l'administration de la composition pharmaceutique. L'invention concerne également une méthode de traitement d'un trouble neurologique ou neurodégénératif, comprenant l'administration de la composition pharmaceutique. L'invention concerne également une méthode de traitement d'un trouble de la douleur, comprenant l'administration de la composition pharmaceutique.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202263402416P | 2022-08-30 | 2022-08-30 | |
US63/402,416 | 2022-08-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024050389A1 true WO2024050389A1 (fr) | 2024-03-07 |
Family
ID=90098813
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2023/073125 WO2024050389A1 (fr) | 2022-08-30 | 2023-08-30 | Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024050389A1 (fr) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080139610A1 (en) * | 2006-08-23 | 2008-06-12 | Valeant Pharmaceuticals North America | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
US20140243350A1 (en) * | 2011-07-05 | 2014-08-28 | Contera Pharma Aps | Use of serotonin receptor agonists for treatment of movement disorders |
US9675567B2 (en) * | 2008-07-22 | 2017-06-13 | Ramot At Tel-Aviv University Ltd. | Potassium ion channel modulators and uses thereof |
US20210130299A1 (en) * | 2018-03-19 | 2021-05-06 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
WO2022215080A1 (fr) * | 2021-04-08 | 2022-10-13 | Yeda Research And Development Co. Ltd. | Utilisation combinée de kétamine et de rétigabine (ézogabine) pour le traitement de troubles psychiatriques |
-
2023
- 2023-08-30 WO PCT/US2023/073125 patent/WO2024050389A1/fr unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080139610A1 (en) * | 2006-08-23 | 2008-06-12 | Valeant Pharmaceuticals North America | Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
US9675567B2 (en) * | 2008-07-22 | 2017-06-13 | Ramot At Tel-Aviv University Ltd. | Potassium ion channel modulators and uses thereof |
US20140243350A1 (en) * | 2011-07-05 | 2014-08-28 | Contera Pharma Aps | Use of serotonin receptor agonists for treatment of movement disorders |
US20210130299A1 (en) * | 2018-03-19 | 2021-05-06 | Knopp Biosciences Llc | Kv7 channel activators compositions and methods of use |
WO2022215080A1 (fr) * | 2021-04-08 | 2022-10-13 | Yeda Research And Development Co. Ltd. | Utilisation combinée de kétamine et de rétigabine (ézogabine) pour le traitement de troubles psychiatriques |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021078285A1 (fr) | Inhibiteurs à base de groupes cycloalkyle et hétéroalkyle, procédé de préparation associé et utilisation associée | |
AU2018332887B2 (en) | Bisamide sarcomere activating compounds and uses thereof | |
CA2870264C (fr) | Compose heterocyclique contenant de l'azote ou sel de celui-ci | |
US10221167B2 (en) | Hydroxyalkylamine- and hydroxycycloalkylamine-substituted diamine-arylsulfonamide compounds with selective activity in voltage-gated sodium channels | |
US10968203B2 (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating IRE1-related diseases and disorders | |
TW201840556A (zh) | 金屬酶抑制劑化合物、醫藥組成物及使用該金屬酶抑制劑化合物之方法 | |
CN107567438A (zh) | 利鲁唑前药及其用途 | |
CN107406412A (zh) | TGF‑β抑制剂 | |
KR20180096683A (ko) | 전압-게이팅 나트륨 채널에서 선택적 활성을 갖는 디아미노-알킬아미노-연결 아릴술폰아미드 화합물 | |
CA2438231A1 (fr) | Derives de 2,4-disubstitue pyrimidine-5-carboxamide en tant que modulateur des canaux potassium kcnq | |
CA3217565A1 (fr) | Cycloalkyl 3-oxopiperazine carboxamides et cycloheteroalkyle 3-oxopiperazine carboxamides en tant qu'inhibiteurs de nav1.8 | |
JP2005538099A5 (fr) | ||
US20240336574A1 (en) | Methyl-substituted pyridine and pyridazine compounds, derivatives thereof, and methods of their use | |
CA2803055A1 (fr) | Composes et compositions d'heteroaryle en tant qu'inhibiteurs de proteine kinases | |
CN102686578A (zh) | Pde4的双环杂芳基抑制剂 | |
CN112839945A (zh) | 补体因子d抑制剂的形态形式 | |
CA3145738A1 (fr) | Inhibiteurs de derive de difluorohaloallylamine sulfone de lysyl oxydases, leurs procedes de preparation et leurs utilisations | |
JP2021536496A (ja) | フェノキシ−ピリジル−ピリミジン化合物及び使用方法 | |
US20240285596A1 (en) | Solid dosage forms and dosing regimens comprising (2r,3s,4s,5r)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide | |
RU2013103754A (ru) | Новые кристаллические формы n-[-2[[(2,3,-дифторфенил)метил]тио]-6-{[(1r, 2s)-2,3-дигидрокси-1-метилпропил]окси}-4-пиримидинил]-1-азатидин-сульфонамида | |
US20220267306A1 (en) | Heterocyclic prolinamide derivatives | |
EP4041725B1 (fr) | Composés de quinoléine et compositions en tant qu'inhibiteurs de ezh2 pour le traitement des maladies de cancer | |
WO2024050389A1 (fr) | Polythérapies comprenant des activateurs des canaux métalliques et des antagonistes des récepteurs nmda | |
CA2577667A1 (fr) | Amides de l'acide 5- et 6-aminoalkyl indole-2-carboxylique substitue en position 3 et analogues apparentes en tant qu'inhibiteurs de la caseine kinase i epsilon | |
WO2024054807A1 (fr) | Polythérapies comprenant des activateurs de canaux métalliques et des modulateurs de tdp-43 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23861512 Country of ref document: EP Kind code of ref document: A1 |